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Abstract
Colorectal cancer is the second most common cause of death from cancer in the 
UK. One of the reasons for this high mortality rate is the late presentation of patients to 
the clinic, i.e. when they have late stage invasive or metastatic tumours. The 
development of new therapeutic compounds for late stage disease is therefore 
paramount to tackling the disease. Better models of colorectal cancer are also needed 
to test new therapeutic compounds, and to try to improve understanding of the 
processes underlying tumour progression and metastasis. Currently, most mouse models 
of colorectal cancer only recapitulate the early stages of the disease and rarely progress 
to an invasive late-stage tumour. The tumour suppressor PTEN, the oncogene KRAS and 
the cell adhesion component E-cadherin have all been implicated in the progression, or 
poor prognosis of colorectal cancer. I have used the cre-loxP recombination system to 
alter the expression of these genes in the mouse intestine, and to further define their 
role in tumourigenesis.
I have shown that mutations in Pten and Kras synergise in the context of Wnt 
initiated intestinal tumours to promote progression from adenoma to invasive 
adenocarcinoma. It is also reported here that mutations in Pten and Kras alone, 
predispose to non-Wnt initiated tumours that progress to metastatic carcinoma in the 
intestine. In addition to the synergy of Pten and Kras mutations in tumourigenesis, I 
have shown that they synergise to disrupt normal intestinal homeostasis resulting in 
increased cell number and villus bifurcation. These phenotypes are potentially driven 
through hyperactivation of the phosphatidylinositol-3-kinase (PI3K) pathway.
Investigation of the role of E-cadherin in the small intestine revealed that E- 
cadherin is indispensable for the structural maintenance of the epithelial layer. 
However, heterozygous loss of E-cadherin is viable, and mice do not develop any 
tumourigenic phenotype. Further, despite loss of E-cadherin correlating with invasion in 
human tumours, heterozygous loss of E-cadherin in the context of intestinal 
tumourigenesis does not promote tumour progression in the mouse.
I also investigated the role of Pten in the small intestinal stroma. PTEN is a major 
tumour suppressor in humans. Constitutive heterozygous loss of Pten in the mouse gives 
rise to intestinal tumours, as does intestinal specific, conditional deletion of Pten in the 
epithelium and the underlying supporting stroma and smooth muscle. However, 
epithelial specific loss of Pten does not give rise to rapid tumourigenesis. I therefore, 
used the cre-loxP system to conditionally delete Pten from the stromal fibroblasts and 
smooth muscle of the intestine. These mice developed benign tumours along the length
xxi
of the intestine, in particular the caecum and colon. These findings demonstrate the 
role of Pten in stromal-epithelial interactions in the intestine.
Taken together, my data demonstrate that appropriate regulation of Pten and 
Kras together, contribute to the maintenance of homeostasis in the small intestinal 
epithelium, and alteration of the expression of these genes concomitantly in intestinal 
epithelial cells leads to the formation of intestinal metastatic carcinoma. My findings 
also indicate that the tumour suppressor function of Pten is not confined to epithelial 
cells, as deficiency of Pten exclusively in the supporting stroma and smooth muscle of 
the intestine results in tumourigenesis.
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Chapter 1: General Introduction
1.1 Colorectal Cancer
1.1.1 Colorectal cancer statistics and causes
After breast and lung cancer, bowel cancer or colorectal cancer (CRC) is the 
third most commonly diagnosed cancer in the UK (excluding non-melanoma skin 
cancer) (CancerResearchUK, 2011). After lung cancer it is the second most common 
cause of death from cancer in the UK (CancerResearchUK, 2010). Its high incidence is 
likely to be attributed to two factors, the high proliferative rate of the epithelium and 
poor diet. The epithelium of the intestinal tract renews itself frequently, this high rate 
of replication increases the likelihood of replication errors coupled with the direct 
contact of these cells with potential carcinogens in foodstuffs increases the chance of 
accumulation of mutations. The high incidence of CRC is linked to obesity and a diet 
rich in red and processed meats, lacking in fibre, and to a lesser extent fruit and 
vegetables (Moghaddam et al., 2007, Renehan et al., 2008, Park et al., 2005, Norat et 
al., 2005). Lack of exercise is also thought to be a contributory factor, increasing the 
risk of CRC by up to 24% (Wolin et al., 2009). Wolin et al suggest a number of possible 
reasons why exercise decreases your risk of CRC, these include: quicker transit of food 
through the gut, anti-inflammatory action and reduced insulin resistance (Wolin et al., 
2009). The high mortality rates associated with CRC are in part due to the relatively 
late detection of the disease i.e. usually when it has metastasised. In this regard, it 
has been shown that one round of fecal occult blood screening reduces the risk of 
death by 25% (Hewitson et al., 2007), confirming that early detection of the disease 
increases the patients chance of survival.
1.1.2 Dukes staging of CRC
When a patient presents with CRC the course of treatment used will depend on 
the severity of the cancer. Cuthbert Dukes first proposed a system of classification of 
the differing stages of CRCs in 1932. This system classified colorectal tumours into four 
categories A-D, A - a tumour confined to the intestine, B - a tumour that has invaded 
through the muscle wall of the intestine, C - a tumour that has infiltrated regional 
lymph nodes and D - a tumour with distant metastases (Dukes, 1980). This system has 
since been modified by the Union for International Cancer Control (UICC), the system 
takes into account the size of the primary tumour (T), the invasiveness of the primary 
tumour i.e. whether it has invaded through the muscle wall and underlying serosa of
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the intestine, if there are the presence of tumour cells in the lymph nodes (N) and if it 
has spread to other organs (local or distant) (M) (Table 1.1) (Sobin and Wittekind, 
1997, CancerResearchUK, 2009).
UICC/TNM
Modified
Dukes'
Stage
0 Carcinoma in situ
AStage
I
No nodal involvement, no distant metastasis
Tumour invades submucosa (T1, NO, M0)
Tumour invades muscularis propria (T2, NO, M0)
Stage
II
No nodal involvement, no distant metastasis B
Tumour invades into subserosa (T3, NO, M0)
Tumour invades into other organs (T4, NO, M0)
Stage
III
Nodal involvement, no distant metastasis
C1 to 3 regional lymph nodes involved (any T, N1, 
M0)
4 or more regional lymph nodes involved (Any T, 
N2, M0)
Stage
IV Distant metastasis (any T, any N, M1) D
Table 1.1 Colorectal cancer staging (taken from Cancer Research UK, Cancer Stats) 
(CancerResearchUK, 2009)
1.1.3 Current therapeutic strategies for CRC patients
The high mortality rate of CRC patients is largely due presentation of patients 
with late-stage disease, owing to the relatively mild symptoms that occur with early- 
stage disease e.g. diarrhea and frequent bowel movements. Once the stage of the 
cancer is established there are a number of clinical options. These predominantly 
involve resection of the tumour and metastases if possible and the patient is well 
enough, in conjunction with the use of a number of chemotherapeutics in differing 
combinations depending on the severity of the tumour stage (NICE, 2011). Cytotoxics 
such as 5-Fluorouracil, irinotecan and oxaliplatin are used, as well as frequently the 
EGFR inhibitor cetuximab. These are used singularly or in combination to treat CRC 
patients. Cetuximab is used in combination with chemotherapy, or in patients in which 
irinotecan and oxaliplatin have failed. Despite these treatments CRC mortality rates
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remain high, and it is clear that better understanding of how CRC develops and 
progresses, and better drugs are needed for treating late stage metastatic disease.
1.2 Basic anatomy and function of the intestines
The intestines form part of the digestive system, its function is to digest and 
absorb nutrients and water from ingested food, and form part of the body’s defense 
against ingested pathogens. The intestinal structure consists of an open-ended tube 
extending from the stomach to the anus, made up of the small intestine and large 
intestine. The small intestine is made up of three parts, the duodenum (responsible for 
much of the chemical digestion of food), the jejunum and the ileum (distal small 
intestine) (Williams et al., 1989). The luminal surface of the small intestine is covered 
in a single cell layer of polarised epithelial cells that form invaginations called the 
crypts of Lieberkuhn (commonly referred to as crypts) and projections called villi 
(Williams et al., 1989), these increase the surface area of the tissue to maximise 
nutrient absorption (Figure 1.1). The single-cell epithelial layer is supported by 
mesenchymal (stromal) fibroblasts that occupy the space around the crypts and extend 
up into each villus (the stromal component is referred to as the lamina propria). The 
stromal and epithelial component of the small intestine is encased in a layer of smooth 
muscle responsible for peristalsis. Stromal fibroblasts in the intravillus region also 
encase a blood supply to the cells for the transport of sugars and amino acids, and a 
lacteal (part of the lymphatic system), for the transport of lipids in the form of 
lipoproteins. The small intestine also contains nodules of lymphoid tissue called 
peyer’s patches, these help recognise and defend against pathogens that enter the 
body through ingestion (Williams et al., 1989).
The large intestine is made up of the caecum (proximal), colon and rectum 
(distal). The caecum is found at the distal end of the small intestine, at the region 
where the small intestine joins the large intestine, the caecum is also the region of the 
large intestine where the appendix is located. The large intestine is the site in which 
most of the water is absorbed from ingested foodstuffs. At the distal end of the large 
intestine is the rectum, where faeces is stored before egestion. The rectum then opens 
out into the anal canal (Williams et al., 1989). The large intestine, similarly to the 
small intestine has a single cell layer of columnar epithelium, but unlike the small 
intestine, the large intestine epithelium is entirely made up of elongated crypts and 
does not possess any villus projections, and cells instead form a flat surface epithelium 
(Figure 1.1).
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Figure 1.1 Photomicrographs of the mouse small and large intestine
The small intestine is made up of finger-like projections called villi and invaginations 
called crypts. Single cell layers of epithelium supported by stromal fibroblasts make up 
these structures. They face into the lumen and are surrounded on the outside by a 
layer of smooth muscle. The large intestine is comprised of a single cell layer of 
enterocytes and goblet cells but these only form crypts. Scale bars represent 100 i^m.
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1.3 Small intestinal histology
The small intestine has a rapidly renewing epithelium that turns over every 2-3 
days in the mouse and 5-6 days in humans (Wright and Alison, 1984, Creamer, 1967), 
this renewal is driven by the proliferative cell compartment found in the crypts. Crypts 
are much more numerous than villi, approximately 9 crypts feed each villus with cells 
(Cosentino et a l., 1996). Stem cells are found in the base of the crypts that give rise to 
progenitor cells, which are found in the transit-amplifying (TA) zone of the crypt. 
These cells rapidly divide and migrate up the crypt into the villus region. As they 
migrate from the crypt to the villus they become terminally differentiated, with the 
exception of paneth cells that migrate to the base of the crypt. The other major cell 
types found in the villus includes: enterocytes, goblet cells and enteroendocrine cells 
(Figure 1.2). Terminally differentiated cell types continue to migrate up the villus axis 
where they undergo apoptosis and are sloughed from the villus tip (Hall et al., 1994, 
Grossmann et al., 2002). Due to sustained cell proliferation, migration and shedding of 
cells required for continual epithelial renewal, mechanisms controlling proliferation, 
differentiation and apoptosis are tightly controlled in order to maintain intestinal 
homeostasis.
1.3.1 The intestinal stem cell
Stem cells are long-lived pluripotent cells that divide asymmetrically, producing 
daughter cells that give rise to all mature cell types of a particular tissue and are 
required for tissue maintenance. Due to their longevity in intestinal crypts and 
presumed repeated divisions, they are considered to be susceptible to the 
accumulation of mutations and may be the initiating cells that give rise to cancers. 
Evidence in support of this is derived from in vivo experiments in the intestine, here 
the tumour suppressor Adenomatous polyposis coli (Ape) was selectively deleted from 
either the stem cell compartment or the TA progenitor cell region of the crypt. Mice 
that possessed Ape deficient stem cells had macroscopic tumours present in the small 
intestine after 3-5 weeks, whereas mice with Ape deficient cells in the TA region 
possessed few macroscopic intestinal tumours, even after 30 weeks post deletion of 
Ape (Barker et al., 2009). Intestinal stem cells possess a number of intrinsic 
mechanisms in an effort to prevent these cells from becoming neoplastic. Stem cells 
are thought to be slow cycling (or quiescent), undergo conservative strand replication 
of DNA and a have high susceptibility to apoptosis after genetic insult to prevent 
accumulation of mutations (Potten et al., 1997, Potten et al., 1978). By unknown 
mechanisms stem cells are able to replicate their DNA by conserved strand replication.
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Figure 1.2 Schematic diagram of the small intestinal cell types
The intestinal epithelium is divided into two distinct cellular compartments: the crypt, 
which constitutes the proliferative transit-amplifying (TA) zone made up of immature 
progenitor cells, and the villus, which is made up of differentiated cells. The stem cell 
compartment is found at the base of the crypt, the stem cells are surrounded by 
paneth cells and stromal fibroblasts, which are thought to provide factors to maintain 
stem cell pluripotency and therefore constitute the stem cell niche. As the progenitor 
cells divide they migrate up the crypt-villus axis, as the cells migrate out of the crypt 
into the villus region they become terminally differentiated into enterocytes, goblet 
cells and enteroendocrine cells (paneth cells terminally differentiate and migrate to 
the base of the crypt). These mature cells continue to migrate up the villus (driven by 
repeated division of crypt progenitor cells) and are sloughed from the villus tip.
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Here the same strand of DNA is retained and used as the template for replication 
during each division, thus any DNA errors occurring from replication are passed onto 
daughter cells that differentiate and are eventually lost from the tissue (Potten et al., 
1978, Potten et al., 2002). Potten and colleagues have shown that small intestinal 
stem cells readily undergo apoptosis after genetic insult created by irradiation, thus 
preventing the retention of stem cells with DNA damage (Potten et al., 1997, Potten 
and Grant, 1998). Undamaged stem cells or uncommitted progenitor cells that still 
have the capacity to revert back to a stem cell state then replace the ablated stem 
cells.
Over the years there has been much research into the location of the small 
intestinal stem cell. It has commonly been regarded to reside in the +4 cell region of 
the crypts, elucidated by functional assays that exploit the property of stem cells to 
replicate their DNA by conserved strand replication. Here, DNA undergoing replication 
was labeled using tritiated thymidine (3HTdR) during a period in which the stem cells 
were undergoing regeneration (post irradiation). The position of the label retaining cell 
(i.e. small intestinal stem cells that incorporated 3HTdR into their conserved DNA 
strand) were then able to be visualised a number of weeks after administration of 
3HTdR (Potten et al., 1997, Potten et al., 1978).
The elucidation of the position of the small intestinal stem cell has led to the 
identification of a number of putative intestinal stem cell markers including, musashi-1 
(Potten et a l., 2003), CD133 (prominin-1) (Zhu et al., 2009), the polycomb ring finger 
oncogene Bmi1 (Sangiorgi and Capecchi, 2008) and doublecortin and 
calcium/calmodulin-dependent protein kinase-like-1 (DCAMKL-1) (May et al., 2008). All 
these putative stem cell markers label cells predominantly at the +4 position. Bmi1+ 
cells in particular possess strong evidence of stem cell functionality, lineage tracing 
has shown that they are capable of giving rise to all intestinal cell types (Sangiorgi and 
Capecchi, 2008) and single Bmi1+ cells are capable of forming intestinal organoids in 
culture (Ootani et al., 2009). However, recent work from Hans Clevers’ group has 
amassed evidence to show that the previously identified crypt-base-columnar cells 
(CBC) (Cheng and Leblond, 1974), found at the crypt base interspersed between 
paneth cells, can function as small intestinal stem cells. These cells can be identified 
by their unique expression of the Wnt target gene Leucine-rich repeat-containing G- 
protein coupled receptor 5 (Lgr5) (Barker et al., 2007), they were found to be actively 
cycling in contrast to the traditional view of a largely quiescent stem cell. The CBC 
compartment can also be located by expression of the markers achaete scutelike 2 
(Ascl2) and olfactomedin 4 (Olfm4) (van der Flier et al., 2009b, van der Flier et al.,
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2009a). Clevers’ group has also shown that when Lgr5+ cells are isolated they can be 
cultured in vitro  to successfully form intestinal organoids, further validating that Lgr5+ 
cells are small intestinal stem cells (Sato et al., 2009). Barker et al also noted that 
Lgr5+ cells also constitute the stem cells in the colon (Barker et al., 2007). Clevers’ 
group have shown that each small intestinal crypt contains approximately 16 Lgr5+ 
cells, and along with Douglas Winton’s group, have shown that the monoclonality of 
cells in the crypt-villus axis is attributed to the neutral drift of one stem cell 
populating the stem cell compartment with its progeny (Lopez-Garcia et al., 2010, 
Snippert et a l., 2010). The study by Snippert et al suggests that stem cells may actually 
divide symmetrically. They propose that progenitor cells may arise not from 
asymmetric division but as they divide some stem cells move out of the stem cell niche 
and lose their ‘sternness’ to become progenitor cells (Snippert et al., 2010).
1.3.2 Quiescent and active stem cells?
The studies described above establishes that Lgr5 clearly marks a CBC stem cell 
population, however as previously mentioned there is also evidence that Bmi1 may also 
mark a population of stem cells. This has led to the hypothesis that there may be two 
pools of small intestinal stem cells, one actively cycling Lgr5 expressing cell, and a 
quiescent Bmi1 expressing cell (Li and Clevers, 2010). Studies investigating Bmi1 and 
Lgr5 as putative stem cell markers have revealed some similarities between the 
properties and positions of Bmi1 and Lgr5 expressing cells. For example, both Bmi1 + 
and Lgr5+ cells are capable of populating the crypt-villus axis with their progeny as 
evidenced by lineage tracing experiments (Barker et al., 2007, Sangiorgi and Capecchi, 
2008), and both are able to be cultured to give rise to intestinal organoids (Sato et al., 
2009, Ootani et al., 2009). There were also rare incidences of CBC cells that express 
Bmi1 and +4 position cells that express Lgr5 (Barker et al., 2007, Sangiorgi and 
Capecchi, 2008). However, despite Bmi1 being predominantly expressed in cells found 
at position +4 (the position of the label retaining cell in the Potten experiments) it is 
not known whether these cells are actively cycling, so it cannot be concluded that 
Bmi1+ cells are indeed quiescent. It was suggested by Potten et al that stem cells can 
be replaced by another uncommitted cell during stem cell loss (Potten et al., 1997), 
and maybe the Bmi1 expressing pool of cells represent that subpopulation of cells. This 
would give some explanation as to why both Bmi1 and Lgr5 expressing cells can form 
intestinal organoid cultures. Further support of a quiescent stem cell population has 
come from a study by Montgomery et al. They show that cells expressing mouse
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telomerase reverse transcriptase (mTERT) are long-lived, slowly cycling cells found at 
position +4. mTERT cells were able to produce all intestinal cell types (established by 
lineage tracing experiments) and contribute to regenerative response after injury. 
Interestingly, mTERT cells were also predominantly BmiT, and mTERT cells were also 
found to give rise to Lgr5+ cells, which suggests that these cells can replace Lgr5+ 
actively cycling cells when needed (Montgomery et al., 2011). However, it is not 
addressed in this study whether this is a unique property of mTERT cells or any cell 
within the crypt could give rise to an Lgr5+ cell.
It may also be possible that the +4 position of the crypt (which lies just above 
the CBC/paneth cell compartment), may act as a ‘ lay-by’ or ‘pit-stop’ for actively 
cycling stem cells that have sustained DNA damage. Damaged CBC cells may migrate 
into the +4 position and enter a quiescent state and remain like this until either the 
damage is repaired and they re-enter the CBC compartment, or they undergo 
apoptosis. This hypothesis gives some explanation as to why Bmi1+ cells can produce 
intestinal organoids in culture, and are capable of populating the crypt-villus axis with 
their progeny in lineage tracing experiments in vivo. It may also provide an explanation 
as to why Potten and colleagues frequently observed apoptosis at the +4 position after 
irradiation, and why these cells retain DNA labeling long term. Why the intestine would 
require such a system is unclear, one hypothesis may be to preserve an epigenetic 
signature present in CBC cells that allows them to maintain pluripotency. Much more 
research is needed to fully understand the role and reason for these two cell 
populations.
1.3.3 Regulation of intestinal stem cell function and the stem cell niche
Stem cell function must be tightly controlled in order to maintain intestinal 
homeostasis, and it is thought that all stem cells require a niche to provide factors to 
control its activity, such that if the stem cells were removed from this niche they 
would lose their stem cell functionality. The mesenchymal stromal fibroblasts in the 
lamina propria surrounding the crypts are thought not just to provide structural 
support but they are also thought to constitute the intestinal stem cell niche (Shaker 
and Rubin, 2010) (Figure 1.2). Recent work from Sato et al has shown that the mature 
paneth cells provide a niche for Lgr5+ crypt base columnar stem cells (Sato et al., 
2011). Stromal-epithelial interactions between the intestinal stem cell niche and the 
overlying epithelium have been demonstrated in the intestine in vivo, with deletion of 
genes that alter signalling pathways in the underlying stroma of mice being shown to
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impact on normal intestinal homeostasis. Deletion of the bone morphogenic signalling 
pathway receptor type II (BMPRII) specifically in the underlying stroma of the colon in 
mice resulted in the formation of epithelial hamartomas (Beppu et al., 2008). 
Similarly, stromal specific deletion of the serine/threonine kinase LKB1, which 
regulates AMPK and insulin receptor signalling, causes the development of epithelial 
hamartomas throughout the intestine through downregulation of the TGF(3 pathway 
(Katajisto et al., 2008). Knockout mice have also been generated in which genes are 
disrupted that are expressed specifically in stromal cells, such as epimorphin (a protein 
involved in targeting vesicles to the plasma membrane) and the transcription factor 
FoxL1 (also known as Forkhead homologue 6 - Fhk6 ). Ablation of epimorphin in the 
mouse induced proliferation of the intestinal epithelium, in turn resulting in the 
alteration of crypt-villus architecture, evidenced by the lengthening of crypts and villi 
and villus bifurcation. Epimorphin loss was accompanied by concurrent downregulation 
of BMP signalling and upregulation of Wnt signalling, providing a mechanism by which 
this phenotype arises (Wang et al., 2006). Similarly, deletion of FoxL1 caused 
disruption of intestinal homeostasis resulting in abnormal crypt and villus size, 
expansion of the proliferative zone in the crypt and increased numbers of goblet cells. 
Again these phenotypes were coupled with downregulation of bone morphogenic 
proteins (BMPs), implicating the pathway in intestinal homeostasis (Kaestner et al.,
1997). The Hedgehog signalling pathway is strongly implicated in intestinal homeostasis 
through its regulation of the Wnt pathway. Ligands secreted from the crypt epithelial 
cells activate the Hedgehog signalling pathway in neighbouring intestinal stromal cells, 
which in turn regulate epithelial cell function through upregulation of BMP expression. 
These interactions are further discussed in section 1.4.2. The role of signalling 
pathways in intestinal homeostasis will also be discussed further in section 1.4.
1.3.4 The colorectal cancer stem cell
It is known that each tissue type contains a number of stem cells that have the 
ability to give rise to many tissue cell types and maintain tissue homeostasis, the 
cancer stem cell theory postulates that cancers also possess ‘stem cell-like’ cells that 
have the capacity to maintain the bulk of the tumour with cells. It is thought that 
cancer stem cells may also be refractory to chemotherapy, therefore after the bulk of 
the tumour cells are depleted the cancer stem cells divide and give rise to more 
tumour cells causing relapse (Wicha et al., 2006, Clarke et al., 2006). There has been 
much research to identify these pools of cancer stem cells in order to develop
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therapeutics that could potentially target these cells, thus preventing tumour growth. 
A number of studies have identified various cell surface markers that potentially 
identify cells with increased proliferative capacity, either by the ability to form 
colonies in culture or by serial transplantation in xenograft mouse models. Some of the 
candidate intestinal cancer stem cell markers include CD133, Lgr5, the epithelial cell 
adhesion molecule (EpCAM) and CD166 (Dalerba et al., 2007, O’Brien et al., 2007, 
Ricci-Vitiani et al., 2007, Takahashi et al., Vermeulen et al., 2008). Some of these 
markers are currently implicated as markers of normal intestinal stem cells. One could 
postulate that as these proteins mark cells that have increased proliferative and self- 
renewal capacity in normal tissue, they could also mark intestinal cancer stem cells. 
The ability of cancer cells to efflux drugs has also been used to select for the cancer 
stem cell population (Hirschmann-Jax et al., 2004), however this has been found not to 
be a useful marker of cancer stem cells in CRC (Burkert et al., 2008)
CD133 has been the most prominent candidate as a colorectal cancer stem cell 
marker. CD133+ cells have been shown to have the capacity to initiate tumours upon 
transplantation into non-obese diabetic/severe combined immune deficiency 
(NOD/SCID) mice, but at low frequencies (O'Brien et al., 2007, Ricci-Vitiani et al., 
2007). Vermeulen et al suggested that the cells used in these studies were not 
monoclonal, and this resulted in low frequency of tumour formation. They showed, by 
single cell cloning experiments, that 1 in 16 CD133+ cells produced a colony, and 1 in 5 
cells that expressed both CD133 and CD24 produced a colony. All colonies were able to 
form tumours when transplanted into mice, which resembled the primary CRC from 
which they were derived (Vermeulen et al., 2008). Other proposed markers to 
determine the colorectal cancer stem cell population include EpCAM expressing cells 
(EpCAMh,gh/CD44+/CD166+) (Dalerba et al., 2007), Lgr5 and Wnt activated cells 
(Takahashi et al., Vermeulen et al., 2010).
Despite many elegant experiments in which cells are purified by their cell 
surface marker expression, and then serially transplanted into mice to produce 
tumours consistent in morphology to the primary tumour, there are a number of 
caveats raised by Hill and Kelly et al. to be taken into consideration. 1. Dissociation 
and culture of tumour cells may alter the cell surface marker expression, therefore 
cells expressing the markers with increase proliferative capacity in vitro  may be 
different to those found in vivo (Hill, 2006). 2. Transplantation of tumour cells into 
mice does not recapitulate the human situation entirely, as it is unlikely that cells can 
be transplanted into the same environment from which they came, which may affect 
tumour cell growth (Hill, 2006). 3. Mouse growth factors required for tumour
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propagation may not be compatible with growth of human tumours, so occasions when 
cells failed to reproduce tumours in vivo may be attributed to lack of compatible 
growth factors rather than the cells capacity to proliferate (Kelly et al., 2007). Finally 
in addition to the points raised by Hill and Kelly et al, 4. The in vivo transplantation 
experiments are carried out in immunocompromised mice, and thus is an artificial 
environment lacking in immune response to tumour cells. This could impact upon the 
frequency at which cells reproduce tumours. Despite these caveats, the possibility of 
identifying a pool of tumour cells that are responsible for sustained tumour growth and 
progression has great therapeutic implications.
1.3.5 Terminally differentiated intestinal cell types
1.3.5.1 The main mature cell lineages o f the small intestine
The four main mature cell types in the small intestinal epithelium are either of 
an absorptive or secretory lineage. Enterocytes make up the majority of the 
differentiated cell types found in the villus and are of the absorptive lineage, 
responsible for uptake of nutrients. Enterocytes are specialised cells that are tightly 
packed together via cell-to-cell adhesions, this close association of cells helps to 
maintain cell polarity and provides a barrier to prevent microbes from entering the 
blood stream. The apical surface of enterocytes is made up of microvilli, which are 
specially adapted to increase the surface area of the cell to maximise absorption 
(Wright and Alison, 1984). Enterocytes express the enzyme alkaline phosphatase on 
their apical surface, which is a useful indicator of maturity of the enterocytes and 
polarisation of the epithelium.
The other three main cell types found in the small intestine are goblet cells, 
enteroendocrine cells and paneth cells, which are all of the secretory lineage. Goblet 
cells are found throughout the villus and are often found in the crypt around the crypt- 
villus junction. The function of goblet cells is to secrete mucins required for 
lubrication and protection of the epithelium, as it is subject to a substantial amount of 
mechanical stress through movement of food through the intestine. They also secrete 
trefoil proteins, which facilitate repair to damaged tissue (Mashimo et al., 1996). 
Alcian blue staining can be used to stain intestinal tissue sections to visualise the 
location of goblet cells. The stain binds to mucins present in goblet cells and marks 
them blue in colour. Enteroendocrine cells are found throughout the crypt-villus axis 
and are the least abundant of the four major cell types. They are part of the endocrine 
system and secrete hormones responsible for controlling gut function (Wright and
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Alison, 1984). Grimelius silver staining can be used to locate enteroendocrine cells in 
the intestinal epithelium, argyrophilic granules present in the cells reduce silver ions 
marking the cells with black deposits. Goblet and enteroendocrine cells along with 
enterocytes, differentiate towards the upper region of the crypt, migrate upwards, and 
are lost from the villus tip after 2-3 days. The final mature cell type, paneth cells, are 
located at the base of the crypt and their migration pattern and turnover does not 
follow the same pattern as the other three cell types. Paneth cells differentiate and 
migrate downwards where they are long-lived cells. There is debate as to their 
lifespan, but it is thought to be between 3-8 weeks (Bjerknes and Cheng, 1981b, 
Ireland et a l., 2005). Paneth cells are found exclusively in the small intestine and are 
responsible for innate immunity against pathogens through the secretion of anti­
microbials such as lysozyme (Peeters and Vantrappen, 1975) and crypt defensins 
(Ouellette and Selsted, 1996). Recent findings suggest that paneth cells also form part 
of the stem cell niche for the CBC actively cycling stem cell pool (Sato et al., 2011). 
Paneth cells can be visualised by immunohistochemistry (IHC) in the small intestine by 
their exclusive expression of lysozyme.
1.3.5.2 O ther cell types
Amongst the main four terminally differentiated cell types are two other lesser 
cell types, termed tuft cells and M cells respectively. The functions of these cell types 
are not well established. Tuft cells (also known as brush cells) are infrequently found 
in the intestinal epithelium and are so named due to a protruding ‘tu ft’ of microvilli on 
their apical surface. The function of these cells is currently not fully understood, they 
are found throughout the respiratory epithelia and other epithelia of the digestive 
system. However, it is thought that these cells may have a sensory function in the 
intestine and may act as chemoreceptors (Gebhard and Gebert, 1999). Tuft cells are 
found in crypts and villi of the small intestine, and recently the putative stem cell 
marker DCAMKL-1 was proven to mark tuft cells rather than the small intestinal stem 
cell (Gerbe et al., 2009). M cells represent another intestinal cell type that form part 
of the mucosal immune defense against pathogens. These cells are associated with the 
peyer’s patch lymphoid tissue found in the small intestine (Owen and Jones, 1974), and 
they function as transporters of antigens from the lumen to the underlying immune 
cells (Kraehenbuhl and Neutra, 2000).
13
1.4 Maintenance o f intestinal homeostasis
1.4.1 The Canonical Wnt pathway
The canonical Wnt signalling pathway (Clevers, 2006) was identified through 
analysis of mutations in the Wingless (Wg) gene discovered in Drosophila and the lnt-1 
(Int) gene in mice (a site of insertion for the mouse mammary tumour virus) (Rijsewijk 
et al., 1987), combination of the two gene names resulted in the term Wnt. The Wnt 
pathway is one of the key developmental pathways, and is strongly associated with 
cancer, and in particular CRC. The Wnt pathway is normally in its ‘off state’ (outlined 
in Figure 1.3), activation of the pathway results in transcription of an array of Wnt 
target genes conducive to tumourigenesis, for example genes involved in proliferation, 
migration and adhesion. The Wnt pathway involves many proteins that regulate the 
accumulation and cellular localisation of the transcription transactivator p-catenin. 
The Wnt pathway is controlled by frizzled receptors (7 pass transmembrane proteins) 
on the cell surface that bind Wnt ligands. In the ‘off-state’ , when no Wnt ligands are 
present, a number of proteins form the p-catenin destruction complex that prevent p- 
catenin from accumulating in the cytoplasm and entering the nucleus where it can 
activate transcription of Wnt target genes. The p-catenin destruction complex involves 
the association of a number of proteins, three of the key proteins involved are: 
adenomatous polyposis coli (APC), glycogen synthase kinase-3 (GSK-3) and axis 
inhibitor (AXIN). These proteins bind to p-catenin present in the cytoplasm, allowing 
GSK-3 to phosphorylate p-catenin, marking it for degradation by the proteasome. When 
the Wnt pathway is in its ‘on-state’ , Wnt ligands bind to the frizzled receptor, 
activating the dishevelled protein, which leads to the inhibition the p-catenin 
destruction complex, p-catenin then accumulates in the cytoplasm where it then 
enters the nucleus and allows the transcription of T-cell factor and Lymphoid enhancer 
factor (Tcf/Lef) Wnt target genes (Figure 1.3).
The canonical Wnt signalling pathway drives proliferation in the intestine and 
maintains homeostasis. Studies in which the Wnt signalling pathway was inhibited at 
various points in the pathway, have shown that loss of Wnt signalling perturbs normal 
intestinal structure and proliferation. Overexpression of the Wnt antagonist Dkk1 
resulted in shortening of crypts and villi, a decrease in proliferation and depletion of 
secretory cells (Pinto et al., 2003). Similarly, deletion of p-catenin and the Wnt target 
gene c-Myc in adult mouse intestine results in ablation of the crypts, and in the case of 
p-catenin deficiency, loss of goblet cells (Ireland et al., 2004, Muncan et al., 2006). 
Mice deficient for the Wnt transcription factor Tcf-4, possess no intestinal proliferative
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compartments, only differentiated cells (Korinek et al., 1998). These studies highlight 
the dependence of the proliferative capacity of intestinal stem and progenitor cells on 
activation of the Wnt signalling to maintain intestinal mucosal structure. Conversely, 
studies have also been carried out in which the Wnt pathway is aberrantly activated. 
Homozygous deletion of Ape causes rapid activation of the Wnt pathway throughout 
the epithelium, due to loss of the p-catenin destruction complex. This confers a ‘crypt- 
progenitor’ phenotype on all the epithelial cells, mislocalisation of paneth cells and 
increased proliferation and migration (Sansom et al., 2004). Andreu et al showed that 
it is activation of the Wnt pathway in crypt progenitor cells that drives the Ape loss 
phenotype, even though villus cells are also deficient for Ape they have lost the 
capacity to proliferate (Andreu et al., 2005). Sansom et al showed that the Wnt target 
gene c-Myc is required for the intestinal phenotype after Ape loss, as shown when 
concomitant deletion of Ape and c-Myc rescued the Ape phenotype (Sansom et al., 
2007).
Appropriate control of the Wnt signalling pathway in the stem cell compartment 
via the stem cell niche is pivotal for normal intestinal development and homeostasis. In 
order to achieve this, specific spatial expression of many Wnt agonists and antagonists 
can be detected throughout the intestinal epithelium and underlying stroma 
(Gregorieff et al., 2005). The expression of these Wnt agonists and antagonists 
maintains a gradient of Wnt activity throughout the crypt-villus axis, with the cells 
found at the base of the crypt (i.e. intestinal stem cells) maintaining a high level of 
Wnt activation and progenitors and differentiated cells having no Wnt activation 
(Gregorieff et a l., 2005). Tight regulation of when and where the Wnt pathway is 
activated is also necessary for correct migration and localisation of cell types, as well 
as control of proliferation and homeostasis. Deletion of the Wnt target genes EphB2 
and EphB3 results in perturbed cell migration and positioning of paneth cells (Batlle et 
al., 2002). The Wnt pathway is the main driving force behind maintaining intestinal 
homeostasis, Wnt signalling is therefore the subject of much control by other signalling 
pathways (see below).
1.4.2 The Hedgehog pathway
The Hedgehog signalling pathway is similar to the canonical Wnt signalling 
pathway, in that both pathways involve tight control between degradation and 
activation of a protein involved in the transcription of target genes. The Hedgehog 
pathway is outlined in Figure 1.3. Hedgehog signalling is governed by two membrane-
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spanning proteins called Patched and Smoothened. In the pathways ‘off-state’ , 
Patched normally suppresses the activation of Smoothened via the pumping of 
inhibitory molecules that inhibit the action of Smoothened. When Smoothened is 
inactive, protein kinase A (PKA) is able to phosphorylate the cytoplasmic transcription 
factors GU2/3, resulting in preferential targeting of the Gli2 part of the complex for 
degradation, leaving the truncated Gli3 protein. The truncated Gli3 protein then 
enters the nucleus, binds to the Hedgehog target genes and acts as a transcriptional 
repressor. There are three Hedgehog ligands found in vertebrates, Sonic Hedgehog 
(Shh), Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh). When these bind to Patched 
they prevent the suppression of Smoothened, which when activated prevents the 
phosphorylation and subsequent partial degradation of G li2/3. This active form of 
Gli2/3 is then able to enter the nucleus and bind to Hedgehog target genes and initiate 
transcription of the genes reviewed in (van den Brink, 2007). The FoxL1 and FoxF1 
transcription factors have been shown by Madison et al to be Hedgehog target genes 
through the demonstration that they have Gli binding sites in the non-coding regions of 
the genes (Madison et al., 2009). This finding, along with the previous finding by 
Kaestner et al that FoxL1 deletion downregulates BMP signals and in turn activates Wnt 
signals (Kaestner et al., 1997), places Hedgehog signalling as an upstream regulator of 
canonical Wnt activation. Hedgehog signalling acts in a paracrine manner, Hedgehog 
ligands are expressed in the epithelium and secreted, in turn activating Hedgehog 
signalling in stromal cells (Yauch et al., 2008, Kolterud et al., 2009, Madison et al.,
2005).
The Hedgehog signalling pathway appears to be near the top of a chain of 
signalling events that ultimately leads to the regulation of Wnt signalling and intestinal 
homeostasis. Recently two similar studies by van Dop et al and Kosinski et al showed 
that deletion of the Ihh gene specifically within the intestinal epithelium causes 
increased proliferation, crypt fission, expansion of the stem cell pool, an increase in 
secretory cells, a block of enterocyte differentiation and loss of cellular components of 
the underlying muscularis mucosae (Kosinski et al., 2010, van Dop et al., 2010). Both 
studies showed that these effects were controlled by downregulation of BMPs and 
concomitant upregulation of Wnt signalling. Kosinski et al also demonstrated that Ihh 
signals in a paracrine manner to the underlying stromal and smooth muscle fibroblasts, 
by deleting the Hedgehog activator Smoothened from the intestinal epithelium with no 
phenotypic effects. However, they used an epithelial deletion strategy that resulted in 
post-natal lethality so could not investigate the long term effects of Ihh loss (Kosinski 
et al., 2010). Van Dop et al showed that prolonged deletion of Ihh within adult
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Figure 1.3 Four main pathways that govern intestinal homeostasis
Schematic outlines of the four main signalling pathways involved in maintaining 
intestinal homeostasis. The canonical-Wnt pathway primarily controls proliferation, 
and Hedgehog and BMP signalling form part of a feedback mechanism that controls 
activation of the canonical-Wnt pathway. Notch signalling primarily governs 
differentiation, high Notch activity maintains crypt cells in an immature state. The 
Wnt, TGF-p/BMP and Hedgehog signalling pathways can be activated by autocrine and 
paracrine signalling. The Notch pathway is activated by juxtacrine signalling.
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epithelium resulted in fibrosis of the intestinal epithelium, elicited by an immune 
response provoked by Ihh loss (van Dop et al., 2010). Conversely, constitutive 
activation of the Hedgehog pathway via deletion of Patched causes loss of premature 
intestinal precursors and an increase in differentiation via downregulation of Wnt 
signalling through increases in BMPs (van Dop et al., 2009). van den Brink et al have 
shown that Hedgehog signalling negatively regulates Wnt activity, and increased Wnt 
activity negatively regulates Hedgehog signalling by downregulation of Hedgehog 
ligands (van den Brink et al., 2004). Taken together, these findings implicate active 
Hedgehog signalling as an upstream inhibitor of Wnt mediated through upregulation of 
BMPs, and is responsible in part of tight regulation of Wnt activation in normal 
intestinal epithelium. These interactions are outlined in Figure 1.4.
Despite the activation of Hedgehog having a negative regulatory effect on Wnt 
signalling in normal intestinal conditions, a number of studies in intestinal cancer 
animal models and colorectal cancer cell lines show that Hedgehog signalling is 
upregulated in tumours, and inactivation of the Hedgehog pathway in Wnt activated 
cells or tissues suppresses their proliferative and cancerous capacity (Varnat et al., 
2010, Varnat et al., 2009, Douard et al., 2006). The contrasting roles of Hedgehog 
signalling in normal and neoplastic intestine suggests that perhaps there are non- 
canonical tumour promoting effects of Hedgehog activation.
1.4.3 The TGF-p/BMP pathway
The transforming growth factor beta (TGF-p) superfamily of proteins involved in 
cell signalling include TGF-p, activins and BMP receptors and ligands. The receptors of 
the pathway transduce their signals via a family of proteins called mothers against 
decapentaplegic or Smads. There are usually two types of membrane bound receptors 
(type I and type II). When the pathway is being activated, the ligand binds the type II 
receptor allowing it to dimerise with type I receptors. The type II receptor then 
phosphorylates the cytoplasmic domain of the type I receptor. In the TGF-p/Smad 
signalling pathway the phosphorylated cytoplasmic domain of the type I receptor then 
recruits and phosphorylates either the Smad2 or Smad3 cytosolic proteins. In the case 
of BMP signalling the type I receptor recruits and phosphorylates either Smadl, Smad5 
or Smad8 . The Smads that are recruited to the receptors and phosphorylated are 
collectively known as the receptor regulated Smads (or R-Smads). The R-Smads then 
dissociate from the receptor and form a complex with Smad4 (or also known as the
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Figure 1.4 Signalling pathway interactions that maintain intestinal homeostasis
Appropriate control of the various signalling pathways controlling proliferation, 
differentiation and apoptosis is paramount to maintain intestinal homeostasis. The 
canonical-Wnt pathway drives proliferation of stem and progenitor cells to replace the 
rapid loss of cells from the villus tip. Thus, Wnt pathway activation is tightly controlled 
by secretion of Hedgehog ligands by epithelial cells, that activate Hedgehog signalling 
in the underlying stromal cells of the stem cell niche governing transcription of TGF-p 
and BMP agonists, which control activation of the Wnt pathway in adjacent epithelial 
cells. Juxtacrine activation of the Notch signalling pathway maintains epithelial 
progenitor and stem cells in an undifferentiated state. Notch activation is present in a 
decreasing gradient up the crypt axis, which inversely correlates with differentiation 
state of the epithelial cells along the axis.
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co-Smad), which then allows the translocation of the complex into the nucleus. These 
active Smad complexes bind to TGF-p or BMP target genes and recruit regulatory 
proteins to the gene promoters to allow transcription. When the pathway needs to be 
inactivated inhibitory Smads or l-Smads (Smad6 and Smad7) are expressed which bind 
to Smad4 instead of the R-Smads, preventing its translocation to the nucleus and 
transcription of target genes. Activation of these target genes inhibits cellular growth 
and proliferation, TGF-p/BMP signalling is outlined in Figure 1.3, and described in (Shi 
and Massague, 2003, Massague et al., 2000).
Expression of TGF-p ligands in the intestine is predominantly located at the 
villus tip and the underlying muscularis of the small intestine, and at the surface 
epithelium of the colon (Barnard et al., 1993). TGF-p receptor expression is found in a 
similar pattern but is also expressed in the lamina propria (Winesett et al., 1996). 
Alterations of various TGF-p signalling pathway components in the mouse have given 
rise to a number of gastrointestinal phenotypes. Bhowmick et al showed that deletion 
of the TGF-p type II receptor in stromal fibroblasts results in adjacent epithelial 
abnormalities in the stomach (Bhowmick et al., 2004). Similarly Katajisto et al have 
implicated inactivation of TGF-p (as assessed by downregulation of phospho-Smad2), 
via deletion of the tumour suppressor Lkb1, in stromal fibroblasts of the intestine as 
the driver of intestinal neoplasms (Katajisto et al., 2008). Despite abrogation of TGF-p 
signalling in intestinal stroma causing epithelial aberrations, Munoz et al reported that 
epithelial inactivation of TGF-p signalling via deletion of TGF-pRII has no effect on 
intestinal homeostasis and does not predispose to tumour formation (Munoz et al., 
2006). Mouse models heterozygous for constitutive mutations of Smad4 (the mediator 
of both TGF-p and BMP signalling pathways) are predisposed to the formation of 
intestinal tumours (Takaku et al., 1999, Hohenstein et al., 2003). However, intestinal 
epithelial specific deletion of Smad4 does not give rise to intestinal tumours (Kim et 
al., 2006). TGF-p inactivation in the immune system (particularly T cells) has been 
shown to induce colitis and irritable bowel disease in mice, therefore indicating a role 
for TGF-p in suppression of autoimmune response on the intestine (Coombes and 
Maloy, 2007). Loss of Smad4 specifically within T cells predisposes the mouse to 
intestinal tumours (Kim et al., 2006). It can be concluded from these studies that TGF- 
p potentially acts through stromal-epithelial interactions through both the intestinal 
supporting stroma and immune cells to maintain intestinal homeostasis, and 
inactivation of the pathway results in epithelial aberrations.
The role of BMP signalling in maintaining intestinal homeostasis is well 
characterised. As previously mentioned, Hedgehog signalling appears to control Wnt
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signalling by controlling the expression of BMPs that in turn inhibit Wnt signalling (see 
section 1.4.2). Ectopic expression of the BMP inhibitor Noggin in the mouse intestine 
resulted in the de novo formation of crypts and hyperplastic epithelium (Haramis et 
al., 2004). The hyperplastic epithelium observed in these mice resembled the 
intestinal epithelium of Juvenile Polyposis Syndrome (JPS) patients, a hereditary 
gastrointestinal tumour predisposition disease, in which Smad4 and BMPR deletions 
have been implicated (Howe et al., 2001, Howe et al., 1998). Consistent with the 
Haramis et al study, intestinal inactivation of BMP signalling through deletion of the 
BMP receptor 1a leads to the formation of hyperplastic polyps (He et al., 2004). He et 
al also noted an expansion of the proliferative compartment of the intestine (He et al., 
2004). Another study in which BMPRIa was deleted from the intestinal epithelium 
resulted in increased proliferation and elongated villi but did not result in de novo 
crypt or polyp formation (Auclair et al., 2007). The differences between the Auclair et 
al study and the He et al study may be attributable to differing BMPRIa ablation 
strategies. He et al used a conditional transgenesis technique that acts not only in the 
intestinal epithelium but also in the underlying stroma, thereby implicating a role for 
stromal inactivation of BMP signalling in intestinal tumourigenesis. The role of the BMP 
pathway in stromal-epithelial interactions has previously been mentioned (see section 
1.3.3). Stromal specific deletion of BMP receptor type II results in the formation of 
epithelial polyps (Beppu et al., 2008). The observation that stromal inactivation of BMP 
signalling is sufficient to initiate tumourigenesis, but that epithelial loss of BMP 
signalling also promotes proliferation, suggests that BMP signalling acts in both a 
paracrine and autocrine manner. The observation that the ligand BMP2 is expressed by 
colonic epithelial cell lines and acts in an autocrine manner (Hardwick et al., 2004) 
further supports this.
1.4.4 The Notch pathway
The Notch signalling pathway (Mumm and Kopan, 2000) involves juxtacrine 
transduction of signals between cells outlined in Figure 1.3. The Notch receptor is a 
single pass transmembrane protein expressed on the surface of responding cells, 
named after the disruption of the gene in Drosophila that causes notches in the fly 
wing (Hunt Morgan, 1919). Mammalian Notch receptors include Notch 1-4. Notch 
ligands (mammalian Notch ligands are Delta like 1,3 and 4 and Jagged 1 and 2)) are 
expressed on the cell surface of adjacent cells and are able to bind Notch receptors of 
neighbouring cells when in close contact. The binding of Notch ligands to the Notch
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receptor causes two irreversible proteolytic cleavages of the extracellular domain by 
the membrane-bound enzyme, tumour necrosis factor converting enzyme (TACE), and 
an intramembrane cleavage by y-secretase which in turn releases a the Notch receptor 
intracellular domain (NICD) into the cytoplasm. Once the released cytoplasmic 
fragment of the Notch receptor is in the cytoplasm it translocates to the nucleus where 
it binds to the transcription factor CBF1/RBP-jK/Suppressor of Hairless/LAG-1 (CSL) to 
activate Notch target genes. The Notch receptor, once activated, undergoes 
irreversible cleavage, so therefore the extracellular domain must undergo recycling 
and the receptors and ligands must be replaced. This is in contrast to other types of 
signalling where the receptors can switch between on and off states by ligand binding 
(e.g. Wnt, PI3K, TGF-p signalling).
Notch signalling plays a role in controlling the differentiation of intestinal 
epithelial cells, Notch is predominantly active in the intestinal crypts and is thought to 
maintain the crypt progenitors in an undifferentiated state via upregulation of 
transcriptional repressor Hes1, which in turn represses Mathl (van Es et al., 2005). Loss 
of Mathl results in loss of secretory goblet and enteroendocrine cells (Yang et al., 
2001, van Es et a l., 2010). Whereas inhibition of Notch signalling, either via deletion of 
the Notch transcription factor CSL, the administration of y-secretase inhibitors 
(therefore preventing the cleavage of the NICD) or ectopic expression of Mathl in the 
adult intestine, causes the conversion of immature progenitors into terminally 
differentiated secretory cells (van Es et al., 2005, VanDussen and Samuelson, 2010). 
VanDussen and Samuelson also showed that epithelial ectopic expression of Mathl also 
induces expansion of stromal cells, which suggests that the intestinal stem cell niche 
may have expanded to try and maintain the undifferentiated status of the epithelial 
stem cells (VanDussen and Samuelson, 2010). A recent study by Pellegrinet et al 
further implicates inactivation of Notch, via deletion of Notch ligands Deltal and 
Delta4, with regulation of intestinal cell differentiation. Consistent with previous 
studies, inactivation of Notch signalling in the adult mouse intestine resulted in 
conversion of immature progenitors into secretory cell types. Interestingly these mice 
died rapidly after loss of Deltal and 4 due to crypt loss. Quantification of intestinal 
stem cells in this model indicated that loss of Deltal and 4 ablates the stem cell 
population (Pellegrinet et al., 2011). The observation made in Pellegrinet et al that 
intestinal epithelial specific deletion of Notch ligands DU1 and 4 phenocopies intestinal 
epithelial deletion of CSL and Notch receptor suggests that paracrine Notch signalling 
must be activated by neighbouring epithelial cells, unlike Hedgehog signalling which 
relies on stromal-epithelial interactions (see section 1.4.2). However, as manipulation
22
of Notch components in the stroma has not been investigated the contribution of 
activation of Notch from neighbouring stromal cells cannot be ruled out.
From the conditional manipulation of Notch signalling in the adult intestine it is 
established that Notch signalling is essential for maintaining the progenitor status of 
intestinal crypt cells and in maintaining sternness. Notch works in concert with Wnt 
activation to prevent differentiation of crypt cells whilst Wnt controls homeostasis by 
regulating proliferation.
1.4.5 The JNK pathway
The c-Jun N-terminal Kinase (JNK) signalling pathway is one of the Mitogen 
Activated Protein Kinase (MAPK) cascades. It phosphorylates the N-terminal of the 
oncoprotein c-Jun (a canonical-Wnt target gene) and activates it, amongst other 
proteins such p53 and Smad4, which then go on to allow the transcription of their 
target genes. JNK can be activated in many ways through the non-canonical Wnt 
signalling pathway (Boutros et al., 1998), receptor tyrosine kinases (RTKs), cytokine 
receptors (Minden et al., 1994, Sluss et a l., 1994), G protein-coupled receptors (Coso 
et al., 1995) and through stress conditions (Adler et al., 1995). Most of the pathways 
converge on activation of Mitogen activated protein kinase kinase kinases (AAAPKKK), 
which in turn activates MAP kinase kinase4/7 (MKK4/7) that activates JNK, others 
activate Rac which is upstream of MAPKKK.
There has been little research into the role of JNK in the intestine, however one 
study by Sancho et al showed that intestinal specific activation of JNK disrupts 
intestinal homeostasis (Sancho et al., 2009). JNK activation in mice caused an in 
increase in villus length, the proliferative zone and an increase in proliferation of CBC 
cells. They found an upregulation of c-Jun target genes such as cyclin D1 and CD44, 
interestingly they also found upregulation of genes associated only with the canonical- 
Wnt pathway, which were also Tcf4 target genes. They showed that certain Tcf4 target 
genes also have binding sites for c-Jun. This overlap in gene expression between the 
JNK and canonical-Wnt pathways is likely to be driving the JNK activated phenotype, as 
deletion of c-Jun results in a contrary phenotype of shorter villi and decreased 
proliferation. They also noted that activated JNK accelerates colitis-induced 
tumourigenesis, but has no effect on tumourigenesis in the Apc^"1 mouse intestinal 
tumour model (Sancho et al., 2009). Sancho et al postulated that this differential 
effect of JNK activation on the two models of intestinal tumourigenesis is due to 
activation of c-Jun. c-Jun is present at low levels in colitis induced intestinal tumours,
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so therefore JNK activation would accelerate tumourigenesis in this model by 
activation of c-Jun. However, tumours present in the Ape**"1 mouse model already have 
high levels of c-Jun present so activation of JNK would have no effect on 
tumourigenesis (Sancho et al., 2009).
1.5 The Fearon-Vogelstein model of colorectal cancer progression
Modulation of the aforementioned signalling pathways involved in intestinal 
homeostasis, through mutations in key tumour suppressors and oncogenes gives rise to 
CRC. The development of CRC is a multistep process in which the accumulation of a 
number of genetic mutations leads to the progression of a tumour from dysplastic 
epithelium, to benign adenoma through to metastatic carcinoma. In their seminal 
paper Fearon and Vogelstein proposed a model of the genetic pathway of CRC 
progression, by the comprehensive review of available histopathological and genetic 
data (Fearon and Vogelstein, 1990). This model has become the classical view of CRC 
progression. It describes mutations in the APC gene as the initiating mutation in the 
formation of a benign lesion, then subsequent mutations in kirsten rat sarcoma viral 
oncogene homolog (KRAS), allelic loss of 18q locus and mutation in p53, all 
contributing to the progression of a benign tumour to malignant disease (Figure 1.5). 
However, it would be naive to assume that all CRCs followed this pathway of 
progression exactly, Fearon and Vogelstein observed an increase in the number of 
these specific genetic alterations in more advanced tumours but each advanced tumour 
did not possess all alterations. They also suggested that it is not necessarily the order 
that these alterations occur for the formation of carcinoma but simply the 
accumulation of alterations that leads to advanced disease (Fearon and Vogelstein, 
1990). A further study by Smith et al into the common genetic alterations outlined by 
Fearon and Vogelstein, found that in a large cohort of CRCs only 6 .6% of the tumours 
analysed carried concomitant mutations in APC, KRAS and p53, suggesting that 
alternative pathways to the Fearon-Vogelstein progression pathway must also be 
involved in progression to carcinoma in the intestine (Smith et al., 2002).
1.5.1 APC and the canonical-Wnt pathway
APC is the first mutation implicated in the formation of CRC, loss of APC results 
in early adenoma formation (Powell et al., 1992). APC encodes a protein that plays a 
central role in the canonical-Wnt signalling pathway. As previously described, the 
canonical-Wnt signalling pathway is the main driving force behind sustained 
proliferation in the crypt and intestinal homeostasis (see section 1.4.1). Mutations that
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activate the canonical-Wnt pathway are thought to be the primary mutation in 
intestinal tissue that leads to tumour initiation. This is easy to understand, as acute 
Wnt pathway activation in the mouse driven by homozygous Ape deletion leads to rapid 
expansion of crypt progenitor-like cells and mouse morbidity (Sansom et al., 2004). 
There are other mutations in CRC, as well as loss of APC function, that result in Wnt 
pathway activation i.e. mutations that stabilise p-catenin (Morin et al., 1997) and 
deletion of the scaffold protein AXIN (Liu et al., 2000). Germline mutations in the gene 
APC give rise to the inherited condition familial adenomatous polyposis (FAP), where 
the patient is predisposed to the formation of many intestinal polyps that frequently 
progress to CRC (Kinzler et al., 1991). Deletion of APC or stabilisation of p-catenin 
renders the destruction complex of the canonical-Wnt pathway useless. APC associates 
with p-catenin allowing it to be marked for degradation via phosphorylation by GSK-3 
(the canonical Wnt pathway is outlined in Figure 1.3). Loss of Ape, Axin or mutation of 
p-catenin preventing its phosphorylation results in constitutively active Wnt signalling.
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Figure 1.5 The Fearon-Vogelstein step wise progression of CRC
The schematic diagram outlines the proposed pathway of progression in the formation 
of metastatic colorectal cancer from normal epithelium. Below each stage is a 
schematic view of the intestinal epithelium, the pink circles represent neoplastic cells, 
the straight line represents the smooth muscle wall. Loss of APC is regarded as the 
initiating mutation and the first step towards tumour formation, additional activation 
of oncogenes such as KRAS and loss of the 18q chromosome arm culminate in the 
formation of invasive adenocarcinomas. Finally, loss of the tumour suppressor p53 
promotes metastasis of the tumour.
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1.5.2 Kras and the MAPK/Erk pathway
Mutations in the oncogene KRAS are the next step in progression from early 
adenoma to intermediate adenoma. KRAS is the downstream mediator of the Mitogen 
activated protein kinase/Extracellular regulated MAP kinase (MAPK/Erk) pathway. The 
MAPK/Erk pathway is an elaborate kinase cascade signalling pathway, one of the family 
of MAPK cascades, which is primarily implicated in development, growth and cancer. 
The MAPK/Erk pathway is stimulated by RTKs, integrins and influx of calcium ions. In 
the case of RTKs and integrin mediated stimulation, activation of the receptors lead to 
the activation of Growth factor receptor-binding protein 2 (Grb2), which activates Sons 
of Sevenless homolog (SOS) that in turn activates the small GTPase KRAS. SOS 
facilitates the dissociation of GDP and subsequent binding of GTP to Kras, which causes 
the protein to become active. Kras activates both CRAF and BRAF, which 
phosphorylates the mitogen activated kinase1/2 (MEK1/2), and which in turn 
phosphorylates Erk that then goes on to act on its cytoplasmic and nuclear targets, the 
majority of which are transcription factors.
Mutations in KRAS are frequently found in many cancers, and it is thought to be 
one of the most activated oncogenes (Kranenburg, 2005). Approximately 40% of CRCs 
contain mutations in the KRAS gene (Bos et al., 1987, Smith et al., 2002), and the 
majority of these mutations occur at codon 12 (Bos et al., 1987). Mutations in codon 12 
prevent the association of guanine nucleotide exchange factor (GEF) with KRAS 
therefore inhibiting the dissociation of ATP, leaving Kras permanently bound to GTP 
and therefore permanently in an ‘on state’ . Mutations in other proteins involved in 
MAPK include BRAF. For example, a study by Rajagopalan et al found that in a set of 
primary CRCs, BRAF mutations occur less frequently than KRAS mutations and that 
mutations in these genes are mutually exclusive (Rajagopalan et al., 2002). The dual 
role of KRAS in activating the PI3K pathway (see section 1.5.5.1) may explain why this 
gene is more commonly mutated in cancers than BRAF. KRAS and BRAF mutations are 
commonly regarded to be involved in tumour progression (Fearon and Vogelstein, 1990, 
Rajagopalan et al., 2002). However, there is also evidence to suggest that these 
oncogenes may also be involved in the initiation of intestinal tumours (Jass et al., 
1999) and they form the basis of an alternative pathway of CRC formation called the 
Serrated Adenocarcinoma pathway (Makinen, 2007).
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1.5.3 Allelic loss of 18q and TGF-p/BMP pathway
Fearon and Vogelstein describe allelic loss of the 18q chromosomal region as a 
common genetic aberration found in 70% of carcinomas and 50% of late adenomas. 
They suggest that the candidate tumour suppressor deleted in colorectal cancer (DCC) 
found in this region of the chromosome may be responsible for tumour progression, as 
it is commonly lost in carcinomas but present in normal mucosa (Fearon and 
Vogelstein, 1990, Fearon et al., 1990). The DCC gene encodes a receptor for the ligand 
netrin that controls axonal growth in development (Keino-Masu et al., 1996). The role 
of DCC in the intestine is unclear despite its loss in carcinomas, deletion of gene in the 
mouse had no phenotypic effect on the intestine (Fazeli et al., 1997). DCC'7' mice died 
shortly after birth, however DCC+/' mice survived into adulthood but did not possess 
any predisposition for intestinal tumours. Heterozygous DCC loss did not promote 
tumour progression or multiplicity in Apc^" mice. Fazeli et al suggest that the loss of 
DCC in human CRC may only be a consequence of loss of part of chromosome 18 and 
other linked genes may be responsible for tumour phenotypes (Fazeli et al., 1997).
Another gene found at the 18q locus that may be linked to CRC is Smad4 (also 
known as DPC4) (Thiagalingam et a l., 1996). As previously described in section 1.4.3, 
Smad4 is involved in the downstream signalling of the TGF-p/BMP pathway, known also 
as the co-Smad. When bound to its coactivators, Smad4 activates transcription of the 
pathways target genes. Smad4 is commonly found to be mutated in the germline of JPS 
patients (Howe et al., 1998). As previously mentioned, Smad4+/' mice are predisposed 
to intestinal tumours, through loss of heterozygosity (LOH) of the gene (Hohenstein et 
al., 2003, Takaku et al., 1999). In another study Takaku et al showed that Smad4 
deletion in cis with Ape mutation (Ape is also on chromosome 18 in the mouse) 
enhances the malignancy of tumours arising in these mice through LOH, specifically 
loss of the remaining whole chromosome 18 (Takaku et al., 1998). Despite these 
studies confirming a role for Smad4 in intestinal tumourigenesis, epithelial specific loss 
of Smad4 does not promote tumour initiation, but T cell specific loss does (Kim et al.,
2006). Takaku et al show evidence of enhanced stromal components in Ape**1" Smad4+/' 
tumours (Takaku et al., 1998). Evidence in JPS patients also suggests a stromal role for 
the gene in promoting tumourigenesis (Kinzler and Vogelstein, 1998). Taken together 
these findings suggest that stromal loss of Smad4 plays a role in tumourigenesis. 
Another gene associated with CRC also located on chromosome 18q and implicated in 
TGF-p signalling is Smad2 (Eppert et al., 1996). There have been no reported mouse 
models of intestinal specific Smad2 knockout, and constitutive Smad2 knockout mice 
are embryonic lethal so no intestinal phenotype has been observed (Waldrip et al.,
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1998). Taken together, allelic loss of 18q is closely associated with CRC progression, 
this association is likely to be linked to a number of tumour suppressors found at this 
locus most likely Smad4 and Smad2.
1.5.4 Mutation of p53 and malignancy
The final mutation in the Fearon-Vogelstein model of CRC progression occurs in 
the p53 gene, which is thought to be responsible for progression to malignant disease 
(Fearon and Vogelstein, 1990). The p53 gene was the first tumour suppressor gene to 
be discovered (Vogelstein et al., 2000), it responds to cellular stresses that cause DNA 
damage allowing the cell to either repair the damaged DNA, or undergo apoptosis. In 
normal cellular conditions p53 is present in cells at low levels and bound to the protein 
mouse double minute 2 homolog (MDM2), MDM2 ubiquitinates p53 causing it to be 
degraded. Modifications of the p53 protein (e.g. phosphorylation, acetylation and 
sumoylation) induced by cellular stress and DNA damage cause conformational changes 
in p53 preventing its association with MDM2, which allow it to enter the nucleus and 
promote transcription of cell cycle inhibitors or mediate apoptosis, p53 function is 
reviewed in (Vogelstein et a l., 2000). Loss of p53 function therefore removes the 
‘braking-system’ of the cell that allows it to repair DNA damage or undergo apoptosis 
before continuing to proliferate, thus predisposing the cell to mutations and neoplastic 
transformation. Germline mutations in the p53 gene underline the hereditary condition 
called Li-Fraumeni syndrome, in which the individual is predisposed to cancers at 
multiple sites (Malkin et al., 1990). The fundamental role of p53 as ‘guardian of the 
genome’ means that as observed in Li-Fraumeni patients, p53 mutations are found in 
an array of sporadic cancers (Nigro et al., 1989). In CRC, lacopetta et al found that in a 
large cohort study p53 mutations are more frequent in late stage tumours and are 
associated with poor prognosis (lacopetta et al., 2006). Despite the strong association 
of p53 mutations with CRC, mouse models of p53 loss in the context of intestinal 
tumourigenesis have failed to show progression to malignancy. Clarke et al 
demonstrated that mice predisposed to intestinal tumour formation and deficient for 
p53 (Ape*'" p53'/ ) displayed no increase in intestinal tumourigenicity or tumour 
progression (Clarke et al., 1995). Similarly Reed et al showed that p53 loss has no 
effect on acute activation of the Wnt pathway in the intestine, and hence no role in 
early adenoma formation (Reed et al., 2008). One caveat with mouse models of p53 
deficiency is that in humans, more frequently the p53 gene acquires point mutations 
that do not compromise the production of the full length p53 protein but render it
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unable to transactivate gene transcription (Petitjean et al., 2007). In light of this 
Muller et al crossed mice bearing a mutated allele of p53 with mice heterozygous for 
Ape (Apc/,/+) and compared them to mice that were had heterozygous deficiency of p53 
and Ape. They found that the mice bearing the mutated p53 allele bore similar 
numbers of intestinal tumours to mice deficient for p53, but the tumours in the mutant 
p53 mouse were more advanced. They suggest that some mutations in p53 cause a 
gain-of-function in which the mutated p53 is able to promote invasion, so in intestinal 
mouse models of p53 deficiency the tumours do not become more malignant as they do 
not have the gain-of-function mutation (Muller et al., 2009).
1.5.5 Other signalling pathways implicated in CRC
1.5.5.1 The PI3K/mTOR pathway
Alterations in a number of genes in the PI3K/mTOR pathway are associated with 
CRC. Genes such as phosphatase and tensin homolog deleted on chromosome ten 
(PTEN), which is a negative regulator of the PI3K pathway and serine theronine kinase 
11 (STK11 or LKB1), which is negative regulator of the mammalian target of rapamycin 
(mTOR) pathway (which is activated by PI3K) are both implicated in famlial intestinal 
tumour predisposition syndromes. The germline mutation of tumour suppressor PTEN is 
associated with PTEN Hamartoma Syndromes (PTHS) the most common of which being 
Cowden’s syndrome (Blumenthal and Dennis, 2008), and germline mutation of LKB1 is 
associated with Peutz-Jeghers syndrome (Jenne et al., 1998).
The Phosphatidylinositol-3-Kinase (PI3K) signalling pathway (Katso et al., 2001) 
controls proliferation, apoptosis and cell growth by regulating the activation of 
thymoma viral oncogene homolog also known as Akt or Akt1, the downstream effector 
protein of the pathway. The PI3K protein is activated either by receptor ligand binding 
(receptors include, receptor tyrosine kinases, integrins, G protein coupled receptors 
and cytokine receptors) or by direct activation of its p110 catalytic subunit by 
activated KRAS. When activated PI3K phosphorylates the inositol ring of 
phosphatidylinositol 4,5-bisphosphate (PI[4 ,5]P2 or PIP2) converting it to
phosphatidylinositol (3,4,5)-trisphosphate (PI[3,4,5]P3 or PIP3), PIP3 allows the 
recruitment of Akt to the membrane where it is phosphorylated and therefore 
activated by phosphoinositide-dependent protein kinase 1 (PDK1). Akt is a kinase and 
when phosphorylated it is able to, in turn phosphorylate many proteins such as mTOR, 
GSK-3 and p21Clp, phosphorylation of these proteins results in increased proliferation, 
protein synthesis, glucose metabolism and enhanced cell survival. Negative regulation 
of Akt activation is controlled by the phosphatase PTEN. PTEN dephosphorylates the
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inositol ring of PIP3 converting it back to PIP2 thus preventing recruitment of Akt to the 
cell membrane and its subsequent phosphorylation. In sporadic CRCs Samuels et al 
showed that mutations in the PIK3CA gene that encodes the catalytic subunit of PI3K 
were found in 32% of CRCs that they analysed, and these mutations were more 
frequently found in more advanced cancers (Samuels et al., 2004). Findings by Parsons 
et al corroborate this, with 40% of CRCs bearing mutations in genes involved in the 
PI3K pathway (Parsons et al., 2005). The association of PI3K activation with more 
advanced carcinomas was demonstrated in vivo in a study by Marsh et al, in which 
invasive adenocarcinomas were observed in mice that were heterozygous for Ape and 
were also deficient for Pten (Marsh et al., 2008).
1.5.5.2  Mutations in DNA repair machinery
Other mutations that are commonly associated with CRC occur in genes 
associated with mismatch repair of DNA. Mismatch repair (MMR) involves proteins that 
proofread newly synthesized DNA and repair erroneous bases or microsatellite repeats 
that have been miscopied and have become elongated. Germline mutations of genes 
involved in MMR cause Hereditary Nonpolyposis Colorectal Cancer (HNPCC), commonly 
mutation of the genes MutS E.Coli homolog of 2 (MSH2) and MutL homolog 1 (MLH1) are 
associated with the condition (Fishel et al., 1993, Leach et a l., 1993, Bronner et al., 
1994). HNPCC is an autosomal dominant disease, patients have an increased risk of CRC 
but are not subject to multiple intestinal polyps. It is reported that an estimated 4-6% 
of all CRC cases are a result of HNPCC (Lynch et al., 1991). As well as mutation of 
mismatch repair genes, epigenetic silencing of MSH2 has also been observed as a 
mechanism of heritable CRC (Chan et al., 2006). As expected mice that are deficient 
for Mlh1 bear many intestinal tumours (Prolla et al., 1998). Msh2 deficient mice 
develop lymphomas at an early age and most mice die from these tumours, however 
the mice that do not succumb to lymphoma develop Ape deficient intestinal tumours 
(Reitmair et al., 1996).
1.6 Conditional transsenesis techniques
Development of the techniques by Capecchi, Evans and Smithies required to 
generate mice with targeted disruptions in a gene of interest (knockout mice) (Evans 
and Kaufman, 1981, Thomas and Capecchi, 1987, Doetschman et al., 1987), was a 
turning point in how we now investigate how genes work in a whole body system. Prior 
to this technology cancer research relied on the random disruption of genes induced by
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a mutagenic compound, and once a tumour arose the arduous task of identifying the 
gene that was responsible had to be undertaken. Some, but not all, of the genes 
required for carcinogenesis are often also required for development (i.e. genes 
controlling cell proliferation, death and growth), so when these genes are inactivated 
in the mouse it often results in embryonic or perinatal lethality. Despite this, often a 
mouse can reach adulthood with only one intact copy of the gene. These mice can 
therefore be used to study the heterozygous effects of gene loss. The drawbacks with 
this kind of study are that homozygous loss or mutation of gene is often needed for 
tumourigenesis. Gene loss in the context of a particular tissue is also difficult to 
evaluate as knockout is achieved in every cell type, often resulting in tumours arising 
in a number of tissues. To circumvent the drawbacks with constitutive knockout mice, 
the techniques pioneered by Capecchi, Evans and Smithies have been used to 
incorporate systems into the mouse genome that allow the conditional alteration of 
gene expression in a specific tissue of interest at a particular point in mouse 
development or at adulthood.
1.6.1 Tet-on and Tet-off systems of conditional gene expression
The tet-on system of gene expression is a reversible system used to spatially 
and temporally control the expression (or knock in) of a particular transgene, for 
example the oncogenic form of a gene. The tet-on system utilises the protein-DNA 
interactions of the tetracycline repressor protein and its target 19-bp DNA operator 
sequences of the tetracycline operon from E. coli, and the transactivating domain of 
the herpes simplex virus protein VP16 to direct transcription of a specific gene inserted 
downstream of the tetracycline operon. Two transgenes are inserted into the mouse 
genome, one under the control of a tissue specific promoter encoding the tetracycline- 
controlled transactivator (tTA) - a fusion protein of the tetracycline repressor protein 
and the VP16 protein transactivation domain, and the other encoding the gene of 
interest downstream of Tet operon (tetO) sequences. The tTA is expressed in the tissue 
of interest and binds to the tetO sequences, present only in the transgene. The 
transactivating domain of the tTA protein then allows expression of the downstream 
target gene of interest. Tissue specific expression of the tTA occurs constitutively, so 
therefore expression of the transgenic gene of interest is also constitutively active. 
However, when doxycycline is present it binds to the tTA and prevents it from binding 
the tetO sequences and switches off expression of the transgenic gene of interest 
(Gossen and Bujard, 1992, Kistner et al., 1996). The tet-off system of transgene
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expression utilises the reverse tetracycline-controlled transactivator (rtTA), which only 
binds tetO DNA sequences in the presence of doxycycline. The tet-on/off systems can 
be used to allow expression of an oncogenic form of a gene, or to allow tissue specific 
expression of a ere recombinase gene that in turn deletes a gene of interest (see 
section 1.6 .2 ).
1.6.2 Site specific DNA recombination
Recombinase enzymes, found in bacteria and yeast, are able to recognise small 
specific sequences of DNA, cut and ligate DNA at these sequences, resulting in deletion 
or inversion of a region of DNA. The insertion of recombinase transgenes, along with 
their recognition sequences into the mouse genome has allowed site-specific 
recombination of DNA in the mouse that can be temporally and spatially controlled. 
These systems can be used to delete sections of DNA in a gene to cause knockout of 
the gene, delete sequences to alter the function of a gene and they can also be used 
to activate expression of a gene (knock-in genes). The two recombinase genes that 
have been inserted into the mouse genome are the ere recombinase gene from 
bacteria, and the flippase (FLP) gene from yeast, along with their 34-bp recognition 
sites, locus of crossover of bacteriophage P1 (loxP) and FLP recognition target (FRT) 
sites respectively, flanking the gene of interest. LoxP and FRT sites are not found 
endogenously in the mouse genome, hence genetic manipulation is restricted to the 
DNA sequence of interest. Recombination events can also occur between loxP or FRT 
sites inserted in different regions of a chromosome and in different chromosomes to 
give rise to chromosomal translocations and rearrangements.
The cre-loxP system was first shown to be useful for site-specific recombination 
in mammalian cells to manipulate the genome (Sauer and Henderson, 1988), and later 
shown to be useful in vivo (Schwenk et al., 1995, Orban et al., 1992). Manipulation of 
the mouse genome by the addition of a ere recombinase transgene and homologous 
recombination of a loxP flanked gene of interest (replacing the endogenous gene) is 
carried out in mouse embryonic stem (ES) cells and inserted into separate embryos, 
therefore producing mice with just the ere recombinase transgene and mice with the 
loxP targeted allele. An animal bearing a specific ere recombinase transgene can then 
be crossed with an animal bearing loxP sites to generate mice that have both. When 
ere recombinase is expressed in this mouse it will recombine the DNA at the loxP sites, 
removing the section of DNA between them. A tissue specific promoter upstream of the 
ere recombinase gene allows spatial control over where it is expressed in the mouse,
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further temporal control of ere recombinase can be achieved by using the CreER1 
transgene. The CreER1 transgene encodes for a ere recombinase-estrogen receptor 
fusion protein, ere recombinase is fused to a mutated ligand binding domain of the 
human estrogen receptor, which is activated by only tamoxifen binding but not by 
endogenous mouse estradiol (Figure 1.6). When tamoxifen binds it allows re­
localisation of ere recombinase to the nucleus where it can act on the DNA (Feil et al.,
1996). The insertion of an inducible promoter upstream of ere recombinase constitutes 
another mechanism of temporal control of ere recombinase action. Examples of this 
type of ere recombinase induction include Ahcre and Mx1 ere. Ahcre recombinase is 
expressed from the cyplal promoter, which is induced in response to introduction of a 
xenobiotic. Xenobiotics such as p-naphthoflavone can be administered via 
intraperitoneal (i.p .) injection. These then bind to Ah (aryl hydrocarbon) receptors 
that are translocated to the nucleus to induce expression of cyplal target genes - 
allowing the expression of ere recombinase (Ireland et al., 2004). Similarly to Ahcre, 
Mx1 ere expression is induced by the introduction of synthetic double stranded DNA or 
interferon (Kuhn et al., 1995). Inducible and tissue-specific expression of ere 
recombinase is outlined in Figure 1.6.
The FLP-FRT system works in the same manner as the cre-loxP system. A site 
specific recombinase from the yeast saccharomyces cerevisiae FLP is inserted as a 
transgene (with a tissue specific promoter) into the mouse genome, along with its 
recognition sequences (FRT sites) flanking the gene of interest (O’Gorman et al., 1991, 
Dymecki, 1996). Much like the ere recombinaseER transgene, a flippaseER transgene 
has been generated that allows temporal control of its action (Hunter et al., 2005).
The Cre-loxP and FLP-FRT systems as well as being used to excise a region of 
DNA they can also be used to change its orientation. This is achieved by inserting loxP 
or FRT sites so that they are in opposite orientation to each other. The ere 
recombinase or flippase then excises the region of DNA between them and inverts the 
section of DNA. The Brainbow® system exploits the excision and inversion properties of 
the recombinase systems to allow the expression of a number of different coloured 
fluorescent proteins. This system allows the labeling of cells with up to 90 different 
colours due to the inversion or excision of four different coloured fluorescent proteins 
in different combinations (Livet et al., 2007).
1.6.3 Modeling colorectal cancer in the mouse
One of the first mouse models to demonstrate intestinal tumourigenesis was the 
Min (Multiple Intestinal Neoplasia) mouse. The Min mouse was derived from a line of
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mice which were treated with ethylnitrosurea and were predisposed to the formation 
of intestinal tumours (Moser et al., 1990). These mice developed multiple benign 
adenomas but they did not progress to adenocarcinoma. After establishment of the Min 
mouse line, the gene mutation responsible for the phenotype was mapped and 
discovered to be present in murine homologue of the APC gene. Therefore, the Min 
(Ape*'") mouse was a model of the human hereditary CRC predisposition syndrome FAP 
(Su et al., 1992). This mouse model has been used extensively to study how 
environmental changes, genetic alterations and drugs impact on intestinal 
tumourigenesis, as frequently mentioned throughout this introduction. As homozygous 
Ape loss is embryonic lethal, a conditional Ape knockout mouse was generated, 
therefore allowing temporal and spatial control of Ape deletion as well as investigation 
of homozygous Ape loss, which is not possible in the Ape**1" mouse (Shibata et al.,
1997).
Conditional transgenesis allows the generation of mice that bear many loxP 
targeted tumour suppressors and oncogenes, that can be deleted or activated in a 
spatial and temporal manner, thus allowing more faithful recapitulation of human 
cancer, which has mutations in many genes. The availability of many loxP targeted 
genes and the development of tissue specific transgenic expression of ere recombinase, 
such as VillinCre (intestinal specific) and AtoCre (intestinal and other epithelial tissues) 
(El Marjou et al., 2004, Ireland et al., 2004), has allowed the development of mouse 
models that possess more invasive intestinal tumours than those observed in the Ape**1'1 
mouse. For example the Apc/,/+ Pten/,7// mouse that develops invasive adenocarcinoma 
of the small intestine (Marsh et al., 2008) and the lnk4a/Arf/,//* KrasG,2D mouse that 
develops metastatic intestinal carcinoma (Bennecke et al., 2010). Currently all drug 
testing is carried out on xenografted human tumours in immunocompromised mice 
which often fail when they reach clinical trials (Garber, 2006), so the development of 
mouse models of CRC that represent the array of human tumour types and the differing 
stages of malignancy observed in the clinic is advantageous for the future of 
translational research.
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Figure 1.6 Mechanisms of controlling the activity of Cre recombinase
Key: IP - inducible promoter, TSP - tissue specific promoter
Top panel: Schematic diagram of inducible Cre recombinase. Mice are administered an 
inducing molecule such as interferon or p-naphthoflavone, which enters the cell and 
initiates transcription of the Cre recombinase gene. For further control of Cre 
recombinase activity it is sometimes fused to a mutated estrogen receptor that 
requires tamoxifen binding to translocate the protein to the nucleus. In this case 
tamoxifen is administered with the inducing molecule.
Bottom panel: Schematic diagram of tissue specific expression of Cre recombinase. 
Some mice possess a Cre recombinase transgene that is expressed from a tissue 
specific promoter so is only expresses in the tissue of interest. In order to gain 
temporal control an estrogen receptor-Cre recombinase fusion protein is expressed (as 
described above) so Cre recombinase even though is constitutively expressed only 
translocates to the nucleus after administration of tamoxifen.
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1 .7  Aims and O bjectives
The two main objectives of this thesis are to develop better models of CRC that 
possess more advanced disease than the currently published models, and to investigate 
the role of the tumour suppressor Pten in adult mouse intestinal stromal fibroblasts 
and smooth muscle.
To address the first objective I will be drawing on a previously published study by 
Marsh et al. This study showed that intestinal Pten loss in the context of Ape driven 
tumourigenesis promoted tumour progression. This resulted in the mouse developing 
invasive intestinal adenocarcinoma but not metastatic carcinoma (Marsh et al., 2008). I 
will be investigating potential synergy between Pten and Kras in the Apc/,/+ Pten/<;/* 
model of intestinal tumourigenesis, achieved by the addition of an oncogenic Kras 
(G12V) mutation to generate Apc/,/+ Pten//7// KrasLSL/+ mice. I will also be investigating 
the synergistic effect of Pten loss and Kras activation on normal intestinal homeostasis. 
These studies are outlined in Chapters 3-6.
Further to this study I will take another approach to achieving metastasis in the 
Apc/,/+ Pten;,//< model, through the additional deletion of the Cadherinl (Cdh1) gene, 
which encodes the cell-adhesion protein E-cadherin. Down regulation or loss of E- 
cadherin is associated with tumour progression and invasiveness of CRC. This is 
primarily owing to its role in cell adhesion. Therefore, its loss may result in easier 
detachment of tumour cells. I will first investigate the effect of homozygous and 
heterozygous loss of Cdh1 on the intestinal epithelium, and I will then investigate the 
role of this gene in tumour formation and progression in the Apc/,/+ Ptenfl,fl model. 
These studies are described in Chapter 7.
The rationale behind the second objective also arises from findings in the Marsh 
et al study. Here, intestinal epithelial Pten loss does not result in predisposition to 
intestinal tumours (Marsh et al., 2008). However, a study by He et al found that Pten 
loss from both the intestinal epithelium and underlying stroma gives rise to rapid 
tumourigenesis (He et al., 2007). To address the stromal role of Pten in intestinal 
tumourigenesis, I will investigate the short term and long term effects of Pten loss in 
the intestinal stroma. This will be achieved by conditionally deleting Pten 
homozygously from intestinal stromal and smooth muscle fibroblasts, using a fibroblast 
specific Cre recombinase (Col1A2 cre). This study is described in Chapter 8.
36
Chapter 2: Materials and Methods
2 .1 E xperim ental Animals
The house mouse (Mus musculus) was used as an experimental model in this 
thesis. All mice used were of outbred background.
2.1.1 Genetic Mouse Models
A number of transgenic mouse models were obtained from various laboratories 
(outlined in Table 2.1) and crossed to investigate their compound effects on intestinal 
tumourigenesis. Two different cre recombinase transgenes were used, W///nCreERT, 
which is expressed in the intestinal epithelium, and C ollA2CreERT, which is expressed 
in fibroblasts. Both cre recombinase transgenes were fused to a mutated estrogen 
receptor, this allows the cre recombinase protein to only be translocated to the 
nucleus in the presence of tamoxifen. Mice bearing a cre recombinase transgene were 
crossed with mice bearing one or more loxP targeted alleles including Pten, Ape, Cdh1 
and an oncogenic Kras allele controlled by a loxP flanked transcriptional stop cassette. 
A schematic representation of how gene knockout and Kras knock-in was controlled is 
outlined in Figure 2.1.
Transgene Tissue expression
Villin Cre ERT (El Marjou et 
al., 2004)
Intestinal epithelial cells, tamoxifen inducible
Col1a2 Cre ERT (Zheng et 
al., 2002)
Fibroblasts and smooth muscle, tamoxifen inducible
loxP targeted Pten allele 
(Suzuki et al., 2001)
Endogenous Pten allele bearing loxP sites flanking exons 4 
and 5
LoxP targeted Ape allele 
(Shibata et al., 1997)
Endogenous Ape allele bearing loxP sites flanking exon 14
Kras knock-in (Guerra et 
al., 2003)
Mutated Kras allele (G12V) bearing a loxP flanked 
transcriptional stop cassette in the 5’UTR replacing the 
endogenous allele
loxP targeted Cdh1 (E- 
cadherin) allele (Derksen 
et al., 2006)
Endogenous Cdh1 allele bearing loxP sites flanking exons 3 
and 15
Table 2.1 Outline of the transgenic mice used in this thesis
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loxP flanked gene
A essential exons A
-A — i----------h -------- i— A -
loxP
Conditional Gene Knockout
Cre recombinase transgene
- X -
loxP
Tissue
sp ec ific -
p ro m o te r
Cre recom binase
Induce w ith  
tamoxifen
Floxed gene 
Oncogenic Kras Knock-in
loxP
loxP flanked stop 
cassette
stop  cassette
Cre recombinase transgene
-L v w - r
loxP Kras<G12V)
Tissue  
spec ific - 
p ro m o te r
Cre recom binase
^___________  Induce w ith
tamoxifenv
Kras(G12V)
Figure 2.1 Outline of conditional transgenesis models used
Mice were generated that bore both loxP flanked genes and a cre recombinase 
transgene. Conditional knockout animals such as Ape, Pten and Cdh1 had the 
endogenous allele replaced by an allele containing loxP sites flanking essential exons of 
the gene. When cre recombinase is activated it recombines DNA at these loxP sites 
causing gene knockout. Conditional knock-in animals such as the oncogenic Kras knock- 
in mouse have one endogenous allele of Kras replaced with an oncogenic version of the 
gene (in this case G12V missense mutation), the expression of this oncogenic allele is 
controlled by the insertion of loxP flanked transcriptional stop cassette upstream of 
the gene. When cre recombinase is activated in this case, it removes the 
transcriptional stop cassette and allows expression of the oncogenic allele.
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2.1.2 Animal Husbandry
All animals were housed according to UK Home Office Regulations, mice were 
given access to diet (Special Diets Service UK, RM3[E] expanded diet) and fresh tap 
water ad libitum .
2.1.3 Colony Maintenance
Some animals were used for breeding. This was carried out by setting up cages 
of trios consisting of one male and two females. Pups were weaned at approximately 4 
weeks of age and ear biopsies taken for identification and DNA extraction (see section
2.3.1). Mice were genotyped to ascertain the correct alleles were present before being 
used for breeding or experimental procedures.
2.1.4 Experimental cohorts
Cre recombinase mediated recombination was induced in mice aged around 6-12 
weeks. They were then monitored closely and sacrificed either at a set time point or 
when they became symptomatic of intestinal tumour burden or other disease. Signs of 
intestinal tumour burden were intestinal prolapse, anaemia (as judged by paling of 
foot pads), swelling of the abdomen and diarrhoea.
2.2 Experimental Procedures
All procedures were conducted according to UK Home Office Regulations.
2.2.1 Ear Biopsies
Lucie Pietzka and Aneta Gerstyn provided assistance in carrying out routine ear 
biopsies on newly weaned mice. Ear biopsies were taken using a 2mm ear punch 
(Harvard Apparatus) from each mouse for identification, and the tissue removed was 
subsequently used to extract DNA for genotyping (see section 2.3.1).
2.2.2 Administration of Tamoxifen
Induction of cre recombinase activity in mice bearing the W///nCreERT and 
Col1A2CreERJ transgenes was controlled by tamoxifen binding to a mutated estrogen 
receptor fused to the cre recombinase protein. Tamoxifen (Sigma) was dissolved at a 
concentration of 1 mg/ml in corn oil (Sigma) in a waterbath at 80°C. An 80mg/kg dose
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of tamoxifen was administered to each experimental mouse via intraperitoneal (i.p .) 
injection daily, for four consecutive days. For the administration of an 8mg/kg dose, 
1 mg/ml tamoxifen in corn oil stock was diluted 1 in 10 in corn oil, and was used to 
administer an 8mg/kg dose via i.p. injection for four consecutive days.
2.2.3 Administration of 5-Bromo-2-deoxyuridine
Some experimental animals were injected i.p. with an excessive dose of 0.2ml of 
5-Bromo-2-deoxyuridine (BrdU, Amersham Biosciences) (a thymidine analogue) either 
2, 24 or 48 hours before sacrifice in order to label cells currently undergoing or have 
passed through S-phase in the two hours in which the molecule is bioavailable.
2.3 Polymerase Chain Reaction (PCR) Genotyping
Mark Bishop and Lucie Pietzka provided assistance in routine PCR genotyping of 
animals.
2.3.1 DNA extraction from tissue samples
DNA was extracted from ear biopsies, taken from mice after weaning and/or 
intestinal mucosal scrapings (see section 2.4.5.1). The tissue sample was stored at - 
20°C prior to extraction. Tissue was digested in 250^1 lysis buffer (Puregene) containing 
0.4mg/ml Proteinase K (20mg/ml stock, Roche), overnight at 37°C with agitation. 
Protein was precipitated by addition of 100pl of protein precipitation solution 
(Puregene), the solution was mixed by inversion and protein and any insoluble debris 
was pelleted by centrifugation at 14000 x g for 10 mins. The supernatant was removed 
and added to a tube containing 250pl of isopropanol to precipitate the DNA. The tube 
was inverted to mix, and centrifuged at 14000 x g for 15 mins to pellet the DNA. The 
supernatant was removed and the pellet left to air dry for 1 hour, the DNA was then 
resuspended in 250pl of PCR grade water (Sigma).
DNA extracted from ear biopsies was used to carry out the polymerase chain 
reaction (PCR) to determine the genotypes of newly weaned animals, and on DNA from 
experimental animals that had been dissected to re-confirm the original PCR 
genotyping. DNA extracted from intestinal mucosal scrapings was used to determine 
the presence of the recombined loxP targeted alleles (described in section 2.10)
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2.3.2 Generic protocol for PCR genotyping
PCR reactions were carried out to detect the presence of loxP sites in targeted 
alleles, and a cre-specific PCR was used to detect the presence of both V////nCreERT 
and Co/M2CreERT recombinase transgenes. The primers used in each PCR reaction 
(unless previously published primers were used) were designed using the web-based 
program Primer 3 (h ttp ://frodo.w i.m it.edu/prim er3/), and then primers were verified 
for mis-priming using a web-based in silico PCR program, UCSC In-Silico PCR 
(http://genome.cse.ucsc.edu/cgi-bin/hgPcr?command=start). Reactions were carried 
out in either 96-well PCR plates (Grenier Bio-One), or thin-wall 12-well strip tubes 
(Grenier Bio-One). 2.5^1 of gDNA extracted from ear biopsies (described in section
2.3.1) or control PCR grade water was pipetted into each well (singular reactions for 
each gene of interest were carried out on each sample, but were repeated when 
mouse was dissected to confirm genotype), and a PCR reaction mix containing PCR 
grade water (Sigma), magnesium chloride (Promega), dNTPs (25mM, dATP, dTTP, 
dCTP, dGTP, Bioline), DNA polymerase (either Dream Taq [Fermentas] or GO Taq 
[Promega]), PCR buffer (Promega) and gene specific primers (Sigma Genosys) were 
added to each well to make a final volume of 50^1 (specific primer sequences for each 
reaction are outlined in Table 2.2. Reaction mixtures for each PCR are outlined in 
Table 2.3). 96-well plates were sealed with aluminium foil (Grenier Bio-One) and 12- 
well strip tubes sealed with caps (Grenier Bio-One), air bubbles were removed by 
tapping the sealed wells on a hard surface. The PCR reaction was then run in a GS4 
thermocycler (G storm). Cycling conditions for each reaction are described in Table 
2.3.
2.3.3 Visualisation of PCR products
After the PCR reactions were carried out, PCR products were visualised by gel 
electrophoresis. 2% agarose gels were made by dissolving agarose (Eurogentech) 2% 
[w/v] in 1X Tris-Borate-EDTA (TBE) buffer (Sigma) and heated in a microwave until 
boiling. Once boiled the gel was cooled quickly under cold running water and 14^1 of 
Safe View (NBS Biologicals) was added per 400ml of gel (Safe View is a nucleic acid 
stain that binds to DNA and fluoresces under UV light allowing visualisation of DNA). 
Gel was then poured into moulds (Bio-Rad) and combs placed to create wells. After 
gels were set they were placed in a gel electrophoresis tank (in their moulds) and 
covered with 1X TBE (Sigma). Safe View (NBS Biologicals) was also added to the buffer.
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PCR product samples were prepared by adding 5pl of loading dye (50% Glycerol 
[Sigma], 50% ultrapure dH20 , 0.1% [w/v] bromophenol blue [Sigma]), ensuring 
adequate mixing by gentle pipetting. PCR samples (20pl) were added to the wells and a 
molecular weight marker e.g. 100bp ladder (Promega) was added to one well in order 
to assess PCR product size. The gel was then run at 120V for approximately 30 mins, 
and products visualised using a GelDoc UV transilluminator (Bio-Rad), and images of 
PCR products captured using GelDoc software (Bio-Rad).
Gene Forward Primer Sequence (5’-3’> Reverse Primer Sequence (5’-3’>
Cre specific T G ACCGT ACACC AAAATTT G ATT GCCCCT GTTT CACT AT C
Pten-loxP CTCCTCTACTCCATTCTTCCC ACTCCCACCAATGAACAAAC
Apc-loxP GTTCTGTATCATGGAAAGATAGGTGGTC CACTCAAAACGC!ITTGAGGGi IGAI IC
Kras-lox-stop AGGGT AGGT GTTGGGATAGC CT GAGT CATTTT CAGC AGGC
Cdh1-loxP TCAATCTCAGAGCCCCACCTA CCT GCCATGATTGTCATGG AC
Table 2.2 Primer sequences used for each gene specific PCR
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Cre specific Pten-loxP Apc4axP Kras CdhMoxP
PCR reaction mix
gDNA
PCR-grade water 
GO Taq PCR buffer (5X) 
MgQj (25mM) 
dNTPs (25mM)
Primer 1 (100mM)
Primer 2 (100mM)
Taq DNA polymerase 
Brand of Taq polymerase
2.5pl
31.7pl
10pl
V
0.4pl 
0.1pl 
0.1|il 
0.2pl 
GO Taq
2.5pl
31.7|il
10pl
5pl
0.4pl 
Q.1|il 
0.1pl 
0.2pl 
Dream Taq
2.5pl 
31.7|il 
10|il 
5pl 
0.4pl 
0.1pl 
O.tyl 
0.2pl 
Dream Taq
2.5pl
31.7pl
m  
5pl 
0.4pl 
O.tyl 
0.1pl 
Q.M 
Dream Taq
2.5pl
31.7|il
10pl
V
0.4pl 
0.1pl 
0.1pl 
0.2pl 
GO Taq
PCR cycling conditions
Initial denaturatton 3 0*1,94* 5 min, 94* 3 o*i, 95* 5o*i,94* 2.5 min, 94*
Cycle number 
Step 1: denaturatton 
Step 2: annealing 
Step 3: Extension
30 cycles of: 
30 sec, 95* 
30 sec, 55* 
1 mln, 72*
35 cycles of: 
1 mln, 94*
1 mln, 58*
1 mln,72*
30 cycles of: 
30 sec, 95* 
30 sec, 60* 
1 0* 1,72*
30 cycles of: 
1 0* 1,94*
1 0* 1,60*
1 o*i, 72*
35 cycles of: 
30 sec, 94* 
30 sec, 60* 
1 0*1,72*
Final extension 5 min, 72* 
Hold at 15*
5o*i,72* 
Hold at 15*
5 min, 72* 
Hold at 15*
5mto,72* 
Hold at 15*
5 min, 72* 
Hold at 15*
PCR product sizes Presence of
transgene:
1000bp
WT: 228bp 
Targeted: 335bp
WT:226bp 
Targeted: 315bp
WT: 4G3bp
Targeted stop 
cassette: 621bp
WT: 200bp 
Targeted: 330bp
2.4 Tissue Sample Preparation
Tissues were dissected immediately after animal sacrifice in order to prevent 
degradation of RNA, protein and phospho-proteins.
2.4.1 Tissue Dissection
2.4 .1 .1  Dissection o f Organs
Mice were culled by cervical dislocation, 70% ethanol was sprayed over the 
abdomen of the mouse and the abdominal cavity opened by cutting first through the 
skin then through the smooth muscle wall. The genitourinary tract (i.e. bladder, 
testes, seminal vesicles, prostate and preputial glands) was taken out and fixed 
together (fixation is described in section 2.4.2.1). The stomach and the intestines were 
then dissected out (see section 2.4.1.2), the stomach was opened up and the contents 
removed, the kidneys were dissected out and one cut transversely and the other 
longitudinally, spleen, pancreas and lungs were also removed and fixed together 
(fixation is described in section 2.4.2.1).
2 .4 .1 .2  Dissection o f Intestines
The intestines were removed by first cutting the attachment of the stomach to 
the oesophagus, then gently removing the intestine, being careful to remove all 
attached mesentery, (mesentery was then fixed separately see section 2.4.2.1). Once 
the length of the small intestine was removed, it was cut at the ileal-caecal junction 
and the stomach removed and fixed separately (see section 2.4.1.1). The colon was 
then removed with the caecum and the caecum was cut from the colon, contents 
emptied and fixed separately (see section 2.4.2.1 and 2.4.2.2). In some cases the 
length of the small intestine was measured using a ruler. The contents of the intestines 
were removed by flushing with 1X Phosphate Buffered Saline (PBS) (Invitrogen) and 
fixed as described in section 2.4.2.
2.4.2 Fixation of Tissues
2.4 .2 .1  Formalin Fixation
Most of the tissues taken were fixed in 10% neutral buffered formalin (Sigma), 
as formalin fixed tissues work well with the majority of commercially available 
antibodies for immunohistochemistry applications.
44
The liver, lungs, pancreas, spleen, kidneys, mesentery and genitourinary tract 
of each mouse was fixed immediately after dissection in ice cold 10% neutral buffered 
formalin (Sigma) for 24 hours prior to processing. The contents of the small intestine 
and colon were removed by flushing with 1X PBS and were fixed in 10% neutral 
buffered formalin in one of two ways. Either 1cm sections were fixed and sectioned 
transversely, or the gut was opened longitudinally and rolled into a ‘swiss roll-like’ 
structure (secured by a needle), and was then sectioned end-on, allowing sectioning of 
the whole length of the intestine.
2.4 .2 .2  Methacarn Fixation o f Intestines
To assess the total macroscopic tumour number, methacarn fixation of the 
small intestine and colon was utilised. The contents of the small intestine and colon 
were removed by flushing with 1X PBS. Then, the intestines were placed on a piece of 
blotting paper and opened up longitudinally. The paper was then placed in a bath of 
methacarn (made up from Methanol, Chloroform, Glacial Acetic Acid in a 3:2:1 ratio) 
and fixed overnight. The intestines were then rolled into a ‘swiss roll-like’ structure 
and placed in 96% ethanol. The action of Methacarn fixation on the intestine allowed 
the number of macroscopic tumours to be visualised and accurately measured, so this 
method was of intestinal fixation was primarily used for quantifying overall 
macroscopic intestinal tumour number. Methacarn fixed intestines were also sectioned 
and stained with haematoxylin and eosin (H&E) for histological analysis.
2 .4 .2 .3  Fixation o f Small Intestine fo r Scanning Electron microscopy (SEM)
The small intestine was flushed with PBS and 1cm sections were opened 
longitudinall. The intestine was then pinned, mucosal side up, to a petri dish half filled 
with hardened paraffin wax. Pinning the tissue on the wax dish kept it flat and 
prevented the tissue from curling. The pinned intestinal sections were fixed in 2.5% 
Glutaraldehyde, EM grade (Agar Scientific) in Sorensen’s phosphate buffer (pH 7.4, 
buffer was made by adding 95ml of a 0.015M KH2P04 solution to 405ml of a 0.075M 
Na2HP04 solution [Sigma]) for 1 hour. The tissue was then prepared for SEM (described 
in section 2.5)
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2.4.3 Processing of Fixed Tissues
Derek Scarborough and Marc Isaac provided assistance in carrying out the 
processing of fixed tissues, sectioning of embedded tissue and H&E staining of tissue 
sections.
After fixation for 24 hours, all tissues were removed from fixative, placed in a 
cassette (Fisher) and processed using an automatic processor (Leica TP1050). The 
tissues were dehydrated through an increasing gradient of alcohols (70% ethanol for 1 
hour, 95% ethanol for 1 hour, 2x 100% ethanol for 1 hour 30 mins, 100% ethanol for 2 
hours) and then in xylene (2 x xylene for 2 hours). The tissue was then placed in liquid 
paraffin for 1 hour, then again twice for 2 hours. The tissue samples were then 
removed from the cassette and embedded in paraffin wax by hand and left to harden.
2.4.4 Sectioning of Fixed Tissues
Paraffin embedded tissues were then cut to 5 i^m sections using a microtome 
(Leica RM2135) and were then placed on Poly-L-Lysine (PLL) coated slides, and then 
baked at 58°C for 24 hours. The sections were then prepared either for Haematoxylin 
and Eosin (H&E) staining (described in section 2.6.2) or immunohistochemistry (IHC) 
(described in section 2.7).
2.4.5 Epithelial Cell Enrichment for DNA, RNA and Protein samples
In order to obtain intestinal samples for DNA, RNA or protein extraction that 
were enriched for epithelial cells two methods were used: crude epithelial cell 
enrichment and HBSS-EDTA epithelial cell extraction (see below).
2.4 .5 .1  Crude Epithelial Cell Enrichment fo r DNA and RNA
The small intestine was flushed with 1X PBS and cut into small sections (1-5cm), 
and opened up longitudinally. A crude enrichment of epithelial cells was obtained by 
scraping the mucosal surface of the intestine with a scalpel. These samples were then 
used either for DNA extraction (described in section 2.3.1), or placed immediately into 
Trizol for RNA extraction (described in section 2.9.1). The samples were then stored at 
-20°C prior to extraction.
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2 .4 .5 .2  HBSS-EDTA Epithelial Cell Enrichment fo r  RNA and Protein
The method used for isolation of intestinal epithelial cells was adapted from 
Bjerknes and Cheng (Bjerknes and Cheng, 1981a).
The small intestine was flushed with 1X PBS and a 5cm section was inverted by 
tying off one end of the intestine with non soluble suture (Mersilk, Ethicon), and then 
using a needle, the intestine was inverted by piercing the intestine below the tied off 
section and pulling the end of the intestine in on itself. The inverted intestine was 
then placed in a 50ml conical tube containing approximately 45ml of pre warmed 
(37°C) extraction buffer solution (1X Hanks Balanced Salt Solution [HBSS] [Gibco], 
containing no calcium or magnesium ions and 10mM EDTA pH 8.0 [Sigma]). The 
intestine was then agitated in the solution by attachment to a vortex mixer set to the 
lowest setting for 15 mins. After 15 mins the intestine was removed and placed in 
another 50ml conical tube containing extraction buffer and agitated for a further 15 
mins, to obtain a second cell extract. The two extracts were obtained from each 5cm 
section of intestine and were temporarily stored on ice until needed. Tubes containing 
extracts were then centrifuged at 3000g at 4°C for 15 minutes to yield a pellet of 
epithelial cells. The remaining extraction buffer was then decanted off and the pellet 
was either prepared for RNA or protein extraction (see below).
2 .4 .5 .3  Preparation of epithelial cell extract fo r RNA extraction
In preparation for RNA extraction, the pellet was resuspended in Trizol 
(Invitrogen), and stored at -20°C prior to RNA extraction (described in section 2.9).
2 .4 .5 .4  Preparation of epithelial cell extract fo r  protein extraction
In preparation for protein extraction the pellet was resuspended in 1ml 1X PBS, 
transferred to a 1.5ml microcentrifuge tube and re-pelleted by centrifugation at 3000 x 
g at 4°C for 15 mins. The 1X PBS was carefully removed using a pipette and the pellet 
was then snap frozen and stored at -80°C for subsequent protein extraction (as 
described in section 2.8.1).
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2.5  Scanning Electron Microscopy
Dr Anthony Hann provided assistance in preparing small intestinal samples for 
scanning electron microscopy.
2.5.1 Preparation of samples and scanning EM
The tissue was fixed and prepared as described in section 2.4.2.3. The excess 
fixative was then washed off the tissue samples using Sorensen’s phosphate buffer 
(recipe is described in section 2.4.2.3), the samples were washed 3 times for 5 mins 
with agitation, followed by 2 x 5 min washes in 0.15M glycine (Sigma) diluted in 
Sorensen’s phosphate buffer. The samples were washed well in order to quench excess 
aldehyde groups from the glutaraldehyde to allow better uptake of osmium tetroxide. 
The tissue was then fixed in osmium tetroxide (Sigma) for 1-2 hours. The samples were 
then washed again for 2 x 5 mins in Sorensen’s phosphate buffer, and for 10 mins in 
deionised water before being dehydrated through a gradient of ethanols (30%, 60%, 
70%, 80%, 90%, 2 x 100%, Fisher Scientific) and finally in acetone (Sigma). The sample 
was flushed with liquid C02, then was critical point dried using critical point drying 
apparatus (Balzers) at 45°C and 1450Psi. The samples were then mounted on 12mm 
metal stubs and coated in gold, and viewed using a Philips XL20 scanning electron 
microscope operated at an accelerating voltage of 20-25 kV.
2.6 Histological Analysis
2.6.1 Preparation of Sections for IHC or Staining
Paraffin embedded tissue sections on PLL coated slides were first de-waxed by 
placing in a bath of xylene for 5 mins, and then transferred to another xylene bath for 
a further 5 mins. The sections were now devoid of all paraffin wax and could be 
rehydrated down a gradient of alcohols. The sections were washed in baths of 
descending gradients of ethanol (100%, 100%, 95%, 70%) for 2 mins each and finally 
placed in a bath of deionised water (dH20) in preparation for immunohistochemistry 
(IHC) or staining.
2.6.2 Haematoxylin and Eosin (H&E) Staining
In order to visualise tissue sections for phenotypic analysis, tissue sections were 
stained with haematoxylin to mark nuclei and eosin to stain the cytoplasm of cells. 
Tissue sections on PLL coated slides were de-waxed and rehydrated as previously
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described in section 2.6.1, and were then stained by immersing the sections in a bath 
of Mayer’s Haemalum (R. A. Lamb) for 45 secs, then washed in running tap water for 5 
mins. Sections were then stained in an aqueous solution of 1% Eosin (R. A. Lamb) for 5 
mins followed by two 15 second washes in tap water. Tissue sections were then 
dehydrated, cleared and mounted as described in section 2.7.1.9.
2.6.3 Cell Type Specific Stains
2.6.3 .1 A ldan blue Staining fo r Goblet Cells
Alcian blue stains the mucins present in Goblet cells, the secretory cell lineage 
of the intestinal epithelium.
Tissue sections were de-waxed and dehydrated as previously described and 
immersed in a bath of Alcian blue staining solution pH 2.5 (1% [w /v] Alcian blue 
[Sigma] in 3% [v/v] Acetic acid [Fisher Scientific]) for 5 mins, then washed in running 
tap water for a further 5 mins. The tissue sections were then counter stained with 0.1% 
Nuclear fast red in 5% aluminium sulphate (Sigma) for 5 mins, and washed in running 
tap water for a further 5 mins. Tissue sections were then dehydrated, cleared and 
mounted as described in section 2.7.1.9.
2 .6 .3 .2  Grimelius Staining fo r Enteroendocrine Cells
Grimelius staining marks argyrophilic granules, found in hormone secreting 
enteroendocrine cells of the intestinal epithelium. Argyrophillic granules bind silver 
ions, which are then precipitated in the presence of a reducing solution staining the 
cells turn black in colour.
Tissue sections were de-waxed and dehydrated, all glassware used was washed 
in ultrapure double distilled water (ddH20) to eliminate any reducing agents that may 
be present. All solutions were freshly prepared according to the recipes in Table 2.4. 
Sections were incubated in silver staining solution at 65°C for 3 hours, the sections 
were then immersed in preheated reducing solution at 45°C for 1-10 mins until tissue 
sections had a yellow background stain (no counter stain was required due to yellow 
background stain).
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Silver Staining Solution
10ml Acetate Buffer pH 5.6 (see below)
87ml ddHzO
3ml 1% w /v Silver nitrate
Acetate Buffer
4.8ml 0.2M Acetic acid
45.2ml 0.2M Sodium acetate
50ml ddH20
Reducing Solution
2.5g Sodium sulphite (hydrated)
0.5g Hydroquinone 
50ml ddH20
Table 2.4 Recipe for solutions required for Grimelius staining
2 .6 .3 .3  Alkaline Phosphatase Staining fo r Enterocytes
Alkaline phosphastase is an enzyme expressed specifically on the brush border 
of the enterocytes, which make up the vast majority of the intestinal epithelial layer. 
Alkaline phosphastase staining allows visualisation of these cells by utilisation of the 
enzymatic activity of the alkaline phosphatase that is expressed. Alkaline phosphatase 
catalyses a chromogen to produce a red stain, which demarcates the epithelial brush 
border.
Tissue sections were de-waxed and dehydrated as described in section 2.6.1. 
The Liquid Permanent Red kit (DAKO) was used according to manufacturer’s 
instructions. The alkaline phosphatase substrate was made up by the addition of 1 drop 
of Liquid Permanent Red chromagen (DAKO) to 3ml of Liquid Permanent Red substrate 
buffer (DAKO). Tissue sections were demarcated using a hydrophobic barrier pen 
(Vector labs) and 200pl of the prepared substrate solution was applied to slides and 
incubated at room temperature for 20 mins. Sections were then washed briefly in dH20  
and counterstained with Mayer’s Haemalum for 45 secs, then washed for 5 mins with 
running tap water. The slides were then mounted using Vector Shield Aqueous 
Mounting Medium (Vector Labs), as alcohol and xylene have adverse effects on liquid 
permanent red staining.
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2.6.4 Cell Scoring
Scoring the number and type of cells present along the crypt-villus axis can 
reveal alterations in intestinal homeostasis. 50 half crypt-villi from each section were 
scored for various indicators of disrupted intestinal homeostasis (outlined below), at 
least 3 biological replicates per cohort were scored.
2 .6 .4 .1 Crypt Cell Scoring
To assess small intestinal crypt length, the number of cells per half crypt were 
scored from H&E stained sections. Cells were counted from the base of the crypt 
adjacent to the paneth cells, upwards to the top of the crypt at the crypt-villus 
junction.
2 .6 A .2 Villus Cell Scoring
To assess villus length, the number of cells were scored per half villus from the 
crypt villus junction to the tip of the villus from H&E stained sections.
2 .6 A .3 Apoptosis and Mitosis Scoring
The presence of mitotic figures and apoptotic bodies per half crypt were scored 
from H&E stained sections.
2.6 A  A  Caspase 3 Scoring
Caspase 3 IHC was carried out on tissue sections as described in section 2.7.1 
(specific antibody conditions outlined in Table 2.7), and positive cells were scored per 
half crypt and half villus.
2 .6 .4 .5  Ki67 Scoring
Ki67 is an antigen that is expressed in cells that are undergoing all stages of the 
cell cycle. IHC against Ki67 antigen was carried out on tissue sections, and the number 
of positive cells per half crypt were scored.
2 .6 .4 .6  BrdU Scoring
Some animals were given a pulse of BrdU via i.p. injection at either 2 hours or 
48 hours prior to sacrifice. The incorporation of BrdU was then visualised via IHC and 
then the number of positive cells and their position along the crypt villus axis was 
scored.
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2.6.A .7 Cell type scoring
Goblet cells and enteroendocrine cells were scored per half crypt-villus from 
tissue sections alcian blue and grimelius stained sections (as described previously
2.6.3.1 and 2.6.3.2) respectively. Goblet cell and enteroendocrine cell scores were 
normalised to take into account alterations in the number of cells present along the 
crypt-villus axis. This was achieved by dividing the total number of goblet or 
enteroendocrine cells per half crypt-villus with the total number of cells per half 
crypt-villus. The number of paneth cells per whole crypt were scored from small 
intestinal sections immunostained for lysozyme (see section 2.7).
2.6.5 Tumour severity grading
Tumour grading was carried out on intestinal tumours found in Apc/,/+ P te n ^  
KrasLSL/+ mice and control cohorts. H&E stained sections of ‘swiss-rolled’ whole 
intestine were examined under the microscope, and the number and severity of 
tumour invasiveness was scored. Each tumour was scored and graded according to the 
following criteria outlined in Table 2.5 and in Figure 2.2. Intestines from a minimum of 
n=3 mice for each cohort were examined and graded.
Tumour grade Tumour description
1 microadenoma
2 adenomas with no evidence of invasion
3
adenocarcinoma with evidence of invasion into the intestinal 
submucosa
4
adenocarcinoma with evidence of invasion through the smooth 
muscle wall and underlying serosa
Table 2.5 Tumour invasiveness scoring system
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Figure 2.2 Stages of intestinal tumour progression
H&E stained sections of the whole small intestine were examined, and the level of 
progression of each tumour observed within the intestine was graded (staged). Grade 1 
- microadenomas, small lesions often observed within villi, Grade 2 - adenomas, 
tumours that vary in size but do not invade into the underlying submucosa, Grade 3 - 
adenocarcinoma with submucosal invasion, a tumour that has progressed further than 
an adenoma and has evidence of invasion into the underlying submucosa but does not 
break through the smooth muscle cover of the intestine, Grade 4 - adenocarcinoma 
with smooth muscle invasion, a tumour that has progressed further and invaded 
through the smooth muscle and has invaded locally into the peritoneum.
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2 .7  Immunohistochemistry (IHC)
IHC was carried out on tissue sections to visualise the presence and localisation 
of various proteins. A generic outline of the order in which IHC protocols were carried 
out is detailed in this section. However, specific conditions for individual protocols are 
detailed in Table 2.6 and Table 2.7.
2.7.1 Generic IHC protocol
2 .7 .1 .1  Preparation o f sections fo r IHC
Tissues were fixed and sectioned onto PLL coated glass slides as described in 
section 2.4. The tissue sections were then dewaxed and dehydrated in preparation for 
IHC as described in section 2.6.1.
2 .7 .1 .2  Antigen retrieval
Antigen retrieval was carried out in order to break cross-linking bonds formed 
during fixation, and therefore unmasking the antigens. This typically involved heat 
mediated retrieval carried out by either boiling the tissue section slides in citrate 
buffer (pH6, Thermo) or antigen unmasking solution (DAKO), in either a microwave, a 
pressure cooker or a 100°C water bath for around 30 mins, then the slides were left to 
cool at room temperature for 30 minutes and then washed in deionised water.
2 .7 .1 .3  Blocking o f endogenous peroxidases
As the system of antibody visualisation used involves the enzymatic reaction of 
3,3’-diaminobenzidine (DAB) catalysed by horse radish peroxidase (HRP), to avoid non­
specific enzymatic action of the endogenous peroxidases present in the tissue they 
must first be blocked. Peroxidase blocking was achieved by incubating the slides in a 
hydrogen peroxide solution for around 15 mins, which irreversibly inactivates the 
endogenous peroxidases. After peroxidase blocking the slides were then washed in 
deionised water and then in wash buffer.
2 .7 .1 .4  Blocking o f non-specific antibody binding
Non-specific binding of antibodies was blocked by incubating tissue sections 
with serum obtained from an animal that is different to the animal in which the 
primary antibody was raised, for example normal goat serum could be used to block
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tissue sections that will be incubated with antibodies raised in rabbit. Tissue sections 
on PLL coated slides were first outlined using a hydrophobic barrier pen, Immedge pen 
(Vector labs) before incubation with serum. Serum was diluted in wash buffer to a 
concentration that adequately blocks non-specific binding and therefore decreases 
background DAB staining. Serum block was removed and then tissue sections were 
incubated with primary antibody without washing.
2 .7 .1 .5  Primary antibody incubation
Tissue sections were then incubated with a primary antibody at an optimised 
concentration or one recommended by the manufacturer. Antibodies were diluted in 
the same serum at the same concentration used for the previous blocking stage 
(specific antibody concentrations can be found in Table 2.6 and Table 2.7). Antibodies 
were generally incubated over night in a humidified chamber at 4°C, or at room 
temperature for 1 hour. After incubation the slides were then washed three times in 
TBS/T to remove residual unbound primary antibody.
2 .7 .1 .6  Secondary antibody incubation
Tissue sections were then incubated with the secondary antibody, diluted 
typically 1 in 200 in normal serum. Secondary antibodies are raised against antibodies 
from the animal in which the primary antibody was raised, so they bind to any primary 
antibodies that are bound to the antigen of interest. Tissue section slides were 
incubated with secondary antibody for 30 mins in a humidified chamber. The slides 
were then washed in wash buffer three times. Typically the secondary antibodies were 
biotinylated, so therefore an additional signal amplification step was required in which 
HRP binds to the secondary antibody. However, a few of the protocols required the use 
of the Envision plus kit (DAKO). In these cases the tissue sections were incubated with 
a prediluted secondary antibody conjugated to HRP so an amplification step was not 
needed, and antibody binding could be visualised after washing off the secondary 
antibody.
2 .7 .1 .7  Signal amplification
When biotinylated secondary antibodies were used, a signal amplfication step 
was required. This involved the formation of a complex between the biotin bound to 
the secondary antibody and a protein called avidin, which was bound to HRP, the
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Vectastain Avidin-Biotin Complex (ABC) kit (Vector labs) was used. The ABC reagent 
was prepared in wash buffer 30 mins before use and left at room temperature. Tissue 
sections were incubated with ABC reagent for 30 mins before being washed three times 
in wash buffer. HRP enzyme was now bound to secondary antibodies that remained 
bound to primary antibodies, so the antigen could be visualised.
2 .7 .1 .8  Detection o f signal
The presence of the antigen of interest was visualised by the production of a 
coloured stain, produced from a substrate catalysed by the HRP enzyme bound to the 
secondary-primary antibody complex. The substrate used was 3,3’-diaminobenzidine 
(DAB), which could be catalysed by HRP to produce a brown stain. The DAB reagents 
(DAKO) were prepared just prior to incubation, tissue sections were incubated with 
DAB reagents for 2-10 mins or until adequate staining was achieved visually by eye. 
Excess DAB reagent was removed and tissue sections washed in deionised water.
2 .7 .1 .9  Counterstaining and slide mounting
The slides were incubated in Mayer’s Haemalum (R.A. Lamb) for 45 secs to stain 
nuclei, and washed in tap water for 5 mins. Slides were then dehydrated through a 
gradient of alcohols ( 1 x 2  mins 70% ethanol, 1 x 2 mins 95% ethanol, 2 x 2  mins 100% 
ethanol) and then cleared in 2 x 5 mins xylene. Slides were then removed from xylene, 
mounted in DPX mounting medium (R.A. Lamb) then coverslipped and left to air dry in 
a fume hood.
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Primary
Antibody
Manufacturer Antigen
retrieval
Non-spedflc signal block Wash
buffer
Primary
antibody
conditions
Secondary
antibody
Signal
amplification
step
Anti-Pten Cell Signaling
Technobgy
#9188
30rnbs, 100°C 
W/B, citrate 
buffer 
(Thermo)
Peroxidase: 3% H20 2 
10mbs
Serum: 5% NGS 30mbs 
both RT
3 washes in
TBS/T,
5rrins
1:50 in 5% 
NGS 1hr 9  
RT
Bbtbylated 
anti-rabbit 
1:200 (Vector 
Labs), 30mbs
ABC kit 
(Vector Labs)
Antl-phospho 
Akt (ser473)
Cell Signaling
Technobgy
#4060
30mbs, 100°C 
W/B, citrate 
buffer 
(Thermo)
Peroxidase: 3% H20 2 
10mbs
Serum: 5% NGS 30mbs 
both RT
3 washes in
TBS/T,
5mbs
1:50 b 5% 
NGS 0/N 9 
4°C
Bbtbylated 
anti-rabbit 
1:200 (Vector 
Labs), 30mbs
ABC kit 
(Vector Labs)
Anti*
phospho44/42
MAPK
(phospho-
ERK1/2)
(Thr202/Tyr204)
Cell Signaling
Technobgy
#4376
Boll 15mbs In 
M/W, citrate 
buffer 
(Thermo)
Peroxidase: 1.5% H20 2 
15mins
Serum: 10% NGS 30rrins 
both RT
3 washes in
TBS/T,
5rrins
1:75 b 10% 
NGS 0/N 9
4°C
Bbtbylated 
anti-rabbit 
1:200 (DAKO), 
30mbs RT
ABC kit 
(Vector Labs)
Antl-phospho 
MEK1/2 (ser221)
Cell Signaling
Technobgy
#2338
Boll 15mbs In 
M/W, citrate 
buffer 
(Thermo)
Peroxidase: 1.5% H2O2 
15mbs
Serum: 10% NGS 30mbs 
both RT
3 washes In
TBS/T,
5rrins
1:100 b 10% 
NGS 0/N ® 
4PC
Bbtbylated 
anti-rabbit 
1200 (DAKO), 
30mbs RT
ABC kit 
(Vector Labs)
Antl-phospho 
mTOR (ser2448)
Cell Signaling
Technobgy
#2971
Boll 15mins In 
M/W, citrate 
buffer 
(Thermo)
Peroxidase: 3% H20 2 
20mbs
Serum: 10% NGS 45irins 
both RT
3 washes In
TBS/T,
5rrins
1:100 b 10% 
NGS 0/N ®
4°C
Bbtbylated 
anti-rabbit 
1200 (DAKO), 
30mbs RT
ABC kit 
(Vector Labs)
Antl-W67 Vector Labs 
#VPK452
30mbs, 100°C 
W/B, citrate 
buffer 
(Thermo)
Peroxfdase:0.5% H20 2 
20mbs
Serum: 20% NRS 30mbs 
both RT
3 washes b
TBS/T,
5mbs
1:20b 20% 
NRS 0/N 9  
4°C
Bbtbylated 
anti-mouse 
1200 (DAKO), 
30mbs RT
ABC kit 
(Vector Labs)
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Table 2.7 Table 2 of IHC conditions
Key: W/B - water bath, M/W - microwave, P/C - Pressure Cooker, NRS - normal rabbit 
serum, NGS - normal goat serum, BSA - bovine serum albumin, RT - room temperature, 
O/N - over night, TBS/T - tris buffered saline with tween, PBS - phosphate buffered 
saline
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2 .8  Protein E xtrac tion  and W estern B lot Analysis
2.8.1 Protein Extraction and quantification
Protein was extracted from epithelial cell pellets obtained from HBSS-EDTA 
epithelial cell extraction, the pellet was prepared as described in section 2.4.5.4, and 
stored at -80°C prior to protein extraction.
2.8 .1 .1  Protein extraction
Pellets were removed from frozen storage and immediately placed on ice, 200pl 
of lysis buffer (20mM Tris-HCl pH 8.0, 2mM EDTA pH8.0, 0.5% [v/v] NP-40 [Sigma]) 
containing protease inhibitors (Complete mini protease inhibitor tablets, one tablet 
per 5ml lysis buffer [Roche]), and phosphatase inhibitors (25mM sodium beta- 
glycerophosphate [Calbiochem], 100mM sodium fluoride [Sigma], 20nM Calyculin A 
from Discodermia calyx [Sigma], 10mM sodium pyrophosphate [Sigma]), was added to 
each epithelial cell pellet (400pl was added for larger pellets). Whilst the pellet 
defrosted, the cells were lysed by shear action to extract proteins by passing through a 
21 or 23 gauge needle. The samples were then left on ice for 10 mins before 
centrifugation at 9500 x g for 10 mins at 4°C. Centrifugation allowed formation of a 
pellet of insoluble material. The supernatant containing the extracted proteins was 
then removed, aliquoted and snap frozen in liquid nitrogen before being stored at - 
80°C.
2 .8 .1 .2  Protein quantification
After protein extraction and prior to snap freezing, an aliquot of each sample 
was taken and the protein content quantified. Proteins were quantified using the 
bicinchoninic acid (BCA) method. The BCA method utilises the biuret reaction in which 
Cu2+ ions are reduced to Cu1+ ions to produce a purple colour. The reaction is 
facilitated by the presence of the amino acids cysteine, tyrosine and tryptophan and 
the universal peptide backbone. The extent to which the copper ions are reduced can 
be quantified by the colourimetric detection as the BCA reagent strongly absorbs light 
at 562nm. A high absorbance reading therefore indicates a high protein concentration. 
Protein samples were measured in duplicate, 2pl was added to 198pl of PBS, mixed and 
serially diluted twice more to produce three concentrations of protein sample (1 in 
100, 1 in 200 and 1 in 300), in a final volume of 100pl. As a standard bovine serum 
albumin (BSA) was diluted from stock in lysis buffer (recipe above), and then in PBS to
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generate a concentration range of 5-25^ig/ml. All samples were diluted in a colourless, 
flat bottom 96-well plate, BCA reagents were made up according to manufacturer’s 
instructions and 100pl added to each sample. The plate was then incubated at 37°C for 
1-2 hours. The absorbance of each sample was read on a plate reading 
spectrophotometer at the nearest wavelength to the optimum (562nm). Samples were 
read on an ELx800 plate reading spectrophotometer (BioTek) at 590nm. The 
concentration of each diluted sample was calculated using the standard curve.
2.8.2 Western Blot Analysis
2.8 .2 .1  Preparation o f protein samples
Protein samples were removed from -80oC freezer and defrosted on ice prior to 
resolution of the proteins. 30jig of total protein samples were used and made up to 
25jil using Laemmli buffer (0.125M Tris-HCl pH6.8, 4% w /v  sodium dodecyl sulphate 
[SDS][Sigma], 40% [v/v] Glycerol [Sigma], 0.1% [w /v] bromophenol blue [Sigma], 6% 
[v/v] p-mercaptoethanol [Sigma] in double deionised water). Samples were then kept 
on ice prior to loading into gels. The samples were then heated to 95°C for 5-10 mins 
and quenched on ice before loading into wells.
2 .8.2 .2  Casting o f polyacrylamide gels
The Mini-Protean III (Bio-Rad) gel casting apparatus was used to prepare 
polyacrylamide gels. Gel solutions were made up to produce a 5% stacking gel and 10% 
resolving gel (for gel mix solutions see Table 2.8), without the addition of TEMED. 
Combs were placed in the assembled gel apparatus, and the gel glass plates were then 
marked with a line approximately 0.5cm below the edge of the comb teeth as a guide 
for pouring the resolving gel. Combs were removed and gel apparatus placed in a fume 
hood, TEMED was then added to the solution, quickly mixed and poured between the 
glass plates to the pre marked line. Then 200pl of butanol was added on top of the gel 
to ensure the surface of the gel was flat. The gel was then left to set, using the excess 
resolving gel as a guide to when it was set, and the butanol was poured off. TEMED was 
then added to the 5% stacking gel and poured on top of the resolving gel to the edge of 
the glass plates and a 10-well or 12-well comb was inserted. Before loading the 
samples, the combs were removed and plates placed in sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) apparatus, and running buffer added
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(see recipe Table 2.8). The combs were removed and each well was flushed out using a 
pipette to remove excess gel.
2 .8 .2 .3 SDS-PAGE
Polyacrylamide gels were set up in an SDS-PAGE Mini-Protean III apparatus rig 
(Bio-Rad) and 1X running buffer was added. Prepared protein samples (as described in 
section 2.8.2.1) were added to each well. 7pl of pre-stained full-range Rainbow 
molecular weight ladder (GE Healthcare) was added to one lane according to 
manufacturers’ recommendations. The gels were then run at 120-200V until the dye 
front reached the end of the gel.
2 .8 .2 .4  Protein transfer to nitrocellulose f i l te r
After the proteins had been separated in the polyacrylamide gel, the gels were 
removed from glass plates and placed in transfer buffer (see recipe in Table 2.8), 
before cutting off the stacking gel. Amersham Hybond-ECL nitrocellulose filter (GE 
Healthcare) was cut to size and briefly soaked in transfer buffer, the nitrocellulose 
filter was placed on top of the polyacrylamide gel and was sandwiched between two 
sheets of 3MM blotting paper (Whatman) and sponge, each pre-soaked in transfer 
buffer. This ‘sandwich’ was then placed into plastic transfer supports, and placed into 
a transfer tank orientated so that the current runs through the gel towards the filter (- 
to +) in order to transfer the negatively charged proteins to the nitrocellulose filter. 
Transfer buffer was then added to the tank, and it was run at 100V for 1 hour. After 
transfer the nitrocellulose filter was carefully removed and placed in TBS/T (Tris 
Buffered Saline with 0.1% Tween, Sigma).
2 .8 .2 .5  Antibody probing of f i lte r
The nitrocellulose filter was first blocked for 1 hour in 5% [w/v] non-fat milk 
powder diluted in TBS/T with agitation. Agitation allowed total coverage of the filter 
with blocking solution and prevented the filter from drying out. The filter was then 
washed 3 times for 5 mins in TBS/T before addition of primary antibody, diluted in 
either 5% non-fat milk in TBS/T or 5% BSA in TBS/T (for antibody conditions see Table 
2.9). The filte r was incubated with the primary antibody either overnight at 4°C with 
agitation, or for 1 hour at room temperature with agitation (see Table 2.9), before 
washing 3 times for 5 mins in TBS/T. The filte r was then incubated with HRP-linked 
secondary antibody diluted in 5% non-fat milk in TBS/T for 1 hour at room temperature
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with agitation. The filter was then washed 3 times for 10 mins each time in TBS/T prior 
to signal detection.
2 .8 .2 .6  Signal detection
The electrochemiluminescence (ECL) reagent kit (GE Healthcare) was used 
according to manufacturers’ instructions for detection of antibody signal. These 
reagents utilise a chemifluorescent reaction catalysed by HRP to expose X-ray film. ECL 
reagents were prepared according to manufacturers’ instructions just prior to use, 
filters were incubated with the reagents then excess solution removed. The filter was 
then taken to a dark room under safelight conditions, and X-ray film (Fujifilm Super 
RX, blue background) was exposed, and the film processed using an automatic 
processor (Xograph Compact X4 automatic X-ray film processor). A number of 
exposures of X-ray film for varying amounts of time were generated to produce clear 
images. These images were then overlaid on the filte r in order to confirm the correct 
protein band size according to the prestained molecular weight ladder.
2 .8 .2 .7  Confirmation o f equal loading
Filters were reprobed with an antibody for p-actin (see Table 2.9 for conditions) 
to confirm that equal amounts of protein were added to each well. In order to confirm 
that increased presence of phospho-Akt and phospho-Erk was not due to higher 
abundance of unphosphorylated Akt and Erk protein in a particular sample, the same 
samples were run on two gels were run and one filter was probed with a total-Akt and 
total-Erk antibody, and the other with a phospho antibody (Table 2.9).
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5% stacking polyacryalmide gel (2 gels) 10% resolving polyacrylamide gel (2 gels)
6.9ml Ultrapure double deionised H20  
1.7ml 30% acrylamide/bisacrylamide 
(Sigma)
1.3ml 1MTris-HCl pH6.8 
100pl 10% [w/v] SDS (Sigma)
66pl 25% [w /v] Ammonium persulphate 
(Sigma)
13.2pl N,N,N’ ,N’-
teramethylethylenediamine(TEMED,
Sigma)
6.8ml Ultrapure double deionised H20  
8.4ml 30% acrylamide/bisacrylamide 
(Sigma)
9.4ml 1M Tris-HCl pH8.8 
250(i 1 10% [w /v] SDS (Sigma)
72pl 25% [w /v] Ammonium persulphate 
(Sigma)
13.2|il N,N,N’ ,N’ -
teramethylethylenediamine(TEMED, Sigma)
5X Running buffer (1L) 1X Transfer buffer (1L)
950ml deionised H20  
15.1s Tris base (Sigma)
94g Glycine (Sigma)
50ml 10% [w /v] SDS (Sigma)
800ml deionised H20  
200ml Methanol (Fisher) 
2.9g Tris base (Sigma) 
14.5g Glycine (Sigma)
Table 2.8 Recipes for various buffers used during protein analysis
Primary
Antibody
Manufacturer Primary antibody 
conditions
Secondary antibody
Anti-Pten Cell Signaling 
Technology #9559
1:1000 in 5% BSA in 
TBS/T, 0 /N  @ 4°C
HRP-conjugated anti-rabbit 
(GE Healthcare) 1:2000 5% non 
fat milk in TBS/T, 1 hr @ RT
Anti-phospho 
Akt (ser473)
Cell Signaling 
Technology #9275
1:1000 in 5% BSA in 
TBS/T, 0 /N  @ 4°C
HRP-conjugated anti-rabbit 
(GE Healthcare) 1:2000 5% non 
fat milk in TBS/T, 1 hr @ RT
Anti-Akt (total) Cell Signaling 
Technology #9272
1:1000 in 5% BSA in 
TBS/T, 0 /N  @ 4°C
HRP-conjugated anti-rabbit 
(GE Healthcare) 1:2000 5% non 
fat milk in TBS/T, 1 hr @ RT
Anti-Erk (total) Cell Signaling 
Technology #4695
1:1000 in 5% BSA in 
TBS/T, 0 /N  @4°C
HRP-conjugated anti-rabbit 
(GE Healthcare) 1:2000 5% non 
fat milk in TBS/T, 1 hr @ RT
Anti-phospho
Erk
(Thr202/Tyr204)
Cell Signaling 
Technology #4376
1:1000 in 5% BSA in 
TBS/T, O/N @ 4°C
HRP-conjugated anti-rabbit 
(GE Healthcare) 1:2000 5% non 
fat milk in TBS/T, 1 hr @ RT
Anti-p Actin Sigma #A5316 1:5000 in 5% non fat 
milk in TBS/T, 1 hr @ 
RT
HRP-conjugated anti-mouse 
(GE Healthcare) 1:2000 5% non 
fat milk in TBS/T, 1 hr @ RT
Table 2.9 Antibody conditions for western blot protein analysis
Key: BSA - Bovine Serum Albumin, TBS/T - Tris buffered saline with 0.1% Tween 20, RT 
- room temperature, 0 /N  - overnight
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2.9 RNA extraction and Gene Expression analysis
2.9.1 RNA isolation and quantification
RNA was isolated from epithelial cell pellets obtained from HBSS-EDTA epithelial 
cell extraction. The pellet was prepared as described in section 2.4.5.3 and stored at - 
20°C prior to RNA extraction.
2.9 .1 .1  Homogenisation of epithelial cells
Epithelial cell pellets were frozen in Trizol (Invitrogen) in homogenising lysing 
matrix D tubes (MP Biomedicals), and were homogenised from frozen using a Precellys 
24 Homogeniser (Bertin Technologies) at 6000RPM for 2 cycles of 25 seconds.
2 .9 .1 .2  Extraction and purification o f RNA
Unless stated, all samples were kept on ice during RNA isolation. After 
homogenisation the whole solution was transferred to 2ml clean RNAse/DNAse free 
1.5ml microcentrifuge tubes (Starlab) and centrifuged at 9500 x g for 10 mins at 4°C to 
pellet insoluble material. The supernatant was then transferred to a new 1.5ml 
microcentrifuge tube before adding 200pl of chloroform (Fisher) to each tube in a fume 
hood, the samples were then shaken vigorously by hand before being incubated at 
room temperature for 3 mins. The samples were then centrifuged at 9500 x g for 15 
mins to separate the solution phases. 400pl of the aqueous phase was removed and 
added to 400pl of isopropanol (Fisher) in a clean 1.5ml microcentrifuge tube and mixed 
gently to precipitate RNA. The RNeasy Minikit (Qiagen) was then used to isolate and 
purify RNA. The RNA containing solution was added to RNeasy mini spin columns and 
centrifuged at 9500 x g for 30 secs at 4°C and the filtrate discarded. The RNA was now 
bound via adsorption to the silica-based column membrane, the RNA was DNase 
treated by incubating with DNase I (GE Healthcare) according to manufacturer’s 
instructions for 10 mins at room temperature. The column was then washed by 
centrifugation of the column with 500pl of RPE buffer (RNeasy Mini Kit, Qiagen) once 
at 9500 x g for 30 secs at 4°C and filtrate discarded, then again at 9500 x g for 2 mins 
at 4°C and filtrate discarded. The column was finally centrifuged at 9500 x g for 1 min 
at 4°C without wash buffer to ensure the column contained no wash buffer.
The column was then incubated with 50pl RNase-free H20  (RNeasy Mini Kit, 
Qiagen) for 3 mins on ice. The column was then placed in a clean RNAse/DNAse free 
1.5ml microcentrifuge tube and centrifuged at 9500 x g for 1 min at 4°C to elute the
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RNA. The RNA was then aliquoted and stored at -80°C. The RNA was quantified in a V I  
sample using a NanoDrop 1000 (Thermo Scientific).
2 .9 .1 .3  cDNA Synthesis
cDNA was prepared from V g  of RNA using Superscript II reverse transcriptase 
(Invitrogen). Random hexamers (Invitrogen) were first annealed to the RNA. An 
annealing mixture solution was made up of RNA, random primers and dH20  (outlined in 
Table 2.10) and was pipetted into strip tubes with appropriate caps (Greiner Bio-One). 
The samples were incubated at 70°C for 10 mins, 25°C for 10 mins and then stored at 
4°C using a PTC-100 Peltier Thermocycler (MJ Research). A further 20^1 of a reverse 
transcriptase enzyme mix (outlined in Table 2.11) was added to each sample whilst 
still in the thermocycler held at 4°C. Reverse transcription was carried out under the 
following conditions: 25°C for 10 mins, 37°C for 45 mins, 42°C for 45 mins, 70°C for 15 
mins. After cDNA synthesis was complete 160pl of RNAse free water was added to each 
sample.
Annealing mixture (per reaction)
1 jig RNA
5(il Random hexamers (25ng/pl) (Invitrogen)
Make up to 20pl RNase free dH20
Table 2.10 Annealing m ixture per reaction
Reverse transcription enzyme mix (per reaction)
8jil 5x First stand buffer (Invitrogen)
4(il Dithiothreitol (DDT) (Invitrogen)
0 .8 |iI dNTPs (25mM) (Bioline)
1pI Superscript II
6.2(il RNAse free water
Total volume 40(il per reaction
Table 2.11 Reverse transcription enzyme mixture per reaction
2 .9 .1 .4  TaqMan Gene expression analysis
Quantification of gene expression of CBC stem cell markers Lgr5 and Ascl2 was 
carried out using TaqMan assays (Applied Biosystems). TaqMan assays involve the use of
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three gene specific probes that allow sensitive quantification of genes expressed at low 
levels. Epithelial cell extracts from which RNA was extracted were made up of cells 
from the whole of the crypt-villus axis, so only a fraction of these cells would be stem 
cells. Thus, only a small proportion of the RNA extracted will represent mRNA 
transcribed from Lgr5 and Ascl2 genes. TaqMan assays are predesigned probes for 
various genes in various species. Each assay contains a forward and reverse primer for 
the gene of interest, and a probe complimentary to an internal region of the PCR 
product of these primers. The probe has a fluorescent molecule attached to the 5’ 
end, and a quencher molecule attached to the 3’ end. During the PCR reaction, the 
probe and primers bind to the DNA and when polymerisation occurs the Taq 
polymerase cleaves the fluorescent molecule from the probe (by 5’-3’ nuclease activity 
of the enzyme) and releases it from its close position to the quencher molecule, 
allowing it to fluoresce.
As the relative abundance of stem cell marker cDNA is low in the intestinal 
epithelial cell cDNA samples, using traditional qRT-PCR reaction reagents such as Sybr 
green (which fluoresces when bound to double stranded DNA) can result in false 
positive readouts, as fluorescence from Sybr green binding to primer dimers that form 
may mask fluorescence from the PCR reaction.
2 .9 .1 .5  Conditions fo r TaqMan gene expression analysis
qRT-PCR reactions were carried out in triplicate (including no DNA control wells), 
in MicroAmp 96-well PCR plates 0.1ml wells (Applied Biosystems), and sealed with 
MicroAmp heat activated optical adhesive film lids (Applied Biosystems). Each reaction 
contained 10ng of cDNA, 10pl TaqMan universal PCR mastermix (containing Taq 
polymerase, buffers and dNTPs) (Applied Biosystems), 1pl gene specific assay (supplied 
as a 20X stock, Applied Biosystems) and was made up to 25pl with PCR-grade H20. The 
assay mixes used for each gene of interest were as follows: Lgr5 (Assay I.D. 
mm00438890-m1, Applied Biosystems), Ascl2 (Assay I.D. mm01268891 -g1, Applied 
Biosystems) and p-actin was used as an internal control. qRT-PCR reactions were 
carried out using the StepOne Plus Real-Time PCR System (Applied Biosystems), all 
reactions were carried out under the same cycling conditions (50°C for 2 min [for 
optimal uracil-N-glycosylase enzyme activity], 95°C for 10 min [for activation of the 
Taq DNA polymerase enzyme], then 40 cycles of: a denaturation step 95°C for 15 sec, 
and an annealing/elongation step - 60°C for 1 min). The data was collected 
automatically using StepOne software (Applied Biosystems).
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2.9.1.6 Analysis of qRT-PCR data
The experimental data were collected automatically using StepOne software 
(Applied Biosystems). The data were examined prior to data analysis to ensure there 
were no fluorescent products in ‘no cDNA’ control wells, and that the fluorescence vs 
cycle plots for each replicate were comparable.
Differences in target gene expression between each cohort was assessed by 
comparing the changes in the number of cycles it takes for the fluorescence levels to 
reach the exponential phase, i.e. the higher the abundance of target gene cDNA the 
lower number of cycles it takes for the level of fluorescence to reach the exponential 
phase. Fluorescence vs cycle number plots were generated and thresholds sets 
automatically by the software, cycle time (CT) and difference in cycle time (ACT) 
values were calculated between cohorts, normalising each reaction using the beta 
actin control. CT values were calculated automatically by the software and were 
verified by manual calculation from the raw data. The average ACT was calculated for 
each cohort, ACT means of each cohort were compared statistically using the Mann- 
Whitney U test to confirm significant changes in cycle time.
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2 .10  Assessment o f recombination o f genomic DNA
Assessment of recombination of loxP sites by ere recombinase was achieved by 
carrying out a PCR reaction that produced a PCR product only when loxP sites had 
recombined in the gDNA. Primers are designed so that they only come into close 
proximity in a gene when the loxP sites have been recombined and the DNA between 
them excised. A distinct PCR product can then be amplified (recombined band). gDNA 
was extracted from crude epithelial enriched samples obtained by scraping the 
intestinal mucosal surface with a scalpel as described in section 2.4.5.1. DNA was 
extracted using the same protocol used for extracting gDNA from ear biopsies outlined 
in section 2.3.1.
2.10.1 Recombined PCR reactions
The recombined PCR protocol was carried out in the same manner as described 
for the genotyping PCR in section 2.3.2. Both the Pten and Kras recombined PCRs could 
be multiplexed, combining the primers used to detect the presence of the WT and loxP 
targeted alleles with the primer used to generate the recombined or ‘floxed ’ PCR 
product, so in these cases 2-3 PCR products were produced. The Ape and Cdh1 
recombined PCRs yielded PCR products similar in size to the genotyping PCR products 
so these could not be multiplexed. The genotyping and recombined PCRs therefore had 
to be carried out separately. The primers required for recombined PCR of each allele 
are outlined in Table 2.12. The PCR reaction mixtures and cycling conditions for each 
allele are described in Table 2.13. The reaction mixtures for Pten and Kras PCRs are 
for the multiplex PCR, so will produce all relevant PCR products. The reaction mixtures 
for Ape and Cdh1 in Table 2.13 will only produce the PCR product for the recombined 
(floxed) allele so a separate genotyping PCR must be carried out to determine 
heterozygosity or homozygosity of the loxP flanked allele. These conditions and 
primers are described in Table 2.2 and Table 2.3.
2.10.2 Visualisation of PCR products
After recombined PCR reactions were carried out, PCR products were visualised 
in the same manner as described for visualisation of genotyping PCR products in 
section 2.3.3. The use of a 100bp ladder (Promega) as a marker of molecular weight of 
products allowed correct identification of PCR products only produced in recombined 
gDNA.
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Gene Primers Reference
Pten 1 Forward: 5’-GGCCTAGGACTCACTAGATAGC-3’
2 Reverse: 5’ -CTCCCACCAATGAACAAACAGT-3’
3 Forward: 5’-GTGAAAGTGCCCCAACATAAGG-3’
Provided by Akira 
Suzuki, Akita 
University, Japan
Kras 1 Forward: 5’-AGGGTAGGTGTTGGGATAGC-3’
2 Reverse: 5’-CTCAGTCAI I I ICAGCAGGC-3’
3 Reverse: 5’-CTGCTCTTTACTGAAGGCTC-3’
(Guerra et al., 
2003)
Ape 1 Forward 5’ -GTTCTGTATCATGGAAAGATAGGTGGTC-3’
2 Reverse 5’-GAGTACGGGGTCTCTCTGTCTCAGTGAA-3’
(Shibata et al., 
1997)
Cdh1 1 Forward 5'-ACATGTTTGTATCGATCTCAG-3'
2 Reverse 5’-CCTGCCATGATTGTCATGGAC-3'
(Derksen et al., 
2006)
Table 2.12 Primers required for recombined PCR reactions
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Pten Recombined Ape Recombined Kras Recombined Cdh1 Recombined
PCR reaction mix Multiplex PCR Multiplex PCR
gDNA 3pl 2.5V 3V 2.5V
PCR-grade water 31.V I 31.7V 31.1V 31.7V
GO Taq PCR buffer (5X) 10V 10V 10V iov
Mgdj (25mM) 5pl 5V 5V 5V
dNTPs (25mM) 0.4V 0.4V 0.4pl 0.4V
Primer 1 (100mM) 0.1pl o.iv 0.1V 0.1V
Primer 2 (100mM) 0.1V o.iv o.iv o.iv
Primer 3 (100mM) o.iv N/A o.iv N/A
Taq DNA polymerase 0.2pl 0.2V 0.2pl 0.2pl
Brand of Taq polymerase GoTaq GoTaq GoTaq GOTaq
PCR cycling conditions
Initial denaturation 5 0*1,94^ 3 min, 95°C 5 min, 94°C 2.5 min, 94°C
Cycle number 35 cycles of: 30 cycles of: 30 cycles of: 35 cycles of:
Step 1: denaturation 1 min, 9**C 30 sec, 99C 1 min, 94°C 30 sec, 94*C
Step 2: annealing 1 min, 58°C 30 sec, 60C 1 min, 60^ C 30 sec, 60>C
Step 3: Extension 1 min, 72°C 1 min, 72°C 1 min, 72°C 1 min, 72°C
Final extension 5 min, 72°C 
Hold at 15°C
5 min, 72°C 
Hokiat15°C
5 min, 72°C 
Hold at 15°C
5m*n,72°C 
Hold at 15°C
PCR product sizes Targeted: 514bp 
Recombined: 705bp
Recombined:
258bp
WT band: 403bp 
Targeted stop 
cassette: 621bp 
Recombined: 669bp
Recombined: 320bp
Ta
ble
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2.11 Data Analysis
2.11.1 Graphical representation of data
Raw data obtained from scoring, grading and quantitative PCR were inputted 
into Excel (Microsoft) spreadsheets. All means, standard deviations and sums were 
calculated using the calculator functions. Graphical representation of all data was also 
produced in Excel (Microsoft).
2.11.2 Comparison of means
The Minitab 15 (Minitab Inc.) statistical package was used to carry out normality 
tests of data (using the Andresson-Darling normality test) and comparison of means 
(using the Mann Whitney U test). Comparison of means analysis was carried out on cell 
scoring and ACT data from qPCR using the Mann-Whitney U test, as all data collected 
was not normal.
2.11.3 Comparison of Cell Migration
BrdU positive cell positions were plotted as cumulative frequency curves, and 
were analysed using the Kolmologrov-Smirnov test using SPSS 16 (SPSS Inc.).
2.11.4 Survival Analysis
Survival data were analysed using MedCalc (MedCalc), Kaplan-Meier plots were 
used to present data, and significance was measured using the Log Rank test.
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Chapter 3: Analysing the short term intestinal phenotype of Pten 
loss and Kras activation
3.1 Introduction
PTEN (Phosphatase and tensin homolog deleted on chromosome ten) is a tumour 
suppressor gene that is a negative regulator of the PI3K pathway. In humans germline 
mutations of PTEN give rise to a group of inherited diseases collectively called PTEN 
hamartoma tumour syndromes, reviewed in (Blumenthal and Dennis, 2008), the most 
common of which being Cowden syndrome. Symptoms of this autosomal dominant 
disease include neural developmental defects (Padberg et al., 1991), and the formation 
of well-differentiated benign tumours called hamartomas found in multiple organs 
including the Gl tract (Carlson et al., 1984, Merg and Howe, 2004). The individual is 
predisposed to cancer as these benign tumours are subject to malignant transformation. 
Somatic mutations in PTEN are commonly found in many sporadic cancers, examples 
include prostate (Feilotter et al., 1998, Wang et al., 1998), breast (Li et al., 1997, Saal 
et al., 2008), and endometrial cancer (Tashiro et al., 1997, Risinger et al., 1997). Due to 
PTEN’s role in the development of benign tumours in the Gl tract of Cowden syndrome 
patients, and its role in sporadic CRC, it is the subject of much research. For example in 
a study of CRC tumours, 40% harboured mutations in the PI3K pathway (including PTEN 
mutations), which would result in constitutive activation of the pathway (Parsons et al., 
2005). Also, some studies have suggested that loss of PTEN expression is associated with 
poor clinical outcome of CRC patients (Jang et al., 2010, Li et al., 2009).
Another commonly mutated gene involved in both the PI3K pathway and the 
MAPK/Erk pathway is the oncogene KRAS. It is a member of the Ras family of small 
GTPases, and acts a signal transducer that activates both the p110 catalytic subunit of 
the PI3K protein (Rodriguez-Viciana et al., 1996), and the MAP kinase BRAF or CRAF. It is 
commonly mutated at codon 12 (glycine) which prevents association of guanine 
nucleotide exchange factor (GEF) and the subsequent dissociation of GTP, leaving Kras 
permanently bound to GTP and permanently in an ‘on state’ . The oncogenic form of 
KRAS is associated with many cancer types including lung (Mills et al., 1995), pancreatic 
(Almoguera et al., 1988, Smit et al., 1988) and colorectal cancer. KRAS has been found 
to be constitutively active in 40-50% of CRCs (Bos et al., 1987), its oncogenic activation 
constitutes one of the step-wise mutations required for the formation of colorectal 
cancer as described by (Fearon and Vogelstein, 1990).
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Despite reports of intestinal neoplasia in a number of mouse models of Pten 
mutation (Di Cristofano et al., 1998, Podsypanina et al., 1999), and models of Kras 
activation (Calcagno et al., 2008, Janssen et al., 2002), other studies have reported that 
intestinal epithelial specific homozygous deletion of Pten (Marsh et al., 2008, Langlois et 
al., 2009) or inducible activation of Kras (Sansom et al., 2006, Haigis et al., 2008) alone 
do not result in tumour formation. As both PTEN and KRAS act within the same pathway,
I hypothesise that there may be synergy between the two mutations in the context of 
murine intestinal neoplasia. Synergy between Pten and Kras has been noted in a number 
of tumour models including mouse models of endometrial, lung and pancreatic cancer 
(Dinulescu et al., 2005, Iwanaga et al., 2008, Hill et al., 2010). Unpublished data from 
the Clarke lab have also demonstrated synergy between Pten and Kras. These findings 
demonstrated that Pten deletion and activation of oncogenic KrasG12V, result in the 
formation of both cholangio carcinoma and hyperplasia of the forestomach. Pten 
deletion and Kras activation was achieved by conditional transgenesis in this model, 
using the AhCre recombinase transgene. Expression of this transgene is driven by the 
Cyp1a1 promoter, which is induced by the presence of xenobiotics (Ireland et al., 2004). 
The AhCre transgene is expressed in a range of tissues including the epithelium of bile 
ducts, stomach, bladder, intestine and hepatocytes. Due to its wide range of expression, 
the effect of Pten deletion and KrasG12V activation on the intestinal epithelium was 
unable to be investigated using this ere recombinase transgene, as the onset of 
morbidity after induction of ere recombinase activity was rapid in these mice (around 40 
days).
The following four chapters will address synergy between Pten and Kras in the 
small intestine at various time points after induction, both alone and in the context of 
Wnt activated tumourigenesis. In order to achieve intestinal specific recombination the 
V/7//nCreERT recombinase transgene was used, which is expressed throughout the 
intestinal epithelium (El Marjou et al., 2004). In this chapter I will investigate the short 
term effects of Pten loss and Kras activation alone, and with the addition of a 
heterozygous Ape mutation in the small intestine at day 15 post induction. Mice were 
generated bearing the W///nCreERT recombinase transgene and were homozygous for 
loxP flanked alleles of Pten (Suzuki et a l., 2001), heterozygous for lox-stop-lox 
oncogenic KrasG12V (KrasLSL/+) (Guerra et al., 2003) and with or without one loxP flanked 
allele of Ape (Shibata et al., 1997). Mice homozygous for oncogenic Kras are essentially 
Kras knockouts as the stop cassette inserted upstream of the gene prevents any 
expression, this lack of Kras expression causes homozygous embryos to die in utero, 
therefore oncogenic Kras heterozygotes are only available to study. VillinCreERJ-Ptenfl/fl
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KrasLSL/+ (hereafter referred to as Pten///;' KrasLSL/+) and W//mCreERT-Apc/,/+ Pten/,//< 
KrasLSL/+ mice (hereafter referred to as Apc///+ Pten;,//< KrasLSL/+) along with their 
appropriate controls were induced and sacrificed at 15 days post induction.
3.2 Results
3.2.1 Permanent recombination of loxP sites at the Ape, Pten and Kras locus is
achieved in the intestinal epithelium
Mice were dissected and crude epithelial cell extracts were obtained from the 
small intestine by scraping the mucosal surface. To ascertain ere-mediated 
recombination of gDNA, gDNA was extracted from these samples and PCR for the 
recombined alleles of each of the loxP targeted genes was carried out. PCR was carried 
out on all samples to confirm recombination of the loxP sites. Figure 3.1 shows PCR 
products of representative samples of each of the cohorts induced.
VillinCre recombinase is expressed in all intestinal epithelial cells, including stem 
cells, but can only enter the nucleus when tamoxifen is present and binds to its fused 
estrogen receptor. Recombination at each locus in the stem cell compartment allows 
permanent manipulation of the genome in cells that are maintained long term in the 
intestinal epithelium. The presence of a band corresponding to the recombined allele 
for each locus (a 705bp band for the Pten locus, 669bp band for Kras and a 258bp band 
for Ape), confirmed that the genes of interest had been successfully mutated. A PCR 
product for the recombined allele was present for each loxP flanked sample using DNA 
obtained from mice induced 15 days previously. Given that the intestinal epithelium 
renews itself every 2-3 days and mice were examined 15 days following induction, this 
strongly implies recombination has occurred within the stem cell population.
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Figure 3.1 Recombined PCR confirmed that successful recombination at each loci 
was achieved and maintained at 15 days post induction
Recombination of loxP sites, and therefore gene mutation, was confirmed in each cohort 
by PCR carried out on gDNA from intestinal epithelial cells for the recombined allele. 
Primers are designed so that they only come into close proximity in a gene when loxP 
sites have been recombined and the DNA between them excised, a distinct PCR product 
can then be amplified (recombined band). Pten and Kras recombined PCRs could be 
multiplexed, whereas the recombined PCR for Ape was split due to similar product sizes. 
Pten: 705bp recombined band, 514bp loxP site targeted band, 428bp WT band. Kras: 
669bp recombined band, 621 bp loxP site targeted band, 403bp WT band. Ape: 314bp 
loxP site targeted band, 226bp WT band, ApcR: 258bp recombined band.
3.2.2 Pten and Kras synergise to cause hyperplasia of the crypt-villus axis
Short term synergy between Pten and Kras alone in the small intestine was first 
investigated in Pten/,//f KrasLSL/+ mice. Histological examination of H&E stained small 
intestinal sections from Pten/,//4 KrasLSL/+ mice revealed no gross changes in crypt-villus 
structure compared to control and WT tissue (Figure 3.2).
To investigate any effect Pten loss and Kras activation has on homeostasis of the 
intestinal epithelium, the number of cells per half crypt and half villus were scored 
(Figure 3.3). There were significantly higher numbers of cells per half crypt in Pten/4//< 
KrasLSL/+tissue (30.7 ± 1.56 cells) compared to controls (P ter/l/fl 26 ± 1.84 cells, KrasLSL/+ 
27.8 ± 0.45 cells) and WT tissue (25 ± 2.42 cells) (p values = 0.0259, n;>3, Mann Whitney 
U test). KrasLSL/+ control tissue also had a significantly higher number of cells per crypt 
compared to WT tissue (p value = 0.04, n;>3, Mann Whitney U test).
Similarly there were higher numbers of cells per half villus in Pterfl/fl KrasLSL/+ 
tissue (129.5 ± 17.67 cells) compared to P ter/l/fl control tissue (104.3 ± 2.63 cells) and 
WT tissue (82.4 ± 6.93 cells) (p values = 0.0259, ns=3, Mann Whitney U test). There was 
no significant difference between the number of cells per half villus in P te n ^  KrasLSL/+ 
tissue and the KrasLSL/+ control tissue (118.9 ± 4.4 cells). However, there was a trend 
towards higher villus cell number in PterJl,fl KrasLSL/+ compared to KrasLSL/+ tissue. The 
number of cells per half villus in KraS1547* tissue was significantly higher than Pten/,//4 and 
WT tissue.
Despite increases in crypt and villus cell number in Pten/,//< KrasLSL/+ tissue, they 
do not appear to be accompanied by an increase or decrease in apoptosis (Pten/,//< 
KrasLSL/+ = 0.06 ± 0.016, Pten"'" = 0.047 ± 0.064, KrasLSL/+ = 0.047 ± 0.05, WT = 0.03 ± 
0.02 apoptotic bodies) and mitosis (PterJl/fl KrasLSL/+ = 0.59 ± 0.17, Pten/4/// = 0.61 ±0.17, 
KrasLSL/+ = 0.071 ± 0.15, WT = 0.52 ± 0.09 mitotic figures) or Ki67 positive cycling cells 
(Pten/4/// KrasLSL/+ = 27 ± 4.03, Pten'"" = 21.4 ± 1.81, KrasLSL/+ = 24 ± 2.54, WT = 21.1 ± 1.5 
cells). Thus, despite an increasing trend in Ki67 positive cells in Pteril/fl KrasLSL/+ and 
KrasLSL/+ tissue compared to WT none of these changes were significant. However, 
KrasLSL/+ tissue had a significantly higher abundance of mitotic figures (0.71 ±0 .15 cells) 
compared to WT tissue (0.52 ± 0.09) (p value = 0.0383, m>3, Mann Whitney U test) 
(Figure 3.3, Figure 3.4).
Taken together, these data indicate that concomitant Pten loss and Kras 
activation disrupts normal intestinal homeostasis resulting in increased numbers of cells 
along the crypt-villus axis. Surprisingly, these changes in Pter^l,fl Kras4-547* tissue were not 
accompanied by an increase in mitotic figures or Ki67 positive cycling cells.
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Figure 3.2 Pten loss and Kras activation causes no gross alteration of the crypt-villus 
structure at day 15 post induction
Histological examination of H&E stained small intestinal sections revealed no overt 
changes in crypt-villus structure of Pten/,//< KrasLSL/+ mice compared to the controls and 
WT tissue. Scale bars represent 200|xm.
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Figure 3.3 Pten loss and Kras activation results in increased crypt and villus cell 
number
Key: WT - Wild Type, K - KrasiSi' \  P - Pten/,/;', PK - Ptenfl/fl KrasiSU+
Crypt cell scoring revealed increased number of cells per half crypt in PterJl/fl KrasLSL/+ 
tissue compared to controls and WT tissue. The number of cells per half crypt in KrasLSL/+ 
control tissue was also significantly higher compared to PterJl/fl and WT tissue. Villus cell 
scoring revealed increased number of cells per half villus in PterJl,fl KrasLSL/+ tissue 
compared to Pten/,/;/ and WT tissue (p value = 0.0259, n&3, Mann Whitney U test). 
However Pten////f KrasLSL/+ villus cell number was not significantly different from KrasLSL/+ 
tissue (p value = 0.1884, m>3, Mann Whitney U test). KrasLSL/+ tissue also had significantly 
higher numbers of cells per half villus compared to P te n ^  and WT tissue (*, p value 
<0.05, n^3, Mann Whitney U test). There were no changes in the number of apoptotic 
bodies or mitotic figures as scored by H&E examination in Pten/,/// KrasLS/7+ tissue 
compared to controls and WT tissue (p values >0.05, n&3, Mann Whitney U test), KrasLSi/+ 
tissue had significantly higher number of mitotic figures compared to WT (*, p value = 
0.0383, ns3, Mann Whitney U test). Error bars indicate standard deviation.
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Figure 3.4 Pten loss and Kras activation does not affect the number of cycling cells 
present per half crypt
IHC against the cell cycle marker, Ki67, was carried out on small intestinal sections. 
There appeared to be no gross alteration in the positioning or abundance of Ki67 positive 
cells in Ptenfl/fl KrasLSL/+ tissue compared to controls and WT tissue, scale bars represent 
50pm. This was confirmed by scoring the number of Ki67 positive cells per half crypt. 
There were no significant changes in the abundance of Ki67 positive cells (p values 
>0.05, ns3, Mann Whitney U Test). However Ptenfl,fl KrasLSi-/+ and KrasLSL/+ tissue trended 
towards higher numbers of Ki67 positive cells compared to Ptenfl/fl and WT tissue. Error 
bars indicate standard deviation.
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3.2.3 Pten loss and Kras activation affects the abundance of enteroendocrine cells and
paneth cells in the small intestine
As Pten loss and Kras activation disrupts small intestinal homeostasis, as 
evidenced by hyperplasia of the crypt and villus, the number and localisation of the four 
major small intestinal mature cell types was determined. Grimelius staining was carried 
out on small intestinal sections to mark enteroendocrine cells. Enteroendocrine scoring 
per half crypt-villus (and normalising for alterations in crypt-villus cell number) revealed 
significantly reduced numbers of enteroendocrine cells in PterfUfl KrasLSL/+ tissue (0.0035 
± 0.0003 cells) compared to WT tissue (0.005 ± 0.0005 cells) (p value = 0.0404, n^3, 
Mann Whitney U test) (Figure 3.5). The number of enteroendocrine cells present in 
Pten//X// tissue (0.004 ± 0.0005 cells) was also lower than WT tissue (p value = 0.0404, 
n;>3, Mann Whitney U test) but was not significantly different from Ptenfl,fl KrasLSL/+ 
tissue (p value = 0.0952, n^3, Mann Whitney U test) indicating that the observed 
decrease in enteroendocrine cells may be solely attributed to Pten loss.
Goblet cells were visualised by staining small intestinal sections with alcian blue; 
they appeared to be unchanged in number and localisation. The number of goblet cells 
present per half villus was then scored and normalised. Scoring revealed no changes in 
goblet cell number in each cohort compared to WT tissue (PteiV7^  KrasLSL/+ = 0.05 ± 
0.006, Ptenfl/fl = 0.05 ± 0.004, KrasLSL/+ = 0.04 ± 0.008, WT = 0.06 ± 0.006 goblet cells) 
(Figure 3.6).
To visualise paneth cells IHC against lysozyme was carried out on small intestinal 
sections (Figure 3.7). Lysozyme immunostaining revealed normal localisation of paneth 
cells (at the base of the crypt) in Pten//7// KrasLSL/+ tissue. However, paneth cell scoring 
revealed that Pten//7/< tissue had significantly lower numbers of paneth cells per crypt 
(3.12 ± 0.156 cells) compared to WT tissue (3.49 ± 0.117 cells) (p value = 0.0404, n^3, 
Mann Whitney U test). Additional mutation of Kras in Ptenfl/fl KrasLSL/+ mice further 
enhances this phenotype, as Pten//;// KrasLSL/+ tissue possessed significantly lower 
numbers of paneth cells (1.85 ± 0.306 cells) compared to Pten/,7/* tissue (3.12 ± 0.156 
cells) as well as KrasLSL/+ (2.96 ± 0.410 cells) and WT tissue (3.49 ± 0.117 cells) (p values 
= 0.0404, n^3, Mann Whitney U test).
The localisation of alkaline phosphatase was visualised using a chromogenic 
substrate for alkaline phosphatase that is catalysed to produce a red stain. Small 
intestinal sections were incubated with the substrate. Alkaline phosphatase is normally 
expressed on the apical surface of enterocytes. The red stain therefore demarcates the 
apical surface of enterocytes and indicates the polarisation of the intestinal epithelium. 
Alkaline phosphatase staining revealed it to be localised to the apical/luminal surface of
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the villus epithelium (Figure 3.8). Alkaline phosphatase is only present in differentiated 
enterocytes at the top of the crypt and along the length of the villus. There appeared to 
be no changes in alkaline phosphatase localisation in PterJUfl KrasLSL/+ tissue compared to 
control and WT tissue.
In summary, staining for the various markers of each mature cell type confirmed 
the presence of each cell lineage and their normal localisation, in Ptevfl/fl KrasLSL/+ tissue 
and control tissue compared to WT. Pten loss appears to impact on enteroendocrine and 
paneth cell number. However Pten loss in concert with Kras activation causes a further 
reduction in paneth cells.
3.2.4 Concomitant mutations in Pten and Kras results in a subtle increase of phospho-
Akt immunostaining
To investigate the mechanism through which mutations in Pten and Kras are 
synergising, IHC against the active form of the PI3K pathway effector protein Akt was 
carried out (Figure 3.9). Immunostaining revealed a subtle increase in the presence of 
the active form of Akt (pAkt [ser473]) in Ptenfl,fl KrasLSL/+ tissue compared to WT tissue. 
However, there also appeared to be a subtle elevation of pAkt present in the control 
tissue (both Pten/,//< and KrasLSL/+) compared to WT tissue. The subtle elevation of pAkt 
staining, and therefore PI3K pathway activation, presents a mechanism by which the 
phenotypes observed in Pter/l/fl KrasLSi-/+ and control tissue may be driven.
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Figure 3.5 Pten loss reduces the number of enteroendocrine cells present in the 
small intestine
Grimelius staining of small intestinal sections to visualise the number of enteroendocrine 
cells present (indicated in WT intestine by arrows). Staining revealed normal localisation 
of enteroendocrine cells throughout the crypt-villus axis in Pten/,//' KrasLSL/+ tissue 
compared to control and WT tissue. Scale bars represent 100pm. The number of 
enteroendocrine cells present per half crypt-villus was scored and divided by the 
average number of cells per half crypt-villus, to normalise for the varying numbers of 
cells per half crypt-villus. Both experimental Pten////f KrasLSL/+ tissue and Pten/,//z control 
tissue had significantly lower numbers of enteroendocrine cells per half crypt-villus 
compared to WT tissue (*, p values = 0.0404, n;>3, Mann Whitney U test). Error bars 
indicate standard deviation.
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Figure 3.6 Goblet cell number is unchanged in Pten/,//; KrasLSL/+ small intestine
Small intestinal sections were stained with alcian blue in order to mark goblet cells 
(indicated in WT intestine by arrows). Staining revealed normal localisation of goblet 
cells throughout the crypt-villus axis in Pten;,/// KrasLSL/+ tissue compared to control and 
WT tissue. Scale bars represent 200pm. The number of goblet cells present per half 
villus were then scored and divided by the average number of cells per half villus, to 
normalise for varying villus cell number. There were no changes in goblet cell number in 
?tenfl/fl KrasLSt/+ tissue compared to controls and WT (p values >0.05, n^3, Mann Whitney 
U test). Error bars indicate standard deviation.
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Figure 3.7 Pten loss and Kras activation reduces the number of paneth cells present 
in small intestinal crypts
IHC against lysozyme was carried out on small intestinal sections to indicate the 
presence and location of paneth cells, (indicated in WT intestine by arrows). Staining 
revealed normal localisation of paneth cells throughout the crypt in Pten/f//< KrasLSL/+ 
tissue compared to control and WT tissue. Scale bars represent lOO^m. Subsequent 
scoring of paneth cells revealed that Pten loss causes a reduction in paneth cell number 
compared to WT tissue (*, p value <0.05, ns3, Mann Whitney U test). The addition of a 
Kras mutation in Pten/,/;/ KrasLSL/+ compounds this effect, causing a significant decrease 
in the number of paneth cells present per crypt compared to both controls and WT 
tissue (*, p values <0.05, n^3, Mann Whitney U test). Error bars indicated standard 
deviation.
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Figure 3.8 Alkaline phosphatase remained localised to the apical membrane of 
differentiated enterocytes
Small intestinal sections were incubated with a chromogenic substrate for alkaline 
phosphatase (catalysed to produce a red stain). Alkaline phosphatase is normally 
expressed on the apical membrane of differentiated enterocytes. Staining revealed 
normal localisation of alkaline phosphatase and therefore intact polarisation of the 
intestinal epithelium in PterJl/fl KrasLSL/+ and control tissue. Scale bars represent 100pm.
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Figure 3.9 Loss of Pten and activation of Kras alone and concomitantly, subtly 
enhances the level of phospho-Akt
IHC against pAkt (Ser473) was carried out on small intestinal sections. Examination of 
the sections revealed a subtle increase in cytoplasmic and nuclear immunostaining in 
Pten/,//( KrasLSL/+ tissue and also in the control tissues compared to WT tissue. 
Immunostaining in both Pten/,7// KrasLSL/+ and control tissue is predominantly found in the 
crypt region. Scale bars represent lOO^m.
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3.2.5 Investigating short term synergy between Pten and Kras in the context of
heterozygous Ape deletion
Synergy between Pten and Kras was also investigated in the context of 
heterozygous Ape mutation in the small intestine from mice sacrificed at 15 days post 
induction. Locus-specific recombination was assessed by PCR for the recombined loci of 
Ape, Pten and Kras, confirming mutation of each of the genes of interest (Figure 3.1). 
Examination of H&E stained small intestinal sections revealed no overt changes in crypt- 
villus structural morphology (Figure 3.10). Assessment of histological changes was 
carried out on Apc/Z/+ Pter\fl,fl KrasLa/+ tissue, by scoring the number of cells per half 
crypt-villus and levels of apoptosis, mitosis and proliferation as previously carried out on 
P te n ^  KrasLSL/+ tissue in section 3.2.2. Unlike Pten/,7/' KrasLSL/+ mice, crypt cell scoring 
revealed no significant changes in crypt cell number in any of the cohorts (Figure 3.11) 
(Apc/,/+ Ptenfl/fl KrasL* /+ = 29.8 ± 3.26, Apc/,/+ Pten;,///= 26.7 ± 2.71, Apc/,/+ KrasLSL/+ = 28.9 
± 5.15, Apc///+ = 26.1 ± 0.36, WT = 25 ± 2.42 cells) (p values >0.05, m>3, Mann Whitney U 
test). However, there appeared to be a trend towards higher crypt cell numbers in 
Apc/,/+ Pten/<7/< KrasLSL/+ and Apc///+ KrasLSL/+ tissues compared to control and WT tissue. 
Similarly to PterJufl KrasLSL/+ mice, villus cell number was significantly higher in Apc/,/+ 
Pten/,//f KrasLSL/+ (134.2 ± 20.6 cells) and Apc/,/+ KrasLa/+ (120.5 ± 10.9 cells) tissue 
compared to WT tissue (82.4 ± 6.93 cells) (p values = 0.0259, ns3, Mann Whitney U test). 
Villus cell scoring also revealed higher numbers of cells in Apc/,/+ tissue (104.5 ± 7.67 
cells) compared to WT tissue (82.4 ± 6.93 cells) (p value = 0.0404, ns3, Mann Whitney U 
test). Despite an increasing trend in villus cell number in Apc/,/+ Pten/,7/< KrasLSL/+ and 
Apc/</+ KrasLSL/+tissue compared to Apc/,/+ tissue it was not significant (p values = 0.0558, 
ns3, Mann Whitney U test) (Figure 3.11).
Levels of cell death and proliferation in Apc/,/+ Pten/,7/< KrasLSL/+ tissue was 
assessed by scoring apoptotic bodies and mitotic figures present in H&E stained sections. 
Proliferation was further assessed by scoring the number of Ki67 positive cycling cells 
per half crypt. There were no significant changes in apoptosis, mitosis and Ki67 positive 
cells in Apc/,/+ P te n ^  KrasLSL/+ tissue compared to controls and WT tissue. Apoptosis: 
Apc/,/+ Pten/f//' KrasLSL/+ = 0.09 ± 0.044, Apc/,/+ Pten'"'' = 0.06 ± 0.057, Apc/,/+ KrasiSU+ = 
0.11 ±0.116, Apc;'/+ = 0.14 ± 0.072, WT = 0.03 ± 0.023 apoptotic bodies. Mitosis: Apc/,/+ 
Pten//7// KrasLSi-/+ = 0.57 ± 0.139, Apc/</+ P ten ^ ' = 0.7 ± 0.085, Apc/,/+ KrasLSL/+ = 0.74 ± 
0.141, Apc/,/+ = 0.49 ± 0.095, WT = 0.52 ± 0.092 mitotic figures. Ki67 positive 
proliferating cells: Apc/,/+ Pten/,7/< KrasLSL/+ = 21.9 ± 2.71, Apc/,/+ P te n ^  = 21.8 ± 1.66, 
Apc/</+ KrasLSL/+ = 25.1 ± 1.68, Apc/,/+ = 22.5 ± 0.65, WT = 22.5 ± 0.64 Ki67 positive cells,
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(p values >0.05, n;>3, Mann Whitney U test) (Figure 3.11, Figure 3.12). However, there 
were some significant changes within the control groups.
Heterozygous Ape loss alone resulted in a significant increase in the number of 
apoptotic bodies per half crypt (0.14 ± 0.072 cells) compared to WT tissue (0.03 ± 0.023 
cells) (p value = 0.0383, n;>3, Mann Whitney U test). Apoptosis levels in Apc/,/+ Pten////( 
KrasLSL/+, Apc/,/+ KrasLSL/+ and Apc/,/+ Ptenfl/fl tissue were not significantly altered from the 
WT (p values >0.05, ns3, Mann Whitney U test). Therefore suggesting additional 
mutation of either Pten or Kras alone, or both together suppresses the apoptotic effects 
of heterozygous Ape deletion. Data obtained from mitosis and Ki67 scoring revealed 
significant increases in mitotic bodies only in Apc/,/+ Pten/,/// tissue (0.70 ± 0.085 mitoses) 
compared to Apc///+ (0.49 ± 0.095 mitoses) and WT tissue (0.52 ± 0.092 mitoses) (p value 
= 0.0249, nss3, Mann Whitney U test), and Apc/,/+ KrasLSL/+ tissue has significantly higher 
numbers of Ki67 positive cells (25.1 ± 1.68 positive cells) compared to WT tissue (21.1 ± 
1.50 cells) (p value = 0.0404, ns=3, Mann Whitney U test).
Taken together these data suggest that there is synergy in the small intestinal 
epithelium between Pten and Kras in the context of heterozygous Ape deletion. This was 
evidenced by an increase in villus cell number. This phenotype may be driven by Pten 
loss and Kras activation alone, as the number of cells per half villus in Apc/,/+ Pten//X// 
KrasLSL/+ mice (134.2 ± 20.6 cells) was not significantly altered from the number of cells 
per half villus in Pten/,7/< Kras1^  mice (129.5 ± 17.67 cells, p value = 0.4426, ns3, Mann 
Whitney U test). However, an increase in the number of crypt cells was not observed in 
Apc/,/+ Pten/,7// KrasLSL/+ mice unlike Pten/,//< KrasLSL/+ mice, suggesting that additional 
mutation of Ape rescues this phenotype.
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Figure 3.10 Pten loss and Kras activation causes no gross alteration of the crypt- 
villus structure in the context of a heterozygous Ape deletion
H&E stained small intestinal sections revealed no gross changes in crypt-villus structure 
in Apc/,/+ Pten/,/;/ KrasLSL/+ tissue compared to control and WT tissue. Scale bars represent 
200nm.
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Figure 3.11 Pten loss and Kras activation in the context of a heterozygous Ape 
mutation results in increased villus cell number
Key: WT - Wild Type, A - Apc/,/+, AK - Apc/</+ KrasLSL/+, AP - Apc/,/+ Pten//;//, APK - Apc/,/+ 
Pten////f KrasLSL/+
Crypt cell scoring revealed no significant changes in crypt cell number in Apc/,/+ Pten////f 
KrasLSL/+ tissue compared to control and WT tissue. However, villus cell scoring revealed 
increased number of cells per half villus in Apc/</+ Pten/,//< KrasLSL/+ tissue compared to 
Apc///+ Pten/,/;' and WT tissue (*, p values <0.05, n^3, Mann Whitney U test). There were 
no changes in the number of apoptotic bodies or mitotic figures as scored by H&E 
examination in Apc/,/+ Pten/,/;' KrasLSL/+ tissue compared to controls and WT tissue (p 
values >0.05, n^3, Mann Whitney U test). However Apc/,/+ control tissue had higher levels 
of apoptosis compared to WT tissue. Apc/,/+ Pten/,7// control tissue had significantly higher 
levels of mitosis than both Apc///+ and WT tissue (*, p values <0.05, n^3, Mann Whitney U 
test). Error bars indicate standard deviation.
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Figure 3.12 Simultaneous Pten loss and Kras activation causes no changes in the 
number of cycling cells in the context of a heterozygous Ape deletion
IHC against cell cycle marker, Ki67, was carried out on small intestinal sections. There 
appeared to be no gross alteration in the positioning or abundance of Ki67 positive cells 
in Apc/,/+ Ptenfl/fl KrasLSL/+ tissue compared to controls and WT tissue. Scale bars 
represent 50^m. This was confirmed by scoring the number of Ki67 positive cells per half 
crypt. There were no significant changes in the abundance of Ki67 positive cells in 
Apc/,/+ Pten//;// KrasLSL/+ tissue compared to controls and WT tissue (p values >0.05, n^3, 
Mann Whitney U Test). However, Apc/,/+ KrasiSU* control tissue had significantly higher 
numbers of Ki67 positive cells per half crypt compared to WT tissue (*, p value <0.05, 
n^3, Mann Whitney U test). Error bars indicate standard deviation.
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3.2.6 Pten loss and Kras activation in the context of heterozygous Ape loss affects the
abundance of enteroendocrine cells and paneth cells in the small intestine
Alterations in cell lineage in Apc7"+ Pten7"7* KrasLS*"+ mice were assessed by 
scoring the number and/or localisation of mature cell types along the crypt-villus axis, 
i.e. goblet cells, enteroendocrine cells, paneth cells and the brush border of enterocytes 
as described for Pten7"7* KrasLSL/+ tissue in section 3.2.3.
Grimelius staining revealed normal localisation of enteroendocrine cells in all 
cohorts. Lower numbers of enteroendocrine cells were observed in Apc7*/+ Pten7"7* 
KrasLSL/+ tissue (0.0028 ± 0.00061 cells) compared to the Apc/,/+ (0.0046 ± 0.00027 cells) 
and Apc/,/+ KrasLSL/+ (0.0046 ± 0.00008 cells) controls and WT tissue (0.005 ± 0.00047 
cells) (p values = 0.0404, m>3, Mann Whitney U Test) (Figure 3.13). It is likely that this 
effect on enteroendocrine cell lineage is solely attributed to Pten loss and Kras 
activation, as the number of enteroendocrine cells present in Pten7"7* KrasLSL/+ tissue 
(0.0035 ± 0.0003 cells) is not statistically different to the number of enteroendocrine 
cells present in Ape7"* Pten7"7* KrasLSL/+ tissue (0.0028 ± 0.00061 cells) (p value = 0.1914, 
ns3, Mann Whitney U Test). However, heterozygous Ape loss appears to have rescued 
the enteroendocrine cell loss phenotype observed in Pten7"7* tissue. Thus, 
enteroendocrine cell number in Apc7*/+ Pten7"7* tissue is not statistically different from 
the control and WT tissue (p values = 0.0952, ns3, Mann Whitney U test).
Alcian blue staining revealed normal localisation of goblet cells in each cohort, 
but heterozygous Ape loss appears to have a negative effect on goblet cell number. 
Apc7*/+ and Apc7*/+ KrasLSL/+ had significantly lower numbers of goblet cells per half villus 
(0.045 ± 0.001 cells and 0.042 ± 0.002 cells respectively) compared to WT tissue (0.056 ± 
0.006 cells), (p values = 0.0404, n^3, Mann Whitney U test) (Figure 3.14). Interestingly 
this phenotype is rescued by Pten loss and Kras activation, as goblet cell number in 
Apc/,/+ Pten7"7* KrasLSL/+ (0.049 ± 0.006 cells) was not significantly altered from WT tissue 
(p values = 0.1914, ns3, Mann Whitney U test).
Lysozyme immunostaining revealed normal localisation of paneth cells in Apc7*/+ 
Pten7"7* KrasLSL/+ tissue, at the base of the crypt (Figure 3.15). However, paneth cell 
scoring revealed a reduction in the abundance of paneth cells in Apc7*/+ Pten7"7* KrasLSL/+ 
(2.75 ± 0.43 cells), Apc7*/+ KrasLSL/+ (2.75 ± 0.43 cells) and Apc/,/+ Pten7"7' (2.86 ± 0.242 
cells) tissue compared to WT tissue (3.49 ± 0.117 cells) (p values <0.05, ns*3, Mann 
Whitney U test) (Figure 3.15). Heterozygous loss of Ape alone (Apc/,/+) had no effect on 
paneth cell number (p value = 0.0606, n&3, Mann Whitney U test).
Alkaline phosphatase staining was used to demarcate the brush border of mature 
enterocytes as described for Pten7"7* KrasLSL/+ tissue in section 3.2.3. Alkaline
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phosphatase staining revealed normal staining localised to the apical/luminal surface of 
the villus epithelium in Apc/,/+ P te n ^  KrasLSL/+ tissue. There appeared to be no changes 
in alkaline phosphatase localisation in Apc/,/+ P te n ^  KrasLSL/+ tissue compared to control 
and WT tissue (Figure 3.16).
In summary the alterations in the abundance of mature cell types observed in 
Ptenfl/fl KrasLSL/+ mice remain the same in Apc/Z/+ Ptenfl/fl KrasLSL/+ mice i.e. a reduction in 
enteroendocrine and paneth cells, and no changes in goblet cell number compared to 
WT. Additionally, the decrease in enteroendocrine cell number appears to be driven by 
Pten loss and Kras activation alone, as the figures observed in Apc/,/+ Pten/,7/' KrasLSL/+ 
tissue are not significantly altered from those observed in Pterf"*1 KrasLSL/+ tissue (p 
value = 0.1914, n;>3, Mann Whitney U test). Heterozygous loss of Ape decreases goblet 
cell number shown in Figure 3.14, Pten loss and Kras activation rescues this phenotype 
to bring goblet cell numbers back to normal WT levels. The loss in paneth cells observed 
in Apc/,/+ P te n ^  KrasLSL/+ and Ptenfl/fl KrasLSL/+ tissue does appear to be rescued partially 
by heterozygous Ape loss, as Apc/,/+ Ptenfl,fl KrasLSL/+ tissue has significantly higher 
numbers of paneth cells compared to PterJl,fl KrasLSL/+ tissue (2.75 ± 0.43 cells vs 1.85 ± 
0.306 cells, p value = 0.0404, m>3, Mann Whitney U test). However, paneth cell number 
is not restored to normal WT levels (Figure 3.15).
3.2.7 Concomitant mutations in Pten and Kras in a context of a heterozygous Ape
mutation result in a subtle increase of phospho-Akt immunostaining
The level of pAkt immunostaining was again assessed to investigate synergy 
through the PI3K pathway, as in section 3.2.4. Immunostaining of pAkt in Apc/,/+ Pten/,7/< 
KrasLSL/+ tissue was substantially increased compared to control tissue (Figure 3.17), 
unlike what was observed in Ptenfl/fl KrasLSL/+ tissue in Figure 3.9. There appeared to be 
no overt differences in pAkt immunostaining in control tissue, pAkt was found within the 
cytoplasm of cells in the crypt region. Mutations in Pten and Kras appear to be 
synergising through the PI3K pathway in the Apc/,/+ P te n ^  KrasLSL/+ model.
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Figure 3.13 Pten loss and Kras activation in the context of heterozygous Ape loss 
reduces the number of enteroendocrine cells present in the small intestine
Grimelius staining of enteroendocrine cells was carried out on small intestinal sections 
to visualise the number of enteroendocrine cells present (indicated in Apc/,/+ tissue by 
arrows). Staining revealed normal localisation of enteroendocrine cells throughout the 
crypt-villus axis in Apc/,/+ Pten/,y/< KrasLSL/+ tissue compared to control and WT tissue. 
Scale bars represent 100pm. The number of enteroendocrine cells present per half 
crypt-villus was scored and divided by the average number of cells per half crypt-villus, 
to normalise for the varying numbers of cells per half crypt-villus. Apc///+ Pten/,/;' 
KrasLSL/+ tissue had significantly lower numbers of enteroendocrine cells per half crypt- 
villus compared to Apc/</+, Apc/,/+ KrasLSL/+ control and WT tissue (*, p values = 0.0404, 
n^3, Mann Whitney U test), in a similar manner to what was observed in Pten/,7/< KrasLSL/+ 
tissue. Unlike Pten/,7// tissue, enteroendocrine cell number in Apc///+ Pten////Z tissue is not 
statistically different from the control and WT tissue (p values = 0.0952, n^3, Mann 
Whitney U test). Error bars indicate standard deviation.
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Figure 3.14 Pten and Kras synergise to rescue goblet cell decrease caused by 
heterozygous Ape loss
Small intestinal sections were stained with alcian blue in order to mark goblet cells 
(indicated in Apc/,/+ tissue by arrows). Staining revealed normal localisation of goblet 
cells throughout the crypt-villus axis in Apc/,/+ Pten/,//< KrasLSL/+ tissue compared to 
control and WT tissue. Scale bars represent 200jxm. The number of goblet cells present 
per half villus was then scored and divided by the average number of cells per half 
villus, to normalise for varying villus cell number. Heterozygous Ape loss appears to 
negatively affect the goblet cell lineage resulting in decreased numbers per half villus 
compared to WT (p value = 0.0404, ns3, Mann Whitney U test). This effect is further 
compounded by activation of oncogenic Kras (p value = 0.0404, n;>3, Mann Whitney U 
test). Addition of Pten loss appears to rescue this phenotype, however despite a trend 
towards higher numbers of goblet cells, Apc/,/+ Pten/,y/I is significantly lower than WT (p 
value = 0.0404, m>3, Mann Whitney U test). Goblet cell number in Apc///+ Pten^' KrasLSL/+ 
mice is not significantly altered from the WT (p value = 0.1914, n^3, Mann Whitney U 
test). Error bars indicate standard deviation.
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Figure 3.15 Paneth cell scoring revealed a reduction in abundance in all Apc/,/+ 
cohorts
IHC against lysozyme was carried out on small intestinal sections to indicate the 
presence of paneth cells (indicated in Apc/,/+ tissue by arrows). Immunostaining revealed 
normal localisation of paneth cells in the base of the crypt in Apc/,/+ Pten/,7/* KrasLSL/+ 
tissue compared to control and WT tissue. Scale bars represent 50^m. Subsequent 
scoring of lysozyme positive paneth cells revealed that additional mutation of Pten loss 
or Kras activation both individually or together in Apc///+ mice significantly reduces the 
abundance of paneth cells compared to WT tissue (p values <0.05, m>3, Mann Whitney U 
test). Error bars indicate standard deviation.
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Figure 3.16 Alkaline phosphatase remained localised to the apical membrane of 
differentiated enterocytes
Small intestinal sections were incubated with a chromogenic substrate for alkaline 
phosphatase (catalysed to produce a red stain). Alkaline phosphatase is normally 
expressed on the apical membrane of differentiated enterocytes. Staining revealed 
normal localisation of alkaline phosphatase and therefore intact polarisation of the 
intestinal epithelium in Apc;'/+ Pter\fl/fl KrasLSL/+ and control tissue. Scale bars represent 
100pm.
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Figure 3.17 Loss of Pten and activation of Kras in the context of a heterozygous Ape 
mutation enhances phospho-Akt immunostaining
IHC against pAkt (Ser473) was carried out on small intestinal sections. Examination of 
the sections revealed increased immunostaining of pAkt in Apc///+ P te n ^  KrasLSi-/+ tissue 
compared to control tissue. pAkt immunostaining remains localised to the crypt region in 
the control tissues as was observed in the Ape and WT controls in Figure 3.9. Scale bars 
represent lOO^m.
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3.3 Discussion
3.3.1 P te n ^  KrasLSL/+ and Apc/,/+ Pten//7// KrasLSL/+ mice maintain recombined intestinal 
epithelial cells and are healthy at day 15 post induction
The mice described in this chapter were induced via i.p. injection of tamoxifen 
at around 6 weeks of age. They were then sacrificed at 15 days post induction. All mice 
appeared to be in good health up to 15 days post induction. In particular, mutation of 
Pten and Kras alone, and in conjunction with Ape (Pten/,/// KrasLSL/+ and Apc/,/+ Pten/,//f 
KrasLSL/+ mice) appeared to have no overt impact on mouse health at this timepoint.
To confirm that ere recombinase had successfully recombined the DNA at the 
loxP sites and that this recombination had taken place in intestinal epithelial cells, PCR 
for the recombined alleles of interest was carried out on gDNA from small intestinal 
epithelial cells. Recombined PCR indicated that each allele had recombined 
successfully, and recombination must have occurred in the stem cell compartment as 
epithelial cells retained the recombined alleles 15 days after induction, in which time 
the intestinal epithelium has turned over at least two times. This confirmed that loss of 
Pten, activation of Kras and heterozygous loss of Ape in small intestinal stem cells is 
viable and these genetically manipulated stem cells remain 15 days after induction.
3.3.2 Synergy between Pten and Kras is evidenced by disruption of intestinal 
homeostasis in P te n ^  KrasLSL/+ mice
At day 15 post induction there appears to be active synergy between Pten and 
Kras, evidenced by disrupted small intestinal homeostasis. Despite no obvious changes in 
the structural morphology of the small intestinal crypt-villus axis, histological analysis of 
the tissue revealed hyperplasia of the crypts and villi. Numerous changes in cell number 
including crypt-villus cell number and the alterations in the abundance of various cell 
types were observed. Both the crypts and villi of PterJl,fl KrasLSL/+ mice contained greater 
number of cells compared to WT tissue (Figure 3.3). Mutation of Pten and Kras alone 
disrupts intestinal homeostasis in some cases for example, Kras activation alone results 
in an increased abundance of cells in the crypt. However, when combined with a 
mutation in Pten, this phenotype is further enhanced, evidenced by a significant 
increase in the number of crypt cells in PterfUfl KrasLSL/+ tissue compared to KrasLSL/+ 
tissue. Thus, indicating synergy between Pten and Kras mutations.
Surprisingly, despite an increase in crypt and villus cell number, there was no 
statistical significance between the number of the Ki67 positive cells in P te n ^  KrasLSL/+ 
tissue and WT tissue (Figure 3.4), which suggests that this phenotype is not driven by an
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increase in proliferating cells. Therefore, one possible hypothesis to how Pten loss and 
Kras activation are driving the disruption of intestinal homeostasis may not be by an 
increase in cell proliferation but by a decrease in apoptosis at the tip of the villus. If 
cells are not undergoing apoptosis and are not sloughed from the villus tip then a build 
up of cells would ensue, resulting in increased number of cells occupying the crypt-villus 
axis. One possible mechanism for this may be through the subtle accumulation of pAkt in 
control and experimental intestine (Figure 3.9). A number of pro-apoptotic factors are 
inactivated by pAkt, such as Bad, Bim and Bax, which are all involved in the intrinsic 
apoptotic pathway. Activation of pAkt has been shown to reduce apoptosis in colorectal 
cancer cell lines (Itoh et al., 2002). Additionally, this has also been shown in vivo in a 
number of mouse models of intestinal mucosal barrier damage. In these models, 
intestinal mucosal barrier damage is alleviated by a reduction in apoptosis mediated by 
upregulation of PI3K signalling (Huang et al., 2011, Chen et al., 2010, Qiu et al., 2010). 
Accumulation of pAkt cannot be correlated with a reduction in apoptosis in this study, as 
no changes in the level of apoptosis in the crypt were observed. However, the number of 
apoptotic events in normal intestinal tissue is very low, and perhaps the effect of pAkt 
on apoptosis levels is only evident in instances when the intestine is undergoing high 
levels of cell death, such as mucosal barrier damage.
Disruption of small intestinal homeostasis was also evident when scoring 
differentiated cell types in Pten/,7// KrasLSL/+ tissue. There was a reduction in 
enteroendocrine and paneth cells in Pten/,//7 KrasLSL/+ and P te n ^  tissue compared to WT 
tissue (Figure 3.5, Figure 3.7), but there was no alteration in the abundance of goblet 
cells and enterocytes appeared to be differentiating normally as assessed by alkaline 
phosphatase staining (Figure 3.6, Figure 3.8). Synergy between Pten and Kras appears to 
preferentially affect the differentiation of enteroendocrine and paneth cells. Both 
enteroendocrine and paneth cells are secretory cells, and the fate of secretory cell 
lineages is in part dependent upon the Notch signalling pathway. Activation of the Notch 
pathway maintains intestinal epithelial cells in an undifferentiated state, thus activation 
is highest in the intestinal crypts. Inappropriate activation of the pathway in mice leads 
to the loss of all secretory cell types and conversion of the differentiated epithelia to 
immature progenitor cells (Fre et al., 2005, van Es et al., 2005). Activation of mTOR 
may present as a possible mechanism of modulation of Notch signalling in these mouse 
models. Activation of mTOR in mouse embryonic fibroblasts blocks cellular 
differentiation via upregulation of Notch signalling (Ma et al., 2010).
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3.3.3 Synergy between Pten and Kras is observed in Apc///+ Pten/<7/< KrasLSL/+ tissue,
similar to that observed in Pten;,//' KrasLSL/+ tissue
Scoring of crypt-villus cell number and differentiated cell types in Apc/,/+ Ptenfl,fl 
KrasLSL/+ yielded overall similar results to those observed in Ptedl,fl KrasLSL/+ tissue. 
Apc///+ Pten/,//( KrasLSL/+ mice had significantly more cells per half villus, but this was not 
accompanied by an increase in crypt cell number (Figure 3.11). Apc/,/+ Pten/,/;< KrasLSL/+ 
mice also had lower numbers of enteroendocrine and paneth cells, and no changes in 
goblet cell number or alkaline phosphatase localisation (section 3.2.6). As the 
phenotypes are similar one would assume the pathways governing them in Ptenfl/fl 
KrasLSL/+ mice are the same in Apc///+ P te n ^  KrasLSL/+ mice. In most cases the changes 
observed in cell abundance in Apc/,/+ P te n ^  KrasLSL/+ tissue, were not significantly 
altered from the similar changes observed in Pten/,/// KrasLSL/+ mice, suggesting that 
many of the phenotypes observed in Apc///+ Pten/f/// KrasLSL/+ mice could be attributed to 
Pten and Kras synergy alone.
Interestingly in some incidences heterozygosity of Ape also appeared to impact on 
intestinal homeostasis. Apc/,/+ mice have significantly higher numbers of cells per half 
villus and increased levels of apoptosis compared to WT (Figure 3.11). This is consistent 
with observed increases in villus length that has previously been shown in the normal 
mucosa of Apc '^" mice (You et al., 2006). However, an increase in cell number does not 
necessarily equate to an increase in villus length. Apc/,/+ mice also have lower numbers 
of goblet cells per crypt-villus, which is subsequently rescued by Pten loss and Kras 
activation (Figure 3.14). These findings suggest that at short time points, prior to loss of 
heterozygosity and formation of Wnt driven lesions, heterozygosity of Ape can impact 
upon intestinal homeostasis. You et al suggest that the changes observed in the normal 
tissues of Ape**1" mice are a result of excess p-catenin and enhanced Wnt signalling (You 
et al., 2006). This hypothesis could be plausible as acute activation of Wnt signalling in 
the intestine leads to increased proliferation, and loss of differentiation (Sansom et al., 
2004). Thus one may postulate that haploinsufficiency of Ape may result in ‘chronic’ or 
‘higher than baseline’ activation of Wnt signalling which may give rise to the phenotypes 
observed here and by You et al. However, the level of canonical-Wnt pathway activation 
was not assessed in Apc/,/+ intestine, so it cannot be confirmed if the phenotypes 
observed are attributed to this.
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3 .4  Summary
Taken together, the histological data from Pten////( KrasLSL/+ and Apc/,/+ P te n ^  
KrasLSL/+ mice provide evidence that even at a short time point after induction there is 
synergy between Pten and Kras, resulting in disrupted intestinal homeostasis and 
hyperplasia of the crypt-villus possibly driven by activation of the PI3K pathway. It also 
appears that most of the phenotypes observed in Apc/,/+ Pten/,;/< KrasLSL/+ mice are 
independent of Ape heterozygosity and are attributed to Pten and Kras synergy alone.
3 .5  Further Work
In order to deduce a mechanism by which Pten and Kras give rise to the resulting 
phenotypes, it would be useful to assess the level of Notch pathway and mTOR 
activation in Ptenfl/fl KrasLSL/+ and Apc/,/+ Pten^* KrasLSL/+ intestine. As Ape 
haploinsufficiency results in an intestinal phenotype, it would be interesting to assess 
the level of canonical-Wnt pathway activation in Apc///+ cohorts.
As there is genetic evidence that knockout/in of the genes of interest is achieved 
and maintained in both Pten/,7/* KrasLSL/+ and Apc/</+ Pten/,7/< KrasLSL/+ mice up until at 
least day 15 post induction, and it has no immediate effect on mouse health, it will be 
next investigated how these genetic alterations effect mouse lifespan and intestinal 
tumourigenesis in chapters 4 and 6. Further characterisation of synergy between Pten 
and Kras independently of Ape heterozygosity is carried out in chapter 5.
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Chapter 4: Investigating synergy between Pten and Kras in an
intestinal tumour model
4.1  Introduction
Mice that are heterozygous for Ape, whether constitutive (Ape**"1) or conditional 
(Apc///+), are commonly used to study the effects a particular drug, gene or substance 
has on intestinal tumourigenesis, as Ape heterozygous mice are predisposed to the 
formation of adenomas in the intestinal tract via loss of heterozygosity of Ape (Moser 
et al., 1992, Shibata et al., 1997). Ape heterozygous mice develop benign intestinal 
tumours that do not progress to invasive, advanced tumours. The development of 
mouse models of CRC that recapitulate more advanced stages of disease are therefore 
needed to enhance our understanding of tumour progression, metastasis, and for 
preclinical testing of new therapeutics.
Marsh et al have generated a mouse model of advanced intestinal 
tumourigenesis. They showed that conditional homozygous loss of Pten (Pten/,///) 
promotes tumour progression in conditional Ape heterozygous mice (Apc/,/+ P te n ^  
mice) through upregulation of PI3K pathway activation, to give rise to intestinal 
adenocarcinoma with smooth muscle invasion. However, none of the tumours observed 
progressed to metastatic carcinoma (Marsh et a l., 2008). As progression of the tumours 
occurred through increased activation of the PI3K pathway, it was postulated that the 
additional mutation of Kras may allow ‘hyperactivation’ of the PI3K pathway and 
promote tumour metastasis. As previously described, KRAS is an oncogene that can 
activate both the MAPK/Erk pathway and the PI3K pathway (through association with 
the p110 subunit of the PI3K protein), and activating mutations in KRAS are commonly 
associated with human CRC (Bos et al., 1987, Fearon and Vogelstein, 1990). Synergy 
between Kras and Pten has previously been observed in other tumour mouse models 
including lung, pancreas and endometrium (Dinulescu et al., 2005, Hill et al., 2010, 
Iwanaga et al., 2008).
The addition of a Kras mutation to the Apc/</+ P te n ^  model was first investigated 
in the Clarke lab utilising the AtoCre recombinase transgene to drive recombination in 
epithelial tissues, as was used in the Marsh et al study. AhCre recombinase is expressed 
in an array of tissues including, bile ducts, stomach epithelium, intestine and liver. 
Unpublished data from the Clarke lab have demonstrated that Pten and Kras mutations 
synergise, in the context of a heterozygous Ape mutation, to cause the formation of 
cholangio carcinoma and hyperplasia of the forestomach. These non-intestinal
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phenotypes caused rapid morbidity, primarily owing to large tumours blocking the 
stomach. These data demonstrate that the AhCre transgene was not useful to 
investigate the potential synergy of a Kras mutation with Pten loss in the context of 
Wnt-driven intestinal tumours, owing to the short mouse survival time after induction. 
To circumvent this the VillinCre recombinase transgene was used in replacement of 
AhCre, as VillinCre is expressed specifically in the intestinal epithelium (El Marjou et 
al., 2004).
As shown in chapter 3, there is evidence of synergy between Pten and Kras 
mutations in the context of a heterozygous Ape mutation in the intestine at day 15 
post induction. In this chapter I will investigate the long term effects of deleting Pten 
in conjunction with Kras activation in a mouse model predisposed to Wnt driven 
intestinal tumours (Apc/</+ mouse model). W///nCreERT-Apc/,/+ P te n ^  KrasLSL/+ mice 
(hereafter referred to as Apc/,/+ Pten;,//* KrasLSL/+ mice) were generated and induced 
along with the appropriate controls. They were then sacrificed when they became 
symptomatic of disease.
4 .2  Results
4.2.1 Pten and Kras synergise to significantly shorten Apc/,/+ mouse survival time post
induction
Apc/,/+Pten/,//,KrasLSL/+ mice and controls were induced and culled when they 
became symptomatic of disease, i.e. intestinal prolapse, pale feet, blood in faeces, 
swelling of the abdomen. Mice were dissected, and the small intestine and colon were 
either fixed in formalin in preparation for IHC or fixed in methacarn in preparation for 
H&E staining.
Apc/,/+ P te n ^  KrasLSL/+ mice had a significantly shorter life span compared to 
controls (median of 41 days post induction, p value <0.001, Log Rank test) (Figure 4.1, 
A). Apc///+ P ten^ ' mice had a median survival of 73 days post induction, Apc/,/+ KrasLSL/+ 
mice 196 days post induction and Apc///+ mice 282 days post induction. The number of 
tumours present at death was scored from H&E stained sections of the whole small 
intestine for each cohort (Figure 4.1, B). Apc/,/+ Pten/f/// KrasLSL/+ mice possessed a 
larger number of tumours (average of 50 tumours per section, n=10) compared to the 
Apc///+ P te n ^  (average of 12 tumours per section, n=6) and Apc/,/+ (average of 18 
tumours per section, n=3), which potentially accounts for the difference in survival 
times between the cohorts. However, Apc/,/+ P te n ^  KrasLSL/+ mice had a similar tumour 
burden to the Apc/,/+ KrasLSL/+ control cohort (average of 60 tumours per section, n=7),
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despite the difference in survival times between the two cohorts (41 days and 196 days 
respectively). Interestingly, Apc/,/+ P te n ^  mice possessed a smaller number of tumours 
compared to Apc/,/+ KrasLSL/+ mice, yet had a much shorter survival time post induction.
4.2.2 Pten and Kras synergise to promote progression of tumours in Apc/,/+ mice
To try to understand why Apc/,/+ Pten/f//< KrasLSL/+ had a shorter life span 
compared to Apc/,/+ KrasLSL/+ mice, despite them both possessing similar number of 
tumours, H&E stained sections were again scored for the number of tumours present 
but the tumours were also given a grade corresponding to the level of progression 
(tumours were graded according to the criteria outlined in chapter 2: materials and 
methods section 2.6.5). Tumours were graded as follows: microadenomas were given a 
score of 1, benign adenomas with no evidence of invasion - 2, adenocarcinoma with 
evidence of invasion into the submucosa - 3, and adenocarcinoma with evidence of 
invasion through the smooth muscle wall and underlying serosa - 4 (Figure 4.2).
Grading of tumours revealed that, despite Apc/,/+ Pten/,//f KrasLSL/+ and Apc/,/+ 
KrasLSL/+ mice possessing a similar tumour burden (when the number of tumours per 
section was scored [Figure 4.1, B]), the tumours observed in Apc/,/+ P te n ^  KrasLSL/+ 
mice were more advanced than those observed in Apc/,/+ KrasLSL/+ mice. Apc/,/+ Pten/,x/< 
KrasiSU+ mice had an average tumour distribution of 41.5 microadenomas (grade 1), 5.1 
adenomas (grade 2), 3.1 adenocarcinomas with submucosal invasion (grade 3) and 0.5 
adenocarcinomas with smooth muscle invasion per section (grade 4) (n=10) (Figure 
4.2), whereas Apc/,/+ KrasLSL/+ mice predominantly bore microadenomas, adenomas and 
the rare tumour with submucosal and smooth muscle invasion (0.4 and 0.1 tumours per 
section respectively). Apc/,/+ Pter\fUfl mice possessed an average tumour distribution of 
12 tumours per section yet had a median life span of 73 days post induction (Figure 
4.1). Tumour grading revealed that a significant proportion of these tumours (25%), 
were large adenocarcinomas with submucosal invasion - grade 3 (Figure 4.2). Despite 
these mice possessing a smaller number of tumours, a larger proportion of these 
tumours were more advanced and invasive, resulting in morbidity of the mouse.
4.2.3 Evidence of smooth muscle invasion was only observed in Apc///+ Pten/,7/* KrasLSL/+
mice
H&E stained sections of the most advanced tumours found in each cohort are 
shown in Figure 4.3. Microadenomas and adenomas were the only tumours observed in 
Apc///+ mice, an average of 18 tumours per section were observed. However, none of
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these tumours possessed evidence of invasion, despite some of them becoming very 
large (an example of a large adenoma observed in Apc/,/+ mice is shown in Figure 4.3). 
Apc/,/+ KrasLSL/+ mice possessed a substantially higher tumour burden than Apc/,/+ mice 
and therefore had a shorter life span. Of the 420 tumours scored from H&E stained 
sections in the Apc/,/+ KrasLSL/+ cohort (n=7), only three tumours showed evidence of 
invasion into the submucosa and one through the smooth muscle wall. On average 3 
tumours per section in Apc/,/+ Pten//;// mice were classed as grade 3, adenocarcinoma 
with invasion into the submucosa, as shown in Figure 4.3. Here the tumour remains 
confined to the intestine, as no infiltration of the smooth muscle boundary is observed. 
Evidence of tumour progression to adenocarcinoma with smooth muscle wall invasion is 
frequently observed in Apc/,/+ Pten7^  KrasLSL/+ mice. An average of 0.5 tumours per 
section in Apc/,/+ Pten/,//f KrasLSL/+ mice had progressed to invade through the smooth 
muscle wall, which is likely to be the cause of morbidity in these mice and led to a 
significantly shortened life span. Despite evidence of the adenocarcinoma breaking 
through the confines of the small intestinal smooth muscle wall, no evidence of 
metastasis was observed.
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Figure 4.1 Apc^Pter/^ 'Kras'-^ mice have a significantly shorter lifespan than 
controls, but a similar tumour number to Apc/,/+KrasLSL/+ mice
(A) Apc/,/+Pten////,KrasLSL/+ mice have a significantly shorter lifespan compared to all 
Apc/,/+ controls (p value <0.001, Log Rank test). Apc///+Pten/ '//,KrasLSL/+ mice lived to a 
median time of 41 days post induction, Apc/,/+Pten///// -median 81 days, Apc/,/+KrasLSL/+ - 
median 192 days and Apc/</+ - median 282 days. (B) Key: blue bars - average number of 
tumours per section, red bars - median survival. The number of tumours per H&E 
section were scored for each cohort. Despite A pc^Pten^K ras^^ mice having a 
shorter life span than Apc/,/+KrasLSL/+ mice, they possessed a similar number of tumours.
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Tumour grade 4
1 2 3
r — —
4
■Ape Pten Kras 41.5 5.1 3.1 0.5
■Ape Pten 4.8 5.0 2.5 0.0
Ape Kras 53.4 6.0 0.4 0.1
■Ape 14.0 3.7 0.0 0.0
Figure 4.2 Grading of tumours revealed that tumours in Apc///+ ?tenfl/fl KrasLSL/+ mice 
are the most invasive, invading through the smooth muscle wall
Tumours present in H&E stained small intestinal sections for each cohort were scored 
and graded according to the level of invasiveness. Grading revealed that Apc///+ Pten/,x// 
KrasLSL/+ mice (dark blue bars) possessed the most invasive tumours, an average of 0.5 
tumours per section were classed as adenocarcinomas with smooth muscle invasion 
(grade 4). Tumours observed in Apc/,/+ KrasLSL/+ mice (yellow bars) were predominantly 
early stage tumours (grade 1 and 2), which would account for the longer survival time 
of this cohort compared to Apc/,/+ Pten;,//< KrasLS/-/+ mice, which have a similar overall 
number of tumours. Despite having an overall lower tumour number compared to the 
other cohorts, Apc/,/+ Pten;,/// mice (red bars) possessed higher numbers of 
adenocarcinomas with submucosal invasion (grade 3) compared to Apc///+ KrasLSL/+ and 
Apc///+ cohorts.
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2x magnification 2x magnification
Figure 4.3 H&E stained sections of the most advanced tumours in each cohort
Apc/,/+ mice predominantly bore microadenomas and adenomas, none of which showed 
any signs of invasiveness. Apc///+ KrasLSL/+ mice also predominantly bore microadenomas 
and adenomas but at a much higher frequency than Apc///+ mice, some of these 
tumours possessed invasive characteristics (i.e. submucosal invasion), but this was a 
rare event. Apc/,/+ Pten//7// mice had the lowest tumour number but a large proportion 
of these tumours had invaded into the submucosa. The arrow indicates the intact 
smooth muscle wall boundary in the magnified Apc/,/+ Pten/,/// tumour. There was 
frequent evidence of tumours that had invaded through the smooth muscle wall and 
invaded into the peritoneal cavity in Apcfl/* Ptenfl,fl KrasLSi'/+ mice. However, metastasis 
was not observed. Scale bars represent 500pm, magnified images scale bars represent 
200pm.
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4.2.4 Tumour invasiveness correlates with the increased presence of pAkt
As Kras impinges on both the PI3K and MAPK/Erk pathways, IHC was carried out 
on intestinal tissue and tumours from Apc///+ Pten////f KrasLSL/+ mice and control cohorts 
for markers of pathway activation. MEK is a kinase that is part of the MAP Kinase 
cascade; it acts downstream of Kras and phosphorylates Erk, the protein that elicits 
the effects of the pathway. MEK must be phosphorylated in order to become active. 
Immunostaining for phosphorylated MEK (pMEK) therefore indicates activation of the 
MAPK/Erk pathway. IHC against pMEK (ser221) revealed increased levels of pMEK in 
tumour tissue from both the experimental and control cohorts compared to normal 
intestinal tissue (Figure 4.4). pMEK immunostaining was confined to the crypt region of 
normal intestinal tissue, but staining was homogenous in tumour tissue, indicating that 
tumour cells are perhaps in an immature progenitor-like state. However, there was no 
discernable difference in the level of pMEK immunostaining in Apc/,/+ Ptenfl/fl KrasLSL/+ 
tumours compared to the control tumours. Therefore it can be concluded that the 
MAPK/Erk pathway is upregulated in all tumours initiated by Ape loss, and additional 
mutation of Pten and Kras does not enhance activation of the pathway.
Akt is the downstream effector protein of the PI3K pathway; phosphorylation of 
the protein by PDK1 allows it to become active. IHC against pAkt (ser473) and pmTOR 
(a downstream target of pAkt) was carried out on normal intestine and tumour tissue 
sections (Figure 4.5, Figure 4.6). Most tumours in Apc/,/+ mice had little or no staining 
for pAkt. In some tumour sections areas of the tumour appeared to have stronger 
staining (particularly in the nucleus) than the rest of the tumour (Figure 4.5). The 
same was evident for tumours observed in Apc///+ KrasLSL/+ mice, despite the role of 
Kras in activation of the PI3K pathway. The nuclear localisation of pAkt is likely to 
coincide with areas of the tumour that are proliferating, as nuclear pAkt was also 
observed in the normal tissue in cells undergoing mitosis. There was strong 
immunostaining for pAkt in all tumours in Apc/</+ Pten////f KrasLSL/+ and Apc/</+ P te n ^  
mice, particularly in the tumours with evidence of invasion. pAkt appeared to be 
localised to the membrane as well as the cytoplasm, membrane associated staining of 
pAkt is thought to be a marker of high activity of the protein (Mende et al., 2001). 
pmTOR (a downstream target of pAkt) immunostaining correlates with the staining of 
pAkt i.e. strong staining in Apc///+ Pten//7/* KrasLSL/+ and Apc///+ Ptenfl/fl tissue compared 
to Apc/,/+ tumour tissue (Figure 4.6). However, unlike pAkt, pmTOR immunostaining in 
Apc///+ KrasLSL/+ tumours is relatively strong and comparable to Apc/</+ Pten/,7/* KrasLSL/+ 
and Apc/,/+ P te n ^  tissue.
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4.2.5 No evidence of epithelial-to mesenchymal transition observed in invasive 
tumours
E-cadherin forms cell-to-cell junctions called adherens junctions between 
epithelial cells. It is a membrane spanning protein that forms homodimers with E- 
cadherin protein found on the surface of neighbouring epithelial cells. The loss of 
membrane associated E-cadherin is a marker of cells undergoing epithelial-to- 
mesenchymal transition (EMT), which is thought to occur at the leading edge of 
tumours and is associated with increased invasiveness (Vleminckx et al., 1991).
IHC against E-cadherin was carried out on tumour tissue sections. E-cadherin 
was membrane bound in all tumours found in each cohort (Figure 4.7). E-cadherin 
staining does not appear as strong in tumours from Apc/,/+ KrasiSU+, Apc/,/+ PtenfUfl and 
Apc/,/+ P ten^ ' KrasLSL/+ mice, due to the large stromal component that makes up a 
proportion of these tumours. The tumour cells that are invading into the submucosa 
and the smooth muscle wall still maintain membrane associated E-cadherin.
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Figure 4.4 pMEK immunostaining revealed no overt variations in staining intensity 
between tumours from each cohort
IHC against pMEK (ser221) was carried out on tumour and normal tissue sections from 
Apc/,/+ Pten7^  KrasLSi/+ mice and controls. MEK is a MAP kinase protein that is 
downstream of Kras in the MAPK/Erk signalling pathway. The phosphorylated form of 
the protein is the active form, so therefore the presence of pMEK indicates activation 
of the MAPK/Erk pathway. pMEK immunostaining of the tumour sections from all 
cohorts revealed a subtle increase in the presence of staining compared to normal 
tissue. However, there appeared to be no increase in staining intensity in Apc/,/+ 
P te n ^  KrasLSL/+tumours compared to controls. Scale bars represent 100|^m.
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Figure 4.5 Presence of pAkt as assessed by IHC staining, correlates with tumour 
invasiveness
IHC against pAkt (ser473) was carried out on tumour and normal tissue sections from 
Apc/,/+ Pten7,/// KrasLSL/+ mice and controls. Immunostaining for pAkt in Apc///+ and Apc///+ 
KrasLSL/+ tumours appeared to be no stronger than that of normal tissue, some areas of 
the tumours appeared to stain stronger and in particular the staining was nuclear. This 
nuclear staining is likely to correlate with a more proliferative part of the tumour, as 
cells that are undergoing mitosis in the normal tissue also have stronger nuclear 
staining (arrow). Staining in all tumours from Apc/,/+ Pten7,//< KrasLSL/+ and Apc7//+ Pten7*77* 
mice, and particularly in the tumours with evidence of invasion, was markedly stronger 
than the staining seen in both control tumours and normal tissue. This staining was 
both cytoplasmic and membrane bound (as shown in the magnified image), membrane 
localisation of pAkt is thought to indicate strong activation of the PI3K pathway. Scale 
bars represent 100 i^m.
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Figure 4.6 pmTOR immunostaining revealed no overt differences between Apc///+ 
Ptenfl/fl and Apc/,/+ Pten^' KrasLSL/+ tumours
IHC against the activated form of mTOR, pmTOR (ser2448), was carried out on tumour 
and normal tissue sections from Apc/,/+ Pten/,//( KrasLSL/+ mice and controls. mTOR is 
activated by pAkt, and therefore is a useful marker of its downstream activity. pmTOR 
immunostaining appears stronger in Apc/,/+ Pten/,//< KrasLSL/+ tissue and in the Apc/,/+ 
?tenfl/fl and Apc///+ KrasLSL/+ controls compared to Apc/,/+ tissue. However, there is no 
overt difference between the staining in any of these tumours, so is not a useful 
marker in determining hyperactivation of Akt and the PI3K pathway. Scale bars 
represent lOO i^m.
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magnification magnification
Figure 4.7 Invasive tumours still possess membrane bound E-cadherin
Apcf"+Pten/"/' Apc^/+P te nfl ffl K r asLSL/+
IHC against E-cadherin was carried out on small intestinal tumour tissue sections from 
each cohort. Staining revealed that the epithelial component of all tumours from 
benign adenomas in Apc/Z/+ mice to invasive adenocarcinomas in Apc/,/+ Pten/,//z KrasL5L/+ 
mice, maintain membrane associated E-cadherin. Arrow heads indicate that the 
invasive components of tumours still maintain membrane localised E-cadherin 
immunostaining. Scale bars represent 200pim, magnified images lOO^m.
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4.3 Discussion
4.3.1 Pten and Kras synergise to reduce mouse life span in the context of an
intestinal tumour model
As previously introduced, the AhCre recombinase transgene had first been 
implemented to investigate synergy between Pten and Kras mutations in the context of 
intestinal tumourigenesis. However, these mice rapidly succumbed to cholangio 
carcinoma (neoplasia of the gall bladder and bile ducts) and benign forestomach 
hyperplasia, thus preventing long term investigation of potential synergy in an 
intestinal setting. To circumvent this, an intestinal-specific ere recombinase (VillinCre) 
was used to drive recombination. Experimental (VillinCre-Apcfl/* Pten/,7// KrasLSL/+) and 
control groups (W///nCre-Apc/,7+, VillinCre-Apcfl/+ KrasLSL/+ and VillinCre-Apcfl,+ Pten/,7//) 
were generated, induced and culled when symptomatic of disease.
Apc/,/+ Pten/,7// KrasLSi’/+ mice had a significantly shorter survival time post 
induction compared to the control cohorts (Figure 4.1, A). Interestingly, VillinCre- 
Apc/,/+ Pten/,7// mice survived to a median of 78 days post induction, compared to the 
previously published AhCre-Apc/,/+ Pten//7// mice, which survived to a median of 99 days 
post induction (Marsh et al., 2008). Despite morbidity in these mice being caused by an 
intestinal tumour phenotype, the difference in lifespan is likely to be attributed to 
differences in experimental strategy. AhCreER7 was used in this model and ere 
recombinase is activated at lower levels in the intestinal epithelium compared to 
VillinCre due to the requirement of both a xenobiotic and tamoxifen being present to 
allow its activation. Therefore, in AhCre mice a lower proportion of intestinal cells 
undergo mutation of Ape, Pten and Kras. This lower activity of AhCre is evident when 
the number of tumours were scored; AbCre-Apc/,/+ Pten//7// mice bore an average of 7 
intestinal tumours, whereas VillinCre-Apcfl/+ Pten/,7//mice bore an average of 12.
Scoring of the number of tumours present in H&E stained sections revealed that 
Apc///+ Pten//7// KrasLSL7+ mice bore a large number of tumours (average of 50 per 
section) (Figure 4.1, B), which could be responsible for the low mortality rate of the 
cohort. The number of tumours scored in Apc/,/+ Pten7'7'7 KrasLSL/+ mice was higher than 
those scored in Apc/,/+ Pten/,7/' mice, suggesting that Pten and Kras synergise to enhance 
initiation of tumourigenesis. However, Apc/,/+ KrasLSL/+ mice possessed an average of 60 
tumours per section, a higher tumour number than Apc/,/+ Pten7'77' KrasLSL7+ mice, yet 
these mice had a median survival time of 196 days post induction (Figure 4.1,B), thus 
suggesting, that the short survival time of Apc/,/+ Pten/,7// KrasiSU+ mice cannot not be 
solely attributed to tumour number.
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4.3.2 Loss of Pten alone and in conjunction with Kras activation promotes tumour
invasiveness in Apc/,/+ mice
The level of tumour invasiveness was scored in each cohort. This revealed that 
only Apc/,/+ Ptenfl,fl KrasLSL/+ and Apc///+ Pten/,//f mice possessed advanced tumours that 
had progressed from benign adenomas and become invasive (Figure 4.2, Figure 4.3). 
Apc/,/+ KrasiSU+ mice were predominantly predisposed to the formation of 
microadenomas and adenomas, and these tumours rarely progressed to invade the 
submucosa or smooth muscle. However, the addition of a Kras mutation enhances 
tumour initiation in Apc/,/+ mice, which is consistent with other studies (Janssen et al., 
2006, Luo et al., 2009, Sansom et al., 2006). The level of tumour progression in both 
Apc///+ Pten/,;// KrasLSL/+ and Apc/,/+ Pten/,;// mice is likely to be the cause of reduced 
lifespan in both these cohorts compared to controls.
Again there were differences between the tumours observed in VillinCre-Apc/,/+ 
Pten/,7// mice and those in AhCre-Apcfl,+ Pten////7 mice. The tumours in AhCre-Apcfl/+ 
Pten^/f' mjce were aiso invasive, and a proportion of these tumours (21.5%) had 
infiltrated through the smooth muscle wall (Marsh et al., 2008). Adenocarcinoma with 
smooth muscle invasion was not observed in VillinCre-ApcfU+ Ptenfl,fl mice, only in 
VillinCre-Apcfl/+ Ptenfl/fl Kras^^ mice. The lower efficiency of recombination in AhCre 
mice compared to VillinCre mice, may offer explanation as to why adenocarcinomas 
with smooth muscle invasion are not observed in VillinCre-Apcfl/+ Ptenfl/fl mice. The 
lower number of tumours arising in AhCre-Apcfl,+ Pter\fl,fl mice due to lower DNA 
recombination efficiency, allows these mice to live longer. Therefore, the tumours 
present have a longer period in which to progress and invade further into the smooth 
muscle. VillinCre-Apcfl/+ P ten^ ' mice succumb to an earlier death due to a higher 
tumour number, so these tumours do not have adequate time to invade further into 
the smooth muscle.
4.3.3 Comparison of Apc/,/+ P ten ^ ' KrasLSL/+ and Apc///+ P te n ^  models
IHC against pAkt (ser473) indicated that the PI3K pathway was being highly 
activated in tumours in VillinCre-Apcfl/+ Pten/,/// KrasLSL/+ and VillinCre-Apcfl/+ Pten/,/;/ 
mice compared to tumours arising in control mice (Figure 4.5). The observed 
association of strong immunostaining for pAkt with highly invasive tumours in both 
VillinCre-Apcfl/+ Ptenfl,fl KrasLSL/+ and VillinCre-Apcfl/+ Ptenfl/fl mice is consistent with 
the AhCre-Apc/,/+ PtenfUfl mouse model (Marsh et al., 2008) and other studies, which
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have implicated the PI3K pathway in neoplastic progression (Rychahou et al., 2006, 
Samuels et al., 2005). These studies have demonstrated that activation of the PI3K 
pathway increases the propensity of CRC cell lines to invade in in vitro assays, and 
form metastases in vivo when injected into nude mice (Rychahou et al., 2006, Samuels 
et al., 2005).
As the tumours found in VillinCre-Apcfl/+ Ptenfl/fl KrasLSL/+ mice had invaded 
through the smooth muscle wall of the small intestine, and tumours found in VillinCre- 
Apc///+ P ten^ ' mice were confined to the small intestine, one would assume that the 
PI3K pathway is being activated more strongly in the tumours found in VillinCre-Apcfl/+ 
Ptenfl/fl KrasLSL/+ mice. However, despite there being an overt difference in the level of 
invasiveness of the tumours from VillinCre-Apc///+ Pten/,7// KrasLS/-/+ and VillinCre-Apcfl/+ 
Ptenfl/fl mice, hyperactivation of pAkt was unable to be determined in VillinCre-Apcfl/+ 
Pten//7//KrasLSL/+ tumours. IHC against the active form of mTOR (pmTOR), a downstream 
target of pAkt, was carried out to assess any possible increase in the downstream 
activity of pAkt in VillinCre-Apcfl/+ Ptenfl/fl KrasiSU+ mice (Figure 4.6). pmTOR 
immunostaining proved not to be a useful marker of the downstream activity of pAkt 
and the PI3K pathway, as there were no overt differences between the tumours. 
Surprisingly, the level of pmTOR immunostaining in Apc/,/+ KrasLSL/+ tumours also 
appeared elevated, despite low levels of pAkt activation. Interestingly, the AAAPK 
pathway did not appear to be more active in tumours bearing Kras mutations (Figure 
4.4), and therefore it appears to not play a role in tumour progression.
IHC proved not be useful in discerning the level of PI3K activation in the 
tumours from each cohort. However, as the tumours arising in these mice possess a 
large stromal component, it would be difficult to obtain a homogenous sample of 
tumour epithelial cells needed for protein extraction and quantification of protein 
levels. Due to the heterogeneous nature of the tumours, IHC proves to be the most 
useful method for indicating pathway activation, specifically in tumour cells. As IHC is 
purely qualitative, it is difficult to determine levels of pathway activation.
Despite being unable to prove that the PI3K pathway is hyperactivated in 
tumours of VillinCre-Apcfl/+ Ptenfl/fl KrasLSL/+ mice, an argument for synergy between 
Pten and Kras through the PI3K pathway can be made when comparing the tumours 
observed in VillinCre-Apcfu+ Ptenfl/fl KrasLSL/+mice and AhCre-Apc///+ Pten7^ ' mice. In 
both these models, adenocarcinoma with smooth muscle invasion is observed, it can be 
argued that as AhCre-Apcfl/+ Pter\fl/fl mice live longer post induction, the tumours have 
additional time to accumulate pAkt, and therefore enhance activation of the PI3K 
pathway. As VillinCre-ApcfU+ Ptenfl/fl KrasLSL/+ mice have the same observed tumour
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phenotype but do not live as long, it can be postulated that these tumours therefore 
have enhanced activation of pAkt at earlier time points, driven by activation of Kras 
and the combined loss of negative regulation of PI3K via Pten loss.
4 .4  Summary
Pten loss and Kras activation act synergistically in the context of a ViUinCre- 
Apc///+ intestinal tumour model to promote tumour initiation and progression, which is 
likely to be driven by hyperactivation of the PI3K pathway. However, addition of an 
oncogenic allele of Kras did not promote tumour progression through to metastasis as 
was hypothesised.
4 .5  Further Work
Loss of Pten and activation of Kras promotes tumour progression, which appears 
to be driven by activation of the PI3K pathway. However, there are many downstream 
targets of PI3K, and so therefore it would be useful to determine which of these 
targets promotes tumour progression and invasion for potential therapeutic targeting. 
One potential target may be the forkhead transcription factors (FKHR). Some studies 
have shown that inactivation of FKHR via pAkt mediated phosphorylation, reduced the 
tumourigenic potential and invasiveness of colorectal cancer cell lines (Khaleghpour et 
al., 2004, Samuels et al., 2005). Therefore, it would be interesting to assess the level 
of FKHR phosphorylation in tumours arising in Apc/,/+ Pten^'KrasLSL/+ mice.
The large number of tumours, invasiveness of the tumours observed and its well- 
defined survival curve, make the W///nCreERT-Apc/,/+ P ten ^ ' KrasiSU+ intestinal tumour 
model a good candidate for testing the efficacy of anti-cancer drugs on intestinal 
tumours.
As E-cadherin expression was maintained in invasive tumours in both Apc/,/+ 
Pten////f KrasLSL/+ and Apc/,/+ P te n ^  mice, further work on the loss of E-cadherin and its 
role in promoting invasion of tumours will be investigated in the context of tumours 
arising in Apc/,/+ Ptenfl/fl mice in Chapter 7.
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Chapter 5: Investigating short term synergy between Pten and Kras 
in the intestinal epithelium
5 .1 Introduction
Pten acts as a negative regulator of the PI3K pathway, and Kras can cause 
activation of the PI3K pathway through its interaction with the p110 catalytic subunit of 
the PI3K protein. Mutations in Pten and Kras, causing loss of function and constitutive 
activation of the proteins respectively, may act synergistically through the PI3K 
pathway. Loss of Pten alone would cause elevation of the active form of the downstream 
PI3K effector protein Akt. However, additional mutation of Kras may result in 
hyperactivation of the PI3K pathway causing further accumulation of active Akt.
Findings in chapter 3 suggested that mutations in Pten and Kras synergise, to give 
rise to hyperplasia of the small intestinal epithelium, and a decrease in the abundance 
of differentiated cell types. There was a subtle increase in PI3K pathway activity in the 
small intestines of mice that bore mutations in Pten and Kras either alone or 
concomitantly in chapter 3. I have also demonstrated that mutations in Pten and Kras 
synergise in the context of tumourigenesis to promote tumour progression and decrease 
mouse survival.
Further to the finding that Pten loss and Kras activation disrupts small intestinal 
homeostasis in the mouse at day 15 post induction (outlined in chapter 3), I wished to 
investigate potential synergy between Pten and Kras mutations in normal small intestine 
at longer time points after induction. VillinCreERJ-Pter\fl/fl KrasLSL/+ mice (hereafter 
referred to as PtenfUfl KrasLSL/+ mice) and the appropriate controls, (W///nCreERT-Pten+/+ 
KrasLSL/+ [KrasLSL/+] and VillinCreERJ-Ptenfl,fl Kras+/+ [Pten'"''] and V/7/inCreERT-Pten+/+ 
Kras+/+ [WT]) were generated, induced and sacrificed at 50 days post induction. At least 
8 mice were induced in each cohort and were given either a 2 hour or 48 hour pulse of 
BrdU prior to sacrifice.
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5.2 Results
5.2.1 Recombination of loxP sites at the Pten and Kras locus is maintained at 50 days 
post induction
VillinCre  recombinase is expressed in all small intestinal epithelial cells including 
the stem cell compartment. Therefore, due to recombination of DNA in the stem cells, 
presence of the recombined allele is maintained long term throughout the small 
intestine epithelium. A multiplex PCR for the recombined alleles of Pten and Kras was 
carried out on gDNA extracted from intestinal epithelial cell enriched samples, obtained 
from scrapings of the mucosal surface of the intestine at day 50 post induction. PCR 
showed that the recombined alleles of Pten and Kras were still present at day 50 post 
induction (Figure 5.1, A). Another epithelial enriched sample was obtained from the 
small intestines of day 50 mice using the HBSS-EDTA epithelial isolation method. 
Inverted small intestinal samples were shaken in a solution of HBSS-EDTA and 
centrifuged to obtain a cleaner epithelial cell sample, suitable for the extraction of 
protein and RNA. Protein was extracted from these epithelial enriched samples and 
western blot was carried out against the Pten protein. Western blotting showed that 
Pten had been lost at the protein level (Figure 5.1, B).
5.2.2 Pten loss and Kras activation results in gross alteration of villus structure at 50 
days post induction
The intestines from mice sacrificed at day 50 post induction were dissected, a 
10cm section of the small intestine was fixed and processed for H&E staining, and a 1cm 
section of the small intestine was prepared for visualisation by SEM. The same region of 
the intestine (relative to the stomach) was dissected each time.
Examination of the intestine at day 50 post induction by H&E section revealed a 
high proportion of villi to be bifurcated or branched in P te n ^  KrasLSL/+ mice, but not in 
controls (Figure 5.2, left panel). 3-dimensional imaging of the mucosal surface of the 
small intestine by SEM confirmed these morphological changes of the villus structure. It 
would appear that the synergy between Pten and Kras that drives hyperplasia of the 
small intestine evident at day 15 post induction, becomes more pronounced at later 
stages, evidenced by gross alterations of the villus structure at day 50 post induction.
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Figure 5.1 Recombined PCR for the Pten and Kras locus, and loss of Pten protein 
prove maintenance of the recombined alleles in the intestinal epithelium at day 50 
post induction
(A) Key: M = DNA marker, 100kb ladder. Multiplex PCRs for the recombined alleles of 
Pten and Kras showed the presence of a recombined band for Pten (upper panel) and 
Kras (lower panel) in Pten7'^  KrasLSL/+ mice. The correct recombined bands were seen for 
each of the controls. PCR carried out on DNA samples from both Pter/"7' KrasLSL/+ and 
Pten/,/7< mice yielded products for the targeted unrecombined allele. This is likely to be a 
result of DNA from unrecombined epithelial cells and non epithelial cells (i.e. stromal 
cells where W///nCreERT is not expressed) being present in the epithelial cell samples.
(B) Western blot for Pten revealed a significant reduction of Pten protein in Pter/,/7< and 
Pten;///< KrasiSU+ samples compared to controls. However, there are some faint bands 
visible in the Pten7*/7/ samples, which are again likely to be caused by underlying 
intestinal stromal cells or unrecombined epithelial cells.
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H&E SEM
Figure 5.2 Gross alterations in villus morphology were evident in both H&E sections 
and in SEM images.
H&E sections in the left panel reveal changes in villus structure in P te rf1'*1 KrasLSL/+ small 
intestine compared to the controls (scale bars represent 200nm). Villi appeared to be 
bifurcating and branching (arrows), and there are no longer finger-like projections. This 
finding was confirmed by SEM (right panel), which shows clearly that the villi in PterJl,fl 
KrasLSL/+ small intestine are made up of a number of projections from a common base 
compared to the WT and controls.
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5.2.3 Pten loss and Kras activation disrupts intestinal homeostasis at the histological
level
H&E stained small intestinal sections were scored for the number of cells per half 
crypt and the number of cells per half villus. 50 half crypt-villus structures were scored 
for each mouse in both experimental (Pten;,/// KrasLa/+) and control cohorts.
Histological analysis revealed a significant increase in the number of cells per 
half crypt and villus in Pten/,//7 KrasLSL/+ mice compared to WT and controls (p value <0.05 
for both crypt and villus length, Mann Whitney-U test, n=4) (Figure 5.3). Pten/,7/'KrasLSL/+ 
mice possessed an average of 40 ± 3 cells per half crypt, compared to P te n ^  (32 ± 4 
cells per half crypt), KrasLSL/+ (33 ± 2 cells per half crypt) and WT (32 ± 4 cells per half 
crypt). Ptenfl/fl KrasLSL/+ mice possessed an average of 124 ± 18 cells per half villus, 
compared to Ptenfl,fl (83 ± 14 cells per half villus), KrasLSL/+ (94 ± 10.6 cells per half 
villus) and WT (74 ± 16 cells per half villus).
The number of apoptotic bodies and mitotic figures per half crypt was scored 
from H&E stained small intestinal sections as described in the methods chapter. 50 half 
crypts were scored for each mouse in both experimental (Pten/,//< KrasLSL/+) and control 
cohorts.
Despite an increase in both crypt and villus cell number, statistical comparisons 
of the level of apoptosis and mitosis in Pten//7// KrasLSL/+ tissue revealed no significant 
differences compared to control and WT tissue, and within controls (p values >0.05, 
Mann-Whitney U test, n=4) (Figure 5.4). Apoptosis scoring of Pten/,/// KrasLSL/+ tissue 
revealed an average apoptotic count of 0.06 ± 0.06 apoptotic bodies per half crypt, 
compared to Pten/f//< (0.05 ± 0.06 apoptotic bodies per half crypt), KrasLSL/+ (0.11 ± 0.05 
apoptotic bodies per half crypt) and WT (0.06 ± 0.04 apoptotic bodies per half crypt). 
Mitosis scoring of Pten/<7// KrasLSL/+ tissue revealed an average mitotic count of 0.63 ±0.2  
mitotic figures per half crypt, compared to P te n ^  (0.42 ±0.13 mitotic figures per half 
crypt), KrasLSL/+ (0.54 ± 0.25 mitotic figures per half crypt) and WT (0.06 ± 0.04 mitotic 
figures per half crypt).
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Figure 5.3 Crypt and villus scoring revealed significantly more cells per half crypt- 
villus in Pten/i fl KrasLSL/+ intestine compared to controls
Crypt size (upper panel) and villus size (lower panel) was determined by scoring the 
number of cells per half crypt and villus on H&E stained intestinal sections of 
experimental (PterYl/fl KrasLSL/+) and control mice. Scoring revealed that Pten/,/;/ KrasLSL/+ 
mice had significantly higher numbers of cells along crypt-villus axis compared to 
controls and WT mice (*, p values <0.05, n=4, Mann Whitney U Test). Error bars indicate 
standard deviation.
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Figure 5.4 Apoptosis and mitosis scoring per half crypt revealed no changes in 
Ptenfl/fl KrasLSL/+ tissue compared to control
Number of apoptotic bodies per half crypt (upper panel) and mitotic figures per half 
crypt (lower panel) was determined by scoring H&E stained intestinal sections of 
experimental (Pterr,//* KrasLSL/+) and control mice. Scoring revealed that there were no 
changes in apoptotic or mitotic levels in Ptenfl,fl KrasLSL/+ mice compared to controls and 
WT, neither was there any changes between the control cohorts (Pten7^  and KrasLSL/+) 
compared to WT tissue (p values >0.05, n=4, Mann Whitney U Test). Error bars indicate 
standard deviation.
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5.2.4 Pten loss and Kras activation causes a subtle increase in proliferation in the 
intestinal crypts
Half of all the mice used for the day 50 time point were given a 2 hour pulse of 
BrdU via i.p. injection prior to sacrifice. IHC against BrdU was carried out on small 
intestinal tissue sections and the number of cells that had incorporated BrdU into their 
DNA were scored per half crypt. BrdU is incorporated during S phase, therefore cells 
that stained positive for BrdU were either within S phase or had undergone S phase after 
administration of BrdU. The number of BrdU positive cells can therefore be used to 
quantify the level of proliferation.
BrdU scoring analysis revealed an increase in BrdU positive cells in Pter^l,fl 
KrasiSU+ tissue compared to WT (p value <0.05, n^3, Mann Whitney U test), but not 
compared to controls Pten/,7// and KrasLSL/+ (p values >0.05, n^3, Mann Whitney U test) 
(Figure 5.5). BrdU scoring of Pter\fl/fl KrasLSL/+ tissue revealed subtle changes in BrdU 
positive cells, with an average of 6.4 ± 0.9 BrdU positive cells per half crypt, compared 
to WT tissue 5.1 ±0 . 5  cells, Pten//7// and KrasLSL/+ controls had averages of 5.0 ± 0.7 cells 
and 5.6 ± 0.9 cells respectively.
5.2.5 Pten loss and Kras activation together has a compound effect on the migratory 
phenotypes observed in both Pten/,//v and KrasiSU+ controls
Half of all the mice used for the day 50 post induction time point were given a 2 
hour pulse of BrdU via i.p. injection, the remaining half were given a 48 hour pulse of 
BrdU via i.p. injection prior to sacrifice. IHC against BrdU was carried out on intestinal 
tissue sections and the number and position of positive cells along the crypt-villus axis 
were scored per half crypt-villus. The cumulative position of BrdU positive cells along 
the crypt-villus after 2 and 48 hours was compared in a cumulative frequency curve 
(Figure 5.6).
The cumulative frequency of BrdU positive cell position after a 2 hour pulse of 
BrdU revealed that positive cells were found in lower and higher cell positions along the 
crypt-villus axis in Pten/,7// KrasLSi-/+ tissue compared to WT (p value <0.05, Kolmologrov- 
Smirnov test). The proliferative zone is therefore expanded in these mice. BrdU positive 
cells labeled significantly lower positions in the crypt in Ptenfl/fl control tissue compared 
to WT tissue (p value <0.05, Kolmologrov-Smirnov test) (Figure 5.6, A). Cumulative 
frequency of BrdU positive cell position after a 48 hour pulse of BrdU revealed that in 
both experimental (Pten/,/// KrasLSL/+) and control (KrasLSL/+ and Pten;////) tissue BrdU 
positive cells were found higher up the crypt-villus axis after 48 hours compared to WT 
tissue (p values <0.001, Kolmologrov-Smirnov test) (Figure 5.6, B). Therefore, the cells
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have migrated faster up the crypt-villus axis. Synergy between Pten and Kras is evident 
as increases in cell migration in control cohorts appear to be compounded in the 
experimental cohort, as the Pten/,7// KrasLSL/+ cumulative frequency curve is significantly 
shifted from control cohorts (p value <0.001, Kolmologrov-Smirnov test).
5.2.6 Increases in the abundance of proliferative cells and the proliferative zone are 
not attributed to an increase in intestinal stem cell number 
Significant increases in the number of proliferative cells per half crypt (see 
section 5.2.4), and an expansion of the proliferation zone in the crypt (see section 
5.2.5) of Pten//7// KrasLSL/+ mice may be driven by an expansion in the number of stem 
cells. As a surrogate marker of relative stem cell abundance, RNA was extracted from 
epithelial cell enriched pellets and the corresponding cDNA was synthesised, qRT-PCR 
was carried out using the TaqMan assay for the small intestinal CBC stem cell markers 
Lgr5 and Ascl2. TaqMan assay was used to ensure accurate readouts of stem cell marker 
expression as their endogenous expression level is very low.
Quantification of Lgr5 and Ascl2 expression revealed no changes in relative 
expression levels in Ptenfl/fl KrasLSL/+ small intestine compared to control and WT tissue 
(Figure 5.7). The average ACT for Lgr5 expression in Pten//7// KrasLSL/+ intestinal tissue was 
12.64 ± 1.03, compared to the averages of Pten/,//< (12.58 ± 0.78), KrasLSL/+ (12.24 ± 0.63) 
and WT (12.02 ± 1.02). The average ACT for Ascl2 expression in Pten/,7/* KrasiSU+ 
intestinal tissue was 13.36 ± 1.22, compared to the averages of P ten^' (12.81 ± 0.64), 
KrasLSL/+ (13.25 ± 0.33) and WT (12.34 ± 0.79). The average ACT for each cohort was 
compared using the Mann Whitney U test. Statistical analysis revealed that there was no 
significant changes in average ACT value for both Lgr5 and Ascl2 in PtenfUfl KrasLSL/+ mice 
compared to controls and WT. Therefore, increases in the number of proliferative cells 
in P te n ^  KrasLSL/+ tissue may be attributed to expansion of transit-amplifying (TA) cell 
number, but is not a result of stem cell expansion.
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Figure 5.5 BrdU scoring revealed a subtle proliferative phenotype in Pten^'KrasLSL/+ 
compared to WT
IHC against BrdU (upper panel) suggests there may be an increase in the number of BrdU 
cells in P te n ^  KrasiSi/+. Scoring of BrdU positive cells per half crypt revealed that there 
is only a significant increase in Pten;//// KrastSL/+ tissue compared to WT tissue (*, p value 
<0.05, n^3, Mann Whitney U test). There was no significant difference between Pten7^ ' 
KrasLSL/+ and controls (Pten/,;/,and KrasLSL/+). Error bars indicate standard deviation.
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Figure 5.6 Scoring BrdU positive cell position revealed expansion of the proliferative 
zone and increased migratory rate in Pten^' KrasLSL/+ tissue
Key: WT - dark blue diamond, KrasLSL/+ - green square, Pten/</;/ - orange triangle, Pten/;//* 
KrasLSL/+ - light blue crosses
(A) Cumulative position of BrdU positive cells per half crypt after a 2 hour pulse of BrdU 
revealed lower and higher positioning of proliferative cells in Pten7^  KrasLSL/+ tissue 
compared to WT, suggesting an increase in proliferative zone. Positioning of 
proliferative cells in Pten//7// control tissue was significantly lower compared to WT (*, p 
value <0.05, Kolmologrov-Smirnov test). (B) Cumulative position of BrdU positive cells 
per half crypt after a 48 hour pulse of BrdU revealed that cells in Pten/,y// KrasL5L,+ and 
control tissues positioned significantly higher than WT tissue (**, p value <0.001, 
Kolmologrov-Smirnov test). Therefore the rate of migration was increased in 
experimental and control tissues compared to WT.
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Figure 5.7 qRT-PCR expression analysis of stem cell markers Ascl2 and Lgr5 revealed 
no changes in expression levels in Pten//X/' KrasLSL/+ small intestine
The expression of intestinal stem cell specific markers Ascl2 (upper panel) and Lgr5 
(lower panel) was quantified by qPCR to ascertain the number of stem cells present in 
the small intestine in each cohort. There was no change in the average ACT value in 
Pten//7/' KrasLSL/+ tissue compared to control and WT samples for both Ascl2 and Lgr5 (p 
value >0.05, Mann Whitney U test).
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5.2.7 Pten loss and Kras activation decreases the abundance of paneth and goblet cells 
To further investigate the effects of Pten loss and Kras activation on intestinal
homeostasis, stains and IHC to identify the major mature cell types was carried out. The 
localisation and abundance of each cell type was then scored. Histological examination 
of grimelius stained sections revealed normal localisation of enteroendocrine cells in 
Pten//7// KrasLSL/+ tissue and control tissue compared to WT tissue (Figure 5.8). Scoring 
revealed no changes in enteroendocrine cell abundance in experimental (Pterfl/fl 
KrasLSL/+ tissue) and controls compared to WT (p values >0.05, m»3, Mann Whitney U 
test). However, P te n ^  tissue had significantly more enteroendocrine cells than Pten/,7/< 
KrasiSU+ tissue (*, p value = 0.0204, ns3, Mann Whitney U test).
Histological examination of alcian blue stained sections revealed normal 
localisation of goblet cells in Pten/<7/< KrasLSL/+ and control tissue compared to WT tissue 
(Figure 5.9). Scoring revealed that both Pten/<//f KrasLSL/+ tissue and control tissue had 
significantly lower numbers of goblet cells compared to WT tissue (p values = 0.0404, 
n;>3, Mann Whitney U test). However goblet cell number in Pten;,//< KrasLSL/+ tissue was 
not significantly altered from the controls (p values >0.05, n;>3, Mann Whitney U test).
Immunostaining for lysozyme revealed no alterations in the localisation of 
lysozyme positive paneth cells in experimental Ptenfl/fl KrasLSL/+ and control tissue 
compared to WT (Figure 5.10). Paneth cell scoring revealed, similarly to goblet cells, 
that both Ptenfl/fl KrasLSL/+ tissue and control tissue had significantly lower numbers of 
paneth cells compared to WT tissue (p values = 0.0404, n&3, Mann Whitney U test), but 
paneth cell number in Pten//X// KrasLSL/+ tissue was not significantly altered from the 
controls (p values >0.05, ns3, Mann Whitney U test).
To visualise the enterocyte brush border, small intestinal tissue sections were 
prepared and stained for alkaline phosphatase using the Liquid Permanent red system. 
Alkaline phosphatase staining on Ptenfl/fl KrasLSL/+ tissue sections demarcated the luminal 
surface of enterocytes revealing the presence of mature enterocytes and that the 
polarisation of the epithelial sheet was comparable to control and WT tissue (Figure 
5.11).
5.2.8 The intestinal phenotypes caused in P te r/^  KrasLSL/+ mice are likely to be driven 
by hyperactivation of pAkt
As Kras has dual roles in controlling the activity of both the PI3K and MAPK 
pathways, IHC and western blotting was carried out to quantify the levels of 
downstream markers of the PI3K and MAPK pathway, pAkt (ser473) and pErk
132
(Thr202/Tyr204) respectively (Figure 5.12). The phosphorylated forms of these proteins 
represent the active state of the protein.
IHC for pAkt indicated that there was a subtle increase in staining intensity in 
Pten//7/* KrasLSL/+ tissue and Ptenfl/fl control tissue compared to WT and the KrasLSL/+ 
control (Figure 5.12, A). Western blot for pAkt confirmed that loss of Pten alone results 
in accumulation of pAkt, and this accumulation is enhanced when Pten loss is combined 
with Kras activation (Figure 5.12, B). However, IHC and western blot for pErk revealed 
normal localisation and abundance of the active form of the protein in experimental 
samples compared to control and WT samples (Figure 5.12). The accumulation of pAkt 
and therefore activation of the PI3K pathway is associated with no obvious phenotypes 
in P te n ^  mice apart from increased epithelial cell migration, whereas higher 
accumulation of pAkt and therefore hyperactivation of the PI3K pathway in P ter/^  
KrasLSL/+ mice is associated with overt changes to villus morphology and intestinal 
homeostasis as well as enhanced epithelial cell migration.
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Figure 5.8 Pten loss and Kras activation has no effect on enteroendocrine cell 
number
Grimelius staining revealed normal localisation of enteroendocrine cells in each cohort. 
Arrows indicate enteroendocrine cells in WT tissue. Scale bars represent 200p.m. 
Enteroendocrine cells were scored and normalised to account for changes in crypt-villus 
cell number. Scoring revealed that enteroendocrine cell number in Pten/,7// KrasLSL/+ 
tissue and the controls was not significantly altered from WT tissue (p values >0.05, n;>3, 
Mann-Whitney U test). Ptenfl/fl tissue trended towards higher enteroendocrine cell
number but was only significantly higher than Pten/,/;/ KrasLiL/+ tissue (*, p value = 
0.0204, n^3, Mann Whitney U test). Error bars indicate standard deviation.
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Figure 5.9 Pten loss and Kras activation causes a reduction in goblet cell number
Small intestinal sections were stained with alcian blue that stains the mucins present in 
goblet cells. Staining revealed no changes in localisation of the goblet cells. They were 
distributed normally throughout the crypt-villus. Arrows indicate goblet cells in WT 
tissue. Scale bars represent 200pm. Goblet cells were scored and normalised to account 
for changes in villus cell number. Scoring revealed that there was a significant reduction 
in Pten^' Kras^^ tissue and control tissue compared to WT tissue (*, p values = 0.0404, 
na3, Mann Whitney U test). Experimental and control scores were not significantly 
altered from each other. Error bars indicate standard deviation.
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Figure 5.10 Lysozyme IHC showed no mislocalisation of paneth cells, but a decrease 
in abundance in Pten/,/7' KrasLSL/+tissue
IHC against lysozyme, an enzyme found in paneth cell granules, revealed that paneth 
cells remained localised to the base of the crypt in Pten/,7// KrasLSL/+ and control tissue 
compared to WT (arrow shows normal position of a lysozyme stained paneth cell). Scale 
bars represent lOO i^m. Paneth cell scoring revealed a significantly lower abundance of 
paneth cells in Pten7^  KrasLSL/+ tissue and control tissue compared to WT (*, p values = 
0.0404, ns3, Mann Whitney U test). Error bars indicate standard deviation.
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Figure 5.11 Alkaline phosphatase staining revealed no apparent changes enterocyte 
maturation
Alkaline phosphatase staining revealed no changes in the localisation of staining, 
expression was maintained on the luminal surface of the enterocytes in PterJl/fl KrasLSi-/+ 
and controls compared to WT tissue. Therefore indicating enterocytes were 
differentiating normally. Scale bars represent lOO^m.
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Figure 5.12 IHC and western blot for pAkt confirmed activation of PI3K pathway in 
Pten^' KrasLSty+ intestinal tissue
(A) IHC against pAkt (ser473) revealed accumulation of pAkt in Pten^'7' KrasLSL/+ and to a 
lesser extent Pten///;< tissue compared to WT and KrasLSL/+ tissue. Scale bars represent 
100pm. IHC against pErk (Thr202/Tyr204) revealed no overt differences between 
experimental and control tissues. Scale bars represent 50pm. (B) Western blot for pAkt 
(ser473) confirmed the presence of pAkt in Pten/,//< KrasLS" + and Pten//7// tissue. 
Hyperactivation of pAkt was evident in Pten7"/' Kras'-*-" samples compared to the Pten7"7' 
control samples. Western blot confirmed that pErk (Thr202/Tyr204) levels were no 
higher than WT in experimental samples.
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5.3  Discussion
5.3.1 Cells that have undergone conditional recombination are maintained in the
intestinal epithelium at day 50 post induction
PCR for the recombined alleles of Pten and Kras was carried out on DNA 
extracted from intestinal epithelial cell samples to confirm that the intestinal stem cells 
had undergone ere mediated DNA recombination, and the recombined stem cells were 
retained in the small intestinal epithelium at day 50 post induction. Unpublished data 
from the Clarke lab has shown that some mutations, such as Stat3 and Brg1, are lethal 
to the stem cell following recombination, with subsequent replacement with a ‘WT’ 
unrecombined cell. PCR products for the Pten and Kras recombined alleles were present 
(Figure 5.1), confirming that ViUinCreERT mediated recombination occurs in the 
intestinal stem cell, that the stem cell is able to survive concomitant deletion of Pten 
and activation of Kras, and is further able to populate the entire crypt-villus axis with 
recombined cells.
5.3.2 Pten and Kras synergise to disrupt homeostasis of the intestinal epithelium
Homeostasis of the intestinal epithelium is tightly controlled, with turnover of
the crypt-villus epithelium occurring every 2-3 days, and subtle changes in cell number 
or proliferation can have a significant effect on the overall maintenance of the tissue 
structure. Pten loss and Kras activation appears to synergistically act to disrupt 
intestinal homeostasis, as evidenced by villus branching or bifurcations, observed at day 
50 post induction (Figure 5.2). The increases in crypt and villus cell number observed in 
control tissue at day 15 post induction are not observed at day 50 post induction, crypt 
and villus hyperplasia is only observed in Pten/,7/* KrasLSL/+ tissue (Figure 5.3). The gross 
changes in villus morphology and increase in abundance of cells along the crypt-villus 
axis in ?tenfl/fl Krastsz7+ mice at day 50 confirm that the more subtle, yet significant 
changes in crypt-villus cell number (hinting at early alterations in intestinal homeostasis) 
in Pten;,//* KrasLSL/+ mice at day 15 post induction were unable to be controlled by 
compensatory mechanisms at later time points, but homeostasis was able to be restored 
in the control mice.
Villus branching has previously been observed in mouse models of intestinal 
specific inhibition of Hedgehog signalling. These branches appear to be driven by 
proliferating cells along the crypt-villus axis that form ectopic crypts (Madison et al., 
2005). The villus bifurcations or ‘branches’ observed in the Pten/,//' KrasiSU+ small 
intestine, are not the result of ectopic crypt formation, as proliferation is confined to 
the crypt (as assessed by BrdU incorporation Figure 5.5). Branching therefore may be the
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result of an ‘overflow mechanism’ to compensate for the large increases in cell number 
along the crypt-villus axis (Figure 5.3). One could hypothesise that normal migration and 
sloughing off of cells from the tip of the villus is no longer able to balance out the 
increasing number of cells being generated through increased proliferation, and so 
therefore the crypt and villus become elongated. Once these extended villi have 
reached a point where it was logistically impossible to extend further in length, due to 
restriction of lumen width, the cells then exude from the central villus structure and 
form branches to alleviate the build up of cells migrating from the crypt. This, as 
suggested in chapter 3, may be a result of decreased apoptosis at the villus tip. 
Apoptosis of cells at the villus tip is thought to account for the majority of cell loss from 
the villus and regulation of cell number (Hall et al., 1994). A decrease in apoptosis may 
be caused by the increased activation of the PI3K pathway, confirmed by increased 
abundance of pAkt in PterJl/fl KrasLSL/+ mice (Figure 5.12). Upregulation of pAkt, and 
therefore PI3K signalling, has been shown to be associated with a decrease in apoptosis 
in colorectal cancer cell lines (Itoh et al., 2002). Apoptosis scoring has only been carried 
out in the crypts in this study; no significant changes in the level of apoptosis were 
observed in Pten^* KrasLSL/+ mice (Figure 5.4). However, apoptosis levels are low in 
tissues that have not undergone cellular damage, so therefore it may be difficult to 
observe a decrease in apoptosis.
Alterations in crypt and villus cell number in Pten/,//f KrasLSL/+ small intestine is 
also accompanied by a decrease in goblet and paneth cell number (Figure 5.9, Figure 
5.10), suggesting that concurrent Pten loss and Kras activation negatively impacts on 
differentiation of these two cell types, resulting in their lower abundance. This effect 
was also observed in both KrasLSL/+ and P te n ^  control tissue, but this decrease was not 
compounded in Pten/,7// KrasLSL/+ tissue suggesting that the two mutations do not 
synergise in the context of differentiation. As previously mentioned in chapter 3, 
activation of the PI3K pathway may be responsible for alterations in differentiated cell 
types, as mTOR (a downstream target of pAkt) plays a role in activation of Notch 
signalling which is responsible for the differentiation of secretory cell types (Ma et al., 
2010). Some of these findings are in contrast to the findings in Pten^ ' KrasLSL/+ mice 
sacrificed at day 15 post induction. There were no changes in the number of 
enteroendocrine cells present in the small intestine at day 50, as was observed at day 15 
post induction, and at day 50 post induction Pten/,//f KrasLSL/+ mice have significantly 
lower numbers of goblet cells than WT tissue, which was not observed at day 15 post 
induction. It is unclear why some of the early phenotypes appear to have been
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circumvented at later timepoints, however it is clear that mutations in both Pten and 
Kras negatively affect intestinal secretory cell differentiation.
5.3.3 Pten loss and Kras activation does not cause expansion of the stem cell
compartment
Loss of Pten in the murine small intestine has been associated with an expansion 
in stem cell number (He et al., 2007). Increases in crypt cell number and proliferation 
along with expansion of the proliferative zone in Pten/,/// KrasLSL/+ mice (Figure 5.3, 
Figure 5.5 and Figure 5.6, A), led to the hypothesis that the phenotypes observed in 
Ptenfl/fl KrasLSL/+ mice may be the result of an increase in stem cell number. Expression 
levels of intestinal CBC stem cell markers Lgr5 and Ascl2 were unchanged in Pten/,7/* 
KrasLSL/+ tissue compared to control and WT tissue (Figure 5.7). The observed increases 
in crypt length and proliferation may therefore be attributed to an increase in transit 
amplifying progenitor cells. Pten loss and Kras activation must therefore be enhancing 
the activity of the stem cell or progenitor cell compartment driving proliferation, 
resulting in an increase in progenitor cells. Increased proliferation observed in P te n ^  
KrasLSL/+ mice, correlated with increased activation of the PI3K pathway (as indicated by 
accumulation of pAkt, Figure 5.12). Wnt pathway activation controls small intestinal 
proliferation and loss of Pten has previously been shown to drive activation of the Wnt 
pathway by inactivation of GSK-3p, through PI3K pathway activation (Persad et al., 
2001). Therefore, it could be possible that Wnt pathway activation may be responsible 
for increased proliferation in these mice. However, the CBC stem cell markers Lgr5 and 
Ascl2 are also Wnt pathway transcriptional targets, so therefore expression of these 
genes would be upregulated if the Wnt pathway was being activated in these mice. It is 
therefore more likely that proliferation is driven by phosphorylation of downstream 
targets of Akt resulting in increased proliferation. Such targets include phosphorylation 
and inactivation of GSK-3p that normally results in degradation of the cell cycle 
promoter, cyclin D1 (Diehl et al., 1998), and phosphorylation of cell cycle inhibitor 
p21cip (L ie t al., 2002).
Synergy between Pten and Kras mutations through upregulation of proliferation 
has previously been noted in a mouse model of pancreatic specific Pten loss and Kras 
activation. The two mutations were shown to synergise in metaplastic tissue and 
tumours to result in higher numbers of proliferating cells, compared to metaplasia and 
tumours that arises in mice with Kras activation alone (Hill et al., 2010). This study also 
observed accumulation of pAkt and other active downstream targets of the PI3K
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pathway in tumours but not metaplastic tissue that possess both Pten and Kras 
mutations (Hill et al., 2010).
5.3.4 Concomitant Pten loss and Kras activation causes hyperactivation of Akt
Synergy between Pten and Kras appears to manifest through activation of the PI3K 
pathway, which may be driving the observed phenotypes. IHC for pAkt indicated that 
there was a subtle increase in staining intensity in P te n ^  KrasLSL/+ intestine compared 
controls and WT (Figure 5.12, A). Western blot for pAkt revealed that loss of Pten alone 
results in accumulation of pAkt and this accumulation is enhanced when Pten loss is 
combined with Kras activation (Figure 5.12, B). Loss of Pten results in a subtle migratory 
phenotype that is accompanied by low levels of pAkt accumulation (Figure 5.12, B). Loss 
of Pten together with activation of Kras results in a range of phenotypes including villus 
bifurcation, increased proliferation a much more severe migratory phenotype. Taken 
together these data suggest that varying levels of pAkt, and hence PI3K pathway 
stimulation, directly correlates with phenotype severity. These findings provide 
evidence that activation of the PI3K pathway in the intestine is not binary, and simply 
‘switching-on’ the pathway by Pten deletion is not sufficient to affect intestinal 
homeostasis. Only when the pathway is hyperactivated, by additional activation of Kras 
in concert with Pten deletion, is evidence of disrupted homeostasis observed. The 
finding that elevated levels of pAkt are associated with hyperplasia, enhanced 
proliferation and increased migratory rate of intestinal epithelial cells in the mouse 
small intestine is consistent with other studies that show PI3K signalling plays a role in 
intestinal cell migration in vitro (Dise et al., 2008), and promotes proliferation in vivo 
(Sheng et al., 2003).
Synergy between Pten loss and Kras activation through PI3K has been shown in 
some tumour models. Hill et al showed that Pten and Kras mutations synergised through 
the PI3K pathway and to a lesser extent MAPK/Erk pathways to promote pancreatic 
tumourigenesis (Hill et al., 2010). A study by Miller et al showed that Pten and Kras 
mutations synergise through the PI3K pathway to promote thyroid tumourigenesis. 
Inhibition of the PI3K pathway conferred a survival advantage on these mice. However, 
unlike the findings I observed in this chapter, Miller et al also demonstrated that 
activation of the PI3K pathway was necessary for activation of the MAPK/Erk pathway in 
the thyroid model, and inhibition of the PI3K pathway also resulted in inhibition of the 
MAPK pathway (Miller et al., 2009).
142
5 .4  Summary
Pten loss and Kras activation acts synergistically to disrupt intestinal homeostasis 
at day 50 post induction. Hyperproliferation of the crypt and villus is observed, along 
with enhanced migration and the formation of villus bifurcations. The phenotypes 
observed at this time point are accompanied by hyperactivation of Akt. Activation of Akt 
is likely to be driving these phenotypes, as the PI3K pathway promotes proliferation by 
inhibition of a number of cell cycle regulators, and promotes migration.
5.5 Further Work
I have proposed that hyperactivation of pAkt and hence, PI3K pathway activation, 
drives the phenotypes observed in Pten/,7/< KrasLSL/+ mice. To mechanistically prove this, 
it would be useful to treat ?tenfl/fl KrasLSL/+ mice with a PI3K inhibitor at day 50 post 
induction for a fixed period of time, for example 2 weeks, to see if the changes 
observed in cell proliferation and migration are restored to WT levels and villus 
bifurcations are lost. To also prove that a decrease in apoptosis at the villus tip is 
driving villus bifurcation, it would be insightful to score the level of apoptosis observed 
at the villus tip via H&E scoring and caspase 3 scoring.
P te n ^  KrasiSL/+ mice maintained good health throughout the duration of this 
experiment, despite major changes in mucosal architecture of the small intestine. In 
light of this, further to this day 50 time point a number of Pten/,7/* KrasLSL/+ mice were 
induced and aged to assess synergy between the genes in the long term. The results 
from this experiment are discussed in chapter 6.
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Chapter 6: Investigating the long term effects of Pten loss and 
Kras activation on the intestinal epithelium
6 .1 Introduction
Previously the Clarke lab and others have shown that Pten loss alone does not 
cause tumour formation, despite mutation of Pten underlying a number of familial 
intestinal tumour syndromes (Marsh et al., 2008, Langlois et al., 2009). Similarly, the 
Clarke lab and others have shown that activation of oncogenic Kras does not result in 
tumour formation in the intestine (Haigis et al., 2008, Sansom et al., 2006). These 
studies also showed that, in the context of Wnt initiated tumours, addition of Kras and 
Pten alone both promote initiation and progression of Wnt activated tumours. Data in 
chapter 4 provided evidence of synergy between Pten and Kras in the context of a Wnt 
initiated tumour model (W///nCreERT-Apc/,/+ Pten;,/// KrasLSL/+ mice). Pten loss and Kras 
activation together promotes both initiation of tumours, and progression of adenomas 
through to adenocarcinoma.
Despite Pten and Kras impinging on the same pathway, a number of mouse models 
have shown synergy between mutations in the two genes. This synergy was evidenced by 
increased tumourigenecity and tumour progression in the endometrium, lung, thyroid 
and pancreas (Miller et al., 2009, Dinulescu et al., 2005, Iwanaga et al., 2008, Hill et 
al., 2010). Unpublished data from the Clarke lab has also demonstrated synergy between 
Pten and Kras mutations, in both the gall bladder and stomach, giving rise to cholangio 
carcinoma and forestomach hyperplasia respectively. I have shown evidence in chapters 
3 and 5 that Pten loss and Kras activation, without an Ape mutation, has a synergistic 
effect on the small intestine, resulting in disrupted homeostasis in the short term (day 
15 and 50 post induction). Disrupted homeostasis observed in VMinCreERJ-Ptenfl/fl 
KrasLSL/+ mice was evidenced by hyperplasia at day 15 post induction, and the formation 
of villus bifurcations at day 50 post induction. The observation that Pten loss and Kras 
activation causes disruption of intestinal homeostasis and the formation of epithelial 
aberrations at short time points after induction, leads to the hypothesis that these 
mutations together may give rise to intestinal neoplasms in the long term. To address 
this question, in this chapter I will investigate the effect of long term Pten loss and Kras 
activation in the murine small intestine.
VillinCreERT-Pten/,//f KrasLSL/+ (hereafter referred to as Pten;,/// KrasiSU+) mice and 
the appropriate controls (ViIlinCreEP?-Ptenfl,fl Kras+/+ [hereafter referred to as Pten^*], 
V/7/;nCreERT-Pten+/+ KrasLSL/+ [hereafter referred to as KrasLSL/+] and W///nCreERT-Pten+y+
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Kras+/+ [hereafter referred to as WT]), were induced at 6-12 weeks of age and sacrificed 
when they became symptomatic of disease.
6.2 Results
6.2.1 Intestinal Pten loss and Kras activation together significantly reduces mouse life
span
Pten//7// KrasLSL/+ mice had a significantly shortened lifespan (median survival 280 
days) compared to control and WT mice, most of which were sacrificed at day 550 post 
induction, the experimental endpoint (Figure 6.1, A). A number of the control mice had 
to be sacrificed before the experimental endpoint, mainly due to the development of 
lymphoma, which is reasonably common in ageing mice. Further to this, one KrasLSL/+ 
mouse had developed ill health as a consequence of intussusception. PterJl,fl KrasLSL/+ 
mice were sacrificed either because of colonic ischemia and resultant colon blockage, or 
because of tumour burden.
When Pten/,7// KrasLSL/+ mice were dissected it was noted that 25% (9/36) of the 
mice appeared to have a large blockage of compacted faeces and blood in the colon 
(Figure 6.1, B). This blockage was always found in mice that also had evidence of 
intussusception (where the intestine has inverted or ‘turned-in on itself’ ), either at the 
ileal-caecal or the colonic-caecal junction. It would appear that the intussusception was 
restricting the blood supply of the colon and causing ischemia, resulting in colonic 
blockage. The cause of the intussusception was likely to be linked to the 
hyperproliferation of the epithelium, i.e. rapid proliferation forces the supporting 
stroma upwards and could potentially pull the smooth muscle up with it, causing 
intussusception. Mice with intussusception had a median survival time of 160 days post 
induction. Some of these mice also possessed benign sessile serrated adenomas (see 
below) but none had evidence of carcinoma.
The remaining 75% (27/36) of the Pten///;* KrasLSL/+ cohort had a median survival 
time of 344 days post induction and were sacrificed due to tumour burden. A number of 
small intestinal tumours at differing stages were observed in the remaining cohort of 
Pten///;< KrasLSL/+ mice: 30% (8/27) of the mice possessed hyperplastic polyps, 78% (21/27) 
of the possessed benign sessile serrated adenomas, 44% (12/27) had adenocarcinoma 
and a further 41% (11/27) had metastatic carcinoma (Figure 6.1, C). Intestinal tumours 
were not observed in WT or KrasLSL/+ mice. However some Pten///;/ mice possessed benign 
tumours. It is of note that villus bifurcations are still frequently observed in aged 
Pten;,/// KrasLSL/+ mice, indicating that once the structures are formed they are unable to 
be reversed in a Pten negative Kras activated setting.
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Figure 6.1 Ptenw / KrasLSi7+ mice have a significantly shorter lifespan compared to 
controls due to colonic ischemia and tumour burden
(A) Survival plot of Pten/,/// KrasLSL/* mice and controls, ?tenfl,fl KrasLSL/+ mice have a 
significantly shorter lifespan compared to control and WT mice (p values <0.001, both 
Log-Rank and Wilcoxon test). The ageing experiment was conducted until 550 days post 
induction. (B) 25% of the Pten;//// KrasLSL/+ ageing cohort were found to have a large 
blockage in the colon caused by restriction of the colonic blood supply (colonic 
ischemia), which was in turn caused by intussusception of the intestine at the ileal- 
caecal or the colonic-caecal junction. Scale bar represents lOOO^ im. (C) A spectrum of 
intestinal tumour types was observed in the remaining Pten^* KrasLSi-/+ ageing cohort. 
The incidence of these tumour types was as follows: 30% - hyperplastic polyps (HP), 78% 
- sessile serrated adenomas (SA), 44% - adenocarcinomas (AC) and 41% - metastatic 
carcinoma (MC).
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6.2.2 Pten loss and Kras activation predisposes to the formation of benign sessile
serrated adenomas
78% of tumours observed in P te n ^  KrasLSL/+ mice were sessile serrated 
adenomas. Serrated adenomas are well-differentiated, benign tumours that differ from 
traditional ‘Wnt-activated’ tumours by the serrated morphology of their edges. They 
were first described in 1990 by Longacre and Fenoglio-Preiser (Longacre and Fenoglio- 
Preiser, 1990). Serrated adenomas are further classified into two sub-types: sessile and 
traditional (Torlakovic et al., 2003). Sessile serrated adenomas are so named because of 
their flat lying form, traditional serrated adenomas have a pedunculated form, rather 
than sessile. Serrated adenomas are also found in humans and are thought to represent 
the early stages of an alternative pathway of CRC formation to the traditional Fearon- 
Vogelstein progression model, called the Serrated Adenocarcinoma pathway (Jass et al., 
2002, Makinen, 2007). In Pten/,7/* KrasLSL/+ mice, sessile serrated adenomas were 
primarily distinguished by histopathological description of the tumour, i.e. serrated 
‘saw-tooth’ like appearance of the crypt-like structures of the tumour (Figure 6.2, A). 
However, some earlier stage hyperplastic polyps with a similar histological appearance 
to serrated adenomas were also observed (Figure 6.2, A). To distinguish between 
hyperplastic polyps and sessile serrated adenomas IHC against Ki67 and descriptive 
histopathological criteria were used1 (Figure 6.2, B).
Classification of a sessile serrated adenoma was determined by evidence of 
dysplasia including: nuclear crowding, loss of serrated architecture towards the luminal 
surface of tumour, strong eosin staining, and with expansion of Ki67 positive cells from 
the crypt towards the periphery of the tumour (Figure 6.2). Conversely hyperplastic 
polyps showed no evidence of dysplasia, and Ki67 positive cells were confined to the 
crypts at the base of the tumour.
Interestingly, sessile serrated adenomas were observed in 40% (4/10) of the 
Pten/,/;/ control mice that had survived over 500 days post induction. This suggests that 
long term loss of Pten alone, can lead to tumour formation in the mouse. Addition of a 
Kras activating mutation synergises with Pten loss to accelerate formation of sessile 
serrated adenomas, as they are observed in P ten ^ ' Kras^^ mice at a higher incidence
1 Histopathological description of the tumours observed was provided by Prof. Geraint Williams, 
Heath Park Campus, Cardiff University, Cardiff
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than in Pten/Z/// mice and at earlier times post induction. Sessile serrated adenomas were 
observed as early at 113 days post induction in Pten/,/// KrasLSL/+ mice.
6.2.3 Sessile serrated adenomas arise independently of Wnt signalling
As Pten and Kras both impinge on the PI3K pathway, and Kras also activates the 
MAPK pathway, IHC for markers of PI3K activation, phospho-Akt(ser473) (pAkt) and AAAPK 
pathway activation, phospho-p44/42 MAPK(Thr202/Tyr204) (pErk) and phospho- 
MEK1/2(Ser221) (pMEK) was carried out on tumour sections and adjacent normal 
intestinal tissue. Sessile serrated adenomas stained strongly for pErk, pMEK and pAkt 
compared to the adjacent normal tissue, indicating activation of the AAAPK and PI3K 
pathways in the tumour (Figure 6.3).
Activation of the Wnt pathway (by mutation of Ape for example) is commonly 
regarded to be the initiating mutation of all intestinal tumours according to the Fearon- 
Vogelstein step-wise model of CRC progression. Serrated adenomas are thought to arise 
from either BRAF or KRAS mutations in humans, hence IHC for the surrogate marker of 
Wnt activation, p-catenin, was carried out to determine its cellular localisation. Staining 
revealed basolateral localisation of p-catenin confirming that the canonical Wnt 
pathway was not being activated in these tumours, and therefore these tumours were 
forming independently of mutations in the Wnt pathway (Figure 6.3).
6.2.4 Pten loss and Kras activation results in a number of intestinal phenotypes
Within the Pten/,//z KrasLSL/+ cohort there was a 44% incidence of intestinal
adenocarcinoma with smooth muscle invasion, and a 41% incidence of metastatic 
carcinoma of the small intestine (Figure 6.1, C). These advanced tumours were 
frequently found in addition to, and alongside, benign sessile serrated adenomas. They 
also possessed serrated features (i.e. saw-tooth like morphology of the epithelial 
component of the tumour), despite overall changes in tumour morphology compared to 
sessile serrated adenomas (Figure 6.4). This evidence of serration in adenocarcinoma, 
carcinoma and metastases leads to the hypothesis that the sessile serrated adenomas 
are precursor lesions that progress into carcinomas. Evidence of the range of benign 
through to metastatic tumours found in Pten/,//z KrasLSL/+ mice is shown in Figure 6.5, 
with the most compelling piece of evidence in support of progression from sessile 
serrated adenoma, being a sessile serrated adenoma with areas of the tumour invading 
into the submucosa - potentially representing the step from benign to invasive tumour. 
The Pten////Z KrasLSL/+ mouse model therefore represents a model of the serrated 
adenocarcinoma pathway.
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Figure 6.2 Ptenfl/fl KrasL5u+ mice were predisposed to sessile serrated adenomas
(A) Benign hyperplastic polyps and sessile serrated adenomas were observed in Pter/,/// 
KrasLSL/+ mice. Both had a ‘sawtooth-like’ serrated appearance to the crypts. Sessile 
serrated adenomas could be distinguished from hyperplastic polyps by evidence of 
strong eosin staining, and dysplasia such as nuclear overcrowding. (B) IHC against Ki67 
helped to further distinguish between hyperplastic polyps and sessile serrated 
adenomas. Immunostaining remained confined to crypts in hyperplastic polyps, but was 
found throughout the sessile serrated adenoma and towards the luminal surface of the 
tumour. Scale bars represent 200|am.
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Figure 6.3 IHC staining revealed that sessile serrated adenomas arise independently 
of Wnt activation and have evidence of PI3K and MAPK pathway activation
IHC staining against the phosphorylated forms of Akt (phospho-Akt ser473), Erk 
(phospho-p44/42 MAPK, Thr202/Tyr204) and MEK (phospho-MEK1/2, Ser221) revealed 
stronger staining in sessile serrated adenomas compared to the adjacent tissue. IHC 
staining against p-catenin revealed basolateral localisation of the protein, indicating 
that the Wnt pathway was not being activated in these tumours. Scale bars represent 
100pm.
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Figure 6.4 Progression of hyperplastic polyp to metastatic carcinoma
Pten/,//< KrasLSL/+ mice developed a spectrum of tumours at different stages of tumour 
progression, from hyperplastic polyp to metastatic carcinoma. However, all these 
tumours possessed ‘serrated-morphology’ of the epithelial component, suggesting that 
the sessile serrated adenomas observed in these mice are the precursor lesions that 
develop into metastatic carcinoma. The likely pathway of progression from benign 
serrated adenoma to metastatic carcinoma is depicted here. (Arrow head shows the 
region of a sessile serrated adenoma that is beginning to invade into the submucosa and 
become more aggressive). Scale bars represent 200pm and 50pm.
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6.2.5 Carcinomas in Pten/,//7 KrasLSL/+ mice frequently metastasise to the liver
41% of Pten////f KrasLSL/+ mice developed metastatic carcinoma. The primary 
tumour shown in Figure 6.5 is a typical large carcinoma observed in these mice. There 
was a large stromal component to all carcinomas, making up the bulk of the tumour, and 
the epithelial component possessed serrated morphology as shown in Figure 6.4.
The sites of metastasis in these mice were scored (11 mice had metastatic 
carcinoma, some with more than one site of metastasis), the sites of metastasis included 
the liver (7/11 mice had metastases to the liver), pancreas (3/11), lung (1/11) (Figure
6.5), and the lymph nodes (2/11). Some metastases occurred in the peritoneum 
associated with the kidneys (1/11), epididymal fat pads and mesenteric connective 
tissue (7/11). Metastases into the peritoneum and pancreas are likely to be the result of 
direct invasion from the primary carcinoma. However, liver and lymph node metastases 
are highly likely to have seeded there through the blood and lymphatic vessels, and lung 
metastases are only able to travel there via the blood stream. Serial sectioning through 
the liver revealed the presence of ‘micro-metastases’ found deep within the tissue, 
which could have only seeded there via blood bourne metastasis.
6.2.6 The canonical Wnt pathway is activated in all invasive adenocarcinomas and
carcinomas in Pten/,7// KrasLSL/+ mice
PI3K, AAAPK and canonical-Wnt pathway activation status was determined by IHC. 
Immunostaining of metastatic carcinoma tissue sections for pAkt (PI3K), pErk and pMEK 
(AAAPK), p-catenin and CD44 (Wnt) was carried out. As observed in sessile serrated 
adenomas, the carcinomas and metastases stained strongly for pErk, pMEK and pAkt 
compared to normal adjacent mucosa, indicating AAAPK and PI3K pathway activation 
(Figure 6.6). However, there was also accumulation of nuclear p-catenin and strong 
staining for canonical Wnt target gene CD44 in both carcinoma and metastases (Figure
6.6), indicating that the canonical Wnt pathway was also being activated in these 
tumours. As both the normal mucosa and the benign serrated adenomas in P ten^1 
KrasLSL/+ do not show evidence of nuclear p-catenin (and therefore Wnt activation), one 
can postulate that a spontaneous somatic Wnt activating mutation must have occurred 
during progression of the tumour. Interestingly, nuclear accumulation of p-catenin was 
present in all observed carcinomas and invasive adenocarcinomas suggesting that a Wnt 
activating mutation is necessary for tumour progression.
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Figure 6.5 Sites of metastasis of carcinomas found in Pten^' KrasLSL/+ mice
Top left image shows a typical primary tumour found in Pten;//// KrasLSL/+ mice (arrow 
shows sessile serrated adenoma also observed in this mouse, scale bar represents 
200pm). Metastases were predominantly found in the pancreas (n=3/11) (top right 
image, scale bar represents 200pm) and liver (n=7/11) (bottom left image, scale bar 
represents 100pm). There was also evidence of metastases to the lung (n=1/11) (bottom 
right image, scale bar represents 100pm).
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Figure 6.6 IHC indicated activation of the PI3K and MAPK pathways in metastatic 
carcinoma, as well as activation of the Wnt pathway
IHC for pAkt (ser473), pErk (Thr202/Tyr204) and pMEK (Ser221) indicated stronger 
staining for each, in both carcinomas and metastases, compared to normal intestinal 
mucosal staining - indicating activation of the PI3K and AAAPK pathways. However, IHC 
staining for p-catenin revealed its subcellular localisation to be nuclear in the carcinoma 
and metastases, compared to basolateral staining in the normal intestinal tissue. 
Therefore, the canonical Wnt pathway was being activated in these advanced tumours, 
further confirmed by intense staining for Wnt target gene CD44 in the carcinomas and 
metastases. Scale bars represent 50 i^m.
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6.2.7 E-cadherin immunostaining of tumours
E-cadherin loss is thought to be a marker of aggressiveness of CRCs in humans, 
with loss of E-cadherin expression associated with increased propensity of the tumours 
to invade and metastasise (Dorudi et al., 1995, Karamitopoulou et al., 2011). Loss of E- 
cadherin expression induces EMT, and it is this change in morphology, along with loss of 
cell-to-cell contacts that is thought to be the cause of increased tumour invasiveness. E- 
cadherin was visualised by IHC, which was carried out on tumour tissue sections
Despite tumours in P te n ^  KrasLSL/+ mice progressing to metastasis, IHC for E- 
cadherin revealed no changes in E-cadherin expression in both carcinomas and 
metastases (Figure 6.7). There were no areas of tumour that appeared to have lost E- 
cadherin expression, and all cells within the tumours still appeared to possess epithelial 
morphology.
6.2.8 Reduced ere expression in Apc/</+ Pten/,//f KrasLSL/+ mice decreases tumour number
but does not give rise to metastatic carcinomas
Despite all adenocarcinomas and carcinomas present in Pten/<//f KrasLSL/+ mice 
possessing evidence of canonical Wnt pathway activation, no Wnt driven tumours in 
W//mCreERT-Apc/,/+ Pten/,7// KrasLSL/+ mice became metastatic, described in chapter 4. 
One possible reason for this may be that as the levels of ere expression and subsequent 
DNA recombination are high, the mouse has a large number of tumours that progress 
quickly to adenocarcinoma and cause rapid morbidity. To circumvent this, a cohort of 
Apc///+ ?ter\fl/fl KrasLSL/+ were induced with a 10x lower dose of tamoxifen (8mg/kg) and 
aged. As predicted, they survived to a median of 324 days compared to the median 
survival time of mice induced with 80mg/kg doses of tamoxifen of 41 days post 
induction. This longevity was due to the decrease in tumour number caused by lower ere 
recombination. 8mg/kg (low dose) Apc///+ Pten/,//f KrasLSL/+ mice had an average of 3.3 
tumours per section, compared to 80mg/kg (normal dose) Apc/,/+ Pten;,//< KrasLSL/+ mice 
that possessed an average of 50 tumours per section. All low dose mice possessed 
invasive adenocarcinomas, 6 out of 7 mice possessed one adenocarcinoma that had 
invaded through the smooth muscle into the peritoneal cavity, but none of these mice 
showed evidence of metastasis (Figure 6.8). These data therefore suggest that a Wnt 
activating mutation is an obligate event for metastasis in P te n ^  KrasLSL/+ mice, and 
they do not arise out of a Wnt initiated adenoma.
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Figure 6.7 IHC reveals no changes in expression of E-cadherin in metastatic 
carcinomas
IHC against E-cadherin revealed no overt loss of expression of the protein, the cells 
maintained basolateral localisation in both the primary tumours and metastases. E- 
cadherin loss is associated with increased invasion, but there was no evidence of loss of 
E-cadherin in all the tumours observed in P te n ^  KrasLSL/+ mice. Scale bars represent 
lOO^m.
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Figure 6.8 Tumours in low recombination Apc///+ Pten^' K ras^* mice do not 
progress to metastasis
(A) Apc/,/+ Pten//7// KrasLSL/+ mice that were given a 10x lower dose of tamoxifen have a 
significantly longer lifespan than those given a normal dose (p value < 0.001, Log-Rank 
test). They have a median survival time of 324 days, compared to the 80mg/kg cohort 
that survived until a median of 41 days post induction.
(B) An example of an adenocarcinoma with smooth muscle invasion observed in low dose 
Apc/,/+ Pter\f  fl KrasLSL/+ mice. All of the low dose Apc/,/+ Pten//7// KrasLSL/+ mice developed 
invasive adenocarcinoma, 6 out of the 7 mice developed invasive adenocarcinoma that 
infiltrated the smooth muscle wall and underlying serosa, but none developed 
metastasis. Scale bar represents 500nm.
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6.3 Discussion
6.3.1 Concomitant intestinal Pten loss and Kras activation reduces mouse lifespan and
predisposes to tumourigenesis
As hypothesised, synergy between Pten and Kras, previously observed at short 
time points, is also observed in the long term, as evidenced by a significant decrease in 
Ptenfl/fl KrasLSL/+ survival compared to control and WT mice (Figure 6.1). A subset of 
Pten/,7/* KrasLSL/+ mice had to be sacrificed due to morbidity caused by intussusception of 
the intestine, intussusception is inversion of the intestine that restricts the blood supply 
and causes bowel ischemia. In humans, intussusception is predominantly caused by 
tumour growth and has been noted in other mouse models of intestinal cancer, including 
Apc+/ p277' and Ape**'" Pten+/' mice (Shao et al., 2007, Yang et al., 2005). In both 
studies, tumour number directly correlated with the incidence of intussusception. The 
growth of a tumour can cause the intestine to invaginate. However there was no 
evidence of tumours at the site of intussusception in Pten/,//f KrasLSL/+ mice. 
Intussusception can also be caused by bacterial infection due to the production of 
lipopolysaccharides (Lin et al., 1998). However, if bacterial infection was the cause of 
intussusception in these mice, one would expect intussusception to be observed in 
control littermates and it was not. Bacterial induced intussusception is thought to be 
caused by intestinal motility dysfunction, which may be the cause of intussusception in 
Ptenfl,fl KrasLSL/+ mice - motility may be reduced by hyperplasia of the mucosal 
epithelium. As previously stated the action of increased proliferation and migration may 
cause intussusception by forcing the supporting stroma upwards and pulling the smooth 
muscle up with it, allowing it to invaginate.
The remaining subset of the P te n ^  KrasLSL/+ mice induced that did not succumb 
to intussusception, become symptomatic of an intestinal tumour burden (swollen 
abdomen, intestinal prolapse, blood in faeces, anaemia), and were sacrificed at a 
median time of 344 days post induction. These mice displayed spectrum of tumours from 
benign sessile serrated adenomas to metastatic carcinoma (Figure 6.4). The Pten///;* 
KrasiSU+ mouse model is one of the few examples of an intestinal tumour model that 
doesn’t require a Wnt activating mutation to drive tumourigenesis. Some of these 
models include Smad4 deletion (Hohenstein et al., 2003), Braf activation (Carragher et 
al., 2010) and TGFpR deletion with Kras activation (Trobridge et al., 2009). It is also 
consistent with mouse models in which an activating Kras mutation, in concert with 
another (non-Wnt activating) mutation, drives intestinal tumourigenesis (Bennecke et 
al., 2010, Trobridge et al., 2009).
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6.3.2 Sessile serrated adenomas appear to be driven by PI3K and AAAPK activation and
arise independently of Wnt activation
Sessile serrated adenomas are also observed in the human colon. They are early 
stage tumours, regarded to be precursors of CRC that form via an alternative pathway to 
the Fearon-Vogelstein pathway of CRC progression (Huang et al., 2004, Makinen et al., 
2001, Makinen, 2007). Serrated adenomas were first described by Longacre & Fenoglio- 
Preiser after re-examination of a large number of tumours originally classified as 
hyperplastic polyps (Longacre and Fenoglio-Preiser, 1990). Hyperplastic polyps are 
considered benign, and are usually not resected during routine colonoscopy. However, 
serrated adenomas are thought to have the propensity to progress to carcinoma, and as 
hypermethylation is common in these tumours, they may be the precursor lesions to CpG 
island methylator phenotype (CIMP) colorectal cancers (Jass, 2005). Serrated adenomas 
were further classified into two sub-types: sessile and traditional. Sessile describing flat 
tumours, and traditional describing pedunculated or stalked tumours (Torlakovic et al., 
2003). The main morphological and histological differences between serrated adenomas 
and ‘traditional ‘W nt-initiated’ adenomas’ are that serrated adenomas have a ‘saw­
tooth appearance’ to the edges of the tumour, they appear more eosinophillic (i.e. 
appear to stain darker with eosin) to the surrounding normal epithelium, the tumours 
are well defined in structure and consist of well differentiated cells (sometimes rich in 
goblet cells). Whereas, traditional ‘Wnt-initiated’ adenomas are made up of more 
immature ‘progenitor-like’ cells (Figure 6.9). The sessile serrated adenomas observed in 
PtenfUfl KrasLSL/+ mice were morphologically distinct from traditional ‘Wnt-driven’ 
adenomas and possessed no evidence of Wnt pathway activation, as there was a lack of 
nuclear p-catenin (a surrogate marker of Wnt activation, Figure 6.3). Strong 
immunostaining for pAkt, pErk and pMEK (active PI3K and AAAPK pathway downstream 
effectors respectively), indicated that these tumours are likely to be driven by these 
pathways.
The observation that Pten and Kras mutations synergise to promote Wnt- 
independent tumour formation is consistent with the evidence in humans that serrated 
adenomas arise via a Wnt-independent mechanism, namely mutations in KRAS or BRAF 
(Chan et al., 2003, Higashidani et al., 2003, Kambara et al., 2004). However, it appears 
from aged control cohorts that loss of Pten in the mouse may be sufficient for initiation 
of sessile serrated adenomas, and additional Kras mutation further promotes this 
initiation. Sessile serrated adenomas were not observed in KrasLSL/+ control mice. 
Contrary to the human situation, the Pten/,7// KrasLSL/+ mouse model gives rise to sessile 
serrated adenomas, linking a Kras mutation with this subtype of serrated adenoma. In
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humans BRAF is commonly associated with sessile serrated adenomas, and KRAS with 
traditional serrated adenomas (Chan et al., 2003, Higashidani et al., 2003, Kambara et 
al., 2004). Interestingly, Carragher et al have recently shown that Braf mutations in the 
mouse intestine give rise to traditional serrated adenomas (Carragher et al., 2010), 
concluding that in mice, Kras mutations are associated with sessile serrated adenomas, 
and Braf mutations with traditional serrated adenomas, in contrast to the findings in 
human tumours.
Traditional ‘Wnt-driven’ adenoma
Sessile serrated adenoma
Figure 6.9 Traditional Wnt driven adenoma vs Wnt independent sessile serrated 
adenoma
Traditional ‘Wnt-initiated’ adenomas are easily distinguished from other types of 
adenoma, such as the serrated adenoma or hyperplastic polyp, simply by their 
morphology. Wnt-initiated adenomas lose normal crypt-villus morphology and the cells 
resemble immature progenitor cells. Serrated adenomas maintain crypt-like structures 
but individual villi are usually not discernable. The crypt-like structures forming the 
adenoma take on a serrated ‘saw-tooth’ appearance to their edges.
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6.3.3 Pten loss and Kras activation also predisposes to the development of Wnt- 
activated metastatic intestinal carcinomas
Pten//;// KrasLSL/+ mice were also predisposed to the formation of invasive 
intestinal adenocarcinomas that had infiltrated the smooth muscle wall, and intestinal 
carcinomas that had metastasised. Similarly to the sessile serrated adenomas, these late 
stage tumours show strong immunostaining for markers of PI3K and AAAPK pathway 
activation. However, immunostaining for p-catenin and Wnt target gene CD44 indicate 
that the Wnt pathway is also active in these tumours (Figure 6.6). As the surrounding 
normal tissue or the benign sessile serrated adenomas do not show any evidence of 
elevated activity of Wnt signalling, it could be assumed that a spontaneous somatic Wnt 
activating mutation must have occurred at some stage in these tumours. It therefore 
appears that in order for a tumour to become invasive and metastasise, it must acquire 
Wnt pathway activation.
There are two possible hypotheses as to when Wnt activating mutations are acquired 
and how the late stage tumours arise in these mice (also outlined in Figure 6.10):
1. A spontaneous Wnt activating mutation occurs within the benign sessile serrated 
adenoma, which then progresses to carcinoma
2. A spontaneous Wnt activating mutation occurs in the mucosa deficient for Pten 
and activated for Kras, which then gives rise to a tumour that progresses to 
carcinoma
Neither hypothesis can be conclusively proven within the constraints of the mouse 
models used in this study. However, there is evidence in favour of the latter hypothesis. 
Apc/,/+ P te n ^  KrasLSL/+ mice that received a ten times lower dose of tamoxifen 
developed one or two large adenocarcinomas that invaded through the smooth muscle 
wall and underlying serosa per mouse, but none of these tumours progressed to 
metastasis - suggesting that an initiating Wnt mutation does not necessarily give rise to 
metastasis even when given a long latency period (Figure 6.8). In Pten//7// KrasLSL/+ mice, 
invasive adenocarcinomas and metastatic carcinomas were frequently observed with 
sessile serrated adenomas (Figure 6.5). This finding, taken together with the 
observations that some sessile serrated adenomas had evidence of invasion, and 
carcinomas and metastases displaying serrated morphology (Figure 6.4) gives strong 
evidence in favour of the first hypothesis. Further evidence to support the hypothesis 
that sessile serrated adenomas are the precursor lesions to the carcinomas observed in 
Pter)fUfl KrasLSL/+ mice through a Wnt-activating mutation, comes from the observation 
that some sessile serrated adenomas have evidence of nuclear p-catenin in humans (Wu 
et al., 2008, Yachida et al., 2009). This also supports the notion that a Wnt-activating
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mutation can promote tumour progression, as well as initiation. In humans, serrated 
adenomas have high levels of methylation, and it is the methylation of tumour 
suppressor promoters that is thought to be the driver of progression tumour progression 
(Jass, 2005). However, the level of methylation in the tumours arising in Pten;,/// KrasLSL/+ 
mice was not investigated, so it cannot be ascertained whether it is indeed methylation 
that is driving loss of expression of additional tumour suppressors.
Metastasis
Figure 6.10 The two possible proposed pathways of tumour progression in P te n ^  
KrasLSL/+ mice
The metastatic carcinomas may arise in two ways in Ptenfl/fl KrasLSL/+ mice. The first 
being a progression from a non Wnt-initiated benign sessile serrated adenoma through to 
metastatic carcinoma by a series of mutations including mutation mechanisms such as 
methylation of various tumour suppressors and a proven Wnt activating mutation. The 
second possible pathway may arise from a the acquisition of a Wnt initiating mutation in 
the epithelium that is deficient for Pten and has activated Kras, which then progresses 
to metastatic carcinoma. In the latter hypothesis sessile serrated adenomas would arise 
independently of this pathway and remain benign.
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6 .4  Summary
The Pter\fl/fl KrasLSL/+ mouse model is one of the few models of serrated adenomas. 
Other published models implicate TGF-p, Kras and Braf activation in the formation of 
these tumours (Bennecke et al., 2010, Hohenstein et al., 2003, Carragher et al., 2010). 
Both the P te n ^  KrasLSL/+ mouse model described here, and a mouse model described by 
Bennecke et al in which KrasG12D is activated along with concomitant Ink4a/Arf deletion, 
give rise to serrated adenomas and metastatic carcinoma in the intestine (Bennecke et 
al., 2010). Both represent potential mouse models of the alternative serrated 
adenocarcinoma pathway of progression to CRC.
6.5 Further w ork
6.5.1 Activation of the canonical Wnt pathway
The observation that late stage adenocarcinomas and metastatic carcinomas have 
evidence of canonical Wnt activation, suggests that the tumours have acquired a Wnt 
activating mutation. In order to ascertain whether the mutations acquired in each late 
stage tumour are the same, it would be useful to sequence gDNA from the tumours for 
genes involved in the canonical-Wnt pathway that are commonly mutated i.e. Ape and 
p-catenin to look for mutations. Further to this, it is unclear from my findings whether a 
Wnt activating mutation occurs as an early event before a benign tumour has formed, or 
as an additional mutation within a benign tumour as a later event (see hypothesis in 
Figure 6.10). In order to test this, it would be useful to introduce a Wnt activating 
mutation at varying stages after induction of Pten loss and Kras activation. This could 
possibly be achieved by use of other conditional transgenesis systems such as, the Tet­
on/off system or FLP/FRT in addition to the Cre-LoxP system, to activate the Wnt 
pathway (through activation of Ape or p-catenin for example) after recombination of the 
Pten and oncogenic Kras alleles. These systems may be useful to manipulate gene 
expression in Pten deficient Kras activated intestinal tissue, however it would be 
difficult to test whether a Wnt activating mutation must occur within a sessile serrated 
adenoma to progress to carcinoma using these systems.
6.5.2 Methylation of DNA in sessile serrated adenomas
Increased methylation of tumour suppressors is observed in human serrated 
adenomas, however I have not addressed whether increased methylation is observed in 
the sessile serrated adenomas in Pten/,//f KrasLSL/+ mice. I could assess the level of 
methylation in sessile serrated adenomas by carrying out IHC against DNA-(cytosine-5)- 
methyltransferase 3 beta, which carries out de novo methylation so may be upregulated
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in these tumours. Methyl specific PCR could also be carried out on the promoter regions 
of genes commonly methylated in human sessile serrated adenomas.
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Chapter 7: Investigating the role of E-cadherin in the
intestinal epithelium
7 .1 In troduction
The integrity of epithelial cell layers is maintained by cell-to-cell and cell-to- 
matrix contacts. Adherens junctions, tight junctions and desmosomes are the three 
major types of cell-to-cell contacts that mediate epithelial cell layer integrity. 
Maintenance of these junctions is paramount to the successful functioning of the 
epithelial cell layer. In the intestine, cell-to-cell contacts prevent diffusion of molecules 
and microbes between epithelial cells, give stability to the epithelial layer and help 
maintain apical and basal polarisation of the cells. The cadherin superfamily of proteins 
contributes to the formation of cell-to-cell adhesions, specifically adherens junctions 
and desmosomes. Epithelial-cadherin (E-cadherin) is the prototypic cadherin. It is a 
transmembrane glycoprotein that mediates the formation of adherens junctions by 
forming Ca2+ dependent homodimers between adjacent epithelial cells. Adherens 
junctions form a circumferential belt around epithelial cells, but are also found along 
the lateral surface of the cells. In an adherens junction, E-cadherin is the membrane 
spanning protein that forms homodimers with E-cadherin molecules on the cell surface 
of neighbouring cells. The cytoplasmic domain of E-cadherin binds to p-catenin and 
p120-catenin which in turn bind a-catenin that links to the actin cytoskeleton. The role 
of E-cadherin and adhesion is reviewed in (Wijnhoven et al., 2000).
Down regulation or loss of E-cadherin has been associated with a number of 
epithelial cancers including colorectal cancer (CRC). Reduction in E-cadherin expression 
in CRCs has been associated with disease progression (Dorudi et al., 1993, 
Karamitopoulou et a l.), and a reduction in patient survival time (Dorudi et al., 1995). E- 
cadherin’s key role in tumour invasion has been demonstrated by the reintroduction of 
E-cadherin into a number of E-cadherin negative cancer cell lines causing a reduction of 
their capacity to invade (Vleminckx et al., 1991). E-cadherin loss may promote 
tumourigenesis and progression through its involvement in cell signalling, either through 
its cellular association with p-catenin (Morin et al., 1997), or through facilitation of 
juxtacrine signalling by maintaining cell-to-cell contacts. Loss of E-cadherin and 
therefore loss of cell adhesions may also promote easier detachment of cells within a 
tumour, thereby promoting metastasis or through induction of EMT, which is thought to 
be a key event that occurs before a neoplastic cell can become metastatic (Huber et al., 
2005, Hay, 1995, Takeichi, 1993).
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A number of studies have shown that deletion of E-cadherin in in vivo tumour 
models of breast and pancreatic cancers enhances the phenotype, promoting tumour 
progression and invasion (Perl et al., 1998, Derksen et al., 2006). In the intestine, one 
study has reported the effects of constitutive heterozygous deletion of E-cadherin in the 
Apc1638N intestinal adenoma model (Smits et al., 2000). In this model, loss of E-cadherin 
promoted adenoma formation but failed to enhance progression, therefore suggesting 
that E-cadherin loss may only be important at later stages of disease and so would not 
promote progression in this early tumour model. To address this question I crossed 
conditional Cdh1 (E-cadherin) floxed mice (Derksen et al., 2006) with W///nCreERT 
Apc/,/+Pten/,//7 mice, which are a model of invasive intestinal adenocarcinoma that bear 
more advanced intestinal tumours than Ape heterozygous mice as described in chapter 
4.
I also generated VillinCreERJ-Cdh1fl/fl and W///nCreERT-Cdh1/,/+ mice to investigate 
the role of the E-cadherin in normal adult mouse intestinal epithelium. Schneider et al 
recently described the phenotype of homozygous Cdh1 loss in the mouse intestine. They 
showed that mice that have lost both alleles of Cdh1 succumb to rapid morbidity due to 
disruption of the colonic epithelial barrier (Schneider et al., 2010). In this chapter I will 
also investigate homozygous Cdh1 loss and heterozygous Cdh1 loss, and compare my 
findings to the Schneider et al findings.
7.2 Results
7.2.1 Homozygous E-cadherin loss causes rapid mouse mortality
E-cadherin null mice are inviable and embryos die at pre-implantation stage 
(Riethmacher et al., 1995). So to investigate the effects of E-cadherin loss alone in the 
intestine, the ere loxP conditional knockout system was used. E-cadherin floxed mice 
were obtained (C d h l^ )  and crossed to the intestinal specific ere recombinase, 
W///nCreERT. W///nCreERT-Cdh1/,/// mice (herein referred to as Cdh1//;//) were generated 
along with the appropriate controls (Cdh1/,/+and Cdh1+/+ [or WT]) induced and sacrificed 
when they became sick.
Cdh1;,/// mice have loxP sites flanking exons 4-15 in the Cdh1 gene. 
Recombination of the DNA at these sites results in a functional null allele (Derksen et 
al., 2006). Cdh1/,//7 mice survived until a maximum of 4 days post induction, whereas 
Cdh1///+ and WT mice remained healthy and were sacrificed at the end of the 
experiment at 346 days post induction (Figure 7.1, A). No intestinal tumour phenotype 
was evident in the aged Cdh1///+ cohort, and histological examination revealed no
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differences from WT tissues. By day 4 post induction C d h l^  mice were hunched, 
dehydrated and had diarrhea. When dissected out, the small intestine was considerably 
shorter than the age matched Cdh1/,/+ control and WT small intestine (Figure 7.1, B). 
However, colon length appeared normal in each cohort. Cdh1/,//f small intestine had an 
average length of 22.6 ± 5.5 cm, compared to the Cdh1///+ average small intestinal 
length of 45.3 ± 5.7 cm and the WT average of 45.8 ± 4.3 cm. C d h l^  small intestines 
were significantly shorter than both Cdh1/,/+ control and WT intestines (p values <0.001, 
ns3, Mann Whitney U test). There was no statistical difference in Cdh1/,/+ small 
intestinal length compared to the WT (p value 0.894, n;>3, Mann Whitney U test).
7.2.2 Homozygous E-cadherin loss causes loss of integrity of the intestinal epithelium
gDNA was extracted from crudely enriched small intestinal epithelial cell samples 
and PCR for the recombined allele was carried out to ensure that intestinal epithelial 
DNA had undergone recombination. Presence of the band corresponding to the 
recombined allele confirmed disruption of the Cdh1 gene in both Cdh1/,/+ and Cdh1/,7// 
mice (Figure 7.2, A). The targeted (unrecombined) bands present in the C d h l^  samples 
are presumed to arise from gDNA from unrecombined epithelial cells and stromal cells 
that do not express ere recombinase, which contaminate the sample due to the crude 
nature of enrichment.
Examination of H&E stained sections of small intestinal tissue revealed loss of 
epithelial sheet integrity in C d h l^  mice, and loss of defined crypt-villus structure 
(Figure 7.2, B). The arrows in Figure 7.2, B indicate the remaining crypt and villus-like 
structures. The stromal cells that support the epithelium remained but formed no 
defined structure. There was also evidence of expansion of the submucosal layer 
indicated by the dashed line in Figure 7.2, B. There appeared to be no apparent changes 
in Cdh1///+ small intestine compared to WT intestine.
7.2.3 E-cadherin deficient intestinal epithelial cells detach from the epithelial sheet
IHC against E-cadherin was carried out on small intestinal tissue sections to 
assess the extent of E-cadherin loss. IHC revealed no obvious changes in E-cadherin 
expression in Cdh1/,/+ tissue compared to WT tissue (Figure 7.3), indicating that the 
presence of one intact allele of Cdh1 is sufficient to maintain E-cadherin expression and 
cell-to-cell adhesions. IHC for E-cadherin in Cdh1/,7/< tissue surprisingly revealed the 
presence of membrane bound E-cadherin on the remaining ‘crypt-villus-like’ structures, 
but there was no evidence of the darker band of E-cadherin between cells at the
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basolateral surface (arrow in the WT IHC image in Figure 7.3) and uniform expression of 
E-cadherin along the apical membrane as observed in WT tissue. Despite the presence of 
E-cadherin immunostaining in C d h 1 ^  tissue, higher power images revealed that the 
cells that had maintained E-cadherin expression no longer possessed the morphological 
features of normal intestinal epithelial cells, and as expected, the cells that were 
detaching from the epithelial sheet no longer expressed E-cadherin (Figure 7.3, lower 
panel).
7.2.4 E-cadherin loss causes morphological changes and apoptosis of intestinal
epithelial cells
High power images of H&E stained intestinal sections further confirmed the 
changes in cell morphology observed in E-cadherin immunostained sections. Loss of E- 
cadherin disrupts the cell-to-cell adhesions and in turn the cells lose polarity. Normal 
intestinal epithelial cells form polarised epithelial sheets (Figure 7.4, left panel), the 
cells are columnar in shape and the nuclei are aligned at the basal surface of the cell, 
the nuclei are uniform in shape and cytoplasm occupies the majority of the cell. Cells 
that have lost E-cadherin in C d h l^ ' mice lose the uniform structure of the epithelium, 
with each epithelial cell differing in morphology to its neighbour (Figure 7.4, right 
panel). The cells have a more rounded shape compared to the normal columnar 
morphology epithelial cells possess. The nuclei also appear larger and more round, and 
the cytoplasm of the cells appears to have been depleted.
IHC against cleaved caspase 3 (which is only present in cells undergoing 
apoptosis) revealed the presence of many apoptotic cells in Cdh1/4/// tissue (Figure 7.5). 
Many of these cleaved caspase 3 positive cells appear to have been shed from the crypt- 
villus epithelium, suggesting that loss of contact of neighbouring epithelial cells initiates 
anoikis (the apoptotic program triggered by loss of cell-to-cell contact). There also 
appeared to be higher numbers of caspase 3 positive cells in Cdh1/,/+ small intestinal 
tissue compared to WT. This will be investigated further in section 7.2.6.
7.2.5 E-cadherin deficiency induces subtle changes in colonic epithelium at day 3 post
induction
The morbidity seen at around day 3 post induction in Cdh^Uft is likely to be 
caused by the severe small intestinal phenotype. The absence of any identifiably normal 
crypt-villus structures is likely to cause the mouse to become rapidly dehydrated and 
malnourished. However, as VillinCre recombinase is also expressed in the colon,
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investigation of any overt changes in the colon was carried out. H&E stained colon 
sections revealed that heterozygous loss of E-cadherin (Cdh1///+) does not alter colonic 
epithelial morphology compared to WT (Cdh1+/+) tissue (Figure 7.6). Homozygous loss of 
E-cadherin (Cdh1//;//) does appear to subtly alter colonic morphology compared to 
control and WT tissue (Figure 7.6). Much like the cell morphology changes observed in 
small intestinal tissue, Cdh1////f luminal epithelium appears to have lost polarity. The 
cells no longer possess a columnar morphology and uniform localisation of the nuclei 
near the basal surface of the cell appears to be disrupted (Figure 7.6, arrow head).
IHC against E-cadherin was carried out on colon tissue sections. Immunostaining 
revealed that the epithelial cells present in the colon maintained some E-cadherin 
expression (Figure 7.7). However, this staining appeared reduced compared to control 
and WT tissue and some luminal epithelial cells appeared to have lost membrane 
localisation of E-cadherin (Figure 7.7, inset images). There also appeared to be an 
increase in the abundance of stromal cells in C d h l^  tissue (which is more evident in 
the E-cadherin stained colon tissue sections).
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Figure 7.1 Homozygous loss of E-cadherin specifically in the intestinal epithelium 
leads to rapid death
(A) Cdh1/f/// mice rapidly die after induction of gene deletion, surviving only 3-4 days 
after induction, Cdh1/,/+ and Cdh1+/+ mice however survive beyond 50 days post 
induction. (B) Cdh1/f//< had significantly shorter small intestines compared to Cdh1//7 and 
WT mice at day 3 post induction (*, p value <0.001, ns3, Mann Whitney U test). Error 
bars indicate standard deviation.
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Figure 7.2 Homozygous E-cadherin loss resulted in loss of the crypt-villus 
architecture of the small intestine
(A) PCR for the recombined allele, revealed presence only in Cdh1/,/+ and Cdh1/,7// 
samples. Upper panel - genotyping PCR, A’ - band corresponding to targeted allele 
(330bp), B’ - band corresponding to (WT) untargeted band (200bp). Lower panel - 
recombined PCR, C’ - band corresponding to recombined (floxed) band (320bp). (B) 
Histological examination of Cdh1;,/// small intestinal tissue and controls at day 3 post 
induction revealed extensive loss of crypt-villus architecture due to apparent loss of 
epithelial cells (arrows indicate remaining ‘crypt’ and ‘villus’ structures, dashed line 
indicates submucosal layer). However, Cdh1/,/+ tissue appeared identical to Cdh1+/+ 
tissue. Scale bars represent 200^im.
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Figure 7.3 E-cadherin IHC staining revealed normal expression in Cdh1///+ mice and 
sparse staining in Cdh1/,7/' mice
Upper panel, IHC against E-cadherin revealed no overt changes in abundance of E- 
cadherin in Cdh1/,/+ tissue compared to WT. E-cadherin staining in Cdh1/,7// tissue was 
only present in cells that formed the only discernible crypt-villus structures, scale bars 
represent lOOpim.
Lower panel, magnified images of E-cadherin stained Cdh1/,7// tissue revealed that the 
cells that had lost E-cadherin expression (arrow heads) also appeared to be detaching 
from the villus structure, whereas the cells that maintained some E-cadherin expression 
remained attached to neighbouring cells forming a ‘villus-like’ structure. However, 
darker staining at the basolateral surface as shown by an arrow in WT tissue was not 
present in Cdh1/,/;< tissue, scale bars represent 50^m.
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Figure 7.4 Intestinal epithelial cells in Cdh1/,/;/ mice lose polarity and their columnar 
morphology
Normal intestinal epithelial cells form a polarised sheet of columnar cells, with their 
nuclei positioned towards the basal surface of the cell (left panel). E-cadherin deficient 
cells lose polarity and have no defined morphology, taking on a rounded or more 
cuboidal shape causing the epithelium to lose uniformity (arrow heads). There also 
appears to be an increased abundance of stromal cells in Cdh1/<7// tissue, which is likely 
to be a result of villus shortening. Scale bars represent 50pm.
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Figure 7.5 E-cadherin loss increased the incidence of caspase 3 positive apoptotic 
cells
IHC against cleaved caspase 3 (Asp175) was carried out on small intestinal tissue 
sections. Staining revealed many positive apoptotic cells (arrow heads) compared to WT 
tissue in both Cdh1/,/+ tissue, which had maintained normal intestinal morphology, and in 
C d h l^  tissue, which had lost normal intestinal morphology. Scale bars represent 
lOO^m.
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Figure 7.6 E-cadherin deficiency resulted in subtle disruption of colonic epithelium
There appeared to be no differences in Cdh1/,/+ epithelium compared to WT. However, 
there was evidence of subtle disruption of the colonic epithelium in C d h l^  mice. The 
luminal epithelium had begun to lose polarity as evidenced by changes in morphology of 
epithelial cells (arrow head). There also appeared to be depletion of goblet cells within 
the crypts. Scale bars represent 100[xm.
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Figure 7.7 IHC revealed reduction of E-cadherin in Cdh1/f/// colonic epithelium
IHC against E-cadherin revealed reduction of expression in the colonic epithelium, much 
like what was observed in the small intestinal epithelium. Some cells in Cdh1/(/// colonic 
tissue appeared to have lost expression of E-cadherin (inset magnified images), whereas 
some cells still appeared to have E-cadherin present but the morphology of these cells 
and pattern of expression was not uniform as observed in Cdh1///+ and WT tissue. An 
increase in the presence of stromal cells in Cdh1//7/' tissue compared to Cdh1/,/+ and WT 
tissue is also evident in these images. Scale bars represent 100jim.
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7.2.6 Heterozygous loss of E-cadherin induces an apoptotic response in the small
intestine
Homozygous loss of E-cadherin causes catastrophic loss of the small intestinal 
epithelium resulting in morbidity of the animal at days 3-4 post induction. However, 
heterozygous loss of E-cadherin appears to have no overt phenotype. To further 
investigate heterozygous loss of E-cadherin in the small intestine, Cdh1/,/+ mice were 
induced and sacrificed at day 3 and day 15 post induction and phenotypic 
characterisation of the small intestine was carried out.
As an overt increase in the presence of caspase 3 positive apoptotic cells was 
evident in Cdh1/,/+ tissue at day 3 post induction, scoring of apoptotic bodies and mitotic 
figures was carried out on H&E stained tissue sections taken at day 3 and day 15 post 
induction. There were no changes in the number of mitotic figures in Cdh1/,/+ tissue 
compared to WT at both day 3 and day 15 post induction (Figure 7.8, lower panel) (p 
values = 0.3313 (day 3), 0.5 (day 15), n;>3, Mann Whitney U test). However, at both day 
3 and day 15 post induction there was a significant increase in the number of apoptotic 
bodies in Cdh1///+ tissue compared to WT (Figure 7.8, upper panel) (p values = 0.0404 
(day 3), 0.0383 (day 15), n^3, Mann Whitney U test). At day 3 post induction there was 
an average of 1.7 ± 0.3 apoptotic bodies per half crypt, compared to the WT average of 
1 ± 0.2 apoptotic bodies per half crypt. At day 15 post induction the average number of 
apoptotic bodies was reduced compared to the score at day 3 post induction in both 
Cdh1/,/+ tissue and WT, but there was still a significant increase in apoptotic score in 
Cdh1/,/+ tissue. Cdh1/</+ tissue had an average score of 0.43 ± 0.31 apoptotic bodies per 
half crypt compared to 0.03 ± 0.02 in WT tissue.
IHC against cleaved caspase 3 (Asp175) was carried out on small intestinal tissue 
sections to visualise cells undergoing apoptosis and positive cells were scored. The 
increase in apoptosis in the crypts of Cdh1/</+ tissue at day 3 and day 15 post induction 
scored from H&E sections was confirmed by cleaved caspase 3 scoring (Figure 7.9) (p 
values = 0.0404 and 0.0383 respectively, n&3, Mann Whitney U test). This increase in 
apoptosis was only evident in the crypts; there was no difference in the number of 
cleaved caspase 3 positive cells present in the villi (p values = 0.1914 (day 3), 0.092 (day 
15), n;>3, Mann Whitney U test).
The level of apoptosis observed in Cdh1///+ and WT tissue at day 3 post induction 
in both H&E stained and caspase 3 immunostained sections was higher than the level of 
apoptosis observed at day 15 post induction. The higher levels of apoptosis at day 3 post 
induction is likely to be attributed to the toxic effects of the tamoxifen present
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systemically in the mouse at this timepoint, due to the 4 day induction regime of 
VillinCreER1 recombinase.
7.2.7 Heterozygous loss of E-cadherin does not alter crypt-villus cell number
As there appeared to be an increase in cell death in Cdh1/,/+ tissue (Figure 7.5) 
the number of cells per half crypt-villus were scored in order to assess whether this 
apparent increase in cell death altered intestinal homeostasis (Figure 7.10). At day 3 
post induction crypt scoring revealed no significant difference between Cdh1/,/+ and WT 
tissue (p values >0.05, Mann Whitney U test). Cdh1///+tissue had an average of 23 cells ±
1.6 per crypt compared to WT tissue which had an average of 22 cells ± 2.2, and villus 
scoring revealed that Cdh1/,/+ tissue had an average of 78 cells ± 10.6 per villus 
compared to WT tissue which had an average of 80 cells ± 7.6. Crypt-villus scoring was 
also carried out on tissue samples taken from mice sacrificed at day 15 post induction, 
scoring again revealed no significant difference between Cdh1/,/+ and WT tissue (p values 
>0.05, Mann Whitney U test). Cdh1/,/+ tissue had an average of 27 cells ± 3.3 per crypt 
compared to WT tissue which had an average of 25 cells ± 2.4, and villus scoring 
revealed that Cdh1///+ tissue had an average of 90 cells ±12 .5  per villus compared to WT 
tissue which had an average of 82 cells ±6 .9 .
7.2.8 BrdU positive cells are found in lower crypt positions in Cdh1/,/+ mice
Cdh1/,/+ and WT mice were induced and at day 3 post induction given a pulse of 
BrdU via i.p. injection and sacrificed at either 2 hours or 24 hours after BrdU injection. 
IHC against BrdU was carried out on small intestinal tissue sections in order to visualise 
the cells that had incorporated BrdU into their DNA, and had hence gone through S 
phase of the cell cycle (Figure 7.11). The position of BrdU positive cells along the half 
crypt-villus axis was then scored in 50 half crypt-villi per mouse, n=4 (number of mice 
per cohort) as well as the number of BrdU positive cells in tissues that had received both 
a 2 hour and a 24 hour pulse of BrdU.
There was no significant difference between the number of BrdU positive cells 
per crypt-villus in Cdh1///+ tissue compared to WT in both mice that had received a 2 
hour and a 24 hour pulse of BrdU (Figure 7.11) (p values >0.05, Mann Whitney U test). 
The most frequently labeled positions of BrdU positive cells after a 2 hour and a 24 hour 
pulse of BrdU could be visualised by plotting the cumulative frequency of BrdU positive 
cells at each position along the crypt-villus axis, the resultant curves for Cdh1/,/+and WT 
positioning could then be compared to each other statistically using the Kolmologrov-
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Smirnov test. The cumulative frequency plot of the position of BrdU positive cells after a 
2 hour pulse of BrdU revealed overall lower positioning of cycling cells in Cdh1/,/+ crypts 
compared to WT (Figure 7.12, upper panel) (p value <0.001, Kolmologrov-Smirnov test). 
The cumulative frequency plot of the position of BrdU positive cells after 24 hours 
allows analysis of the migration of the BrdU labeled cells up the crypt villus axis (as 
BrdU is only bioavailable for 2 hours, so only the cells labeled within the 2 hour period 
will remain labeled). After a 24 hour pulse of BrdU the cumulative frequency curve for 
Cdh1/,/+ tissue was not significantly shifted from the WT curve (p value >0.05, 
Kolmologrov-Smirnov test), so BrdU labeled cells are found in the same positions in 
Cdh1///+ tissue as WT tissue. These data suggest that the intestinal epithelial cells in 
Cdh1/,/+ tissue migrate faster up the crypt villus axis, given that after a 2 hour pulse of 
BrdU labeled cells are found in significantly lower positions in the crypt compared to WT 
tissue. However, after 24 hours the cumulative positions of BrdU labeled cells are not 
significantly different from the positions of BrdU positive cells in WT tissue, suggesting 
that the cells must migrate faster to maintain normal cell positioning.
7.2.9 Apoptosis frequently occurs in the lower portion of the crypt in Cdh1/,/+ mice
Quantification of the cumulative positioning of BrdU labeled cells after a 2 hour 
pulse of BrdU revealed that the cycling cells were frequently found at lower positions in 
the crypt compared to WT tissue (Figure 7.12). This finding could not be explained by 
shortening of the crypt, as crypt cell scoring revealed no changes in the number of cells 
per crypt compared to WT tissue (section 7.2.7). However, heterozygous loss of E- 
cadherin enhances the level of apoptosis in the crypt as described in section 7.2.6. 
Similarly to scoring the position of BrdU labeled cells, the position of caspase 3 positive 
cells along the crypt length was scored in Cdh1///+ tissue. This scoring revealed that the 
positions that were most frequently occupied by caspase 3 positive apoptotic cells (cell 
positions 5-7), were also the most frequent positions to be occupied by BrdU labeled 
cycling cells (Figure 7.13). There are two possible hypotheses to explain why BrdU 
positive cells are found lower in the crypt in Cdh1/</+ mice. The first being that the 
proliferating cells are actively migrating downwards in order to compensate for the 
frequent loss of cells via apoptosis in the lower portion of the crypts, therefore those 
positions will also frequently be labeled by BrdU. The second possibility is that as there 
are frequently more instances of apoptosis at these positions in the crypt, therefore 
cells undergoing proliferation are also frequently found in this position to compensate
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for a loss of cells. This in turn would result in a higher cumulative frequency of BrdU 
positive cells being found in the lower portion of the crypt.
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Figure 7.8 Heterozygous E-cadherin loss increases the number of apoptotic bodies 
per half crypt compared to WT, but does not effect the number of mitotic figures
Scoring of apoptotic bodies in H&E stained sections revealed an increase in Cdh1/,/+ 
tissue compared to WT at both day 3 and day 15 post induction (* p values 0.0404 and 
0.0383 respectively, n>3, Mann Whitney U test). However, there was an overall decrease 
in the level of apoptosis at day 15 compared to day 3 post induction. Scoring of mitoses 
revealed no changes between Cdh1/,/+ and WT tissue. Error bars indicate standard 
deviation.
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Figure 7.9 IHC against cleaved caspase 3 confirms an increase in apoptotic cells in 
Cdh1///+ mice
Scoring of cleaved caspase 3 (Asp175) positive cells revealed an increase in apoptosis in 
the crypts of Cdh1/,/+ mice compared to WT at both day 3 and day 15 post induction (*, p 
values 0.0404 and 0.0383 respectively, ns3, Mann Whitney U test). There was an overall 
decrease in the number of apoptosis in the crypt in both Cdh1/,/+ and WT tissue at day 15 
compared to day 3. There was no difference in the presence of cleaved caspase 3 
positive cells in the villi (p values 0.1914 and 0.092 respectively, n>3, Mann Whitney U 
test). Error bars indicate standard deviation.
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Figure 7.10 Heterozygous E-cadherin loss had no effect on the number of cells per 
half crypt-villus
Despite a significant increase in apoptosis in Cdh1/,/+ mice, the number of cells present 
per half crypt and half villus in Cdh1///+ tissue was not significantly altered from WT 
tissue at day 3 and day 15 post induction (p values >0.05, n^3, Mann Whitney U test). 
Error bars indicate standard deviation.
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Figure 7.11 IHC against BrdU revealed no changes in the abundance of cells going 
through S phase in Cdh1/,/+ mice
(A, Left panel) IHC against BrdU was carried out on small intestinal tissue samples from 
mice that had been administered with a pulse of BrdU at 2 hours prior to sacrifice, IHC 
revealed the position of cells that had incorporated BrdU. Scale bars represent 50[xm. 
(A, Right panel) BrdU positive cells were scored per half crypt of mice that had been 
administered with a 2 hour pulse of BrdU. Scoring revealed no changes in the abundance 
of BrdU positive cells in Cdh1/,/+ compared to WT tissues (p value >0.05, ns3, Mann 
Whitney U test). Error bars indicate standard deviation. (B, Left panel) IHC against BrdU 
in mice that had been administered with BrdU 24 hours prior to sacrifice. Staining 
reveals the position BrdU labeled cells have migrated to after 24 hours. Scale bars 
represent lOO^m. (B, Right panel) BrdU positive cells were also scored per half crypt- 
villus of mice after 24 hours. Scoring revealed no changes in the abundance of BrdU 
positive cells in Cdh1/,/+ compared to WT tissues (p value >0.05, ns3, Mann Whitney U 
test). Error bars indicate standard deviation.
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Figure 7.12 Cycling cells occupy lower positions in the crypt in Cdh1///+ mice 
compared to WT
Key: blue line - Cdh1/,/+, red line - WT.
(Upper panel) Cumulative frequency plot of the average position of BrdU labeled cells 
after a 2 hour pulse of BrdU. The cumulative frequency curve of Cdh1/,/+ mice is 
significantly shifted from the WT curve (p value <0.001, n&4, Kolmologrov-Smirnov test). 
(Lower panel) Cumulative frequency plots of the average position of BrdU labeled cells 
after a 2 hour (left) and 24 hour (right) pulse of BrdU. There is no significant difference 
in the curves after 24 hours.
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Figure 7.13 Quantification of BrdU and caspase 3 positive cell positions in Cdh1///+ 
tissue revealed that the most frequent positions of apoptosis coincide with the most 
frequent positions of BrdU incorporation
Key:
Blue histogram bars - average number of BrdU positive cells at each position along the 
crypt length
Black line graph- average number of caspase 3 positive cells in each position along the 
crypt length
Quantification of the position of caspase 3 positive apoptotic cells and BrdU positive 
cells revealed that the positions in which caspase 3 positive apoptotic cells are 
frequently found coincides with the positions in which BrdU positive cells are frequently 
found.
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7.2.10 E-cadherin loss alters the frequency of differentiated cell types in the small
intestine
The effect of E-cadherin loss on the various differentiated cell types present in 
the small intestine was investigated by scoring quantity and localisation of each cell 
type in Cdh1//7// tissue and controls at day 3 post induction and Cdh1/,/+ tissue at day 15 
post induction. Methods used to visualise the various cell types were: alcian blue 
staining to mark mucins present in goblet cells, grimelius staining to mark argyrophilic 
granules in enteroendocrine cells, IHC against lysozyme present in the granules of 
paneth cells, and alkaline phosphastase staining to mark the apical/luminal membrane 
of absorptive enterocytes.
Homozygous E-cadherin loss (Cdh1/,x//) results in an overt loss of goblet and 
enteroendocrine cells (both predominantly found in the villus). In the few discernable 
‘crypt-villus’ structures still present in Cdh1////f tissue very few goblet cells were 
observed (Figure 7.14), similarly in grimelius stained small intestinal sections very few 
enteroendocrine cells were observed (Figure 7.15). However, due to the disordered 
nature of the crypt-villus like structures the abundance of differentiated cell types was 
not quantified. Despite obvious goblet and enteroendocrine cell loss in the remaining 
‘crypt-villus-like’ structures the number of lysozyme positive paneth cells appeared to 
not differ greatly from WT tissue. However these cells were distributed throughout the 
‘crypt-like’ structure rather than confined to the base (Figure 7.16). Alkaline 
phosphatase staining, which is normally expressed on the apical surface of absorptive 
enterocytes, appears to be very weak compared to WT tissue but the staining present is 
still localised to the luminal surface of the villus (Figure 7.17). This reduction in staining 
is likely to be caused by changes in cell morphology induced by E-cadherin loss, and loss 
of apical-basal polarity of the cells.
Alteration or loss of differentiated cell types in Cdh1/,/;< tissue is not a surprising 
finding, due to the severe disruption of intestinal epithelium integrity. More 
interestingly, changes in the abundance of some differentiated cell types occurs in 
tissues heterozygous for E-cadherin (Cdh1;'/+). At day 3 post induction there were no 
alterations in the abundance of goblet, enteroendocrine and paneth cells (Figure 7.14, 
Figure 7.15, Figure 7.16). In Cdh1/,/+ small intestinal tissue at both day 3 and day 15 post 
induction (images not shown for tissue taken at day 15 post induction) alkaline 
phosphatase remained localised to the luminal surface of enterocytes (Figure 7.17). 
However, at day 15 post induction there was a significant reduction in both goblet cells 
(5 ± 0.22 cells in Cdh1/,/+ tissue compared to 6 ± 0.66 cells in WT tissue) and 
enteroendocrine cells (0.38 ± 0.05 cells in Cdh1/,/+ tissue compared to 0.53 ± 0.05 cells
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in WT tissue), (p values <0.05, m>3, Mann Whitney U test) (Figure 7.14, Figure 7.15). 
However, there were no alterations in the number of paneth cells per crypt (p value = 
0.5, ns3, Mann Whitney U test) (Figure 7.16).
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Figure 7.14 Loss of goblet cells is evident in Cdh1/,/;/ and Cdh1/,/+ mice
Small intestinal tissue sections from animals sacrificed at day 3 post induction were 
stained with alcian blue in order to visualise mucins present in goblet cells (images are 
of tissue from day 3 post induction). Scale bars represent 200pim. There was little 
evidence of goblet cells in CdhVl/fl tissue compared to control and WT tissue. There 
appeared to be no overt changes in goblet cell number between Cdh1/,/+ and WT tissue, 
which was confirmed by goblet cell scoring per half crypt-villus at day 3 post induction. 
However, there was a significant decrease in the number of goblet cells per half crypt- 
villus in Cdh1/,/+ tissue compared to WT tissue at day 15 post induction (*, p value 
0.0404, n;»3, Mann Whitney U test). Error bars indicate standard deviation.
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Figure 7.15 Loss of enteroendocrine cell is evident in C d h l^  and Cdh1/,/+ mice
Grimelius staining was carried out on small intestinal sections to mark argyrophilic 
granules present in enteroendocrine cells (images are of tissue from day 3 post 
induction). Staining on tissue from mice sacrificed at day 3 post induction revealed no 
overt changes between Cdh1/,/+ and WT tissue, but in the ‘crypt-villus like’ structures 
remaining in Cdhl^'tissue there appeared to be a reduction of this cell type. Scale bars 
represent 100pm. Scoring of enteroendocrine cells at day 3 post induction in Cdh1/,/+and 
WT tissue revealed no changes, but a significant decrease in the abundance of 
enteroendocrine cells in Cdh1^/+ tissue compared to WT was observed at day 15 post 
induction (*, p value 0.0404, n;>3, Mann Whitney U test). Error bars indicate standard 
deviation.
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Figure 7.16 Paneth cells are mislocalised in Cdh1w / mice
IHC against lysozyme was carried out on small intestinal sections to mark granules 
present in paneth cells from mice sacrificed at day 3 and day 15 post induction (images 
are of tissue from day 3 post induction). Staining revealed that paneth cells were 
confined to the base of the crypt in Cdh1/,/+ mice at day 3 and day 15 post induction, but 
homozygous loss of E-cadherin (C d h l^ )  causes mislocalisation of the paneth cells. 
Dashed line indicates the remaining ‘crypt-like’ structures present in Cdh1;,/// tissue. 
Scale bars represent 50pm. Scoring of paneth cells revealed no alterations in the 
number of paneth cells per crypt in Cdh1///+ mice at day 3 and day 15 post induction (p 
values >0.05, n*3, Mann Whitney U test). Error bars indicate standard deviation.
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Figure 7.17 Reduction in alkaline phosphatase staining in C d h l^  mice
Alkaline phosphatase staining was carried out on small intestinal tissue sections from 
C d h l^  mice and controls sacrificed at day 3 post induction. Staining revealed no overt 
changes in Cdh1/,/+ tissue compared to WT, alkaline phosphatase remained localised to 
the apical surface of enterocytes. The abundance of alkaline phosphatase appeared to 
be depleted in C d h l^  tissue compared to control and WT tissue. However, the little 
staining present remained localised to the luminal surface of the ‘villus-like’ structure. 
Scale bars represent 200^im for Cdh1/,/+ and WT images and 100[xm for the Cdh1//7^  
image.
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7.2.11 Heterozygous E-cadherin loss in the context of intestinal tumourigenesis
To investigate the role of E-cadherin in the development of invasive intestinal 
tumours, W///nCreERT Cdh1/,/+ mice were crossed with Apc/,/+ P te n ^  mice to generate 
VillinCreERr Apc/,/+ Ptenfl/fl Cdh1///+ mice (herein referred to as Apc7,/+ Pten7,/// Cdh1/,/+). 
C6hVl/fl mice were not used to investigate E-cadherin loss in this context due to the 
severe intestinal phenotype and rapid morbidity at 3-4 days after induction observed in 
these mice. As described in chapter 4, Vi7//nCreERT Apc///+ Pten7,//< mice develop 
intestinal adenocarcinomas that invade into the intestinal submucosa, so these mice 
were used as a model in which to investigate the role of E-cadherin deficiency in 
tumourigenesis.
Apc;'/+ Ptenfl/fl Cdh1///+ mice had a median survival time of 51 days post induction 
compared to Apc///+ Ptenfl/fl mice that had a median survival time of 81 days post 
induction. Analysis of the survival data revealed no significant difference between to 
the two cohorts. However, visual inspection of the survival curves does raise the 
possibility that there may be two subsets of mice within this cohort, one subset which 
succumb to morbidity more rapidly than controls (prior to 100 days), and one which 
show extended survival (Figure 7.18). The total number of tumours in the small intestine 
was determined by examination of methacarn fixed tissue. Overall, there was no 
significant difference in the number of tumours present in Apc/,/+ Pten7^  Cdh1/,/+ mice 
compared to the control cohort (Figure 7.18, B). However, when this data was plotted 
against mouse survival time there appeared to be a negative correlation between the 
number of tumours present along the length of the small intestine and survival time 
(Figure 7.18, C). Thus, suggesting that the Apc/,/+ Pten7'77* Cdh17'/+ mice that survived 
longer had less small intestinal tumours.
The grade of the tumours in each of the Apc/,/+ Pten/,/7' Cdh1///+ mice was 
determined using the criteria outlined in the methods section 2.6.5. Tumour grading 
revealed that Apc///+ Pten7'/7/ Cdh1///+ mice bore significantly more microadenomas than 
Apc/,/+ Pten/,//f mice (p value = 0.0155, ns6, Mann Whitney U test). However, despite E- 
cadherin loss being associated with tumour invasiveness, there was only a marginal 
increase in the number of invasive tumours (grade 3 and 4) compared to the control 
cohort, which was not significantly altered from the control cohort (Figure 7.19, A). The 
grading data obtained was then separated according to the two groups that were 
suggested from the survival curve in Figure 7.18, A (i.e. the group of mice that 
succumbed to morbidity earlier than controls, and group that survived longer then 
controls), and compared to the grade distribution of tumours observed in Apc///+ Pten7,/// 
mice. These data revealed that the subset of Apc/,/+ Pten/,/// Cdh1/,/+ mice that
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succumbed to rapid morbidity had significantly higher numbers of non invasive benign 
lesions compared to Apc///+ P te n ^  control mice (p value = 0.0096, n^6, Mann Whitney U 
test, Figure 7.19, B). Interestingly, the subset of mice in Apc/,/+ P te n ^  Cdh1/,/+ that 
lived longer then the control cohort had a similar tumour grade distribution to the 
Apc/,/+ Pten/,7/< controls (Figure 7.19, B). In conclusion, there are no significant changes 
in the survival time of Apc/,/+ Pten/,7// Cdh1/,/+ mice after induction, or in the number and 
invasiveness of tumours these mice possess compared to the control cohort. However, 
evidence from the survival curve and the scatterplot of tumour number vs survival time 
suggests that there may be two subsets of mice within the Apc/</+ P te n ^  Cdh1///+ cohort 
that have differing phenotype severities
IHC against E-cadherin was carried out on tumour tissue from Apc/,/+ Pten^' 
Cdh1/,/+ mice to determine if the remaining allele of Cdh1 was still present in the 
tumours. E-cadherin staining revealed no obvious changes in E-cadherin expression in 
Apc/,/+ Pten/f/// Cdh1///+ mice compared to controls. E-cadherin also remained localised to 
the basolateral membrane of the epithelial component of the tumours as observed in 
the control tumours (Figure 7.20).
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Figure 7.18 The survival plot of Apc/,/+ Pten7//// Cdh1///+ mice appeared to be biphasic
(A) Key: blue dashed line - Apc/,/+ Pten/,/// cohort, red solid line - Apc/,/+ Pten7,/// Cdh1/,/+ 
cohort. Apc/,/+ Pten7</7< Cdh1/,/+ mice appeared to have a biphasic survival profile, more 
than 50% of the cohort had a shorter lifespan than the Apc/,/+ Pten7,/// control cohort. 
However, a subset of the Apc7</+ Pten7,/7< Cdh17,/+ cohort had a longer lifespan than the 
control cohort. Statistical analysis revealed P values of 0.770 (Log-Rank test) and 0.205 
(Wilcoxon test).
(B) Key: AP - Apc/,/+ Pten/,/7' cohort, APE - Apc///+ Pten7'7// Cdh1///+ cohort. There was no 
statistical difference between the total number of small intestinal tumours in the Apc///+ 
Pten7,/// Cdh17,/+ cohort compared to the control cohort, (p value = 0.0646, ns3, Mann 
Whitney U test).
(C) A scatterplot of the total number of small intestinal tumours in Apc/,/+ Pten7'^  
Cdh1/,/+ mice against mouse survival time post induction revealed a trend towards less 
tumours as mouse survival increases (as indicated by black solid regression line [R2 = 
0.3356]). There also appeared to be two distinct groups (as indicated by dashed line 
circles). These data suggest that the distinct group of longer lived Apc/,/+ Pten7'^  Cdh1/,/+ 
mice possess less small intestinal tumours than the shorter surviving group.
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Figure 7.19 Tumour grading revealed a substantial increase in the average number 
of smaller non invasive lesions in the majority of Apc/,/+ Ptenfl/fl Cdh1/,/+ mice
Key: grade 1 - microadenoma, grade 2 - adenoma, grade 3 - adenocarcinoma with 
submucosal invasion, grade 4 - adenocarcinoma with invasion through smooth muscle 
wall and underlying serosa (A) Tumour grading for the total in Apc/,/+ Pten/,7// 
Cdh1/,/+cohort. There were significantly more microadenomas present in Apc/,/+ Pten/,/// 
Cdh1/,/+mice compared to controls (*, p value = 0.0155, ns6, Mann Whitney U test)
(B) Short lived Apc/f/+ Pten///;' Cdh1/,/+ mice possessed significantly higher numbers of 
microadenomas (*, p value = 0.0096, ns6, Mann Whitney U test) in the small intestine 
compared to Apc/,/+ Pten/,//( control mice. A higher abundance of adenomas were 
observed in Apc/,/+ P te n ^ ' Cdh1/,/+ mice, however this was not significant (p value =
0.1425, ns>6, Mann Whitney U test). Heterozygous loss of E-cadherin causes a marginal 
increase in the number of invasive adenocarcinomas observed, (n = 12).
(C) Long lived Apc///+ Pten////7 Cdh1/,/+ mice had a similar average number of tumours per 
section to the Apc/,/+ Pten/,/;/controls, (n = 6).
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Figure 7.20 IHC against E-cadherin revealed no loss of heterozygosity of Cdh1 in 
intestinal tumours
IHC against E-cadherin was carried out on tumour tissue from Apc/,/+ Ptenfl/fl Cdh1/,/+ 
mice and control tumour tissue. Staining revealed that E-cadherin expression was 
maintained in all tumours including the most invasive tumours in Apc/,/+ Pten//7/< Cdh1///+ 
mice, therefore concluding that the remaining copy of Cdh1 was not lost in the tumours 
of Apc/,/+ P te n ^  Cdh1/,/+ mice.
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7.3 Discussion
7.3.1 Conditional homozygous E-cadherin loss in the intestine is inviable in adult mice
Intestinal specific conditional recombination of the Cdh1 gene was induced in 
adult mice around 6-12 weeks of age. Recombination of loxP sites removed exons 4-15, 
which results in a null allele. No differences in health status between C d h l^ , Cdh1/</+ 
and WT were evident before and immediately after induction. However, by days 3-4 
post induction Cdh1//X,/ mice had become dehydrated and hunched so were sacrificed 
(Figure 7.1), whilst Cdh1/,/+ and WT mice remained healthy. When dissected Cdh1/<//f 
mice had little  to no contents in their small intestines, suggesting that morbidity in 
these mice was due to dehydration and malnutrition.
7.3.2 Homozygous loss of E-cadherin causes loss of epithelial sheet integrity
When examined histologically, the small intestines of Cdh1/,/;* mice had lost all 
discernible mucosal structure with the remainder of shortened crypt-villus structures 
being engulfed by stromal cells (Figure 7.2). The catastrophic loss of mucosal structure 
is likely to render the organ useless, as the lack of any normal crypt-villus structures 
means that successful absorption of nutrients and water is highly unlikely. As intestinal 
crypt-villus structure was difficult to distinguish, quantification of cell number, 
apoptosis, mitosis and cell types was not possible. It was possible to see from the H&E 
images that there was a loss of crypt and villus cell number, an increase in caspase 3 
positive cells and loss of goblet and enteroendocrine cells.
Interestingly the remaining crypt and villus-like structures remaining in C d h l^  
small intestine appeared to maintain expression of E-cadherin (Figure 7.3). Despite 
maintaining membrane localisation of E-cadherin the epithelial cells appeared to have 
lost uniformity compared to Cdh1///+ and WT tissue, so it is likely that these cells are no 
longer forming sufficient cell-to-cell contacts to maintain cellular structure. It is 
possible at this short timepoint after knockout of Cdh1 that some intact E-cadherin 
protein present prior to knockout has not yet turned over, and therefore is maintaining 
some of the epithelial sheet integrity. E-cadherin loss is evident in cells that were being 
shed from the epithelial sheet, so the protein must be completely lost before the cells 
are shed. Some, but not all of these shedding and shed cells stained positive for cleaved 
caspase 3, which is only found in cells undergoing apoptosis. This suggests that loss of E- 
cadherin and loss of cell-to-cell contacts may induce apoptosis via anoikis. As was 
observed in E-cadherin stained sections, high power H&E images of the remaining 
epithelial structures in the small intestines of C d h l^ ' mice revealed changes in
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epithelial cell morphology and loss of epithelial polarity compared to WT and Cdh1/</+ 
control tissue (Figure 7.4).
7.3.3 Homozygous E-cadherin loss phenotype in the colon
There appeared to be a similar but more subtle phenotype observed in the colons 
of C d h l^  mice compared to the small intestinal phenotype. There appeared to be 
changes in luminal epithelial cell morphology (Figure 7.6), which is accompanied by a 
reduction (but not loss) of E-cadherin staining (Figure 7.7). There appeared to be an 
overt reduction in goblet cells and an increase in the presence of stromal cells. The 
subtle effect nullizygosity of E-cadherin has on the colon could be due to differential 
effects of the knockout on different tissues. However, Cdh1/,7/< mice only survive 3-4 
days after induction so therefore the effects of E-cadherin loss may not be evident in 
the colon at these early timepoints due to its slower epithelial cell turnover compared 
to the small intestine. The latter explanation is more likely as even at day 3 there is 
some evidence of epithelial cell morphology changes, and subtle colonic architecture 
changes. The structural differences between small intestinal and colonic tissue may also 
affect the outcome of the knockout, i.e. the small intestine is made up of villus 
projections which may be more susceptible to mechanical stress and loss of epithelial 
cells than the colon, where the epithelial cells are compacted and form a more smooth 
lining.
The findings in this chapter both confirm and contrast recently published data by 
Schneider et al, where they also used the VillinCreER1 transgene to conditionally delete 
E-cadherin in the intestine using a different loxP flanked Cdh1 construct (loxP sites 
flanking exons 6-10). They reported that homozygous mice survived until 6 days post 
induction and morbidity was a result of loss of the colonic mucosa, whereas in this study 
morbidity was likely to be caused by disruption of the small intestinal mucosa with much 
lesser effects on the colonic mucosa (Schneider et al., 2010). However Schneider et al 
also observed loss of the small intestinal mucosa, a reduction in goblet cell number and 
mislocalisation of paneth cells in Cdh1;//// mice, which was also shown in this study 
(Schneider et al., 2010). The differences in findings could be attributed to differing 
Cdh1 construct as the mouse used in this study had a smaller region of the Cdh1 gene 
deleted compared to the Cdh1 floxed mouse used in this study. Genetic background and 
housing conditions could also be contributory factors to the difference in findings. The 
mice used in the Schneider et al study were on the C57BL/6 background and housed in 
specific pathogen free conditions in a closed barrier system, whereas the mice used in
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this study were on a mixed background and kept in conventional conditions so are likely 
to harbour more pathogens.
7.3.4 Heterozygous loss of E-cadherin has no effect on the integrity of crypt-villus
structure
Unlike C d h l^  mice, Cdh1/,/+ mice were healthy until the end of the experiment 
(-340 days post induction). The Cdh1/,/+ mice that were aged did not develop tumours in 
the small intestine or colon, which is consistent with previous observations in Cdh1+/' 
mice (Smits et al., 2000). The Cdh1/,/+ intestines examined at day 3 and day 15 post 
induction revealed normal intestinal architecture (Figure 7.2, Figure 7.6) and 
maintenance of basolateral E-cadherin staining in both small intestine and colon (Figure 
7.3, Figure 7.7). Crypt and villus cell scoring established that there were no alterations 
in cell number in Cdh1/,/+ mice. Importantly this confirmed that heterozygous loss of E- 
cadherin does not cause an overall loss of cells from the crypt or villus.
7.3.5 Heterozygous loss of E-cadherin enhances levels of apoptosis
Despite there being no overall changes in crypt and villus cell number in Cdh1/,/+ 
mice, there was a significant increase in the number of apoptotic bodies and caspase 3 
positive cells in the small intestinal crypts of Cdh1/,/+ mice (Figure 7.8, Figure 7.9). To 
compensate for an increase in apoptosis one would expect this to be accompanied by an 
increase in proliferation to maintain intestinal homeostasis, yet mitosis and BrdU scoring 
revealed no differences between Cdh1/,/+ and WT tissue at both day 3 and day 15 post 
induction (Figure 7.8, Figure 7.11). Although there was not an increase in BrdU positive 
cells in the crypt there was a significant alteration to the cumulative positioning of BrdU 
positive cells along the crypt axis in Cdh1///+ mice that had received a 2 hour pulse of 
BrdU (Figure 7.12), indicating that BrdU positive cells are found in lower positions in the 
crypt in Cdh1/,/+ mice compared to WT mice. When the positions of caspase 3 apoptotic 
cells along the crypt axis were plotted and overlayed with BrdU labeled cell position 
data it was clear that the most common positions in which apoptotic cells were found 
were also the most common positions in which BrdU labeled cycling cells were found 
(Figure 7.13). These data, taken together with the finding that there is no increase in 
BrdU positive cells in the crypt, leads to two hypotheses:
1. BrdU positive cells are found lower in the crypt due to migration of cycling cells to 
occupy the crypt positions vacated by apoptotic cells. This hypothesis therefore should
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lead to overall smaller crypts, which is not observed, but perhaps the difference of 1-2 
cells per crypt is not sufficient to result in statistical significance.
2. The finding that apoptotic cells are consistently found in the same lower crypt 
positions, may result in a locally higher incidence of proliferation in these positions to 
compensate for the cell loss, therefore, overall resulting in more BrdU positive cells 
observed in these lower crypt positions, which skews the cumulative frequency curve.
The significance of high levels of apoptosis at crypt cell positions 5-7 is unclear. 
One possible hypothesis is when a Cdh1/,/+ cell migrates from the stem cell 
compartment, commonly regarded to be at the base of the crypt (Barker et al., 2007), 
into the transit amplifying (TA) zone it may need to break existing cell-to-cell contacts 
with surrounding paneth cells (that remain in the base of the crypt) and establish new 
cell-to-cell adhesions with neighbouring TA cells. Heterozygosity of Cdh1 may hinder the 
successful formation of new cell-to-cell adhesions and therefore the anoikis apoptotic 
program may be initiated. A study by Hofmann et al showed anoikis of human colonic 
epithelial cells is prevented by the maintenance of cell-to-cell contacts. They showed 
that human colonic epithelial cells that maintain cell-to-cell contacts show continual 
activation of the PI3K and Src pathways. However, when these contacts are broken, the 
pathways are downregulated and the cells undergo anoikis (Hofmann et al., 2007). 
Therefore, these pathways may be governing apoptosis in Cdh1/,/+ mice.
Despite alteration of BrdU labeled cell positions after a 2 hour pulse of BrdU, 
after 24 hours the cumulative distribution of BrdU positive cells in Cdh1/,/+ mice was not 
significantly altered from the WT cumulative distribution (Figure 7.12). This finding 
suggests that as BrdU positive cells are found at lower cell positions in Cdh1/,/+ mice 
when they are initially labeled with BrdU (after 2 hours), the intestinal epithelial cells 
must migrate faster up the crypt-villus axis as after 24 hours they occupy the same 
positions as WT cells. E-cadherin has previously been shown to impact on intestinal cell 
migration; Schneider et al noted that homozygous E-cadherin loss caused expansion of 
BrdU positive cells along the crypt-villus length after a 24 hour pulse of BrdU compared 
to WT control (Schneider et al., 2010) which is consistent with the finding that 
heterozygous E-cadherin loss promotes migration. However the phenotype of 
heterozygous E-cadherin loss in the Schneider et al study was not addressed. Consistent 
with the finding that E-cadherin loss promotes migration, Hermiston et al showed that 
forced expression of E-cadherin in the mouse intestine resulted in retardation of cellular 
migration (Hermiston et al., 1996).
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7.3.6 Heterozygous loss of E-cadherin causes loss of differentiated cell types
Heterozygous loss of E-cadherin had no effect on the abundance and localisation 
of paneth, enteroendocrine and goblet cells at day 3 post induction. However, at day 3 
post induction alterations in cell lineage may not be evident, as the cells in the crypt- 
villus have not yet fully turned over (small intestine turns over every 4-5 days). At day 
15 post induction there was a significant decrease in the abundance of both goblet and 
enteroendocrine cells in Cdh1///+ small intestinal tissue compared to WT tissue (Figure 
7.14, Figure 7.15). At day 15 post induction there was no alteration in paneth cell 
number or localisation in Cdh1/,/+ tissue compared to WT tissue (Figure 7.16). The effect 
on paneth cells may not be evident at day 15 post induction as these cells are reported 
to turn over every 3-8 weeks (Bjerknes and Cheng, 1981b, Ireland et al., 2005). These 
findings could be explained by three hypotheses:
1 - Heterozygosity of Cdh1 affects terminal differentiation of goblet and 
enteroendocrine cells resulting in decreased abundance of the cell lineages. This 
possibly occurs through alteration of the Notch pathway that controls secretory cell 
lineages (Stanger et al., 2005, Fre et a l., 2005).
2 - Early goblet and enteroendocrine cell precursors heterozygous for Cdh1 have 
increased propensity to undergo apoptosis, as higher levels of apoptosis are observed in 
Cdh1/</+ mice.
3. The high level of cell death in these mice may cause stochastic loss of all cell types 
and this is evidenced by loss of these differentiated cell types.
The conditional E-cadherin knockout study by Schneider et al showed that by 
using a low recombination induction regime V7///nCreERT Cdh1///;/ mice can survive whilst 
maintaining some areas of E-cadherin deficient intestine, thus allowing them to study 
the effect of homozygous E-cadherin loss on cell lineage. They found that homozygous E- 
cadherin loss caused abrogation of secretory cell fate, resulting in the reduction of 
goblet and paneth cells and the presence of secretory precursor cells that express both 
goblet and paneth cell markers (Schneider et al., 2010). It is possible that the 
alterations in secretory cell lineages observed both in the Schneider et al study and the 
findings in this study could be attributed to alterations in the Notch pathway. It has 
been shown that constitutive activation of the Notch pathway in mice leads to 
alterations in secretory cell fate decisions leading to loss of secretory cell types such as
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goblet and enteroendocrine cells (Fre et al., 2005, Stanger et al., 2005). As Notch 
signalling relies on juxtacrine signalling abrogation of cell-to-cell adhesions by loss of E- 
cadherin expression may present a mechanism in which Notch signalling is altered.
The reduction of goblet cells and enteroendocrine cells may also be linked to the 
high incidence of apoptosis in Cdh1^/+ mice. Increased apoptosis may cause a stochastic 
loss of all cell types resulting in lower numbers of differentiated cell types compared to 
WT tissue. It may also be possible that apoptosis may be more selective and goblet and 
enteroendocrine precursor cells may be more susceptible to apoptosis in Cdh1/</+ mice.
7.3.7 Heterozygous E-cadherin does not promote tumour progression
Cdh1/,/+ mice were crossed with an invasive intestinal tumour model, W///nCreERT 
Apc/,/+ Pten/,7/< described in chapter 4. Apc/,/+ Pten/</;/ Cdh1/,/+ mice were induced and 
culled when symptomatic of disease. Interestingly, despite no significant difference in 
survival time of Apc/</+ Pten/<7// Cdh1/,/+ mice compared to controls, inspection of the 
survival plot suggests that the Apc///+ ?tenfl/fl Cdh1/,/+ cohort could be separated into two 
subgroups. One group that has a shorter lifespan than controls, and another that has a 
longer lifespan than controls. When the survival data was plotted against tumour 
number for the Apc/,/+ ?tenfl,fl Cdh1/,/+ cohort it suggested that there was a negative 
correlation between tumour number and survival, i.e. mice with a short survival time 
had a higher abundance of tumours, and mice with a longer survival time had a lower 
abundance of tumours (Figure 7.18, C). It is unclear why one group of Apc/,/+ Pten/,7/* 
Cdh1///+ mice live longer than the controls, but one possible explanation is that as 
heterozygous loss of E-cadherin induces higher levels of apoptosis in the small intestine 
as observed in section 7.2.6, there may be a stochastic loss of cells including cells that 
are the precursors of intestinal lesions. The longer lived Apc ,^/+ P te n ^  Cdh1/,/+ mice may 
randomly have lost more cells that would form lesions and therefore have a lower 
tumour burden and have a longer survival time.
Grading of the tumours in Apc/,/+ Pten/,//f Cdh1///+ mice revealed that heterozygous 
E-cadherin loss does not enhance tumour progression (Figure 7.19, A). No evidence of 
metastasis was observed locally or in the mesentery and pancreas, or in more distant 
organs such as the liver and lungs. Immunohistochemistry against E-cadherin revealed 
that E-cadherin was still expressed in even the most advanced tumours so therefore loss 
of heterozygosity of the Cdh1 gene did not occur (Figure 7.20). E-cadherin loss in human 
colorectal cancers is associated with tumour progression. As the second allele of Cdh1 
was not lost in the tumours of Apc///+ Pten////f Cdh1/,/+ mice the tumour cells were still
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able to establish contacts with each other and therefore were not able to detach and 
metastasise. In this model haploinsufficiency of Cdh1 does not promote tumour 
progression however it does appear to promote tumour initiation as evidenced by the 
increased incidence of early lesions i.e. microadenomas and adenomas in Apc/,/+ P te n ^  
Cdh1/,/+ mice (Figure 7.19, A,B). This confirms the finding by Smits et al that 
haploinsufficiency of Cdh1 in the context of an Apc1638N intestinal tumour model 
synergises with Ape loss to promote the initiation of tumours. Smits et al argued that 
this occurred through increased cytosolic p-catenin made available by decreased 
sequestering of the protein by E-cadherin at the cell membrane (Smits et al., 2000). 
Therefore in a situation in which the cell had lost the p-catenin destruction complex via 
loss of heterozygosity of Ape, there would be more p-catenin available and therefore 
enhance Wnt signalling. Further supporting this proposed mechanism of tumour 
initiation is the finding that E-cadherin only sequesters transcriptionally competent p- 
catenin at the cell membrane (Gottardi et al., 2001). Therefore depletion in the 
abundance of E-cadherin via heterozygosity may result in reduced sequestering of 
transcriptionally active p-catenin, which in turn leads to upregulation of Wnt signalling.
7.4  Summary
In summary, homozygous E-cadherin loss in the intestine in adult mice caused 
extensive destruction of the mucosal surface of the small intestine leading to rapid 
death after induction. Heterozygous E-cadherin loss however had no detrimental effect 
on mouse health, and no tumour phenotype long term. However, heterozygous loss of E- 
cadherin had a negative effect on goblet and enteroendocrine cell lineages as evidenced 
by a decreased abundance of these cell types, possibly through abrogation of 
differentiation of the cell types or as a result of the increased levels of apoptosis 
observed in Cdh1/,/+ mice.
When Cdh1/,/+ mice were crossed to an Apc///+ Pten;,//' invasive intestinal tumour 
model, loss of heterozygosity of Cdh1 was not observed in tumours. Haploinsufficiency 
of Cdh1 did not significantly alter survival of Apc/,/+ Pten;///' Cdh1/,/+ mice compared to 
controls. However, inspection of the survival curve suggested that the cohort could be 
split into two subgroups: one that had a shorter survival than control groups, and 
another than had survived longer than the control groups. There were no overall 
changes in the abundance of tumours in Apc/,/+ Pten/,/;/ Cdh1/,/+ mice compared to 
controls, and tumour grading revealed that the tumours present in these mice were not 
more invasive than those observed in the control cohort. However, there was a
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significant increase in the number of early lesions observed in Apc/,/+ Pten/i//z Cdh1/,/+ 
mice compared to controls, suggesting that haploinsufficiency of Cdh1 promotes tumour 
initiation in these mice.
7.5 Further work
7.5.1 Further investigation of the Cdh1/,/+ phenotype
Cdh1///+ mice have increased levels of apoptosis, increased migratory rate and 
decreased abundance of goblet and enteroendocrine cells in the small intestinal 
epithelium. It would first be insightful to determine the localisation of the proteins 
involved in the adherens junction complex and whether the adherens junctions remain 
normal in appearance. Any abrogation or mislocalisation of these proteins and junctions 
would implicate a mechanism by which all these phenotypes may be occurring. For 
example insufficient adherens junctions may: cause apoptosis by a reduction in PI3K and 
Src signalling through induction of integrin/FAK signalling, destabilise cell-to-cell 
adhesions to enhance migration, and may lead to altered juxtacrine signalling i.e. notch 
signalling. It would also be useful to evaluate the activation status of the PI3K, Src and 
notch pathways.
7.5.2 Investigate the mechanism by which E-cadherin loss promotes tumour initiation 
To confirm that it is indeed enhancement of the cytosolic p-catenin pool that
promotes tumour initiation in Apc/,/+ Pten/,7// Cdh1///+ mice, it would be useful to quantify 
the level of Wnt target activation in the tumours arising in these mice compared to 
tumours arising in the control mice. It would also be interesting to compare the 
localisation of p-catenin in normal intestinal tissue in Apc/,/+ P te n ^  Cdh1^/+ mice with 
control tissue by IHC, and to quantify the abundance of transcriptionally active p- 
catenin in the cytoplasm of Apc///+ Pten/,7/* Cdh1///+ mice.
7.5.3 Study the effect of the homozygous E-cadherin loss within tumours 
Homozygous loss of E-cadherin in the context of tumours could not be studied in
this model as W7//nCreERT C d h l^  mice succumb to rapid death after induction. It would 
be useful to be able to homozygously delete the Cdh1 gene specifically within a tumour 
to investigate how it would affect tumour progression. Unfortunately a tumour specific 
ere recombinase is not available, however knockout may be able to be achieved by
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injection of adenoviral ere recombinase directly into a tumour but this would be a highly 
invasive and difficult procedure.
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Chapter 8: Investigating the role of Pten in the stromal fibroblasts 
and smooth muscle of the intestine
8.1 Introduction
As PTEN is implicated in an array of disorders, the effect of its loss has been 
extensively studied in mouse models. There have been a number of constitutive and 
conditional knockouts of the Pten gene in mice. Di Cristofano et al discovered that the 
Pten gene is essential for embryonic development, with Pten deficiency resulting in 
embryonic death at day E7.5. However, one intact copy of the gene was sufficient for 
normal embryonic development, as heterozygous Pten knockouts survived into adult 
hood. Some of these Pten+/' mice subsequently developed colon tumours with evidence 
of tumour invasiveness at about 3.5 months (Di Cristofano et al., 1998). Podsypanina et 
al found that the intestinal tumours found in Pten+/‘ mice only formed over lymphoid 
tissue, and some but not all displayed epithelial hyperplasia as well as abnormal 
lymphoid tissue (Podsypanina et al., 1999). These findings led to the investigation of 
homozygous deletion of Pten specifically within the intestine. A number of studies in 
which Pten had been conditionally deleted specifically in the intestinal epithelium have 
now been published. The first, a study by He et al, showed that deletion of Pten from 
the epithelium results in rapid intestinal tumourigenesis one month after Pten loss (He 
et al., 2007). However, findings from Langlois et al and Marsh et al showed that 
intestinal epithelial Pten loss is dispensable for normal intestinal function and does not 
cause rapid tumourigenesis (Langlois et al., 2009, Marsh et al., 2008).
The disparity between the phenotypes of the Pten loss models leads to the 
question as to why the former models resulted in rapid formation of tumours and the 
other epithelial models did not. One experimental difference between the He et al 
study and the other conditional knockouts of Pten was the Cre recombinase used to 
achieve deletion. He et al used the inducible MxfCre recombinase driven by the 
interferon inducible Mx1 promoter, whereas the other studies used Ah and VillinCre 
recombinase driven by Cyp1a1 and Villin promoters respectively. Mx1 Cre recombinase is 
expressed not only in the intestinal epithelium, but also in the underlying supporting 
stroma and immune cells (Kuhn et al., 1995, Schneider et al., 2003), so similarly to the 
constitutive Pten+/' animals, MxfCre Pten;,/// animals have lost Pten from both the 
epithelium and underlying stroma of the intestine. Both AhCre and VillinCre 
recombinases are expressed only in epithelia and not in stromal cells (Ireland et al., 
2004, El Marjou et a l., 2004). Taken together, the findings from the various Pten
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deletion models suggest that loss of Pten from the supporting stroma is necessary for 
intestinal tumour formation in the mouse. The concept of alterations in the supporting 
stromal component of a tissue leading to an epithelial phenotype is not new. For 
example, the tumour suppressors Lkb1 and BMPRII have both been implicated in stromal- 
epithelial interactions, as when they are ablated from the stroma in the mouse intestine 
tumours develop (Beppu et a l., 2008, Katajisto et al., 2008)
To investigate the role of Pten in the intestinal stroma, mice bearing a fibroblast 
specific Col1A2CreERJ recombinase transgene (Zheng et al., 2002) were crossed with 
Ptenfl/fl mice to generate Col M2CreERT-Pten///// mice. Co/M2CreERT is expressed in the 
intestine in the stromal fibroblasts surrounding the crypts and in the smooth muscle. It is 
an inducible Cre recombinase activated by administration of tamoxifen via i.p. 
injection. Col1A2CreEP?-Pter\fl/fl mice (hereafter referred to as Col1A2Cre+-Ptenfl/fl) and 
control Co/M2CreERT-Pten+/+ mice (hereafter referred to as Co/fA2Cre+-Pten+/+) were 
generated, induced and sacrificed when they became symptomatic of disease.
8.2 Results
8.2.1 Co/M2CreERT recombinase is specifically expressed in the stroma and smooth
muscle of the small intestine
A number of strategies were used to ascertain the location of recombination of 
the Pten allele. IHC against Pten was carried out on small intestinal tissue sections from 
aged Col1A2Cre+-Ptenfl/fl mice, and also on small intestinal tissue sections from 
VrJ7//nCre+-Pten////, mice and V77//nCre+-Pten+/+ mice as negative and positive controls 
respectively (Figure 8.1, B). IHC revealed that Pten protein was still present in the 
epithelium of Col1A2Cre*-PtenfUfl tissue comparable to the Pten immunostaining of 
W///nCre+-Pten+/+ (WT) tissue. The VillinCre+-Pten;,//' negative control tissue clearly 
shows loss of Pten protein specifically in the epithelium. Despite the positive epithelial 
immunostaining of Pten in ColfA2Cre+-Pten/,//' tissue, the location of Pten loss could not 
be definitely established by IHC, as no strong and coherent immunostaining for Pten 
could be visualised in unrecombined samples.
As it was not possible to determine loss of Pten in the stroma of the small 
intestinal tissue by examination of IHC stained sections for Pten, DNA recombination was 
confirmed by PCR carried out on gDNA from cell enriched samples from both the 
epithelial cell layer, and underlying stromal and smooth muscle cell layer of the small 
intestine (Figure 8.1, C). gDNA was extracted from an epithelial enriched sample 
obtained by scraping the mucosal surface of a section of the small intestine with a
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scalpel. gDNA was also extracted from the remaining underlying smooth muscle and 
stromal layer left after mucosal scraping. Separate PCR reactions for the targeted and 
recombined allele of Pten were then carried out, confirming that a recombined band 
was only present in the samples enriched for stromal and smooth muscle cells but not in 
the epithelial cell enriched samples.
8.2.2 Stromal Pten loss does not affect stem cell marker expression or the proliferative
cell compartment
Modulation of the stem cell niche via Pten loss may impact on the epithelial stem 
cell compartment through stromal-epithelial interactions. He et al, observed an increase 
in the abundance of stem cells in Mx1 Cre-Pten/,/// mice (He et al., 2007), so to 
investigate whether Pten loss from the stroma affects stem cell abundance the level of 
expression of stem cell markers, Lgr5 and Ascl2, were quantified by qRT-PCR. 
Col1A2Cre+-Ptenfl/fl mice were induced (via i.p. injection of tamoxifen) along with cre 
negative controls, sacrificed after 22 days and RNA was then extracted from epithelial 
enriched cell samples. There was no increase in the relative expression of stem cell 
markers Lgr5 and Ascl2 in C ollA2Cre+-Pten/,/// mice compared to Col1A2Cre-Ptenfl/fl 
control mice (p values >0.05, n=4, Mann Whitney U test) (Figure 8.2, A). Expression of 
stem cell markers can be used as a surrogate indicator of the abundance of stem cells, 
but it is not informative of the proliferative activity of the stem cell and TA cell 
compartment. To address whether stromal loss of Pten impacted on the proliferative 
activity of epithelial cells, IHC was carried out against the Ki67 antigen on small 
intestinal tissue sections from Col1A2Cre+-Ptenfl/fl mice and control mice that were 
induced and sacrificed at 22 days post induction. The Ki67 antigen is expressed at all 
stages of the cell cycle and therefore is a marker of cell proliferation. The number of 
Ki67 positive cells were scored per half crypt (50 crypts were scored). CollA2Cre+Ptenfl/fl 
tissue appeared to have a lower abundance of Ki67 positive cells compared to cre 
negative control tissue. However this was not statistically significant (p value = 0.0582, 
n=4, Mann Whitney U test) (Figure 8.2, B). There was however a marked increase in the 
presence of Ki67 positive nuclei of stromal fibroblasts, both at the pericryptal and 
smooth muscle region and the intravillus stroma (Figure 8.2, C, arrows).
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Figure 8.1 Recombination of the Pten allele occurs in the stroma and smooth muscle 
cells of Col 7A2Cre+-Pten///// mice
(A) IHC against Pten shows epithelial Pten expression is maintained in Col1A2Cre+- 
Ptenfl/fl mice compared to VillinCre+-Ptenfl/fl mice, which have epithelial specific loss of 
Pten. However, it is not possible to deduce the site of recombination in Col1A2Cre+- 
Ptenfl/fl mice from IHC staining. IHC was carried out on intestinal tissue from aged 
Col 1A2Cre+-Ptenfl,fl mice (image in figure from mouse at day 603 post induction). Scale 
bars represent 200pm. (B) Key: L - 100bp DNA ladder, E - gDNA sample from epithelial 
cells, M - gDNA sample from smooth muscle and stroma. PCR for the recombined allele 
of Pten only yields a band in samples in which gDNA was extracted from intestinal 
samples enriched for smooth muscle and stromal cells taken from mice at 22 days post 
induction.
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Figure 8.2 Loss of Pten from the stromal and smooth muscle fibroblasts of the small 
intestine does not affect the proliferative compartment of the epithelium
(A) Expression of the stem cell markers Lgr5 and Ascl2 was determined by qRT-PCR 
(carried out on small intestinal epithelial cDNA), as a surrogate marker of stem cell 
abundance. Expression analysis concluded that there was no overall change in Lgr5 or 
Ascl2 expression in experimental epithelium (C o l lA2Cre+Pten;////) compared to control 
epithelium. (B-C) IHC was also carried out against proliferation marker Ki67 on small 
intestinal tissue sections and positive cells were scored. Scoring revealed a trend 
towards lower average numbers of Ki67 positive cells per crypt, but it was not 
statistically significant (p value = 0.0582, n=4, Mann Whitney U test). Ki67 IHC revealed 
a marked increase in the presence of Ki67 positive nuclei in the stromal compartment of 
Cre+ P ten^sm all intestine (indicated by arrows).
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8.2.3 Stromal loss of Pten predisposes to the formation of intestinal tumours
Col1A2Cre+-Ptenfl/fl mice were induced at around 6-12 weeks of age via i.p. 
injection of tamoxifen and culled when they became symptomatic of disease. 
Col1A2Cre+~Ptenfl/fl mice had a median survival of 493 days post induction (Figure 8.1, 
A), which was significantly shorter than the control cohort (Co/7A2Cre+-Pten+/+).
During dissection of Coll A2Cre*-Pter\fl/fl mice, tumours in sites throughout the 
intestinal tract were often visible macroscopically, namely in the small intestine, 
caecum and colon. Microscopic examination of the H&E stained tissue sections from 
these mice confirmed the presence of tumours most frequently in the small intestine 
(66%, n=10/16) and colon (56%, n=9/16) and least frequently in the caecum (31%, 
n=5/16) (Figure 8.3). Interestingly, intussusception of the intestine at the ileal-caecal 
junction was observed in (13%, n=2/10) of mice. 15 out of the 16 mice in the cohort 
possessed at least one intestinal tract tumour.
The majority of tumours observed in CollA2Cre+-Ptenfl/fi mice were benign, well 
differentiated tumours with similar pathology to hamartomas (which are observed in 
Cowden’s syndrome). There was one incidence of metastatic carcinoma that had spread 
to the diaphragm (image not shown), in the cohort of 16 Col1A2Cre+-Ptenfl/fl mice. There 
was evidence of activation of Wnt signalling as ascertained by the presence of nuclear p- 
catenin in the carcinoma but this was not observed in any of the other tumours (all 
other tumours were benign) (Figure 8.4).
8.2.4 Tumours in Col 1 A2Cre+-PtenfUfl mice retain Pten expression in the epithelium
Pten IHC was carried out on tumour tissue sections arising in CollA2Cre+-Pten/,//*
mice to confirm the presence of Pten in the epithelial component of the tumours. Pten 
immunostaining was present throughout the epithelial component of the tumours, 
however the stromal component of the tumours appeared to have reduced staining for 
Pten compared to the epithelium of the tumour (Figure 8.5). When the Pten stained 
sections of Col1A2Cre+-PtenfUfl tumours were compared to tumours stained for Pten that 
arose in other mouse models with intact stromal Pten, a striking difference in Pten 
expression was noted (Figure 8.5). Figure 8.5 shows a tumour from a VillinCre+-P te n ^  
KrasLSL/+ mouse stained for Pten. The epithelial component of this tumour is devoid of 
Pten immunostaining as VillinCre recombinase is expressed in the intestinal epithelium, 
however there is strong Pten immunostaining in the stroma of these tumours compared 
to tumours in CollA2Cre+-Pten/</// mice.
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Loss of Pten results in loss of negative regulation of the PI3K pathway, so IHC 
against phospho-Akt (Ser473) was carried out on tumour tissue sections. As predicted, 
phospho-Akt was upregulated in the stroma of the tumours; stromal upregulation of 
phospho-Akt is not observed in tumours from VillinCre+-Ptenfl/fl KrasLSL/+ mice (Figure 
8.5). This indicated that the PI3K pathway was being specifically activated in the stroma 
of CollA2Cre+-Pten/,/// tumours. However, stromal phospho-Akt staining was not found 
ubiquitously throughout the tumour stroma, but in patches.
8.2.5 Stromal Pten loss possibly mediates tumourigenesis through stromal-epithelial 
interactions via the PI3K-MAPK/ERK pathways
Immunostaining of phospho-Akt revealed that the PI3K pathway was active in 
patches of the stroma in intestinal tumours from Col1A2Cre+-Pter\fUfl mice. To begin to 
address how this stromal upregulation might lead to the formation of an epithelial 
tumour, IHC against phospho-Erk a marker of Ras-Raf-Mek-Erk/MAPK pathway activation 
(another commonly implicated pathway in CRC) was carried out.
IHC revealed that in areas of the tumours in which the stroma stained strongly 
for phospho-Akt, the adjacent epithelial cells frequently stained strongly for phospho- 
Erk (Figure 8.6). This suggests that stromal activation of the PI3K pathway in the tumour 
somehow stimulates MAPK/Erk activation in the tumour epithelium. IHC against Ki67 was 
also carried out to visualise the level of proliferation in the tumours. Ki67 
immunostaining revealed that paradoxically the areas of tumour epithelium that stained 
strongly for phospho-Erk, and were hence surrounded by phopsho-Akt positive stroma, 
had very few positive nuclei for Ki67 (Figure 8.6). This indicates that the areas of 
tumour that appeared to have active PI3K and MAPK/Erk signalling were not actively 
proliferating.
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Figure 8.3 Stromal loss of Pten decreases mouse lifespan and predisposes to benign 
intestinal tumours
(A) Survival curve of Col1A2Cre+-Pten///// mice revealed a significant decrease in lifespan 
compared to the WT control cohort (*, p value < 0.001, Logrank test). (B) Distribution of 
tumour types found in Col 1 A2Cre+-Pten/,/// mice (n=16). Key: SI = Small Intestinal tumour, 
CO = Colon tumour, CA = Caecal tumour, IN = intussusception. 15/16 of the tissue 
samples examined possessed at least one tumour in the intestinal tract. (C-E) H&E 
stained sections of the intestinal tumour types observed in Col1A2Cre+-Ptenfl/fl mice.
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Figure 8.4 The Wnt pathway is not active in benign tumours found in Col1A2Cre+ 
Ptenf,/fl mice
IHC for p-catenin (a surrogate marker of Wnt pathway activation) was carried out on 
tumour tissue sections from in Col1A2Cre+-Ptenfl/fl mice. IHC indicated that the Wnt 
signalling pathway is not activated in the majority of intestinal tumours found in 
Col 1A2Cre+-Ptenfl/fl mice - all of which were benign tumours. Only one case of Wnt 
activation in a tumour was observed, in a metastatic carcinoma. Arrow heads indicate 
cells with nuclear p-catenin staining.
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Figure 8.5 Col1A2Cre+-Pten/,7//tumours lack stromal Pten immunostaining but have 
upregulated stromal phospho-Akt immunostaining
IHC for Pten and phospho-Akt (ser473) (pAkt) was carried out on tumour tissue sections 
from Col1A2Cre+-Pter\fl/fl mice in which Pten had been deleted from the stroma and 
tumour tissue from VillinCre+-Ptenfl/fl KrasLSL/+ mice, which had intact Pten in the stroma. 
Pten immunostaining confirmed the presence of Pten protein in the epithelial 
component of Col1A2Cre+-Pter\fl/fl tumours. However the stromal component of the 
tumours appeared to be devoid of Pten immunostaining compared to V il l inCre+-Pten/,//< 
KrasLSL/+ tumours, which had Pten deleted from the epithelia but not the stroma. 
Phospho-Akt immunostaining revealed upregulation of the activated form of the Akt 
protein, predominantly in the stroma of Col1A2Cre+-Ptenfl/fl tumours. The opposite was 
observed in VillinCre+-Ptenfl/fl KrasLSL/+ tumours. Scale bars represent 100^m.
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Figure 8.6 Stromal phospho-Akt staining coincides with strong phospho-Erk staining 
but not Ki67 staining
IHC was carried out on serial sections of tumour tissue for the active forms of Akt and 
Erk, which are involved in the PI3K and Ras-Raf-Mek-Erk/MAPK pathways respectively. 
Immunostaining for phospho-Akt was located in the stromal compartment of the 
tumours; it was not present ubiquitously throughout the tumour but present in patches. 
Phospho-Erk immunostaining was present in the epithelium adjacent to the areas of the 
stroma that stained strongly for phospho-Akt. Ki67 staining revealed that the epithelial 
areas that stained strongly for phospho-Erk were not actively cycling. Scale bars 
represent 200^im low power, 50 i^m magnification.
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8.3 Discussion
8.3.1 Loss of Pten from intestinal stromal fibroblasts and smooth muscle has no impact
on the proliferative component of the epithelium
Coll A2Cre+-Pter\fl/fl mice were induced around 6-12 weeks of age, recombination 
of the loxP flanked Pten alleles was confirmed by PCR at day 22 post induction and Pten 
IHC further confirmed the presence of Pten in the epithelial cell layer of the intestine in 
aged mice (Figure 8.1). At day 22 post induction loss of Pten from stromal fibroblasts 
and smooth muscle (i.e. the stem cell niche) does not impact on the relative expression 
of epithelial stem cell markers compared to control samples (Figure 8.2). Suggesting 
that the abundance of epithelial stem cells is the same in experimental and control 
tissue. He et al showed that conditional loss of Pten in the intestine using Mx1 Cre 
recombinase causes expansion of the epithelial stem cell compartment and causes 
musashi positive stem cells to leave their normally quiescent state, and divide - as 
indicated by an increase in double labeled musashi positive and Ki67 positive cells (He et 
al., 2007). As Mx1 Cre recombinase expression is not confined to the intestinal 
epithelium alone, but is also expressed in the underlying stroma and immune cells, one 
can hypothesise that Pten must be lost from both the epithelium and the underlying 
stroma to cause expansion of the stem cell pool. The observation in chapter 5 that 
expression of epithelial stem cell markers Lgr5 and Ascl2 is unchanged in ViUinCre*- 
Pten/,//( epithelium further supports this suggestion. One caveat of the data presented 
here is that the stem cell markers used to quantify stem cell abundance, Lgr5 and Ascl2, 
represent what is thought to be the actively cycling stem cell pool and musashi positive 
cells are thought to encompass quiescent stem cells and their progenitors (Li and 
Clevers, 2010). Thus, as in the He et al study it would be useful to quantify the numbers 
of musashi and Ki67 double positive cells and the expression of Bmi1, another proposed 
quiescent stem cell marker, in Coll A2Cre+-Pter\fl/fl tissue to see if stromal loss of Pten 
affects the quiescent stem cell population. He et al also showed that M xIC re^P ten^  
mice have an expansion in proliferative cells as indicated by an increase in abundance of 
BrdU positive cells. Scoring of cycling cells indicated that there was no expansion of the 
proliferative compartment in Col1A2Cre*-Ptenfl/fl mice. Despite there being no expansion 
of the proliferative component of the epithelium, IHC for Ki67 revealed an apparent 
expansion of proliferative fibroblasts in the stromal component of the small intestine. 
Normally very few stromal fibroblasts are actively cycling, which is observed in the cre 
negative control in Figure 8.2, C.
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8.3.2 Loss of Pten from the supporting stromal/smooth muscle component of the
intestine alone causes the formation of tumours
Despite loss of Pten from the stromal fibroblasts and smooth muscle having no 
effect on epithelial cell proliferation at short time points, Co/fA2Cre+-Ptenfl,fl mice that 
were induced and aged were predisposed to the formation of intestinal tumours. Aged 
Co/fA2Cre+-Pten/f/// mice became symptomatic of intestinal tumours from approximately 
270 days post induction, as indicated by swelling of the abdomen, prolapse and blood in 
faeces. Benign tumours were observed along the length of the small intestine, caecum 
and colon (Figure 8.3), and all of these tumours still possessed epithelial immunostaining 
for Pten (as visualised by IHC) (Figure 8.5).
In the study by He et al, intestinal tumours were observed rapidly, after one 
month post induction of MxfCre (He et al., 2007). In contrast, tumours were observed in 
Co/fA2Cre+-Pten//7// mice at much later time points post induction. The study described 
in this chapter differed from the He et al study, as Col 1 A2Cre+-Ptenfl/fl mice were only 
sacrificed when they became symptomatic of disease not at one month after induction 
(as was carried out in the He et al study). However, Coll A2Cre+-Pter\fl/fl mice sacrificed 
at day 22 post induction showed no evidence of intestinal tumours. The differences in 
outcome of my experiment and the He et al experiment, are likely to be attributed to 
the exact cellular compartments in which Pten is lost in MxfCre mice. Data from 
Schneider et al show that MxfCre recombinase acts in the underlying stroma and smooth 
muscle cells of the intestine (Schneider et al., 2003) and a different study by He et al 
confirmed that MxICre was expressed in the intestinal epithelium (He et al., 2004). He 
et al used a lacZ/EGFP reporter mouse to assess the sites of recombination in MxfCre 
mice; they confirmed expression of the reporter gene in intestinal epithelium but the 
image in Figure 2 ,a of the report (shown in Figure 8.7) also appears to show expression 
in the underlying stroma and smooth muscle of the intestine (He et al., 2004). Taken 
together these two studies confirm that MxICre  acts in both the epithelial and stromal 
components of the intestine. Indeed, He et al acknowledge that the expansion of 
stromal cells in the tumours found in A4xfCre+-Pten///// mice and therefore the rapid 
onset of tumourigenesis in MxfCre mice could be due to the deletion of Pten in both 
stromal and epithelial compartments of the intestine. It should also be noted that 
induction of MxfCre evokes an immune response and as MxfCre is also expressed in 
immune cells, so this clearly has ramifications for the interpretation of this model.
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Figure 8.7 EGFP reporter expression in the small intestine of MxfCre mice (taken 
from He et al, 2004)
He et al showed using a conditional EGFP reporter mouse that MxICre is expressed and 
acts within the small intestinal epithelium. However, expression was also noted in the 
underlying stroma/smooth muscle of the small intestine, as indicated by the white arrow 
heads.
8.3.3 Stromal-epithelial interactions in C o l lA2Cre+-Pten;///< tumours
IHC carried out on intestinal tumour sections in Figure 8.6 revealed that strong 
immunostaining for phospho-Erk in epithelial parts of the tumour coincided with the 
presence of stromal phospho-Akt immunostaining, suggesting that the stromal-epithelial 
interactions that are governing tumourigenesis involve cross talk between the PI3K and 
MAPK/Erk pathways. A study published by Trimboli et al has implicated the PI3K, JNK 
and MAPK pathways in the stromal contribution of Pten loss to mammary tumourigenesis 
(Trimboli et al., 2009). Similar to the model described in this chapter, they investigated 
loss of Pten from the stromal fibroblasts but in the context of a model predisposed to 
epithelial mammary tumour formation, and found Pten loss to promote tumourigenesis 
through elevated expression and activation of Ets2, a downstream target of the 
MAPK/Erk pathway. They show that stromal specific deletion of Pten results in epithelial 
upregulation of phospho-Erk and phospho-Ets2 in the mammary gland. It is however, 
unclear whether activation of Ets2 would play the same role in the promotion of 
intestinal tumourigenesis as Munera et al have shown that intestinal specific deletion of 
Ets2 actually enhances azoxymethane induced colon tumour formation (Munera et al., 
2011).
How stromal upregulation of phospho-Akt activates the MAPK/Erk pathway in the 
epithelium is unclear. The MAPK/Erk pathway is activated in a number of ways, through 
receptor tyrosine kinases (RTK), integrins and calcium signalling. The downstream
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actions of phospho-Akt in the stromal fibroblasts must some how activate these 
receptors expressed on the epithelial cell surface in order to activate the MAPK/Erk 
pathway. Activation of the PI3K pathway in stromal fibroblasts of the tumour may send 
paracrine signals to the adjacent epithelium to activate the MAPK/Erk pathway through 
the production and secretion of ligands for RTKs or the release of calcium ions, or 
through activation of outside-in signalling via integrins by juxtacrine signaling to 
epithelial cells in contact with stromal fibroblasts. Intestinal stromal fibroblasts are 
known to secrete insulin-like growth factor-1 (IGF-1), which can activate the MAPK/Erk 
pathway. Recent findings have shown that the production of IGF-1 by intestinal stromal 
cells is stimulated by activation of the PI3K pathway (Leen et al., 2011). Therefore, this 
may present a possible mechanism by which stromal cells are signalling to the 
epithelium in these tumours.
IHC for the proliferation marker Ki67 revealed that areas of tumour epithelium 
that had strong phospho-Erk immunostaining were predominantly negative for Ki67 
immunostaining (Figure 8.6). This finding suggests that these areas of the tumour were 
not actively cycling, and therefore may be senescent. The MAPK/Erk pathway has 
previously been shown to induce cellular senescence in intestinal cell lines (Boucher et 
al., 2004). One can postulate that this lack of proliferation maybe the reason why the 
tumours observed in CollA2Cre+-Pten//7// rarely progress to invasive adenocarcinoma and 
carcinoma.
8.3.4 Epithelial vs stromal deletion of Pten
Both Marsh et al and Langlois et al reported that there were no intestinal tumours 
present in mice that had Pten deficient epithelium in mice older than 200 days post 
induction and -500 days after birth respectively (Marsh et al., 2008, Langlois et al., 
2009). However, as described in chapter 6 a subset (40%) of VHUnCre-?tenfl/fl mice aged 
over 500 days post induction that were culled when they were symptomatic of disease 
possessed some benign small intestinal tumours. Col1A2Cre+-Ptenfl/fl mice possessed 
intestinal tumours as early as 270 days post induction and these tumours are well 
differentiated tumours that resemble hamartomas, whereas in VillinCre-Pter\fUfl mice, 
the few tumours that did arise were sessile serrated adenomas. These findings suggest 
that cell specific loss of Pten gives rise to tumours of differing morphologies and Pten 
loss from the intestinal stroma causes earlier onset of tumourigenesis and increased 
tumourigenecity compared to epithelial cell loss of Pten.
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8 .4  Summary
CRC has long been regarded as a cancer of the epithelium and therefore the vast 
majority of CRC research has focused on genetic alterations in the intestinal epithelium. 
The findings in this chapter along with some other studies (Beppu et al., 2008, Katajisto 
et al., 2008) demonstrate the dependence of the intestinal epithelium on a genetically 
intact supporting stroma, and deletion of tumour suppressors can negatively impact on 
intestinal epithelial homeostasis. The findings in this chapter indicate that loss of Pten 
from the stromal and smooth muscle fibroblasts alone, is sufficient for tumour formation 
in the mouse intestine. This is also the first indication that activation of the PI3K 
signalling pathway in the intestinal stroma can give rise to epithelial aberrations and 
tumours through stromal-epithelial interactions. What downstream targets of phospho- 
Akt and how they relay growth signals to the epithelium is unclear, but this mechanism 
is likely to involve MAPK/Erk signalling. The stark contrast in tumourigenicity in mice 
that are deficient for Pten in the stromal/smooth muscle intestinal component and 
those that have Pten deficiency in the epithelial intestinal component, highlights the 
important role Pten plays in the intestinal stem cell niche. In light of these findings, and 
a recent link to PTEN loss in the tumour stroma, which reports an upregulation of the 
non-coding RNA microRNA-21 (which degrades PTEN mRNA) in the stroma of human CRCs 
and its association with poor survival (Nielsen et al., 2011), it would be insightful to 
investigate the stromal components of human CRCs for PTEN alterations.
8 .5  Further Work
8.5.1 Elucidating a mechanism of tumourigenesis
The data presented in this chapter represent the early findings into the 
investigation of how stromal/smooth muscle loss of Pten predisposes to intestinal 
tumourigenesis. Much work needs to be carried out to ascertain the mechanism by which 
this occurs. As tumour formation in the mammary model of stromal Pten loss seems to 
be mediated by a Pten-Ets2 axis, it would be useful to carry out IHC against phospho- 
Ets2, however as previously mentioned the relationship between Pten and phospho-Ets2 
may be mammary specific. As stromal inactivation of both the TGF-p and BMP pathways 
has been implicated in intestinal epithelial aberrations it would be useful to ascertain 
whether these pathways were down regulated in the stromal Pten model. It would also 
be insightful to carry out IHC against IGF-1 to ascertain if it is expressed in the tumour 
stroma. Further work on short time points should also be carried out to statistically 
prove that stromal cells are more actively cycling in CollA2Cre+-PtenfUfl mice.
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8.5.2 Tumour senescence and tumour progression?
As mentioned the tumours in CollA2Cre+-Pter\fl/fl mice appear not to be cycling 
and may be senescent. Further confirmation of this, can be achieved by immunostaining 
for another cell cycle related protein, proliferating cell nuclear antigen (PCNA), and by 
carrying out senescence-associated p-galactosidase staining, along with IHC for 
upregulation of cell cycle inhibitors such as p16 and p21 to indicate whether the 
tumours are indeed senescent.
How stromal loss of Pten contributes to tumour progression would be the next 
step in elucidating the role of Pten in the intestinal stroma. This could be approached by 
crossing a Co/M2Cre+-Pten/,/// mouse with an Ape**"1 mouse, which is predisposed to 
spontaneous intestinal tumour formation.
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Chapter 9: General Discussion
9 .1 Developing a m etastatic  mouse model o f  CRC
Colorectal cancer (CRC) is the second most common cause of death from cancer, 
predominantly owing to patients usually presenting at the clinic when the disease has 
reached the late stages (CancerResearchUK, 2010). Current treatment strategies rely on 
the use of a combination of cytotoxic drugs and the targeted therapeutic cetuximab - an 
epidermal growth factor receptor (EGFR) inhibitor. Despite these treatments, mortality 
rates are still high, therefore better therapies are needed to treat late stage disease. 
Currently, all preclinical drug testing is carried out on xenografted human tumours in 
immunocompromised mice. Most of the drugs that show efficacy in preclinical models 
often fail when they reach clinical trials (Garber, 2006). Therefore, preclinical 
therapeutic testing must become more predictive of how a drug will work on human 
tumours. One of the ways to achieve this, may be by testing new therapeutics on 
autochthonous mouse models of cancer, i.e. mouse models that develop cancers in the 
tissues of interest, for example through genotoxic insult or genetic knockout. This would 
therefore allow drugs to be tested in an in vivo immune proficient setting, on tumours 
arising from endogenous mouse tissues. This would more faithfully recapitulate the 
human situation, in comparison to drug testing on transplanted human tumours in an 
immune deficient setting.
There are very few mouse models of CRC that develop beyond the adenoma stage, 
which is a major caveat when endeavouring to test new therapeutics designed for the 
later stages of disease. The development of mouse models of metastatic CRC has been 
the subject of much research. A model described by Hung et al, has recently shown that 
Apc/,//f Kras^7* develop metastatic colon cancer after induction via adenoviral insertion 
of the cre recombinase transgene (Hung et al., 2010). However, this model involves 
invasive surgical procedures that require anaesthesia of the mouse. Therefore, models 
of metastatic CRC that involve less invasive procedures are required. Previous studies by 
the Clarke lab have described a mouse model that develops invasive intestinal 
adenocarcinomas - the A/?Cre-Apc/,/+ Pten//7/< mouse (Marsh et al., 2008). One aspect of 
the work outlined in this thesis, was to develop this model by the addition of further 
mutations in an attempt to allow the tumours that arise in AhCre-Apc/,/+ Pten/,7// mice to 
become metastatic. Two strategies were taken to try and achieve metastatic intestinal 
tumours. First was the addition of an activating Kras mutation, and the second was 
additional loss of cell adhesion protein E-cadherin. VillinCre recombinase was used to
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achieve intestinal specific transgenesis, to prevent any confounding effects from non- 
intestinal phenotypes.
9.1.1 Pten loss and Kras activation promotes tumour initiation and progression in a
Wnt-driven tumour model
The rationale behind the addition of a Kras mutation to the Apc/,/+ Pten/,//z 
tumour model was based on the potential for synergy between Pten and Kras mutations, 
owing to the role of Kras in activation of both the PI3K and MAPK/Erk pathways 
(Rodriguez-Viciana et al., 1996). The progression of tumours in Apc/Z/+ Pten/Z//Z mice 
coincides with elevated levels of phospho-Akt, and therefore increased activation of the 
PI3K pathway. Thus, synergy between Pten and Kras may allow progression of the 
tumours through enhanced PI3K pathway activation, as Kras activates the PI3K pathway 
and Pten inhibits it.
As hypothesised, the tumours that arose in ViUinCre-Apc/,/+ Pten/,//z KrasLSL/+ mice 
were more invasive than those observed in VUlinCre-Apcfl/+ Pten/,//z mice (described in 
chapter 4). However, Apc/Z/+ Pten/Z//Z KrasLSL/+ mice had an increased number of tumours 
overall compared to Apc/Z/+ Pten/Z/// mice. As a result of this increased abundance of 
tumours, combined with the presence of more advanced tumours, Apc/Z/+ Pten////Z KrasLSL/+ 
mice had a shorter lifespan than Apc/,/+ Pten/,//z mice. Therefore, addition of a Kras 
mutation to Apc/,/+ Pten////Z mice promoted tumour initiation and progression. However, 
these tumours did not progress to metastasis. Despite this, due to the well-defined 
survival profile, the level of tumour progression and the involvement of common 
mutations found in human CRC (i.e. KRAS, APC), this model may be useful for preclinical 
testing of novel therapeutics. For example, patients that bear KRAS mutations often do 
not respond to cetuximab treatment (Lievre et al., 2006). As a result of this, inhibitors 
of pathways downstream of KRAS such as PI3K and MEK inhibitors are being developed. 
Therefore, the ViUinCre-ApcfU+ ?tenfUfl KrasLSL/+ mouse model would be a useful 
preclinical model to test these therapeutics, as the mice bear mutations in genes 
involved in both pathways and later stage invasive adenocarcinomas.
9.1.2 Synergy between Pten and Kras mutations potentially acts through the PI3K
pathway
Synergy between Pten and Kras mutations is evidenced by disrupted intestinal 
homeostasis (outlined in chapters 3 and 5), and accelerated tumourigenesis (outlined in 
chapters 4 and 6). However, whether this synergy occurs through a number of pathways
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or through one pathway is uncertain. The presence of elevated levels of the active form 
of Akt, phospho-Akt, in small intestinal tissue of P te n ^  KrasLSL/+ and Apc/,/+ Pten^' 
KrasLSL/+ mice, in chapters 3 and 5 suggests that homeostasis is altered through 
hyperactivation of Akt, and therefore hyperactivation of the PI3K pathway. PI3K 
activation has previously been associated with increased proliferation and loss of 
apoptosis in vitro  (Itoh et al., 2002) and has been associated with increased 
proliferation in vivo (He et al., 2007) as well as hyperplasia of the intestine in vivo 
(Ferrand et al., 2005). However, activation of the PI3K pathway in the in vivo model 
described in Ferrand et al was also associated concomitantly with activation of a number 
of other signalling pathways, which may have contributed to the phenotype. My findings 
also indicate that the effect of PI3K activation on intestinal homeostasis also appears to 
depend on the level of activation. Low levels of phospho-Akt, hence low levels of PI3K 
pathway activation, results in subtle phenotypes (such as enhanced cellular migration), 
high levels of phospho-Akt results in more severe phenotypes (such as villus bifurcations 
and hyperplasia, these findings are outlined in chapter 5). The role the PI3K pathway 
plays in intestinal homeostasis must however be more robustly tested, through 
administration of PI3K inhibitors to Pten/;/// KrasLSL/+ mice.
9.1.3 Ptenfl/fl KrasLSL/+ mice as a preclinical model of metastatic CRC
Interestingly, long-term control, Pten/,/;' KrasLSL/+ mice, developed metastatic 
carcinoma of the intestine after a long latency period, and the acquisition of a 
spontaneous somatic canonical Wnt-activating mutation. However, Pten/f//' KrasLSL/+ mice 
are unsuitable for therapeutic treatment due to low frequencies of mice possessing 
metastases. The reason why not all mice developed metastases is likely to be due to the 
long period before the mouse is symptomatic of disease, so therefore some mice 
succumbed to other age-related illnesses. Another caveat of using these mice for 
therapeutic treatment is the lack of overt external evidence of the presence of tumours, 
and more importantly metastatic spread. This caveat may be overcome by the use of 
imaging technologies such as positron emission tomography (PET), or magnetic 
resonance imaging (MRI). These imaging techniques can be used to detect the presence 
of metastases at the earliest stages, and then used to monitor the tumours during 
treatment. Pten7"7' KrasLSL/+ mice may also be useful for the study of biomarkers of 
advanced CRC, discovery of a signature of blood biomarkers that correlate with disease 
progression would be a useful tool to screen the animals for disease stage.
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9.1.4 Wnt-activating mutation: tumour initiator or promoter?
The observation that all invasive adenocarcinomas and metastatic carcinomas 
that develop in P te n ^  KrasLSL/+ mice had evidence of canonical-Wnt activation, taken 
together with the observation that Apc/,/+ Ptenfl/fl KrasLSL/+ mice that were induced by the 
low recombination induction regimen do not progress to metastasis, suggests that the 
point at which a Wnt-activating mutation is acquired may be pivotal to whether the 
tumour metastasises. In humans there is evidence of Wnt-activation being a secondary 
event in tumourigenesis, particularly in sessile serrated adenomas (Wu et al., 2008, 
Yachida et a l., 2009). It may also be plausible that during the long latency period 
between induction and morbidity the tumours that arise in P te n ^  KrasLSL/+ mice may 
also have acquired other genetic mutations, e.g. p53 or Smad4 mutations, which may 
also be key factors to explaining why the tumours in these mice metastasise. 
Accumulation of mutations may be driven by Pten loss, as Pten loss has been suggested 
to promote genomic instability, independently of its lipid phosphatase activity but 
through its role in the nucleus. Pten loss has been shown to cause genomic instability 
through its association with centromeres and regulation of Rad51 expression (Shen et 
al., 2007, Gupta et a l., 2009), so causing instability through loss of DNA damage repair 
and alteration of cell cycle checkpoints. Thus, loss of Pten in the mouse intestine may 
confer a mutator phenotype allowing additional mutations to frequently accumulate in 
these mice.
9.1.5 Ptenfl/fl KrasLSL/+ mice may represent a model of serrated adenocarcinoma
The serrated adenocarcinoma pathway is thought to represent an alternative 
pathway of CRC formation to the Fearon-Vogelstein model (Makinen et al., 2001, Huang 
et al., 2004). The differences between the two pathways are not only histological but 
there are also molecular differences, i.e. the traditional Fearon-Vogelstein pathway of 
CRC progression is through LOH, and the Serrated Adenocarcinoma pathway of CRC 
progression is through methylation and microsatellite instability. Through histological 
examination of the array of tumours that arise Pten///;/ KrasLSL/+ mice, one can postulate 
that the adenocarcinomas and metastatic carcinomas that arise in these mice develop 
from benign serrated adenomas (which are often observed synchronously with advanced 
tumours). Benign sessile serrated adenomas are frequently observed in these mice but 
traditional ‘Ape-initiated’ adenomas are never observed. Evidence of serration in 
advanced adenocarcinomas, carcinomas and metastases along with evidence of invasion 
and progression in sessile serrated adenomas support the hypothesis that the metastatic
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carcinomas indeed arise from benign sessile serrated adenomas. However, the caveat of 
being unable to follow an individual lesion longitudinally in this model prevents 
conclusive proof of this hypothesis. The PtenfUfl KrasLSL/+ mouse model represents a 
potential mouse model of the serrated adenocarcinoma CRC progression pathway, and 
challenges the notion that a Wnt-activating mutation is required for tumourigenesis. 
This study, along with a recent study by Bennecke et al, in which mice bearing an 
activating Kras mutation and loss of the cell cycle inhibitor lnk4A/Arf also develop 
serrated adenomas and metastatic carcinoma (Bennecke et al., 2010) supports the 
hypothesis that CRC can arise from serrated adenomas.
9.1.6 The role of E-cadherin in tumour progression
Another strategy used to try and promote metastasis in the Apc/,/+ Pten7<//* mice 
was the additional loss of the cell adhesion protein E-cadherin. Loss of E-cadherin is 
positively correlated with increased progression of CRCs (Dorudi et al., 1995, Dorudi et 
al., 1993), so to address whether E-cadherin loss promotes tumour progression Apc/,/+ 
Pten7"7* Cdh1///+ mice were generated, and the findings described in chapter 7. I was only 
able to investigate the contribution of heterozygous loss of E-cadherin on tumour 
progression, as homozygous loss of E-cadherin in adult mouse intestine resulted in 
extensive disruption of the intestinal epithelium and rapid morbidity. Heterozygous loss 
of E-cadherin does not promote tumour progression and overall survival and tumour 
number was unaltered in Apc/,/+ Pten7</7/ Cdh17*/+ mice compared to control mice. 
However, through careful examination of tumour stage and survival data it remains 
possible that a subgroup of Apc/,/+ Pten7'77* Cdh17</+ mice have higher numbers of small 
lesions than the control group. The observation that heterozygous loss of E-cadherin 
promotes tumour initiation has been previously reported. Increased tumour initiation is 
thought to be driven by release of transcriptionally active p-catenin via E-cadherin loss, 
resulting in activation of the canonical-Wnt pathway (Smits et al., 2000). The tumours 
that arise in Apc///+ Pten7"7* Cdh1/,/+ mice do not show loss or reduction of E-cadherin 
immunostaining. Therefore, loss of heterozygosity of the remaining allele of Cdh1 (E- 
cadherin) did not occur in the tumours. The rapid demise of mice in which E-cadherin 
had been completely ablated proved to be the major caveat of this study, as this 
prevented the investigation of complete loss of E-cadherin within in the context of 
tumour progression.
In humans, loss of E-cadherin expression in a tumour is thought to promote 
tumour progression (Dorudi et al., 1995, Dorudi et al., 1993). However, the tumours
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observed in the various mouse models described in this thesis show no evidence of loss 
or down regulation of E-cadherin expression, and heterozygous loss of E-cadherin in an 
intestinal tumour model does not promote tumour progression. Taken together, these 
findings suggest that E-cadherin does not appear to play a pivotal role in intestinal 
tumour progression in the mouse.
9.2 Strom al-epithelial interactions o f Pten
PTEN is a major tumour suppressor that is commonly found to be mutated in many 
cancers including breast (Li et al., 1997, Saal et al., 2008), prostate (Li et al., 1997, 
Wang et a l., 1998, Feilotter et al., 1998) and endometrial cancer (Risinger et al., 1997, 
Tashiro et a l., 1997). Germline mutation of the gene in humans gives rise to PTEN 
Hamartoma Tumour Syndromes (PHTS), individuals with these syndromes are 
predisposed to benign tumours of the Gl tract that have the capacity to progress to 
malignant disease (Carlson et al., 1984). Mouse models of constitutive deletion of Pten 
showed that homozygotes were inviable, but heterozygotes, like PHTS patients, were 
predisposed to Gl tract tumours (Di Cristofano et al., 1998, Podsypanina et al., 1999). 
Studies in which conditional deletion of Pten was achieved specifically in the intestinal 
epithelium yielded contrasting results. He et al found using MxfCre mediated 
recombination, that loss of Pten from the adult mouse intestinal epithelium resulted in 
rapid tumour formation (He et al., 2007). In contrast, studies from Marsh et al and 
Langlois et al found that intestinal epithelial loss of Pten mediated by AhCre and 
VillinCre recombination did not predispose to intestinal tumour formation (Marsh et al., 
2008, Langlois et a l., 2009). Both constitutive, and Mx1 Cre induced Pten loss, allows 
mutation of the gene from the underlying supporting stroma of the intestine as well as 
the epithelium. The aim of the study outlined in the final chapter of this thesis was to 
investigate how stromal fibroblast specific loss of Pten impacts on the intestinal 
epithelium.
9.2.1 Stromal loss of Pten promotes tumourigenesis
To investigate the disparity between the outcomes of the conditional Pten loss 
mouse models, Col1A2Cre+ Ptenfl,fl mice were generated. Col1A2Cre is expressed 
constitutively in intestinal stromal fibroblasts and smooth muscle, and is activated upon 
administration of tamoxifen. Short-term deletion of Pten from the small intestinal 
stromal compartment did not impact upon the epithelial stem cell compartment or 
enhance epithelial cell proliferation, as was reported in Mx1 Cre+ Ptenfl/fl mice, which
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lack Pten in both the stromal and epithelial compartments (He et al., 2007). However, 
there was an overt increase in the abundance of Ki67 positive cells in the small 
intestinal stroma. Long-term stromal loss of Pten predisposes to the formation of benign 
tumours throughout the intestine; these tumours are similar in morphology to 
hamartomas. The tumours in Col1A2Cre+ Ptenfl/fl mice have a large stromal component, 
and often, elevated levels of phospho-Akt are observed in the stromal component that 
directly correlate with elevated phospho-Erk and lower Ki67 immunostaining in the 
adjacent epithelium. It appears that loss of Pten from the intestinal stroma promotes 
tumourigenesis by stromal-epithelial interactions that involve paracrine activation of 
MAPK/Erk signalling. It also appears that elevated MAPK/Erk activation may result in 
cellular senescence, suggested by areas of strong phospho-Erk immunostaining 
coinciding with low Ki67 immunostaining. However, if the tumours are indeed senescent, 
it could also be driven by non-oncogenic mechanisms but by Pten loss. Pten loss has 
previously been associated with induction of cellular senescence in the prostate, 
through p53 dependent mechanisms (Chen et al., 2005). However, it is not known 
whether Pten loss induced senescence is prostate specific and if the same is observed in 
the intestine.
This is the first study that indicates that stromal loss of Pten is sufficient to 
promote intestinal tumourigenesis. The idea that manipulation of gene expression in the 
stromal component of a tissue can impact on epithelial homeostasis has previously been 
investigated. In particular, intestinal stromal specific ablation of Lkb1 gives rise to 
hamartomas (Katajisto et al., 2008). Interestingly, hamartomas are also observed in 
Co/fA2Cre+ P te n ^  mice; these similar phenotypes may be owing to both loss of Lkb1 
and loss of Pten causing activation of the mTOR pathway. Taken together, these findings 
oppose the traditional view that tumours that are derived from epithelial tissues are 
caused by mutations in the epithelial cells, and genetic alterations in the stromal cells 
surrounding the epithelium may play a pivotal role in tumourigenesis.
9.2.2 The role of Pten in tumourigenesis
The deletion of Pten in the mouse has resulted in inconsistent phenotypes 
between models, in the case of the intestine. Constitutive heterozygous loss of Pten 
predisposes to intestinal tumours (Di Cristofano et al., 1998, Podsypanina et al., 1999), 
as does conditional homozygous loss of Pten from the epithelial and stromal small 
intestinal layers (He et a l., 2007). However, epithelial specific homozygous loss of Pten, 
has been reported to not give rise to intestinal tumours (Langlois et al., 2009, Marsh et
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al., 2008). Despite this, my findings indicate that after a long latency period (>500 days 
post induction), intestinal epithelial specific loss of Pten gives rise to benign tumours, 
but not with complete penetrance (chapter 6). I have also found that homozygous loss of 
Pten, specifically in the stromal fibroblasts and smooth muscle gives rise to benign 
intestinal tumours, similar to hamartomas, at shorter timepoints after induction 
(chapter 8). Taken together, this disparity of phenotypes observed between these 
models leads me to propose two possibilities about the function of Pten.
The first is that Pten may play a role in senescence in the mouse intestine, which 
may be more pronounced depending on the level of Pten loss and the compartment in 
which Pten is deleted. Pten loss induced senescence is also thought to be dose- 
dependent, in mouse embryonic fibroblasts and in vivo, in the prostate, homozygous loss 
of Pten promotes senescence, whereas cells heterozygous for Pten do not undergo 
senescence (Chen et a l., 2005). If Pten has the same effect on cellular senescence in the 
intestine, it may provide some explanation as to why mice that have a constitutive 
heterozygous deletion of Pten develop intestinal tumours. Therefore it would be 
insightful to ascertain whether senescence is induced in the intestine when Pten is 
homozygously deleted in the epithelium, and in addition to this, investigate if epithelial 
specific, heterozygous loss of Pten promotes tumourigenesis. The second possibility is 
that PTEN may play a more intricate role in human CRC, and loss of expression in 
particular compartments of the intestine may promote tumourigenesis. Upregulation of 
microRNA-21, a microRNA that is targeted toward PTEN (among other mRNAs) has been 
noted in human tumours (Nielsen et al., 2011). Therefore, investigation into the 
expression levels of PTEN in human CRCs via IHC would be insightful.
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